<SEC-DOCUMENT>0001161697-21-000374.txt : 20210811
<SEC-HEADER>0001161697-21-000374.hdr.sgml : 20210811
<ACCEPTANCE-DATETIME>20210811170729
ACCESSION NUMBER:		0001161697-21-000374
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210811
DATE AS OF CHANGE:		20210811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39086
		FILM NUMBER:		211164469

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>krmd-20210630_form10q.htm
<DESCRIPTION>FORM 10-Q QUARTERLY REPORT FOR 06-30-2021
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:krmd="http://repro-med.com/20210630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_krmd_repro%2Dmed.com_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20210101_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000704440 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_Segment_5_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityCentralIndexKey">0000704440</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-06-30" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockbasedLitigationSettlementExpense" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:BorrowingsFromIndebtedness" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:CommonStockIssuanceAsSettlementForLitigation" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:LitigationSettlementOptions" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:LitigationSettlementOptions" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:LitigationSettlementOptions" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:NewIssuanceOfCapitalRaiseAmount" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:NewIssuanceOfCapitalRaiseAmount" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" id="xdx2ixbrl0903" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" id="xdx2ixbrl0914" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" id="xdx2ixbrl0915" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" id="xdx2ixbrl0955" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl1071" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="krmd-20210630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-102021-08-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-10</xbrli:startDate>
        <xbrli:endDate>2021-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-222019-04-23_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-22</xbrli:startDate>
        <xbrli:endDate>2019-04-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-132021-02-15_custom_ChiefExecutiveOfficerJamesMBeckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerJamesMBeckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-13</xbrli:startDate>
        <xbrli:endDate>2021-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-212021-03-22_custom_ChiefExecutiveOfficerJamesMBeckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerJamesMBeckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-21</xbrli:startDate>
        <xbrli:endDate>2021-03-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-142021-03-15_custom_ChiefExecutiveOfficerLindaTharbyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerLindaTharbyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-14</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerLindaTharbyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-11</xbrli:startDate>
        <xbrli:endDate>2021-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_EmployeesAndConsultantsUnderThePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:EmployeesAndConsultantsUnderThePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-302019-01-02_custom_NonEmployeeDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-30</xbrli:startDate>
        <xbrli:endDate>2019-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-292019-10-01_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-29</xbrli:startDate>
        <xbrli:endDate>2019-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-30</xbrli:startDate>
        <xbrli:endDate>2021-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-30</xbrli:startDate>
        <xbrli:endDate>2021-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-172021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-17</xbrli:startDate>
        <xbrli:endDate>2021-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-172021-05-18_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-17</xbrli:startDate>
        <xbrli:endDate>2021-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-192020-05-20_custom_SettlementAgreementMember_custom_EMEDTechnologiesCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:EMEDTechnologiesCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-19</xbrli:startDate>
        <xbrli:endDate>2020-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-132021-02-16_custom_ChiefExecutiveOfficerDonaldPettigrewMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerDonaldPettigrewMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-13</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-132020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-13</xbrli:startDate>
        <xbrli:endDate>2020-04-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-232020-06-24_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-23</xbrli:startDate>
        <xbrli:endDate>2020-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PromissoryNoteMember_custom_KeyBankNationalAssociationMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-262020-04-27_custom_KeyEquipmentFinanceMember_custom_ProgressPaymentLoanAndSecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyEquipmentFinanceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:ProgressPaymentLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-26</xbrli:startDate>
        <xbrli:endDate>2020-04-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:PiperSandlerCoAndCanaccordGenuityLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-01</xbrli:startDate>
        <xbrli:endDate>2020-06-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:PiperSandlerCoAndCanaccordGenuityLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-152020-11-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-15</xbrli:startDate>
        <xbrli:endDate>2020-11-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>krmd:Segment</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<div style="width: 7.5in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20210101__20210630_zuacXvNT5Us2"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_90F_edei--DocumentQuarterlyReport_c20210101__20210630_z7D4Xj9unl5e"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">[X]</ix:nonNumeric></span></b>&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Quarterly Period Ended <span style="text-decoration: underline"><span id="xdx_907_edei--DocumentPeriodEndDate_c20210101__20210630_zMrWB7DgZErj"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, 2021</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_edei--DocumentTransitionReport_c20210101__20210630_zwFXkCgmr02b"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">[_]</ix:nonNumeric></span>&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ________ to ________.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityFileNumber_c20210101__20210630_zUuV9KaqKM8j"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityFileNumber">0-12305</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityRegistrantName_c20210101__20210630_zJPRWTJteha6"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityRegistrantName">REPRO MED SYSTEMS, INC.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 3.75in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20210101__20210630_zZojmiK9Kbt5"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></span></b></td>
    <td style="width: 3.75in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20210101__20210630_z6UhZ3SUzQRi"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityTaxIdentificationNumber">13-3044880</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(State or other jurisdiction of incorporation or organization)</td>
    <td style="text-align: center">(I.R.S. Employer Identification No.)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityAddressAddressLine1_c20210101__20210630_z6EOyptkx9gg"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressAddressLine1">24 Carpenter Road</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20210101__20210630_z2JDwjEpxrF4"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressCityOrTown">Chester</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20210101__20210630_zGU3RSEzTeda"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></span></b></td>
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20210101__20210630_zYdScqxRJnbh"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressPostalZipCode">10918</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td style="text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">(<span id="xdx_90A_edei--CityAreaCode_c20210101__20210630_zx1lKpaTbFX9"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:CityAreaCode">845</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20210101__20210630_zHqmiqPeOC5j"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:LocalPhoneNumber">469-2042</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&#8217;s telephone number, including area
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-decoration: underline">N/A</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name, former address and former fiscal year, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 179.9pt; text-align: center"><span style="text-decoration: underline">Title of each class</span></td>
    <td style="width: 1.5in; text-align: center"><span style="text-decoration: underline">Trading Symbol(s)</span></td>
    <td style="width: 3.5in; text-align: center"><span style="text-decoration: underline">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b><span id="xdx_904_edei--Security12bTitle_c20210101__20210630_zic2HS1TcN24"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:Security12bTitle">Common stock, $0.01 par value</ix:nonNumeric></span></b></td>
    <td style="text-align: center"><b><span id="xdx_900_edei--TradingSymbol_c20210101__20210630_zCh8kFtKkMY6"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:TradingSymbol">KRMD</ix:nonNumeric></span></b></td>
    <td style="text-align: center"><b><span id="xdx_902_edei--SecurityExchangeName_c20210101__20210630_zlLgsq4eb1q3"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market</ix:nonNumeric></span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
&#160;<b>[X]</b> <span id="xdx_907_edei--EntityCurrentReportingStatus_c20210101__20210630_zsqz7Lq7ks15"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#160;[_] No</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
&#160;<b>[X]</b> <span id="xdx_907_edei--EntityInteractiveDataCurrent_c20210101__20210630_zlPi1Y3wm5fg"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#160;[_] No</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in">&#160;</td>
    <td style="width: 3.5in">Large accelerated filer [_]</td>
    <td style="width: 3in">Accelerated filer [_]</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span id="xdx_900_edei--EntityFilerCategory_c20210101__20210630_zFs8EHMBXEn4"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> &#160;&#160;<b>[X]</b></td>
    <td>Smaller reporting company <b><span id="xdx_90D_edei--EntitySmallBusiness_c20210101__20210630_zWfcudQu3qm1"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">[X]</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Emerging growth company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20210101__20210630_zRQWHznELIc2"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">[_]</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. [_]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act). &#160;[_] Yes &#160;<b>[X]</b> <span id="xdx_900_edei--EntityShellCompany_c20210101__20210630_zdIRhPf1O5R2"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of August 11, 2021, <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_c20210811_zK8hYl0cTRR9"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-08-11" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,511,162</ix:nonFraction></span> shares of common stock, $<span id="xdx_906_edei--EntityListingParValuePerShare_c20210810__20210811_zEEkIXNX6XP2"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2021-08-102021-08-11" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> par value
per share, were outstanding, which excludes <span id="xdx_90F_eus-gaap--TreasuryStockCommonShares_iI_c20210811_zAuuG0c8i7x8"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2021-08-11" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,420,502</ix:nonFraction></span> shares of treasury stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>REPRO MED SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM 10-Q</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 6.25in">&#160;</td>
    <td style="width: 0.5in; text-align: center"><span style="text-decoration: underline">PAGE</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">PART I. FINANCIAL INFORMATION</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 1.</td>
    <td>Financial Statements (Unaudited)</td>
    <td style="text-align: center">3</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020</td>
    <td style="text-align: center">3</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>Statements of Operations (Unaudited) for the three and six months ended June 30, 2021 and 2020</td>
    <td style="text-align: center">4</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>Statements of Cash Flows (Unaudited) for the six months ended June 30, 2021 and 2020</td>
    <td style="text-align: center">5</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>Statements of Stockholders&#8217; Equity (Unaudited) for the three and six months ended June 30, 2021 and 2020</td>
    <td style="text-align: center">6</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>Notes to Financial Statements</td>
    <td style="text-align: center">7</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 2.</td>
    <td>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</td>
    <td style="text-align: center">16</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 3.</td>
    <td>Quantitative and Qualitative Disclosures About Market Risk</td>
    <td style="text-align: center">21</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 4.</td>
    <td>Controls and Procedures</td>
    <td style="text-align: center">21</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">PART II. OTHER INFORMATION</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 1.</td>
    <td>Legal Proceedings</td>
    <td style="text-align: center">21</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 1A.</td>
    <td>Risk Factors</td>
    <td style="text-align: center">21</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 2.</td>
    <td>Unregistered Sales of Equity Securities and Use of Proceeds</td>
    <td style="text-align: center">21</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>ITEM 6.</td>
    <td>Exhibits</td>
    <td style="text-align: center">22</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>Signatures</td>
    <td style="text-align: center">23</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>PART I &#8212; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 1. &#160;Financial Statements (Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>REPRO MED SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_304_111_pp0p0_zgS1XZNZjNNf" summary="xdx: Statement - BALANCE SHEETS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49A_20210630_zn1loe4pM1Rj" style="text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zV8AY4KVNIr" style="text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 5.1in">&#160;</td>
    <td style="width: 6.9pt">&#160;</td>
    <td style="width: 7.35pt">&#160;</td>
    <td style="width: 65.05pt; text-align: right">&#160;</td>
    <td style="width: 14.65pt">&#160;</td>
    <td style="width: 7.35pt">&#160;</td>
    <td style="width: 64.55pt; text-align: right">&#160;</td>
    <td style="width: 6.95pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsAbstract_iB_z7wgBaVb4bc1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>ASSETS</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_zhkASrjZdNM8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzuul_z8zdElZrnjhl" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,538,478</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,315,286</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzuul_zfZV3ebiVOHa" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accounts receivable less allowance for doubtful accounts of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20210630_zvRac5G58e2i" title="Accounts receivable, allowance for doubtful accounts"><span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20201231_z3vW0FzS0884"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,469</ix:nonFraction></ix:nonFraction></span></span> for June 30, 2021, and December 31, 2020</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,577,400</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,572,954</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InventoryNet_i02I_maACzuul_zlHVYb44Pzri" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,562,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,829,772</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_i02I_maACzuul_zasaHYE1fP2i" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Prepaid expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">461,553</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">807,780</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_mtACzuul_maAzsg5_znkkFNZijnTl" style="vertical-align: bottom">
    <td>TOTAL CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,140,181</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,525,792</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzsg5_ziXjz3BFyhd1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Property and equipment, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,110,550</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,167,623</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maAzsg5_zYFp3tDA4cNg" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Intangible assets, net of accumulated amortization of $<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20210630_zaH4fy8ARw46" title="Patents, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">232,820</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20201231_z86RSs8UaIuh" title="Patents, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">199,899</ix:nonFraction></span> at June 30, 2021 and December 31, 2020, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">834,644</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">843,587</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzsg5_za3J2S3Nm6E6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">166,483</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">236,846</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_maAzsg5_zSo693GkNpG1" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Deferred income tax assets, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,327,230</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,274</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAssetsNoncurrent_i01I_maAzsg5_zBqWRZJqZ3Xj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Other assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,812</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,812</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_i01TI_mtAzsg5_zLNxh3DjDIme" style="vertical-align: bottom">
    <td>TOTAL ASSETS</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,598,900</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,918,934</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zvZYAiWXVCkl" style="vertical-align: bottom">
    <td><b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrentAbstract_i01B_zniwKnJh03Sb" style="vertical-align: bottom">
    <td>CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableCurrent_i02I_maLCzYht_zyRdnbbCADCh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accounts payable</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,005,653</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">624,920</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzYht_zYhK66XbaNP7" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accrued expenses</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,771,666</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,610,413</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCzYht_zDECkueOZA2b" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">390,326</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,130</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCzYht_zvTFrf0vDQDh" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,030</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,646</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzYht_zR5qiFeoBcjf" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,450</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">141,293</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzYht_maLzus8_zUcDm5Bo37lk" style="vertical-align: bottom">
    <td>TOTAL CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,311,125</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,666,402</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzus8_zcas0khRAzHa" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,033</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">95,553</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_mtLzus8_maLASEz0DN_zakKvYsvzHU" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,335,158</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,761,955</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_zcpHhz4D2MR2" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Commitments and contingencies (Refer to Note 3)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">&#8212;</span>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_i01B_zOzMrrsYS937" style="vertical-align: bottom">
    <td>STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i01I_maSEzOcB_zACLq06cGKFc" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20210630_zi4NdDw1AQp4" title="Common stock, par value (in dollars per share)"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20201231_z2k94qERScX7" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20210630_z7qFkSChkgF8" title="Common stock, authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20201231_zVDZkIeEGvHh" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pii_c20210630_zVhpt30a0fD1" title="Common stock, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,910,676</ix:nonFraction></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pii_c20201231_zVZ491Jbr1qd"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,680,119</ix:nonFraction></span> shares issued <span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pii_c20210630_zkx2g24m5kj8" title="Common stock, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,490,174</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pii_c20201231_zdLlMWvGmurd" title="Common stock, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,259,617</ix:nonFraction></span> shares outstanding at June 30, 2021, and December 31, 2020, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">479,106</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">466,801</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maSEzOcB_zeFaHQfL6DVb" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Additional paid-in capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,376,131</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,880,986</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--TreasuryStockValue_i01NI_di_msSEzOcB_zsmYMnChIKI8" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Treasury stock, <span id="xdx_90A_eus-gaap--TreasuryStockShares_iI_pii_c20210630_z38RvOG5Df47" title="Treasury stock"><span id="xdx_900_eus-gaap--TreasuryStockShares_iI_pii_c20201231_zWtJei0f0Aml" title="Treasury stock"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,420,502</ix:nonFraction></ix:nonFraction></span></span> shares at June 30, 2021 and December 31, 2020, respectively, at cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzOcB_zjrnx0Iond81" style="vertical-align: bottom">
    <td style="padding-left: 0.2in; text-indent: -0.1in">Retained earnings </td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,252,067</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,652,754</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i01TI_mtSEzOcB_maLASEz0DN_zcqHJ0XbRMWa" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>TOTAL STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,263,742</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,156,979</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEz0DN_zn1iWtvjL6rc" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,598,900</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,918,934</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>REPRO MED SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF OPERATIONS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Unaudited)</b></p>

<table cellspacing="0" cellpadding="0" id="xdx_306_113_pp0p0_z34piadAfZt3" summary="xdx: Statement - STATEMENTS OF OPERATIONS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_497_20210401__20210630_zsgMwymcaZhd" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_497_20200401__20200630_zKwSBA7SSimd" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_497_20210101__20210630_zdB92zTggxAl" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_492_20200101__20200630_z1dN17zL8qN7" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 202.5pt">&#160;</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 62.4pt; text-align: right">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 62.95pt; text-align: right">&#160;</td>
    <td style="width: 14.2pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 62.4pt; text-align: right">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 62.7pt; text-align: right">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_maGPztSi_z5QUMRd5NS8b" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">NET SALES</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,528,174</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,708,904</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,959,125</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,038,913</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfGoodsAndServicesSold_msGPztSi_zPOpzyXMJD0k" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Cost of goods sold</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,317,990</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,799,024</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,517,087</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,340,823</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GrossProfit_iT_mtGPztSi_maOILzmrZ_zVuEPSytEgQd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Gross Profit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,210,184</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,909,880</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,442,038</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,698,090</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zwrLqwqLTIPc" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">OPERATING EXPENSES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEznU0_zkMjIBkVz9u" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Selling, general and administrative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,085,945</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,201,831</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,078,774</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,964,811</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LitigationSettlementExpense_i01_maOEznU0_zdRBJkKf5Ef3" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Litigation</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0184">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,346,914</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0186">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,446,072</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEznU0_zf3wPLSPQtA9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Research and development</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">386,878</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">298,196</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">723,719</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">554,221</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DepreciationDepletionAndAmortization_i01_maOEznU0_ztiOzU4gnPCb" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">118,415</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,940</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">233,888</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">182,164</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_mtOEznU0_msOILzmrZ_zG0C4CLkAKK4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total Operating Expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,591,238</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,941,881</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,036,381</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,147,268</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_mtOILzmrZ_maILFCOzzEd_ziZujsfY7smi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Net Operating Loss</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,381,054</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,032,001</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,594,343</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">449,178</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zsVrAKHOinH" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Non-Operating Income/(Expense)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maNIEzpAD_zccbSAPZbkaj" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Gain/(Loss) on currency exchange </td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,239</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,594</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">14,478</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,091</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_403_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i01_maNIEzpAD_zCX5ZxuYzYo" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.3in; text-indent: -0.1in">(Loss)/Gain on disposal of fixed assets, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,522</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">736</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,522</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzpAD_z4Xvs3yXgSs2" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Interest income, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,950</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,002</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,721</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,028</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzpAD_maILFCOzzEd_z6Qz05AoBue3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">TOTAL OTHER INCOME/(EXPENSE)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,189</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,118</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,979</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,585</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_iT_mtILFCOzzEd_maNILzMmQ_zWhvySS4OjT3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">LOSS BEFORE INCOME TAXES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,369,865</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,045,119</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,588,364</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">453,763</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzMmQ_zbhCN4KzXJTf" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Income Tax Benefit/(Expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">245,316</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,919</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,187,677</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">172,847</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzMmQ_zDrpNM4mveh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">NET LOSS</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,124,549</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,076,038</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,400,687</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">626,610</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareAbstract_iB_zYtAjLHVYTY5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">NET LOSS PER SHARE</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_i01_pip0_zLLzRr3obE8k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.05</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_405_eus-gaap--EarningsPerShareDiluted_i01_pip0_zPXG2fOQU9Id" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.05</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB_zj12s6bum514" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pii_z40KhmXbQWdi" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,489,853</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,361,924</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,226,936</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,018,559</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pii_zUEfpcF24qn2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,489,853</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,361,924</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,226,936</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,018,559</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>REPRO MED SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<table cellspacing="0" cellpadding="0" id="xdx_300_112_pp0p0_zLRmuqJpIlNe" summary="xdx: Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20210101__20210630_zG2P7J0RvQ6b" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101__20200630_zX33RBT953O3" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>For the<br />
Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 354.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 71.75pt; text-align: right">&#160;</td>
    <td style="width: 13.45pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 71.4pt; text-align: right">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zUXMu06hquo1" style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_maNCPBUz957_zD2sd4YX46Vg" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Net Loss</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,400,687</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">626,610</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zPUzZ6nz2frl" style="vertical-align: bottom">
    <td style="padding-left: 0.3in; text-indent: -0.1in">Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_maNCPBUz957_zaSbQhZVMSHc" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.4in">Stock-based compensation expense </td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,339,356</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">784,821</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockbasedLitigationSettlementExpense_i02_maNCPBUz957_z2qGV4BgWMli" style="vertical-align: bottom">
    <td style="padding-left: 0.4in">Stock-based litigation settlement expense</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockbasedLitigationSettlementExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,285,102</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUz957_z4PosTNjAivj" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.4in">Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">233,888</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">182,164</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxesAndTaxCredits_i02_maNCPBUz957_z7b4IGnQ3fN9" style="vertical-align: bottom">
    <td style="padding-left: 0.4in">Deferred income taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,201,956</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">145,770</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_402_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_di_msNCPBUz957_zLU9HLn24q8a" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.4in">(Gain)/Loss on disposal of fixed assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">736</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,522</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zwjGl04Drdqi" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msNCPBUz957_zs1ttZJEBodd" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.4in">(Increase)/Decrease in accounts receivable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,446</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">268,619</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msNCPBUz957_zNZ2u6D2UYb5" style="vertical-align: bottom">
    <td style="padding-left: 0.4in">Increase in inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">732,978</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,278,811</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msNCPBUz957_zXPAOerWixS8" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.4in">Decrease/(Increase) in prepaid expenses and other assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">346,227</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">156,316</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maNCPBUz957_zEWPKk1Zd07i" style="vertical-align: bottom">
    <td style="padding-left: 0.4in">Increase in accounts payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">380,733</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">347,350</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i02_maNCPBUz957_z0wfhiEVljxe" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.4in">Increase in accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">103,196</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">333,272</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maNCPBUz957_zLAFhLeWlba3" style="vertical-align: bottom">
    <td style="padding-left: 0.4in">(Decrease)/Increase in accrued expenses</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">838,747</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,389,588</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccruedTaxesPayable_i02_maNCPBUz957_zuPWpWMhQcT5" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.4in">Increase in accrued tax liability</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">318,618</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtNCPBUz957_maCACEPzv5n_zMjyjSPGFihk" style="vertical-align: bottom">
    <td>NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,776,150</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,707,549</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E7E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zuYjQVUZHWRi" style="vertical-align: bottom">
    <td>CASH FLOWS FROM INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquireProductiveAssets_i01N_di_msNCPBUzIMB_zVZvUHJM4TL6" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Purchases of property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">152,223</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">363,750</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromSaleOfProductiveAssets_i01_maNCPBUzIMB_zFItlkzHW3J7" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Proceeds from disposal of property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,065</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUzIMB_zH4ukUHqxkqe" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Purchases of intangible assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,978</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,523</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzIMB_maCACEPzv5n_zr0pSTXvWpp4" style="vertical-align: bottom">
    <td>NET CASH USED IN INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">167,136</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">513,273</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E7E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zLcoldrvAo9f" style="vertical-align: bottom">
    <td>CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--BorrowingsFromIndebtedness_i01_maNCPBUznRM_zuth8rnlvjRi" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Borrowings from indebtedness</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:BorrowingsFromIndebtedness" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,500,000</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUznRM_zP3TWD8xzJbb" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Proceeds from issuance of equity</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,230,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,567,861</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--CommonStockIssuanceAsSettlementForLitigation_i01_maNCPBUznRM_zecUgm4g2DB3" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Common stock issuance as settlement for litigation</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:CommonStockIssuanceAsSettlementForLitigation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">938,094</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUznRM_zY6QiurkgXnh" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Payments on finance lease liability</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,616</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,717</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCACEPzv5n_mtNCPBUznRM_zvSmNToFSYF8" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>NET CASH PROVIDED BY FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,166,478</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,064,144</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCACEPzv5n_z9R5qgvpJrGj" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">776,808</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,258,420</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zzxdn1Mqwixl" style="vertical-align: bottom">
    <td>CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,315,286</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,870,929</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zWqdFY3piQT8" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>CASH AND CASH EQUIVALENTS, END OF PERIOD</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,538,478</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,129,349</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zJNbIX1ZCvF1" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Supplemental Information</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalCashFlowElementsAbstract_i01B_zVUph5C3zCra" style="vertical-align: bottom">
    <td>Cash paid during the periods for:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestPaidNet_i02_zkjsKsmrtcF7" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Interest</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,554</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxesPaidNet_i02_zYtmAfehptJ7" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Income Taxes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">850</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E7E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z67BNkNHpPc5" style="vertical-align: bottom">
    <td>Schedule of Non-Cash Operating, Investing and Financing Activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--IssuanceOfCommonStockCompensation_z1fWOz1ed6ra" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Issuance of common stock as compensation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:IssuanceOfCommonStockCompensation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,446</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:IssuanceOfCommonStockCompensation" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,004</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssued1_z3YsYTge3yna" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Issuance of common stock as settlement for litigation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">938,094</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">938,094</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 5 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>REPRO MED SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Unaudited)</b></p>

<table cellspacing="0" cellpadding="0" id="xdx_306_114_zcYzlGmfNxl6" summary="xdx: Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zJjI1Hyx73sb">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zzukdc1ta0uc" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zFaJ5PTkW1D2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zipBntMuTGcf">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4BA_zbHESi6OmzHj" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Total</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>Common Stock</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Paid-in</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Retained</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Treasury</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Stockholders&#8217;</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Amount</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Capital</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Earnings</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Stock</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Equity</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 158.65pt">&#160;</td>
    <td style="width: 7.1pt">&#160;</td>
    <td style="width: 48.7pt; text-align: right">&#160;</td>
    <td style="width: 7.15pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 51.4pt; text-align: right">&#160;</td>
    <td style="width: 7.15pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 47.5pt; text-align: right">&#160;</td>
    <td style="width: 7.15pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 48.15pt; text-align: right">&#160;</td>
    <td style="width: 7.15pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 45.5pt; text-align: right">&#160;</td>
    <td style="width: 7.15pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 53.55pt; text-align: right">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><b>Three and Six Months Ended<br />
June 30, 2021</b></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20210101__20210331_eus-gaap--StockholdersEquity_iS_zfy7R1p5N5Q9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, DECEMBER 31, 2020</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pii_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKs3X7x6Mmgj" title="Balance beginning (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,680,119</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">466,801</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,880,986</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,652,754</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,156,979</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43D_c20210101__20210331_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zSAlL0bUQoSi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance of stock-based compensation</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pii_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcRKdXrUF2r2" title="Issuance of stock-based compensation (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,124</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,149</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,250</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_432_c20210101__20210331_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zkoQnH2DoDDf" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">677,934</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">677,934</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_437_c20210101__20210331_ecustom--NewIssuanceLitigationSettlementAmountIssuance_zHT1zXLY00m6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Litigation settlement share issuance</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--NewIssuanceLitigationSettlementShareIssuance_pii_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbteqaWGGIP2" title="Litigation settlement share issuance (in shares)" style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementShareIssuance" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,238</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">952</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">937,142</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">938,094</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43A_c20210101__20210331_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zxAJ60IE1sLg" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance upon options exercised</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z44F1nhQGNma" title="Issuance upon options exercised (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,110,580</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,106</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,218,894</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,230,000</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43E_c20210101__20210331_eus-gaap--NetIncomeLoss_zkgFFw5Fg8Ke" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Net income </td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,276,138</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,276,138</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_434_c20210101__20210331_eus-gaap--StockholdersEquity_iE_zQTMa4G5tmea" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, MARCH 31, 2021</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZnclSAfVZc9" title="Balance ending (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,896,061</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,960</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,771,105</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,376,616</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,783,119</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43D_c20210401__20210630_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zERRBxR6Szyd" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance of stock-based compensation</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pii_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqhSnMD51si2" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,615</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,050</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,196</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_434_c20210401__20210630_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zBeJr4r2Rtc6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">441,841</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">441,841</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_438_c20210401__20210630_ecustom--AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zUibSUKzvtqb" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to restricted stock awards</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,135</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,135</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20210401__20210630_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zurftpdpxFtc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance upon options exercised</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20210401__20210630_eus-gaap--NetIncomeLoss_z3bfxuaQtdFe" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Net loss </td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,124,549</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,124,549</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_434_c20210401__20210630_eus-gaap--StockholdersEquity_iE_zDQlyVDEg8d8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, JUNE 30, 2021</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zszWrcl2B551" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,910,676</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">479,106</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,376,131</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,252,067</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,263,742</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zrsqybf3dLxk" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zzXXztS6NGcg" style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zq9voV214eR" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zRSSsq6BO16" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BA_z2VwLhW8N023" style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
<tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Additional</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Total</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Common Stock</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Paid-in</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Retained</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Treasury</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Stockholders&#8217;</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Shares</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Amount</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Capital</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Earnings</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Stock</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Equity</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 2.2in">&#160;</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 48.95pt">&#160;</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 50.85pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 47.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 48.15pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 45.45pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 53.7pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><b>Three and Six Months Ended<br />
June 30, 2020</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43D_c20200101__20200331_eus-gaap--StockholdersEquity_iS_z6QlBkW3hYG6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, DECEMBER 31, 2019</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--SharesOutstanding_iS_pii_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znlLpgnz1zul" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,239,788</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422,398</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,293,069</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,864,817</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">344,204</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,236,080</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43F_c20200101__20200331_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z6RwtYQ2xBNe" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance of stock-based compensation</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pii_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmnLDO4P6cLa" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,189</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,910</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,002</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_436_c20200101__20200331_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zAdss914bxU8" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,966</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,966</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20200101__20200331_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zPWykO9xq2Da" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance upon options exercised</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zriJqJUQqDoa" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,500</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_436_c20200101__20200331_eus-gaap--NetIncomeLoss_z6XOjFyZROo9" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Net income </td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,428</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,428</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43D_c20200101__20200331_eus-gaap--StockholdersEquity_iE_ziHTStd0KwP1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, MARCH 31, 2020</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAub94hkKNp2" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,423,977</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">424,240</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,737,695</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,314,245</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">344,204</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,131,976</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43C_c20200401__20200630_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zzcR1Y9OB665" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance of stock-based compensation</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pii_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZH7oU2kRgP1" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,999</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,922</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,002</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_431_c20200401__20200630_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zp1tR1BrVjQ" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,851</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,851</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_437_c20200401__20200630_ecustom--LitigationSettlementOptions_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zseHrBTVSiyb" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Litigation settlement options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:LitigationSettlementOptions" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">347,008</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:LitigationSettlementOptions" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">347,008</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43A_c20200401__20200630_ecustom--NewIssuanceLitigationSettlementAmountIssuance_z4cCCvXXmNRh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Litigation settlement share issuance</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--NewIssuanceLitigationSettlementShareIssuance_pii_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0GQQwVjEMkb" style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementShareIssuance" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,238</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">952</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">937,142</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">938,094</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_434_c20200401__20200630_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zQPtd2LEpRSf" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance upon options exercised</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxIrXqMOcKoh" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">519,156</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,192</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,189</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,381</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_432_c20200401__20200630_ecustom--NewIssuanceOfCapitalRaiseAmount_iP3us-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_zoYh5Nml58L6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Capital raise</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--NewIssuanceOfCapitalRaiseShares_iP3custom--NewIssuanceOfCapitalRaiseAmount_pid_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOCx1hy0lie9" title="Capital raise (in shares)" style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceOfCapitalRaiseShares" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,593,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceOfCapitalRaiseAmount" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,937</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceOfCapitalRaiseAmount" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,436,043</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceOfCapitalRaiseAmount" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,471,980</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43F_c20200401__20200630_eus-gaap--NetIncomeLoss_zrzi8H0A2xja" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Net loss </td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,076,038</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,076,038</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_439_c20200401__20200630_eus-gaap--StockholdersEquity_iE_zKrKHlKUsNy6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, JUNE 30, 2020</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWVP95kaPU3k" title="Balance ending (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,640,120</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">466,401</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,886,850</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,238,207</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">344,204</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,247,254</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 6 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>REPRO MED SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE UNAUDITED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zszxjvrooL89" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_828_z49aNUozAF67">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_843_eus-gaap--NatureOfOperations_zzLB9l9CxQBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_zLuydB9ob6Th">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">REPRO MED SYSTEMS, INC. d/b/a KORU Medical Systems (the &#8220;Company,&#8221;
&#8220;KORU Medical,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management. The Company operates
as one segment.</p>

</ix:nonNumeric><p id="xdx_850_zIB7fjaFPui8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zidEruAYtJTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_zgP7U5inoSBg">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying financial statements should be read in conjunction with
the Company&#8217;s annual report on Form&#160;10-K for the year ended December 31, 2020 (&#8220;Annual Report&#8221;). &#160;Certain
information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted from the accompanying financial statements. &#160;The
accompanying year-end balance sheet was derived from the audited financial statements included in the Annual Report. &#160;The accompanying
interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement
of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. &#160;All such adjustments
are of a normal, recurring nature. &#160;The Company&#8217;s results of operations and cash flows for the interim periods are not necessarily
indicative of the results of operations and cash flows that it may achieve in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyj3kqJ33Zp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zDJ1Jd74IAN6">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20210630_zZrT2AXjEXk3" title="FDIC cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.</p>

</ix:nonNumeric><p id="xdx_853_zmJ7VtTm6Jzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_za3kvhmAk2Y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zBZoxYJedvue">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

</ix:nonNumeric><p id="xdx_857_zMT0PW4qIhic" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zdcRLTdRdq47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zdDUt6WKworh">PATENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Costs incurred in obtaining patents have been capitalized and are being
amortized over the legal life of the patents.</p>

</ix:nonNumeric><p id="xdx_851_z1RjFihRrXcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zHPeWf7pGDT" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_zyL6O3yBD6ea">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment. &#160;Generally, tax years starting with 2018 are subject to examination by income tax authorities.</p>

</ix:nonNumeric><p id="xdx_855_zVnSX2BqyXq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSysJqjHW94b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_864_zdX1YVAMTI4l">PROPERTY, EQUIPMENT, AND DEPRECIATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment is stated at cost and is depreciated using the straight-line
method over the estimated useful lives of the respective assets.</p>

</ix:nonNumeric><p id="xdx_852_zKAiMgdkzQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zHUIHD9awjtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_z8WVD7yOvUPh">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan under which it grants stock options
to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using
the Black-Scholes option-pricing model. &#160;All options are charged against income at their fair value. &#160;The entire compensation
expense of the award is recognized over the vesting period. Shares of stock granted for director fees are recorded at the fair value of
the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_23B_z5wyi0KYprn8" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 7 -</p></ix:exclude>


<ix:exclude><div id="xdx_23D_zWQcgsUq7mKc"> <hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p> </p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company also maintains an omnibus equity incentive plan. There have
been no awards made pursuant to this plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted&#160;stock awards. Restricted stock awards&#160;are
equity classified and measured at the fair market value of the underlying&#160;stock&#160;at the grant date. The fair value of restricted
stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo
lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.</p>

</ix:nonNumeric><p id="xdx_85F_zkL4bwS17Q29" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z1xCcSeSHM86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_864_zsuvcyuQVtEf">NET INCOME PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjTTKoQ7UOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share include only an increase in the weighted average shares by the common
shares issuable upon exercise of employee and consultant stock options. &#160;See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221;
for further detail.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20210401__20210630_zQGpNyK9f178" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20200401__20200630_z1o6TJSbzC97" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_499_20210101__20210630_zPCyGKWfTrf4" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20200630_zGwHFnUPduSh" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 194.55pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.6pt; text-align: right">&#160;</td>
    <td style="width: 13.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.9pt; text-align: right">&#160;</td>
    <td style="width: 13.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.6pt; text-align: right">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.65pt; text-align: right">&#160;</td>
    <td style="width: 7.95pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zv4fw3nRSP6k" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,124,549</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,076,038</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,400,687</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">626,610</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_z837ovkF5Vqd" style="vertical-align: bottom">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pii_z7NebrhraI44" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Outstanding shares</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,489,853</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,361,924</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,226,936</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,018,559</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pii_d0_zNTiRV7g9ts6" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Option shares includable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2F_zilqoIZ4MFU4" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F27_zJzr4rPhUo91">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F25_zRtY9rwURta6" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F2A_zWUKTiWZY6Pi">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2D_zkJ3yzTZ3V1c" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F23_z5t9VBxHgvUc">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2F_zFIcI8Lh1XKj" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F27_zQuAXOll0kba">(a)</sup></td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pii_zX1oRbwIfiv9" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,489,853</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,361,924</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,226,936</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,018,559</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zzOtlyrYekO4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_i01_pii_z8Y5gvNjHD0k" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.05</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i01_pii_zTw8efKpAh0f" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.05</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F0A_ztv2jJQ0taD2" style="width: 0.25in">(a)</td>
    <td id="xdx_F1C_zx8BqlIVozUe" style="width: 7.25in"><ix:footnote id="Footnote000643" xml:lang="en-US">For the three months ended June 30, 2021, and 2020, option shares of <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDdwHQpAnyRe" title="Anti-dilutive shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012021-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">224,336</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWXY5olwk3nh" title="Anti-dilutive shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012020-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,831</ix:nonFraction></span> respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the six months ended June 30, 2021, and 2020, option shares of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoemU54MKHC4"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">214,132</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw5OpqlCcwXb" class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">182,575</ix:nonFraction></span> respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the three and six months ended June 30, 2021 and 2020, restricted shares of 1,000,000 and zero respectively, were not included as the impact is anti-dilutive.</ix:footnote></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zcoJ6QJOJ6S" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_85E_zomDJNCqFr9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_846_eus-gaap--UseOfEstimates_zGpQguJGkmX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zVsp7TWsxiw4">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. Important estimates include but are not limited to asset lives, valuation allowances, inventory
valuation, and accruals.</p>

</ix:nonNumeric><p id="xdx_85F_zQ8xgN9P1Wve" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zuHcfhzK17b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zZ1sOI6AFsCi">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers. &#160;We adopted this ASU effective January
1, 2018, on a full retrospective basis. &#160;Adoption of this standard did not result in significant changes to our accounting policies,
business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or
related disclosures. &#160;As such, prior period financial statements were not recast.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><p id="xdx_234_z9M29G1Pzh74" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 8 -</p></ix:exclude>


<ix:exclude><div id="xdx_239_zXdvt2pLpkN"> <hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p></p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and
pricing specified to select customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="krmd:ScheduleOfNetSalesByGeography"><p id="xdx_892_ecustom--ScheduleOfNetSalesByGeography_z7cjsz1nWk08" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes net sales by geography for the three and
six months ended June 30, 2021, and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Three Months Ended June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 94.75pt"><b>Sales</b></td>
    <td style="width: 8.65pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 18.8pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 18.8pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 8.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Domestic</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__country--US_zdxC0DKEPdY" title="Net sales" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012021-06-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,645,770</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__country--US_z0szl53PSM2f" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-04-012020-06-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,745,810</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__country--US_z5wwga36DHFk" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-06-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,092,559</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__country--US_zFSqCuy1yHse" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-06-30_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,086,676</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zsFa8rlwk9Nc" title="Net sales" style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012021-06-30_us-gaap_NonUsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">882,404</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvK6NueSLZua" style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-04-012020-06-30_us-gaap_NonUsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">963,094</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zIL5FPFBKHb9" style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-06-30_us-gaap_NonUsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,866,566</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zR3hTpRPSqaa" style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-06-30_us-gaap_NonUsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,952,237</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20210401__20210630_z0NvtAvZ1vvg" title="Net sales" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,528,174</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--Revenues_c20200401__20200630_zZX9c8JkcSfi" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,708,904</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98A_eus-gaap--Revenues_c20210101__20210630_zu1g9YmAAPxh" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,959,125</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630_z9ufXfC3UwQ5" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,038,913</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zQalavPH0Wyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_85F_zCDQyBK52ygl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zElmttjoLqif" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_865_zGTMgFRdrB2">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 6 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

</ix:nonNumeric><p id="xdx_850_zKzoVBYfEnN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwFwhCjIm43k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zjMfPKRiyNhd">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes (Topic
740): &#160;Simplifying the Accounting for Income Taxes</i>. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.</p>

</ix:nonNumeric><p id="xdx_857_z4N2lKm2RrWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="krmd:AccountingPronouncementsNotYetAdopted"><p id="xdx_84F_ecustom--AccountingPronouncementsNotYetAdopted_zwRZjiUm8616" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_z2ABr3nPvare">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2020, the FASB issued ASU No. 2020-04, <i>Reference Rate Reform
(Topic 848)</i>, which provided elective amendments for entities that have contracts, hedging relationships and other transactions that
reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. &#160;The amendments may be applied
to impacted contracts and hedges prospectively through December 31, 2022. &#160;The Company is currently evaluating the impact this guidance
will have on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

</ix:nonNumeric><p id="xdx_85B_z92b69M12Eme" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><p id="xdx_236_zzSiTCCJpAS2" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 9 -</p></ix:exclude>


<ix:exclude><div id="xdx_235_z7Ae9CxiliK9"> <hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p></p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyhjpzhOBLu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zuc97anlv0p7">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the six months ended June
30, 2021.</p>

</ix:nonNumeric><p id="xdx_853_z1BKo310pO57" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ziw9pFqYLzgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zpfOF3NqbFAi">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through June 30, 2021.</p>

</ix:nonNumeric><p id="xdx_85C_zDkFyPzM8sTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPXNVb7D2Dz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zveEKIQEFp0i">RECLASSIFICATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain reclassifications have been made to conform prior period data to
the current presentation. &#160;These reclassifications had no effect on reported net income.</p>

</ix:nonNumeric><p id="xdx_851_zDB18J3oGJGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_819_zAeDn2oimQfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRmG5e9KkgJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_82E_zZuPcu0NaFHb">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zs1rgbK88Cv" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment consists of the following at:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30, 2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>December 31, 2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 208.35pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zJmgTQZf9Zqd" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_custom_FurnitureAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">787,694</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zHYJE7kIrEt4" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_FurnitureAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">753,536</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQ8BUBXeDZ28" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">556,907</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8u4zmdSWoNg" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">542,796</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_z4TYy83udBY5" title="Total property and equipment" style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_custom_ManufacturingEquipmentAndToolingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,922,196</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zr9USlS4alu3" style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_ManufacturingEquipmentAndToolingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,856,909</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630_zh4r3Zz9VNvf" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,266,797</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zfpe2OFnicPj" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,153,241</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20210630_zm8TwX9TYpcj" title="Less: accumulated depreciation and amortization" style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,156,247</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zBjXcDBMxh97" style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,985,618</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20210630_zVPRp1qh0RU5" title="Property and equipment, net" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,110,550</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20201231_zKSGcoxr2816" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,167,623</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_z7c96ycr1Txe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Depreciation expense was $<span id="xdx_900_eus-gaap--Depreciation_c20210401__20210630_z4yAt88WdzK6" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,564</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--Depreciation_c20200401__20200630_zGJBJcX5PcOj"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,245</ix:nonFraction></span> for the three months ended
June 30, 2021 and 2020, respectively, and $<span id="xdx_90D_eus-gaap--Depreciation_c20210101__20210630_zGkyfkOey4ui"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,967</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--Depreciation_c20200101__20200630_zzeciJNFrJXh"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,013</ix:nonFraction></span> for the six months ended June 30, 2021 and 2020, respectively.</p>

</ix:nonNumeric><p id="xdx_819_zzW79FDljSR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zb0KtrLyEQbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_82B_zUClJXyOeNv4">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><p id="xdx_236_zDk0K0Ao22Bi" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 10 -</p></ix:exclude>


<ix:exclude><div id="xdx_239_zyPCAmamFci4"> <hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p></p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 12, 2021, the lead plaintiff filed a notice of voluntary dismissal
without prejudice of the claims in the previously disclosed putative class action lawsuit filed in the United States District Court for
the Southern District of New York against the Company and its Chief Financial Officer and former Chief Executive Officer, alleging they
made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company&#8217;s business,
operations and prospects, in the Company&#8217;s earnings communications and Form 10-Q filed during the period August 4, 2020 and January
25, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OTHER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), pursuant to which Command has agreed to manufacture and supply
the Company&#8217;s subassemblies, needle sets and tubing products pursuant to the Company&#8217;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#8220;Effective
Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement. &#160;If the Company terminates the Manufacturing and Supply Agreement other than for those reasons within the first three
years from the Effective Date, the Company is obligated to pay an early termination fee to Command.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.</p>

</ix:nonNumeric><p id="xdx_81E_zKKRM5Npa6ni" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zLZHQnhRfSM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8212; <span id="xdx_82A_z86Bm7GmEt5">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 29, 2016, the Board of Directors amended the Company&#8217;s 2015
Stock Option Plan (as amended, the &#8220;Plan&#8221;)&#160;authorizing the Company to grant awards to certain executives, key employees,
and consultants under the Plan, which was approved by shareholders at the Annual Meeting of Shareholders held on September 6, 2016. &#160;The
total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, may not exceed <span id="xdx_902_eus-gaap--EmployeeStockOwnershipPlanESOPSharesContributedToESOP_pii_c20190422__20190423__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zV2sjZVKZZz8" title="Number of stock option shares"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP" contextRef="From2019-04-222019-04-23_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> pursuant
to an amendment to the Plan approved by shareholders at their annual meeting on April 23, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On February 15, 2021, under the Plan, the Company issued to James M. Beck,
its Interim Chief Executive Officer, a non-qualified option to purchase up to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zTil1egajmA6" title="Number of stock option shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2021-02-132021-02-15_custom_ChiefExecutiveOfficerJamesMBeckMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares of the Company&#8217;s common stock at an
exercise price of $<span id="xdx_900_ecustom--ExercisePrice_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zvnzsXOGRDQa" title="Exercise price"><ix:nonFraction name="krmd:ExercisePrice" contextRef="From2021-02-132021-02-15_custom_ChiefExecutiveOfficerJamesMBeckMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.37</ix:nonFraction></span> per share, of which <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pii_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zqPIste0Jgk6" title="Number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-02-132021-02-15_custom_ChiefExecutiveOfficerJamesMBeckMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> vested on February 15, 2021 and <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pii_c20210321__20210322__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zUzFCWDIvNIk"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-03-212021-03-22_custom_ChiefExecutiveOfficerJamesMBeckMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> vested on March 22, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 15, 2021, under the Plan, the Company issued to Linda Tharby,
its incoming President and Chief Executive Officer, a non-qualified stock option to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zVkS1LdQibmk" title="Number of stock option shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2021-03-142021-03-15_custom_ChiefExecutiveOfficerLindaTharbyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock at an exercise price of $<span id="xdx_900_ecustom--ExercisePrice_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zkaftxGOdFK5"><ix:nonFraction name="krmd:ExercisePrice" contextRef="From2021-03-142021-03-15_custom_ChiefExecutiveOfficerLindaTharbyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.875</ix:nonFraction></span> per share, subject to vesting as follows: <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zxGh16ONFaa8" title="Description of vesting rights"><ix:nonNumeric contextRef="From2021-03-142021-03-15_custom_ChiefExecutiveOfficerLindaTharbyMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">25% on March 15, 2022 and 25% each twelve months
thereafter.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#8217;s President and Chief Executive Officer, the Company issued three restricted stock
awards for an aggregate <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zsg6xIpq7C4d"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of common stock for an aggregate stock price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_pid_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zf50zmUo7Gvf" title="Number of stock option shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310,000</ix:nonFraction></span> and each vesting subject to employment
on the respective vesting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2021, the Company had options to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--EmployeesAndConsultantsUnderThePlanMember_zQpJrfmAab72" title="Number of stock option shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2021-01-012021-06-30_custom_EmployeesAndConsultantsUnderThePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,072,494</ix:nonFraction></span> shares
of Common Stock outstanding to certain executives, key employees and consultants under the Plan, of which <span id="xdx_90D_eus-gaap--EmployeeStockOwnershipPlanESOPSharesContributedToESOP_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--EmployeesAndConsultantsUnderThePlanMember_zkL70w1j48Y2" title="Number of stock option shares"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP" contextRef="From2021-01-012021-06-30_custom_EmployeesAndConsultantsUnderThePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,150,000</ix:nonFraction></span> were issued during
the six months ended June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to January 1, 2021, each non-employee director of the Company was
eligible to receive $<span id="xdx_90C_ecustom--NonemployeeServicesTransactionCost_c20181230__20190102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember_zlutGgmrYSGh" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2018-12-302019-01-02_custom_NonEmployeeDirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> annually (effective January 1, 2019), plus $<span id="xdx_907_ecustom--AmountForChairingBoardCommittee_c20181230__20190102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember_zj6yAk6K7KAd" title="Amount for chairing board committee"><ix:nonFraction name="krmd:AmountForChairingBoardCommittee" contextRef="From2018-12-302019-01-02_custom_NonEmployeeDirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> for chairing a Board committee (effective February 20,
2019), all to be paid quarterly half in cash and half in common stock. &#160;The Chairman of the Board was eligible to receive an additional
$<span id="xdx_909_ecustom--NonemployeeServicesTransactionCost_c20190929__20191001__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zZfBmWpP0ob7" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2019-09-292019-10-01_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> annually (effective October 1, 2019), all to be paid in common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Effective January 1, 2021, each non-employee director of the Company (other
than the Chairman of the Board) and Board advisor are eligible to receive of $<span id="xdx_904_ecustom--NonemployeeServicesTransactionCost_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zdFvSJ0LlIve"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span> annually, <span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zYSvTkrTE0Nd" title="Description of non employee services transaction"><ix:nonNumeric contextRef="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction">to be paid quarterly $12,500 in cash and
$6,250 in common stock.</ix:nonNumeric></span> &#160;The Chairman of the Board is eligible to receive $<span id="xdx_90B_ecustom--NonemployeeServicesTransactionCost_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zovzgh9BnFjb" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> annually, <span id="xdx_905_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zsuAlWmnmsk7" title="Description of non employee services transaction"><ix:nonNumeric contextRef="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction">to be paid quarterly $12,500 in cash
and $12,500 in common stock.</ix:nonNumeric></span> &#160; Effective May 18, 2021, each non-employee director of the Company (other than the Chairman of the
Board) and Board advisor are eligible to receive of $<span id="xdx_906_ecustom--NonemployeeServicesTransactionCost_c20200517__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zI0NheSvSwI"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2020-05-172021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,000</ix:nonFraction></span> annually, <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20200517__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zIS71i90yZF7"><ix:nonNumeric contextRef="From2020-05-172021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction">to be paid quarterly $12,500 in cash and $15,000 in common stock.</ix:nonNumeric></span>
&#160;The Chairman of the Board is eligible to receive $<span id="xdx_90D_ecustom--NonemployeeServicesTransactionCost_c20200517__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z8nwhWts5fF1"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2020-05-172021-05-18_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></span> annually, <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20200517__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zHWsKEPZC938"><ix:nonNumeric contextRef="From2020-05-172021-05-18_srt_BoardOfDirectorsChairmanMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction">to be paid quarterly $12,500 in cash and $22,500 in common stock</ix:nonNumeric></span>.
All payments were and are pro-rated for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><p id="xdx_238_zs3Z857tJ9ed" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 11 -</p></ix:exclude>


<ix:exclude><div id="xdx_237_zE363PDbVIjk"> <hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p></p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 20, 2020, the Company entered into a Settlement Agreement with EMED
Technologies Corporation (&#8220;EMED&#8221;) to settle all claims in connection with all pending litigation matters between them. &#160;Pursuant
to the Settlement Agreement, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200519__20200520__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--EMEDTechnologiesCorporationMember_zjEBEgRlulS4" title="Description of vesting rights"><ix:nonNumeric contextRef="From2020-05-192020-05-20_custom_SettlementAgreementMember_custom_EMEDTechnologiesCorporationMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">the Company issued to EMED (i) 95,238 restricted stock units, which vested on May 21, 2020, and 95,238 restricted
stock units, which vested on January 1, 2021, and (ii) an option to purchase up to 400,000 shares of the Company&#8217;s common stock
at an exercise price of $11.21 per share prior to February 1, 2021, which was not exercised.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On February 16, 2021, Donald Pettigrew, the Company&#8217;s former Chief
Executive Officer, exercised options held by him for an aggregate <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_c20210213__20210216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerDonaldPettigrewMember_zX3wm6WjsQe9" title="Number of options exercised"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2021-02-132021-02-16_custom_ChiefExecutiveOfficerDonaldPettigrewMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of common stock for an aggregate exercise price of
$<span id="xdx_904_eus-gaap--ProceedsFromStockOptionsExercised_c20210213__20210216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerDonaldPettigrewMember_zCY0FxLqmOhg" title="Cash received from option exercises"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-02-132021-02-16_custom_ChiefExecutiveOfficerDonaldPettigrewMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,230,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 18, 2021, our shareholders approved the Company&#8217;s 2021 Omnibus
Equity Incentive Plan (the &#8220;2021 Equity Plan&#8221;). There have been no awards made pursuant to the 2021 Equity Plan to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2015 STOCK OPTION PLAN, as amended</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the six months ended June 30, 2021 and June 30, 2020 was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSpOnHAF6bBh" title="Weighted average grant date fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.06</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUC7u8WoiMNf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.68</ix:nonFraction></span>, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
six months ended June 30, 2021 and June 30, 2020. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5E5tBDLPBT1" title="Tax benefits associated with stock-based compensation"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,817</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLzs4vneJ0K5"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,196</ix:nonFraction></span> for the six months ended June 30, 2021 and 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmyu4wT6pbBa" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 136.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 71.6pt">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 72.35pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zA6qLtvmNho5" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zTvnuPh4j5h4" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zHIqnKC8RgH9" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74.01</ix:nonFraction></span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zfJu2yK49WC8" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74.28</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVRIJdFXiTY6" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.1</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z6vwKr4PyTGl" title="Weighted-average volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlQ9IAIXVwel" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvK0LmrvMbtg" title="Expected dividends" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrRf4DJKBAf4" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zy19u1GF5Zfl" title="Expected term (in years)" style="text-align: right"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJswur0xwyhi" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zksXkYHvgxDg" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.20</ix:nonFraction></span>%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z8nYOJtIoEC2" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.62</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlx3KzqaaXEk" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.63</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zigQswkQPBLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGxmR11YK5ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Plan with respect to time
based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 226pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zo2vXiwdPqsa" title="Outstanding at beginning" style="width: 51.8pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,922,494</ix:nonFraction></td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQApE92Scpol" title="Outstanding at beginning" style="width: 52.1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQfPU7YTCzof" style="width: 51.8pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,647,000</ix:nonFraction></td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJkYbqhcN6Qc" style="width: 52.4pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zP63Rjb8h23b" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zphz7pXf69i2" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.94</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYqLhyOdZxaj" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1UGvet7fAha" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.76</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1EsMWu5DKBi" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1jOtwBme6r6" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.23</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKXkGafFSas5" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">722,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVBcqz6Bvpw8" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.58</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHYItV16tNib" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdgUGvPyBta4" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.94</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zmZ3LHDClJb" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzqhQhrr3H9i" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at June 30</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z18kgkoI4bX2" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,072,494</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zp0CJdBzpM8e" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.41</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjYuBCmwaEna" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,785,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyqxKOs4PKMa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.64</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at June 30</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_ziQra1t9VNk5" title="Options exercisable at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">871,244</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKguv4s32AMj" title="Options exercisable at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQTj58kGXVc" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">812,760</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlo7npOo25Kj" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zpnaRxRZU1h1" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.06</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zd3BUCz4ZTN1" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.68</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zakrN2qX9gC1" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,528,522</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvigHFTvguyb" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,991</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zo5FV1GXVCta" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense was $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zeUFfOVmOM0c" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,528,522</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_znNVxqFE0u4i"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,991</ix:nonFraction></span> for
the six months ended June 30, 2021, and 2020, respectively. Cash received from option exercises for the six months ended June 30, 2021,
and 2020 was $<span id="xdx_907_eus-gaap--ProceedsFromStockOptionsExercised_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zNBcsHiSJJng" title="Cash received from option exercises"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,230,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ProceedsFromStockOptionsExercised_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxasnBV60dl5"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,880</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average grant-date fair value of options granted during the
six months ended June 30, 2021, and 2020 was $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_dm_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUTiWLkSNQ3d" title="Weighted-average grant-date fair value options granted"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">3.8</ix:nonFraction></span> million and $<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_dm_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zakQjRChLDWh"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">0.4</ix:nonFraction></span> million, respectively. &#160;There were <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_dm_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlgB5WqFlHVe" title="Number of options exercised"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitRef="Shares">1.0</ix:nonFraction> million</span> options exercised
during the six months ended June 30, 2021, and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zx83yZBoebma"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">722,000</ix:nonFraction></span> during the six months ended June 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_232_zACvNr5Had3g" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 12 -</p></ix:exclude>


<ix:exclude><div id="xdx_239_zIV2YA0jPz16"> <hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p> </p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z2rniEiNvszl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
at June 30, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 0.5pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Number<br />
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Number<br />
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 63.35pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="width: 55.8pt">&#160;</td>
    <td style="width: 15.1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$0.50-$9.76</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zCwt6XNE6DMe" title="Number Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,072,494</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmTzMyWYowhb" title="Weighted Average Remaining Contractual Term"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.7</ix:nonNumeric></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zYYDYXQlocm9" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.41</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmZI3iZxahba" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">871,244</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmhDWEtPXzjl" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zL3tDKeuG7oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2021, there was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_dm_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJOc14ILmpQ6"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">5.4</ix:nonFraction></span> million of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the Plan. &#160;That cost is expected to be recognized
over a weighted-average period of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtM_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZNdUYsFUQgb" title="Weighted-average period (in years)"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">46</ix:nonNumeric></span> months. &#160;The total fair value of shares vested as of June 30, 2021, and June 30, 2020, was $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z4FAoOM072bi" title="Total fair value of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,378,220</ix:nonFraction></span>
and $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoFINabZD55a"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,110,068</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Performance Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There were no stock options granted during the six months ended June 30,
2021, and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zqNVn5RWIKKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Plan with respect to performance-based
stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 272.95pt">Outstanding at January 1</td>
    <td style="width: 10.5pt">&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zbuKzGTmHC9" title="Outstanding at beginning" style="width: 46.6pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMOlabXcllm2" title="Outstanding at beginning" style="width: 43.6pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></td>
    <td style="width: 14.3pt">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6QbTuusZIMe" style="width: 46.65pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsmdBEHNcf64" style="width: 45.15pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></td>
    <td style="width: 10.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zUTMUOXN6NLh" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztZty21pGmc4" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7QfgIKCHST2" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zHh4YCMASza6" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzaxM9dSfHo" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNahtaB1VSmc" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7h4oPnjqgLb" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyMJU0ac8wlj" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKSA5S4n7u6a" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMffMehLbIWj" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_za8vA2gSyQY3" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeceIHP9Dnhi" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at June 30</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2Hfpq2hfGV9" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zZMlo3MrKwr6" title="Outstanding at ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zBDwzzKqzcSf" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zPE6sbTlZmnl" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at June 30</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zF6NIYePdcXb" title="Options exercisable at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQqf0CJaYwwg" title="Options exercisable at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmcimHmi9TV6" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="background-color: #E6E6E6">Weighted average fair value of options granted during the period</td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E6E6E6; text-align: right">&#8212;</td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E6E6E6">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNgbyNxvXz98" title="Weighted average fair value of options granted during the period" style="background-color: #E6E6E6; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0914">&#8212;</span></td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E0E0E0; text-align: right">&#8212;</td>
    <td style="background-color: #E0E0E0">&#160;</td>
    <td style="background-color: #E0E0E0">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zULar0RDbqVl" style="background-color: #E0E0E0; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">&#8212;</span></td>
    <td style="background-color: #E6E6E6">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zr1hSJTIGdl2" title="Stock-based compensation expense" style="text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">408,747</ix:nonFraction></td>
    <td>)</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z4Pa2bpS9TXk" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,826</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_z2PZ4hSWMR84" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total performance stock-based compensation expense totaled ($<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zvTVgpnknN79" title="Allocated stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">408,747</ix:nonFraction></span>) and
$<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zG0rI9y4oUva"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,826</ix:nonFraction></span> for the six months ended June 30, 2021, and 2020, respectively. All performance-based stock options were forfeited as of June
30, 2021, and there was <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zAHSYShJYz16" title="Total unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> unrecognized compensation cost remaining.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Awards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zC3grbogC7bf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the activities for our unvested restricted
stock awards for the six months ended June 30, 2021, and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br />
Average<br />
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 272.95pt">Unvested at January 1</td>
    <td style="width: 10.5pt">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwtfJaMxqiR6" title="Outstanding at beginning" style="width: 46.6pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zqUzQfmBNsod" title="Outstanding at beginning" style="width: 43.6pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="width: 14.3pt">&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zpiFG5GWMlag" style="width: 46.65pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8BgLBjeFPn9" style="width: 45.15pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="width: 10.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkgHYELz1ITl" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zOhSOSLY25x8" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zT6tzxTQ67tc" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxob1AAVAqR1" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zHLSy0xR69Ph" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zPMRwi7W6cJh" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zaHKowckP4M2" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zZjsCcCGJKJ2" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfBWwYu5fpkj" title="Forfeited/canceled" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkjGU85rRiSl" title="Forfeited/canceled" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfAERmVq9E89" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwDa3ocCpnT6" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at June 30</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zq28dRJMU5u4" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z6UN4qMwz8Bc" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zbJ4Qb6uFM2" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z1Kg27uxR9h8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zZGMqMIqxmX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><p id="xdx_233_zeD2BVCojj0l" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 13 -</p></ix:exclude>


<ix:exclude><div id="xdx_234_zOtZ3QqjxH43"> <hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p></p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2021, there was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8kjUKaC0UF1" title="Total unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,458,451</ix:nonFraction></span> of unrecognized compensation cost
related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtM_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zcbjjUrgf0T5"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">21</ix:nonNumeric></span> months.
We have recognized tax benefits associated with restricted stock award compensation of $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zpaeGnSXdoda"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,888</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_dc_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zLyyxaFwCWtd"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">zero</ix:nonFraction></span> for the six months ended June
30, 2021 and 2020, respectively.</p>

</ix:nonNumeric><p id="xdx_819_zVWfuK9ycOLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zWuPEnWVlbVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_82B_znfyO8NFxJka">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 14, 2020, the Company issued a promissory note to KeyBank in the
aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zxXGZ2WONxsf" title="Face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.5</ix:nonFraction> million</span> (the &#8220;Note&#8221;) as an extension of its line of credit, replacing its then current
line of credit agreement. &#160;The $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zfz9TNBQKtsh" title="Face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.5</ix:nonFraction> million</span> Note is in the form of a variable rate non-disclosable revolving line of credit with
an interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zGwHNv8DPn7c" title="Interest rate terms"><ix:nonNumeric contextRef="From2020-04-132020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember" name="us-gaap:DebtInstrumentInterestRateTerms">Prime Rate announced by the Bank minus 0.75%</ix:nonNumeric></span>. &#160;The Note was renewed on June 24, 2021, in the same form with an
interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateTerms_c20200623__20200624__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_znDD1E6hWY78"><ix:nonNumeric contextRef="From2020-06-232020-06-24_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember" name="us-gaap:DebtInstrumentInterestRateTerms">Prime Rate announced by the Bank minus 1.50%</ix:nonNumeric></span>. Interest is due monthly, and all principal and unpaid interest is due on
<span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zXe7EzbOPXC8" title="Debt instrument, principal and unpaid interest due"><ix:nonNumeric contextRef="From2020-04-132020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">June 1, 2022</ix:nonNumeric></span>. &#160;The $3.5 million Note may be prepaid at <span id="xdx_908_ecustom--DebtInstrumentPrepaidTerms_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_z682Pd5xJ8cb" title="Debt instrument, prepaid terms"><ix:nonNumeric contextRef="From2020-04-132020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember" name="krmd:DebtInstrumentPrepaidTerms">any time prior to maturity with no prepayment penalties.</ix:nonNumeric></span> &#160;The $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20210630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--LineOfCreditFacilityAxis__custom--KeyBankNationalAssociationMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z3kvbYLhMMVa" title="Face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-06-30_custom_PromissoryNoteMember_custom_KeyBankNationalAssociationMember_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.5</ix:nonFraction> million</span>
Note contains events of default and other provisions customary for a loan of this type.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Note, the Company entered into a Commercial Security
Agreement with the Bank dated April 14, 2020 (the &#8220;Security Agreement&#8221;), pursuant to which the Company granted a security
interest in substantially all assets of the Company to secure the obligations of the Company under the Note. &#160;The Security Agreement
contains terms and conditions typical for the granting of security interests of this kind.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company had no amount outstanding against the line of credit as of
June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 27, 2020, the Company entered into a Progress Payment Loan and
Security Agreement (&#8220;PPLSA&#8221;) and a Master Security Agreement (the &#8220;MSA&#8221;), each dated as of April 20, 2020, with
Key Equipment Finance, a division of the Bank (&#8220;KEF&#8221;), to provide up to $<span id="xdx_90A_eus-gaap--ProceedsFromLoans_dm_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_zx72ED2NU07j" title="Loans, principal amount"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2020-04-262020-04-27_custom_KeyEquipmentFinanceMember_custom_ProgressPaymentLoanAndSecurityAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.5</ix:nonFraction> million</span> in financing for equipment purchases
from third party vendors.&#160; The PPLSA allows the Company to make draws with KEF to make certain payments to the equipment suppliers
prior to the commencement of periodic payments under a term loan. Each draw under the PPLSA will bear interest at a variable rate equal
to the then-current Prime Rate and will be secured by the financed equipment under the MSA.&#160; At the end of each calendar quarter
or year, the advances made under the PPLSA will be converted to term loans, subject to KEF&#8217;s approval of the equipment and certain
other closing conditions being met.&#160; Once the draws under the PPLSA are converted into a term loan, each promissory note will bear
interest at a <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateTerms_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_z1qTYyDElNB7" title="Interest rate terms"><ix:nonNumeric contextRef="From2020-04-262020-04-27_custom_KeyEquipmentFinanceMember_custom_ProgressPaymentLoanAndSecurityAgreementMember" name="us-gaap:DebtInstrumentInterestRateTerms">fixed rate of 4.07% per annum</ix:nonNumeric></span>, subject to adjustment based on KEF&#8217;s cost of funds, with principal and interest payable
in <span id="xdx_904_ecustom--PrincipalAndInterestPayableTerms_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_zI7VaEQoTY91" title="Principal and interest payable terms"><ix:nonNumeric contextRef="From2020-04-262020-04-27_custom_KeyEquipmentFinanceMember_custom_ProgressPaymentLoanAndSecurityAgreementMember" name="krmd:PrincipalAndInterestPayableTerms">84 equal consecutive monthly installments.</ix:nonNumeric></span>&#160; Each fixed rate installment promissory note may be prepaid, subject to a penalty if
prepaid before the fifth anniversary of its issuance. &#160;As of June 30, 2021, the Company had no amount outstanding against the PPLSA.</p>

</ix:nonNumeric><p id="xdx_81F_zTGCqZM4j372" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_80E_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zrDYIyOQ8E5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_827_zff4px4vL5Ak">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our leases have remaining lease terms of one year, some of which include options to extend the leases
monthly and annually and some with options to terminate the leases within <span id="xdx_900_ecustom--LessorOperatingLeaseOptionToTerminate1_dtY_c20210101__20210630_zrnqCAMOgl19" title="Operating lease, options to terminate"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear" name="krmd:LessorOperatingLeaseOptionToTerminate1">1</ix:nonNumeric></span> year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zwGa4UfmjYgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_492_20210401__20210630_zZaWvnSpX8yf" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20200401__20200630_zLHKQfG7ngf6" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_497_20210101__20210630_z1dFLYflUgC4" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_493_20200101__20200630_zueWJemDhqng" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 194.9pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.7pt">&#160;</td>
    <td style="width: 13.55pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 65pt">&#160;</td>
    <td style="width: 13.55pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 64.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 65.45pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_maLCzFzn_zPKw9zV4yZnh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,369</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,921</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,290</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,843</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShortTermLeaseCost_maLCzFzn_zdlf8ws9Idwe" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,548</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,231</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,437</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,688</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LeaseCost_iT_mtLCzFzn_zmwTf74rHzT5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,917</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,152</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,727</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,531</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--FinanceLeaseCost1Abstract_iB_ziRIVCloueh9" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_zmIFK3XXlJuh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">794</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,855</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,589</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,711</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseInterestExpense_i01_zGtiDov6Svxh" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zxM3Mq5HgEz8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">813</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,920</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,636</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,863</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zLp4ym2YvjY" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><p id="xdx_230_ziz2IPZ6logc" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 14 -</p></ix:exclude>


<ix:exclude><div id="xdx_236_zQ8931zxCobd"> <hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p></p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><p id="xdx_89B_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHL5nnqh0Om2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20210101__20210630_ziH3O5baTcyj" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20200101__20200630_zp2e2G5j2rL7" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zsR7d49S9s85" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 190.85pt; padding-left: 8.25pt; text-indent: -8.25pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.1pt">&#160;</td>
    <td style="width: 12.75pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 64.45pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeasePayments_i01_z7FiJ4aeNLwc" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,363</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,633</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeasePrincipalPayments_i01_z9AN3VAMTJFk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,616</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,717</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zJcO7zFlV5Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><p id="xdx_89F_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zQiNaXNJlm76" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49A_20210630_zXM0qlgUIPEb" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,<br />
2021</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20201231_z2gCExGJxlWa" style="border-bottom: black 0.5pt solid; text-align: center"><b>December 31,<br />
2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 191.5pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.1pt">&#160;</td>
    <td style="width: 12.75pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.85pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_z8Xv4V1ELMSd" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Operating Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z0BtnOKeqzih" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,483</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,846</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maOLLzUcW_zlW0iahbKple" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,450</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,293</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maOLLzUcW_zHfSi4es3vs7" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,033</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,553</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLzUcW_z4XYNXlvjBzc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,483</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,846</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zTsqDG9fm3c3" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentOther_i01I_maPPAEOzWRu_zN3CAHfvhIBb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,725</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,725</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_msPPAEOzWRu_zvFKBnOKYQSl" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,729</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,139</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01TI_mtPPAEOzWRu_z4FTBdWN2Cvj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">996</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,586</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maFLLzWBu_zdkTQzPiG4ve" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,030</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,646</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_maFLLzWBu_zFy6rVbdwz82" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iTI_mtFLLzWBu_zYWZ33KOnXh7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,030</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,646</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 191.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 7.25pt">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom; width: 70pt; text-align: center"><b>June 30,<br />
2021</b></td>
    <td style="vertical-align: bottom; width: 12.8pt">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 70.75pt; text-align: center"><b>December 31,<br />
2020</b></td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 7.25pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20210630_zusuzvdfX3Ea" title="Operating leases"><ix:nonNumeric contextRef="AsOf2021-06-30" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm">0.9</ix:nonNumeric></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20201231_zArj6Ze92ou9" title="Operating leases"><ix:nonNumeric contextRef="AsOf2020-12-31" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm">1.4</ix:nonNumeric></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20210630_zwamrVGEYzz4" title="Finance leases"><ix:nonNumeric contextRef="AsOf2021-06-30" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">0.4</ix:nonNumeric></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20201231_zmqe0wmYDxa5" title="Finance leases"><ix:nonNumeric contextRef="AsOf2020-12-31" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">0.7</ix:nonNumeric></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20210630_zItnF8QQVqq1" title="Operating leases"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.75</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20201231_zyiJBszJBDxh"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.75</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20210630_zwoj4sguvkyi" title="Finance leases"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.75</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20201231_zLRHQoTe2769"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.75</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zOhQlNTD2Sij" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3pqKhlt91G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom"><b>Year Ending December 31, </b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 261.6pt">2021 (excluding the six months ended June 30, 2021)</td>
    <td style="vertical-align: top; width: 0.1in">&#160;</td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_z5Jyuh1OOA9" title="2021 (excluding the six months ended June 30, 2021)" style="vertical-align: bottom; width: 78.95pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,185</ix:nonFraction></td>
    <td style="vertical-align: bottom; width: 14.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 7.5pt">&#160;</td>
    <td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_zggtra8KoDAd" title="2021 (excluding the six months ended June 30, 2021)" style="vertical-align: bottom; width: 78.95pt; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,042</ix:nonFraction></td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>2022</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20210630_zi6VZGlUJ7Md" title="2022" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,257</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_d0_c20210630_zEzzAZL36opf" title="2022" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2023</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEOac3n1nbGe" title="2023" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEpT69EtF7rj" title="2023" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2024</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_z77X5Crra5sa" title="2024" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_zxg5aSROj5li" title="2024" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zzFmgow3Njr6" title="2025" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zoFMAd54HSj1" title="2025" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zvok11nADIeg" title="Thereafter" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zCMQnUjkpQek" title="Thereafter" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2021-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20210630_znsBgzsFRobe" title="Total undiscounted operating lease payments" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,442</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20210630_zgCMfRA6jxO1" title="Total undiscounted finance lease payments" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,042</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 16.45pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20210630_zr3ss6kxZFL3" title="Less: imputed interest" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeOperatingLeaseImputedInterest" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,959</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_986_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20210630_zOrjha7HuQL4" title="Less: imputed interest" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeFinancingLeaseImputedInterest" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_c20210630_z0xWEDw4gZAb" title="Total operating lease liabilities" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,483</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_c20210630_zyVgjaS92qKb" title="Total finance lease liabilities" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,030</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zdMkoDHIcjt" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_812_zJIGT52zoKfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 15 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgjpf35xkIic" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_826_zdAOnzWMeMY3">EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 18, 2020, the Company entered into a Purchase Agreement with
Piper Sandler &amp; Co. and Canaccord Genuity LLC, as representatives of the several underwriters named therein (the
&#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sel<span id="xdx_90B_ecustom--NumberOfSharesIssued_pid_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8PCG71Fjdw" title="Number of shares issued">l
<ix:nonFraction name="krmd:NumberOfSharesIssued" contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,125,000</ix:nonFraction></span> shares of its common stock. &#160;Under the terms of the Purchase Agreement, the Company granted to the
Underwriters an option, exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtD_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyXZ7QDBB0pa" title="Option excercise period"><ix:nonNumeric contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember" format="ixt-sec:durday" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">30</ix:nonNumeric></span>
days, to purchase up to an additional <span id="xdx_90A_ecustom--AdditionalNumberOfSharesIssued_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1qwrTjSKofb" title="Option to purchase additional number of shares"><ix:nonFraction name="krmd:AdditionalNumberOfSharesIssued" contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">468,750</ix:nonFraction></span>
shares of the Company&#8217;s common stock, which the Underwriters exercised in full on <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBvoxzpk8fxl" title="Option excercise date"><ix:nonNumeric contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember" format="ixt:datemonthdayyearen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">June
19, 2020</ix:nonNumeric></span>. &#160;The Underwriters purchased the shares pursuant to the Purchase Agreement, including the shares subject to the
option, at a price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2dMfslqanpc" title="Share price (in dollars per share)"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.52</ix:nonFraction></span>
per share. &#160;Proceeds to the Company, net of discounts, commissions, fees and expenses, were $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_dm_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6xjXZgtNOq1" title="Proceeds from issuance"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">26.6</ix:nonFraction> million</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 16, 2020, the Company announced that its Board of Directors&#160;had
authorized a stock repurchase program under which the Company may purchase up to $<span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pp5d_dm_c20201115__20201116_zDQwJnWnrwm" title="Maximum amount of stock repurchase program"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2020-11-152020-11-16" format="ixt:numdotdecimal" decimals="5" scale="6" unitRef="USD">10.0</ix:nonFraction> million</span> of its outstanding common stock through
December 31, 2021. &#160;As of June 30, 2021, the Company had purchased <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210630_zwHO69BD8Q0h" title="Number of shares repurchased"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">683,271</ix:nonFraction></span> shares for an aggregate $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210630_zht3Nx4JcKMi" title="Aggregate amount stock repurchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,499,358</ix:nonFraction></span> pursuant to this program.</p>

</ix:nonNumeric><p id="xdx_816_z6IWePg4Y9j7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zfMIFgnPV3gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_821_zDvOHFamnNef">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 12, 2021, the lead plaintiff filed a notice of voluntary dismissal
without prejudice of the claims in the previously disclosed putative class action lawsuit filed in the United States District Court for
the Southern District of New York against the Company and its Chief Financial Officer and former Chief Executive Officer, alleging they
made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company&#8217;s business,
operations and prospects, in the Company&#8217;s earnings communications and Form 10-Q filed during the period August 4, 2020 and January
25, 2021.</p>

</ix:nonNumeric><p id="xdx_81E_zvSAEtXQPbq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>PART I &#8212; ITEM 2. &#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This Quarterly Report on Form 10-Q contains certain &#8220;forward-looking&#8221;
statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based
on the beliefs of the management, as well as assumptions made and information currently available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our actual results may vary materially from the forward-looking statements
made in this report due to important factors such as uncertainties associated with COVID-19, customer ordering patterns, availability
and costs of raw materials and labor and our ability to recover such costs, our ability to convert inventory to a source of cash, future
operating results, growth of new patient starts, Food and Drug Administration and foreign authority regulations and the outcome of regulatory
audits, introduction of competitive products, acceptance of and demand for new and existing products, ability to penetrate new markets,
success in enforcing and obtaining patents, reimbursement related risks, government regulation of the home health care industry, success
of our research and development effort, expanding the market of FREEDOM60<sup>&#174; </sup>demand in the SCIg market, availability of sufficient
capital if or when needed, dependence on key personnel, and the impact of recent accounting pronouncements. When used in this report,
the words &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;anticipate,&#8221;
&#8220;intend,&#8221; &#8220;expect&#8221; and similar expressions are intended to identify forward-looking statements. &#160;Such statements
reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties
that could cause actual results to differ materially from those contemplated in such forward-looking statements. &#160;Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. &#160;The Company does not undertake
any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Throughout this report, the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refers to Repro Med Systems, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OVERVIEW</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company designs, manufactures and markets proprietary portable and
innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU Medical continues to monitor its operations and government recommendations
as they relate to the COVID-19&#160;pandemic. We cannot predict the effects the pandemic may have on our business, in particular with
respect to demand for our products, our strategy, and our prospects, the effects on our customers, or the impact on our financial results.
&#160;For example, our future net sales growth may continue to be impacted due to fewer new prescriptions for individuals with Primary
Immune Deficiency Disease (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;) as a result
of patients not seeking care during the pandemic. We believe that the pandemic has precipitated limited availability and rising costs
of raw materials and labor, which may impact our financial results if current trends continue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 16 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues derive from three business sources: (i) domestic core, (ii)
international core, and (iii) novel therapies.&#160; Our core revenues consist of sales of our products for the delivery of SCIg to treat
PIDD, CIDP, and other disease states that are FDA cleared for use with the KORU syringe driver. &#160;Novel therapies consist of revenues from clinical
trials, which consist of sales of syringe drivers, tubing and needles, as well as non-recurring engineering services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total net sales were $5.5 million, or 28% lower for the three months
ended June 30, 2021, as compared to the prior year period, where we saw stocking orders of approximately $1.1 million that we
believe were due to the uncertainty of the pandemic, as well as higher novel therapies sales of $1.2 million from non-recurring
clinical trials. Sequential quarter net sales from the three months ended March 31, 2021, grew 2%, driven by domestic core growth of
4%. Both the overall domestic market and our end-user sales to the specialty pharmacy channel grew mid-single digits through the second
quarter of 2021, we believe indicating market recovery in new patient starts for SCIg therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our inventory position increased $0.7 million from December 31, 2020, as
we transition manufacturing to our secondary source.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESULTS OF OPERATIONS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Three months ended June 30, 2021, compared to June 30, 2020</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Net Sales</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our net sales for the three months ended
June 30, 2021, and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Three Months Ended June 30,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 0.5pt solid; text-align: center"><b>% of Net Sales</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 97.1pt"><b>Net Sales</b></td>
    <td style="width: 18.05pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 54.2pt">&#160;</td>
    <td style="width: 17.3pt">&#160;</td>
    <td style="width: 9.8pt">&#160;</td>
    <td style="width: 55pt">&#160;</td>
    <td style="width: 17.3pt">&#160;</td>
    <td style="width: 9.8pt">&#160;</td>
    <td style="width: 54.25pt">&#160;</td>
    <td style="width: 18.1pt">&#160;</td>
    <td style="width: 47.45pt">&#160;</td>
    <td style="width: 18.1pt">&#160;</td>
    <td style="width: 42.95pt">&#160;</td>
    <td style="width: 18.1pt">&#160;</td>
    <td style="width: 43.7pt">&#160;</td>
    <td style="width: 9.05pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in">Domestic Core</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">4,597,797</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">5,557,577</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(959,780</td>
    <td>)</td>
    <td style="text-align: right">(17.3%</td>
    <td>)</td>
    <td style="text-align: right">83.2%</td>
    <td>&#160;</td>
    <td style="text-align: right">72.1%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in">Novel Therapies</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">47,973</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">1,188,233</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(1,140,260</td>
    <td>)</td>
    <td style="text-align: right">(96.0%</td>
    <td>)</td>
    <td style="text-align: right">0.9%</td>
    <td>&#160;</td>
    <td style="text-align: right">15.4%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in">Total Domestic</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,645,770</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6,745,810</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(2,100,040</td>
    <td>)</td>
    <td style="text-align: right">(31.1%</td>
    <td>)</td>
    <td style="text-align: right">84.1%</td>
    <td>&#160;</td>
    <td style="text-align: right">87.5%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in">International Core</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">859,694</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">853,043</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6,651</td>
    <td>&#160;</td>
    <td style="text-align: right">0.8%</td>
    <td>&#160;</td>
    <td style="text-align: right">15.5%</td>
    <td>&#160;</td>
    <td style="text-align: right">11.1%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in">Novel Therapies</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">22,710</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">110,051</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(87,341</td>
    <td>)</td>
    <td style="text-align: right">(79.4%</td>
    <td>)</td>
    <td style="text-align: right">0.4%</td>
    <td>&#160;</td>
    <td style="text-align: right">1.4%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in">Total International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">882,404</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">963,094</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(80,690</td>
    <td>)</td>
    <td style="text-align: right">(8.4%</td>
    <td>)</td>
    <td style="text-align: right">15.9%</td>
    <td>&#160;</td>
    <td style="text-align: right">12.5%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">5,528,174</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">7,708,904</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(2,180,730</td>
    <td>)</td>
    <td style="text-align: right">(28.3%</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total net sales decreased $2.2 million, or 28.3%, for the three months
ended June 30, 2021, as compared with the same period last year, driven primarily by lower novel therapies sales of $1.2 million compared
with last year due to a non-recurring clinical trial last year, and lower domestic core sales to our largest distributor, where we believe
pandemic related stocking occurred last year. International core net sales were $0.9 million, up 1% compared with the same period last
year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Gross Profit</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our gross profit for the three months ended June 30, 2021 and 2020 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Three Months Ended June 30,</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: Black 0.5pt solid; vertical-align: top; text-align: center"><b>Change from Prior Year</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>2021</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>2020</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>$</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>%</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 168.4pt">Gross Profit </td>
    <td style="vertical-align: bottom; width: 10.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 11.25pt">$</td>
    <td style="vertical-align: bottom; width: 60.85pt; text-align: right">3,210,184</td>
    <td style="vertical-align: bottom; width: 20.35pt">&#160;</td>
    <td style="vertical-align: bottom; width: 9.95pt">$</td>
    <td style="vertical-align: bottom; width: 59.5pt; text-align: right">4,909,880</td>
    <td style="vertical-align: bottom; width: 18.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 10.6pt">$</td>
    <td style="vertical-align: bottom; width: 65.75pt; text-align: right">(1,699,696</td>
    <td style="vertical-align: bottom; width: 10.9pt">)</td>
    <td style="vertical-align: top; width: 7.25pt; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; width: 40.85pt; text-align: right">(34.6%</td>
    <td style="vertical-align: bottom; width: 9.1pt">)</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 8.25pt">Stated as a Percentage of Net Sales</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">58.1%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">63.7%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gross profit decreased $1.7 million or 34.6% in the three months ended
June 30, 2021, compared to the same period in 2020. &#160;This decrease in the quarter was mostly driven by the decrease in net sales
of $2.2 million as described above. &#160;Gross margin was negatively impacted by lower volumes, resulting in unfavorable absorption in
the quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 17 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Selling, general and administrative, Litigation and Research and development</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our selling, general and administrative, litigation and research and development
costs for the three months ended June 30, 2021 and 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Three Months Ended June 30,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 0.5pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 0.5pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="width: 182.45pt">Selling, general and administrative</td>
    <td style="vertical-align: bottom; width: 15.75pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">$</td>
    <td style="width: 63.1pt; text-align: right">4,085,945</td>
    <td style="vertical-align: bottom; width: 22.55pt">&#160;</td>
    <td style="vertical-align: bottom; width: 11.25pt">$</td>
    <td style="width: 60.1pt; text-align: right">3,201,831</td>
    <td style="vertical-align: bottom; width: 21.8pt">&#160;</td>
    <td style="vertical-align: bottom; width: 11.25pt">$</td>
    <td style="width: 57.1pt; text-align: right">884,114</td>
    <td style="vertical-align: bottom; width: 22.55pt">&#160;</td>
    <td style="width: 42.05pt; text-align: right">27.6%</td>
    <td style="vertical-align: bottom; width: 21.8pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Litigation</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">2,346,914</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">(2,346,914</td>
    <td style="vertical-align: bottom">)</td>
    <td style="text-align: right">(100.0%</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Research and development</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">386,878</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">298,196</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">88,682</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">29.7%</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">4,472,823</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">5,846,941</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(1,374,118</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: bottom">)</td>
    <td style="text-align: right">(23.5%</td>
    <td style="border-bottom: white 1.5pt double; vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Stated as a Percentage of Net Sales</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">80.9%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">75.9%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Selling, general and administrative expenses increased $0.9 million, or
27.6%, during the three months ended June 30, 2021 compared to the same period last year, mostly due to $0.5 million in market research,
testing and consulting fees all to support commercialization, regulatory and strategic initiatives, $0.2 million in costs associated with
the departure and replacement of the former chief executive officer, as well as higher board of director fees and directors and officers
liability insurance of $0.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Litigation fees were zero for the three months ended June 30, 2021 compared
to the same period last year as a result of the settlement reached with our competitor last year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Research and development expenses increased $0.1 million during the three
months ended June 30, 2021 compared with the same period last year mostly due to higher consulting fees to support product development
for novel therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Depreciation and amortization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Depreciation and amortization expense increased by 24.7 % to $118,415 in
the three months ended June 30, 2021 compared with $94,940 in the three months ended June 30, 2020. &#160;We continue to invest in capital
assets, mostly related to manufacturing and computer equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Net Income</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Three Months Ended June 30,</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; vertical-align: top; text-align: center"><b>Change from Prior Year</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>2021</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>2020</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>$</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>%</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 182.25pt">Net Loss</td>
    <td style="width: 11.25pt">&#160;</td>
    <td style="width: 12pt">$</td>
    <td style="width: 63pt; text-align: right">(1,124,549</td>
    <td style="width: 22.5pt">)&#160;</td>
    <td style="width: 10.5pt">$</td>
    <td style="width: 61.5pt; text-align: right">(1,076,038</td>
    <td style="width: 21pt">)&#160;</td>
    <td style="width: 11.25pt">$</td>
    <td style="width: 57pt; text-align: right">(48,511</td>
    <td style="width: 22.5pt">)</td>
    <td style="width: 42pt; text-align: right">(4.5%</td>
    <td style="width: 21.75pt">)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 8.25pt">Stated as a Percentage of Net Sales</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(20.3%</td>
    <td>)&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(14.0%</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our net loss increased $48,511 in the three months ended June 30, 2021
compared with the same period last year mostly driven by lower gross profit and higher selling, general and administrative expenses, offset
by lower litigation costs all as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Six months ended June 30, 2021 compared to June 30, 2020</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Net Sales</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our net sales for the six months ended June
30, 2021 and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 0.5pt solid; text-align: center"><b>% of Net Sales</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 96.75pt"><b>Net Sales</b></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 17.25pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 54.75pt">&#160;</td>
    <td style="width: 17.25pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 47.25pt">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 42.75pt">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 43.5pt">&#160;</td>
    <td style="width: 9pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in">Domestic Core</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">9,010,214</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">10,430,343</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(1,420,129</td>
    <td>)</td>
    <td style="text-align: right">(13.6%</td>
    <td>)</td>
    <td style="text-align: right">82.2%</td>
    <td>&#160;</td>
    <td style="text-align: right">74.3%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in">Novel Therapies</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">82,345</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">1,656,333</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(1,573,988</td>
    <td>)</td>
    <td style="text-align: right">(95.0%</td>
    <td>)</td>
    <td style="text-align: right">0.8%</td>
    <td>&#160;</td>
    <td style="text-align: right">11.8%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in">Total Domestic</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">9,092,559</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">12,086,676</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(2,994,117</td>
    <td>)</td>
    <td style="text-align: right">(24.8%</td>
    <td>)</td>
    <td style="text-align: right">83.0%</td>
    <td>&#160;</td>
    <td style="text-align: right">86.1%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in">International Core</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,838,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,837,910</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">690</td>
    <td>&#160;</td>
    <td style="text-align: right">0.0%</td>
    <td>&#160;</td>
    <td style="text-align: right">16.8%</td>
    <td>&#160;</td>
    <td style="text-align: right">13.1%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in">Novel Therapies</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">27,966</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">114,327</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(86,361</td>
    <td>)&#160;</td>
    <td style="text-align: right">(75.5%</td>
    <td>)</td>
    <td style="text-align: right">0.2%</td>
    <td>&#160;</td>
    <td style="text-align: right">0.8%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in">Total International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">1,866,566</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">1,952,237</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(85,671</td>
    <td>)</td>
    <td style="text-align: right">(4.4%</td>
    <td>)</td>
    <td style="text-align: right">17.0%</td>
    <td>&#160;</td>
    <td style="text-align: right">13.9%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">10,959,125</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">14,038,913</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(3,079,788</td>
    <td style="border-bottom: white 2.25pt double; text-align: left">)</td>
    <td style="text-align: right">(21.9%</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 18 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total net sales decreased $3.1 million or 21.9% for the six months ended
June 30, 2021, as compared to the prior year period, driven primarily by lower novel therapies sales of $1.7 million compared with last
year due to a non-recurring clinical trial last year and lower domestic core net sales driven by what we believe to be pandemic related
stocking last year at our largest distributor. International core net sales were $1.8 million tracking even with the same period last
year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Gross Profit</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our gross profit for the six months ended June 30, 2021 and 2020 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; vertical-align: top; text-align: center"><b>Change from Prior Year</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>2021</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>2020</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>$</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>%</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 182.25pt">Gross Profit </td>
    <td style="width: 11.25pt">&#160;</td>
    <td style="width: 12pt">$</td>
    <td style="width: 63pt; text-align: right">6,442,038</td>
    <td style="width: 22.5pt">&#160;</td>
    <td style="width: 10.5pt">$</td>
    <td style="width: 61.5pt; text-align: right">8,698,090</td>
    <td style="width: 21pt">&#160;</td>
    <td style="width: 11.25pt">$</td>
    <td style="width: 57pt; text-align: right">(2,256,052</td>
    <td style="width: 22.5pt">)</td>
    <td style="width: 42pt; text-align: right">(25.9%</td>
    <td style="width: 21.75pt">)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Stated as a Percentage of Net Sales</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">58.8%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">62.0%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gross profit decreased $2.3 million or 25.9% in the six months ended June
30, 2021, compared to the same period last year. Gross margin decreased primarily due to under absorption due to lower volume.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Selling, general and administrative, Litigation and Research and development</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our selling, general and administrative expenses, litigation and research
and development costs for the six months ended June 30, 2021 and 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 0.5pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 0.5pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="width: 182.45pt">Selling, general and administrative</td>
    <td style="vertical-align: bottom; width: 15.75pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">$</td>
    <td style="width: 63.1pt; text-align: right">9,078,774</td>
    <td style="vertical-align: bottom; width: 22.55pt">&#160;</td>
    <td style="vertical-align: bottom; width: 11.25pt">$</td>
    <td style="width: 60.1pt; text-align: right">5,964,811</td>
    <td style="vertical-align: bottom; width: 21.8pt">&#160;</td>
    <td style="vertical-align: bottom; width: 11.25pt">$</td>
    <td style="width: 57.1pt; text-align: right">3,113,963</td>
    <td style="vertical-align: bottom; width: 22.55pt">&#160;</td>
    <td style="width: 42.05pt; text-align: right">52.2%</td>
    <td style="vertical-align: bottom; width: 21.8pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Litigation</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">2,446,072</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">(2,446,072</td>
    <td style="vertical-align: bottom">)</td>
    <td style="text-align: right">(100.0%</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Research and development</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">723,719</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">554,221</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">169,498</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">30.6%</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">9,802,493</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">8,965,104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">837,389</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: bottom">&#160;</td>
    <td style="text-align: right">9.3%</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Stated as a Percentage of Net Sales</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">89.4%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">63.9%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Selling, general and administrative expenses increased $3.1 million, or
52.2%, during the six months ended June 30, 2021 compared to the same period last year, mostly due to $1.6 million in costs associated
with the departure and replacement of the former chief executive officer and the recruitment of two new Board members, which includes
non-cash equity expense of $0.4 million. &#160;Further contributing to the increase was the rollout impact of higher salary and related
benefits of $0.9 million from new hires in the second half of last year to support commercialization, business development and medical
affairs for our novel therapies initiatives, as well as infrastructure. Market research, testing and consulting fees to support commercialization
and regulatory filings also contributed $0.6 million, as well as higher director fees and director and officer liability insurance of
$0.4 million. Offsetting these expenses were lower professional fees, the Covid-related heroes bonus paid last year and other miscellaneous
expenses in aggregate $0.4 million. Litigation expense was lower by $2.4 million as a result of the settlement agreement entered into
last year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Research and development expenses increased $0.2 million during the six
months ended June 30, 2021 compared with the same period last year mostly due to increases to support product development for novel therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Depreciation and amortization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Depreciation and amortization expense increased by 28.4% to $233,888 in
the six months ended June 30, 2021 compared with $182,164 in the six months ended June 30, 2020. &#160;We continue to invest in capital
assets, mostly related to manufacturing and computer equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Net (Loss)/Income</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; vertical-align: top; text-align: center"><b>Change from Prior Year</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>2021</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>2020</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>$</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>%</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="width: 182.75pt">Net Loss</td>
    <td style="vertical-align: bottom; width: 11.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 12.05pt">$</td>
    <td style="vertical-align: bottom; width: 63.2pt; text-align: right">(2,400,687</td>
    <td style="vertical-align: bottom; width: 22.55pt">)</td>
    <td style="vertical-align: bottom; width: 10.55pt">$</td>
    <td style="vertical-align: bottom; width: 61.65pt; text-align: right">(626,610</td>
    <td style="vertical-align: bottom; width: 21.05pt">)</td>
    <td style="vertical-align: bottom; width: 11.3pt">$</td>
    <td style="vertical-align: bottom; width: 57.15pt; text-align: right">(1,774,077</td>
    <td style="vertical-align: bottom; width: 22.55pt">)</td>
    <td style="vertical-align: top; width: 42.1pt; text-align: right">(283.1%</td>
    <td style="vertical-align: bottom; width: 21.8pt">)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Stated as a Percentage of Net Sales</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(21.9%</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(4.5%</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 19 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our net loss for the six months ended June 30, 2021 was $2.4 million compared
to net loss of $0.6 million for the six months ended June 30, 2020, driven by lower gross profit and higher selling, general and administrative
expenses, offset by litigation expenses incurred last year, all as described above. Offsetting the loss was a tax benefit of $0.5 million
resulting from book to tax differences related to stock option expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our principal source of liquidity is our cash on hand of $26.5 million
as of June 30, 2021. &#160;Our principal source of operating cash inflows is from sales of our products to customers. Our principal cash
outflows relate to the purchase and production of inventory and related costs, and selling, general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended<br />
June 30, 2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended<br />
June 30, 2020</b></td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: top; width: 235.15pt">Net cash (used in)/provided by operating activities</td>
    <td style="vertical-align: bottom; width: 10.5pt">&#160;</td>
    <td style="vertical-align: bottom; width: 11.25pt">$</td>
    <td style="vertical-align: top; width: 84.15pt; text-align: right">(2,776,150</td>
    <td style="vertical-align: top; width: 21.05pt">)</td>
    <td style="vertical-align: bottom; width: 10.5pt">$</td>
    <td style="vertical-align: top; width: 84.9pt; text-align: right">2,707,549</td>
    <td style="vertical-align: bottom; width: 10.5pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">Net cash used in investing activities</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td style="vertical-align: top; text-align: right">(167,136</td>
    <td style="vertical-align: top">)</td>
    <td style="vertical-align: bottom">$</td>
    <td style="vertical-align: top; text-align: right">(513,273</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: top">Net cash provided by financing activities</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td style="vertical-align: top; padding-left: 35.1pt; text-align: right">2,166,478</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td style="vertical-align: top; padding-left: 35.1pt; text-align: right">30,064,144</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Operating Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in operating activities of $2.8 million for the six months
ended June 30, 2021 was primarily due to the net loss of $2.4 million, working capital changes which included an increase in inventory
of $0.7 million related to the transition of manufacturing to our secondary source, and a decrease in accrued expenses of $0.8 million
most of which was non-cash activity related to the issuance of common stock in settlement of litigation, offset by an increase in accounts
payable of $0.4 million and a decrease in prepaids of $0.3 million related to insurance payments. &#160;Further contributing were deferred
tax assets of $1.2 million increased for book to tax differences related to stock option expense. &#160;Offsetting these were primarily
non-cash charges for stock-based compensation of $1.3 million, and depreciation and amortization of $0.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash provided by operating activities of $2.7 million for the six months
ended June 30, 2020, was mostly attributable to non-cash charges for stock-based compensation and litigation settlement expense of $2.1
million, an increase in accounts payable, accrued expenses and accrued payroll of $2.1 million, driven by the litigation settlement with
EMED, the capital raise and customer rebates. Further adding to the cash provided by operating activities was an increase in tax liability
of $0.3 million, resulting from book tax differences related to option expense. &#160;Collection against accounts receivable also contributed
$0.3 million. &#160;Offsetting these were an increase in inventory of $1.3 million as we built inventory to keep pace with sales growth
and to insure timely order fulfillment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Investing Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in investing activities of $0.2 million for the six months
ending June 30, 2021, was for capital expenditures for manufacturing and office equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in investing activities of $0.5 million for the six months
ending June 30, 2020, was for capital expenditures for research and development and strategic initiatives as well as for patent and trademark
applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Financing Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The $2.2 million provided by financing activities for the six months ended
June 30, 2021, is from options exercised and the non-cash activity related to the issuance of common stock in settlement of litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The $30.1 million provided by financing activities for the six months ended
June 30, 2020, is from the $26.5 million capital raise, net of expenses, a $3.5 million draw on the line of credit and $0.1 million from
options exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#8221; in the accompanying financial statements, which is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 20 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#8221; in the accompanying financial statements, which is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 3. &#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 4. &#160;CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s management, including the Company&#8217;s Principal
Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures
as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).
&#160;Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the
period covered by this report, the Company&#8217;s disclosure controls and procedures were effective for the purpose of ensuring that
the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and
Exchange Commission (the &#8220;SEC&#8221;) (1) is recorded, processed, summarized and reported within the time periods specified in the
SEC&#8217;s rules and forms and (2) is accumulated and communicated to the Company&#8217;s management, including its Principal Executive
Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There have been no changes in the Company&#8217;s internal control over
financial reporting during the three months ended June 30, 2021, that have materially affected, or are reasonably likely to materially
affect, the Company&#8217;s internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>PART II &#8211; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 1. &#160;LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 12, 2021, the lead plaintiff filed a notice of voluntary dismissal
without prejudice of the claims in the previously disclosed putative class action lawsuit filed in the United States District Court for
the Southern District of New York against the Company and its Chief Financial Officer and former Chief Executive Officer, alleging they
made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company&#8217;s business,
operations and prospects, in the Company&#8217;s earnings communications and Form 10-Q filed during the period August 4, 2020 and January
25, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 1A. &#160;RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our operations and financial results are subject to various risks and uncertainties,
including those described in &#8220;PART 1, ITEM 1A. RISK FACTORS&#8221; in our Annual Report on Form 10-K for the year ended December
31, 2020, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of
our common stock. &#160;There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended
December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 2. &#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issued an aggregate 14,615 shares of common stock to its non-employee
directors during the three months ended June 30, 2021 in accordance with its non-employee director compensation program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">All of the securities issued by the Company as described in this Item were
issued in reliance on the exemption from registration under Section 4(2) under the Securities Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 16, 2020, the Company announced that its Board of Directors&#160;had
authorized a stock repurchase program under which the Company may choose to purchase up to $10.0 million of its outstanding common stock
through December 31, 2021. &#160;As of December 31, 2020, the Company had purchased 683,271 shares for an aggregate $3,499,358 pursuant
to this program. No purchases have been made since that time, as we continue to evaluate our cash needs in connection with strategic planning
under the leadership of our new Chief Executive Officer.</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 21 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>PART II &#8211; ITEM 6. &#160;EXHIBITS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">10.1</td>
    <td style="width: 6.75in"><a href="ex_10-1.htm">Summary of Non-Employee Director Compensation (effective May 18, 2021)</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>10.2</td>
    <td><a href="ex_10-2.htm">Repro Med Systems, Inc. 2021 Omnibus Equity Incentive Plan</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>10.3</td>
    <td><a href="ex_10-3.htm">Form of non-qualified/incentive stock option award agreement pursuant to the 2021 Omnibus Equity Inventive Plan</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>10.4</td>
    <td><a href="ex_10-4.htm">Form of Indemnification Agreement between Repro Med Systems, Inc. and each of its directors and executive officers</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>31.1</td>
    <td><a href="ex_31-1.htm">Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>31.2</td>
    <td><a href="ex_31-2.htm">Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>32.1</td>
    <td><a href="ex_32-1.htm">Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>32.2</td>
    <td><a href="ex_32-2.htm">Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.INS</td>
    <td>Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded
        within the Inline XBRL document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.SCH</td>
    <td>Inline XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.CAL</td>
    <td>Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.DEF</td>
    <td>Inline XBRL Taxonomy Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.LAB</td>
    <td>Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>101.PRE</td>
    <td>Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>104</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 22 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3.75in">&#160;</td>
    <td style="width: 3.75in">REPRO MED SYSTEMS, INC.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>August 11, 2021</td>
    <td><span style="text-decoration: underline">/s/ Linda Tharby</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Linda Tharby, President and Chief Executive Officer<br />
(Principal Executive Officer)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>August 11, 2021</td>
    <td><span style="text-decoration: underline">/s/ Karen Fisher</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Karen Fisher, Chief Financial Officer and Treasurer<br />
(Principal Financial Officer)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 23 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" />

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>ex_10-1.htm
<DESCRIPTION>SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 12pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 10.1</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Repro Med Systems, Inc.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">d/b/a KORU Medical Systems</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Summary of Non-Employee Director Compensation</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">The Board of Directors of Repro Med Systems, Inc. d/b/a KORU Medical Systems
(the &ldquo;Company&rdquo;) has approved the following compensation for its non-employee directors effective with approval of the Company&rsquo;s
2021 Omnibus Equity Incentive Plan by its shareholders on May 18, 2021.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">In each case payable quarterly at the end of each fiscal quarter beginning
with the quarter ended June 30, 2021 and subject to proration for partial quarter service:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">Non-employee Directors (other than Chairman): $110,000 annually,
of which $50,000 is paid in cash and $60,000 is paid in shares of the Company&rsquo;s Common Stock.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Chairman of the Board: $140,000 annually,
of which $50,000 is paid in cash and $90,000 is paid in shares of the Company&rsquo;s Common Stock.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Chairman of the Audit Committee: additional
$15,000 annually paid in cash.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Chairman of the Compensation Committee:
additional $11,500 annually paid in cash.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Chairman of the Nominating and Corporate
Governance Committee: additional $7,500 annually paid in cash.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Compensation payable in shares of Common Stock is based on the closing
price of the Common Stock on the last day of each fiscal quarter as reported by the Nasdaq Capital Market (or such other quotation system
or exchange on which the Common Stock is then traded).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%"> </DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>ex_10-2.htm
<DESCRIPTION>REPRO MED SYSTEMS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 10.2</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><I>FOR APPROVAL BY BOARD</I></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPRO MED SYSTEMS, INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2021 OMNIBUS EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="width: 6in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 1. Effective Date, Objectives and
        Duration</FONT></TD>
    <TD STYLE="width: 0.5in; text-align: right">3</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 2. Definitions</FONT></TD>
    <TD STYLE="text-align: right">3</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 3. Administration</FONT></TD>
    <TD STYLE="text-align: right">7</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 4. Shares Subject to the Plan</FONT></TD>
    <TD STYLE="text-align: right">10</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 5. Eligibility and General Conditions of Awards</FONT></TD>
    <TD STYLE="text-align: right">12</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 6. Stock Options</FONT></TD>
    <TD STYLE="text-align: right">14</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 7. Stock Appreciation Rights</FONT></TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 8. Restricted Shares</FONT></TD>
    <TD STYLE="text-align: right">17</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 9. Performance Units and Performance Shares</FONT></TD>
    <TD STYLE="text-align: right">18</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 10. Deferred Stock and Restricted Stock Units</FONT></TD>
    <TD STYLE="text-align: right">18</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 11. Dividend Equivalents</FONT></TD>
    <TD STYLE="text-align: right">19</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 12. Bonus Shares</FONT></TD>
    <TD STYLE="text-align: right">19</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 13. Other Stock-Based Awards</FONT></TD>
    <TD STYLE="text-align: right">19</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 14. Non-Employee Director Awards</FONT></TD>
    <TD STYLE="text-align: right">20</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 15. Amendment, Modification, and Termination</FONT></TD>
    <TD STYLE="text-align: right">20</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 16. Section&nbsp;409A</FONT></TD>
    <TD STYLE="text-align: right">20</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 17. Withholding</FONT></TD>
    <TD STYLE="text-align: right">21</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 18. Additional Provisions</FONT></TD>
    <TD STYLE="text-align: right">22</TD></TR>
  </TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPRO MED SYSTEMS, INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2021 OMNIBUS EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 1.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Effective Date, Objectives and
Duration</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date of the Plan</U>. The Board of Directors of Repro Med Systems, Inc., a New York corporation (the &ldquo;Company&rdquo;), adopted the
2021 Omnibus Equity Incentive Plan (the &ldquo;Plan&rdquo;) effective as of March 22, 2021 (the &ldquo;Effective Date&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Objectives
of the Plan</U>. The Plan is intended (a)&nbsp;to allow selected employees of and consultants to the Company and its Affiliates to acquire
or increase equity ownership in the Company, thereby strengthening their commitment to the success of the Company and stimulating their
efforts on behalf of the Company, and to assist the Company and its Affiliates in attracting new employees, officers and consultants and
retaining existing employees and consultants, (b)&nbsp;to optimize the profitability and growth of the Company and its Affiliates through
incentives which are consistent with the Company&rsquo;s goals, (c)&nbsp;to provide Grantees with an incentive for excellence in individual
performance, (d)&nbsp;to promote teamwork among employees, consultants and Non-Employee Directors, and (e)&nbsp;to attract and retain
highly qualified persons to serve as Non-Employee Directors and to promote ownership by such Non-Employee Directors of a greater proprietary
interest in the Company, thereby aligning such Non-Employee Directors&rsquo; interests more closely with the interests of the Company&rsquo;s
stockholders.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Duration
of the Plan</U>. The Plan shall commence on the Effective Date and shall remain in effect, subject to the right of the Board to amend
or terminate the Plan at any time pursuant to Article 15 hereof, until the earlier of the tenth anniversary of the Effective Date, or
the date all Shares subject to the Plan shall have been purchased or acquired and the restrictions on all Restricted Shares granted under
the Plan shall have lapsed, according to the Plan&rsquo;s provisions.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 2.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Definitions</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Whenever used in the Plan, the
following terms shall have the meanings set forth below:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Affiliate</U>&rdquo;
means, with respect to a Person, any Person that directly or indirectly Controls, or is Controlled by, or is under common Control with
such Person. &ldquo;Control&rdquo;, &ldquo;Controlled by&rdquo; and &ldquo;under common Control with&rdquo; shall mean to have a &ldquo;controlling
interest&rdquo; within the meaning of section 1.409A-1(b) (5) (iii) (E) (1) of the regulations under the Code.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Award</U>&rdquo;
means Options (including non-qualified options and Incentive Stock Options), SARs, Restricted Shares, Performance Units (which may be
paid in cash), Performance Shares, Deferred Stock, Restricted Stock Units, Dividend Equivalents, Bonus Shares or Other Stock-Based Awards
granted under the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Award
Agreement</U>&rdquo; means either (a)&nbsp;a written agreement entered into by the Company and a Grantee setting forth the terms and provisions
applicable to an Award granted under this Plan, or (b)&nbsp;a written statement issued by the Company to a Grantee describing the terms
and provisions of such Award, including any amendment or modification thereof. The Committee may provide for the use of</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify">electronic, internet or other non-paper
Award Agreements and the use of electronic, internet or other non-paper means for the acceptance thereof and actions thereunder by the
Grantee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Board</U>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Bonus
Shares</U>&rdquo; means Shares that are awarded to a Grantee with or without cost and without restrictions either in recognition of past
performance, as an inducement to become an Eligible Person or, with the consent of the Grantee, as payment in lieu of any cash remuneration
otherwise payable to the Grantee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>CEO</U>&rdquo;
means the Chief Executive Officer of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Change
in Control</U>&rdquo; shall mean a change in ownership of the Company or a substantial portion of its assets within the meaning of Treasury
Regulation Section 1.409A-3(i)(5) or (vii), or change in effective control of the Company within the meaning of Treasury Regulation Section
1.409A(3)(i)(5)(vi).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Code</U>&rdquo;
means the Internal Revenue Code of 1986, as amended from time to time. References to a particular section of the Code include references
to regulations and rulings thereunder and to successor provisions.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Committee</U>&rdquo;
or &ldquo;<U>Incentive Plan Committee</U>&rdquo; has the meaning set forth in Section&nbsp;3.1(a).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Compensation
Committee</U>&rdquo; means the compensation committee of the Board.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Common
Stock</U>&rdquo; means the common stock, $0.01 par value, of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Corporate
Transaction</U>&rdquo; shall have the meaning set forth in Section&nbsp;4.2(b).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Deferred
Stock</U>&rdquo; means a right, granted under Article 10, to receive Shares at the end of a specified deferral period.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Disability</U>&rdquo;
or &ldquo;<U>Disabled</U>&rdquo; means, unless otherwise defined in an Award Agreement, or as otherwise determined under procedures established
by the Committee for purposes of the Plan:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as provided in (b)&nbsp;below, a disability within the meaning of Section&nbsp;22(e) (3) of the Code; and</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of any Award that constitutes deferred compensation within the meaning of Section&nbsp;409A of the Code, a disability as defined
in regulations under Code Section&nbsp;409A. For purpose of Code Section&nbsp;409A, a Grantee will be considered Disabled if:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Grantee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment
which can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12)&nbsp;months,
or</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Grantee is, by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected
to last for a continuous period of not less than twelve (12)&nbsp;months, receiving income replacement benefits for a period of not less
than three (3)&nbsp;months under an accident and health plan covering employees of the Grantee&rsquo;s employer.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Dividend
Equivalent</U>&rdquo; means a right to receive payments equal to dividends or property, if and when paid or distributed, on a specified
number of Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Effective
Date</U>&rdquo; has the meaning set forth in Section&nbsp;1.1.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Eligible
Person</U>&rdquo; means any individual who is an employee (including any officer) of, a non-employee consultant to, or a Non-Employee
Director of, the Company or any Affiliate; provided, however, that solely with respect to the grant of an Incentive Stock Option, an Eligible
Person shall be any employee (including any officer) of the Company or any Subsidiary Corporation. Notwithstanding the foregoing, an Eligible
Person shall also include an individual who is expected to become an employee to, non-employee consultant of or Non-Employee Director
of the Company or any Affiliate within a reasonable period of time after the grant of an Award (other than an Incentive Stock Option);
provided that any Award granted to any such individual shall be automatically terminated and cancelled without consideration if the individual
does not begin performing services for the Company or any Affiliate within twelve (12)&nbsp;months after the Grant Date. Solely for purposes
of Section&nbsp;5.6(b), current or former employees or non-employee directors of, or consultants to, of an Acquired Entity who receive
Substitute Awards in substitution for Acquired Entity Awards shall be considered Eligible Persons under this Plan with respect to such
Substitute Awards.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended from time to time. References to a particular section of the Exchange
Act include references to successor provisions.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Exercise
Price</U>&rdquo; means (a)&nbsp;with respect to an Option, the price at which a Share may be purchased by a Grantee pursuant to such Option
or (b)&nbsp;with respect to a SAR, the price established at the time a SAR is granted pursuant to Article 7, which is used to determine
the amount, if any, of the payment due to a Grantee upon exercise of the SAR.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Fair
Market Value</U>&rdquo; of a Share means (i) if the Shares principally trade on a national securities exchange other than the Nasdaq Capital
Market, the closing sale price of a Share, and (ii) if the Shares principally trade on the Nasdaq Capital Market or an over-the counter
marketplace, the arithmetic mean of the high and low prices of a Share (and if the mean results in a fractional cent, rounded up to the
nearest cent), in each case as reported on the last trading day before the Grant Date, provided that such quotations shall have been made
within the ten (10) business days preceding the applicable Grant Date. In the event Shares are not so traded at the time a determination
of their value is required to be made hereunder, the determination of their Fair Market Value shall be made by the Committee in such manner
as it deems appropriate provided such manner is consistent with Treasury Regulation Section&nbsp;1.409A-1(b)(5)(iv).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Grant
Date</U>&rdquo; means the date on which an Award is granted or such later date as specified in advance by the Committee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Grantee</U>&rdquo;
means a person who has been granted an Award.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Incentive
Stock Option</U>&rdquo; means an Option that is intended to meet the requirements of Section&nbsp;422 of the Code.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Including</U>&rdquo;
or &ldquo;<U>includes</U>&rdquo; means &ldquo;including, without limitation,&rdquo; or &ldquo;includes, without limitation,&rdquo; respectively.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Management
Committee</U>&rdquo; has the meaning set forth in Section&nbsp;3.1(b).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 5 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Non-Employee
Director</U>&rdquo; means a member of the Board who is not an employee of the Company or any Affiliate.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Option</U>&rdquo;
means an option granted under Article 6 of the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.28 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Other
Stock-Based Award</U>&rdquo; means a right, granted under Article 13 hereof, that relates to or is valued by reference to Shares or other
Awards relating to Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.29 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Performance
Period</U>&rdquo; means, with respect to an Award of Performance Shares or Performance Units, the period of time during which the performance
vesting conditions applicable to such Award must be satisfied.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Performance
Share</U>&rdquo; and &ldquo;<U>Performance Unit</U>&rdquo; have the respective meanings set forth in Article 9.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Period
of Restriction</U>&rdquo; means the period during which Restricted Shares are subject to forfeiture if the conditions specified in the
Plan and the Award Agreement are not satisfied.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Person</U>&rdquo;
means any individual, sole proprietorship, partnership, joint venture, limited liability company, trust, unincorporated organization,
association, corporation, institution, public benefit corporation, entity or government instrumentality, division, agency, body or department.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Restricted
Shares</U>&rdquo; means Shares, granted under Article 8, that are both subject to forfeiture and are nontransferable if the Grantee does
not satisfy the conditions specified in the Plan and the Award Agreement applicable to such Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Restricted
Stock Units</U>&rdquo; are rights, granted under Article 10, to receive cash and/or Shares if the Grantee satisfies the conditions specified
in the Plan and the Award Agreement applicable to such rights.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Rule
16b-3</U>&rdquo; means Rule 16b-3 promulgated by the SEC under the Exchange Act, as amended from time to time, together with any successor
rule.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>SEC</U>&rdquo;
means the United States Securities and Exchange Commission, or any successor thereto.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Section&nbsp;16
Non-Employee Director</U>&rdquo; means a member of the Board who satisfies the requirements to qualify as a &ldquo;non-employee director&rdquo;
under Rule 16b-3.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Section&nbsp;16
Person</U>&rdquo; means a person who is subject to potential liability under Section&nbsp;16(b) of the Exchange Act with respect to transactions
involving equity securities of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Separation
from Service</U>&rdquo; means, with respect to any Award that constitutes deferred compensation within the meaning of Code Section&nbsp;409A,
a &ldquo;separation from service&rdquo; as defined in Treasury Regulation Section&nbsp;1.409A-1(h). For this purpose, a &ldquo;separation
from service&rdquo; is deemed to occur on the date that the Company and the Grantee reasonably anticipate that the level of bona fide
services the Grantee would perform for the Company and/or any Affiliates after that date (whether as an employee, Non-Employee Director
or consultant or independent contractor) would permanently decrease to a level that, based on the facts and circumstances, would constitute
a separation from service; provided that a decrease to a level that is 50% or more of the average level of bona fide services provided
over the</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 6 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">prior 36 months shall not be a separation from service,
and a decrease to a level that is 20% or less of the average level of such bona fide services shall be a separation from service. The
Committee retains the right and discretion to specify, and may specify, whether a separation from service occurs with respect to those
individuals who are performing services for the Company or an Affiliate immediately prior to an asset purchase transaction in which the
Company or an Affiliate is the seller and who continue to perform services for the buyer (or an affiliate thereof) immediately following
such asset purchase transaction; provided, such specification is made in accordance with the requirements of Treasury Regulation Section&nbsp;1.409A-1(h)(4).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Share</U>&rdquo;
means a share of Common Stock, and such other securities of the Company, as may be substituted or resubstituted for Shares pursuant to
Section&nbsp;4.2 hereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Stock
Appreciation Right</U>&rdquo; or &ldquo;<U>SAR</U>&rdquo; means an Award granted under Article 7 of the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Subsidiary
Corporation</U>&rdquo; means a corporation other than the Company in an unbroken chain of corporations beginning with the Company if,
at the time of granting the Option, each of the corporations other than the last corporation in the unbroken chain owns stock possessing
50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Surviving
Company</U>&rdquo; means (a)&nbsp;the surviving corporation in any merger, consolidation or similar transaction, involving the Company
(including the Company if the Company is the surviving corporation), (b) or the direct or indirect parent company of such surviving corporation
or (c)&nbsp;the direct or indirect parent company of the Company following a sale of substantially all of the outstanding stock of the
Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Term</U>&rdquo;
of any Option or SAR means the period beginning on the Grant Date of an Option or SAR and ending on the date such Option or SAR expires,
terminates or is cancelled. No Option or SAR granted under this Plan shall have a Term exceeding 10 years.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Termination
of Affiliation</U>&rdquo; occurs on the first day on which an individual is for any reason no longer performing services for the Company
or any Affiliate in the capacity of an employee of, a non-employee consultant to, or a Non-Employee Director of, the Company or any Affiliate
or with respect to an individual who is an employee of, a non-employee consultant to or a Non-Employee Director of an Affiliate, the first
day on which such entity ceases to be an Affiliate of the Company unless such individual continues to perform Services for the Company
or another Affiliate without interruption after such entity ceases to be an Affiliate. Notwithstanding the foregoing, if an Award constitutes
deferred compensation within the meaning of Code Section&nbsp;409A, Termination of Affiliation with respect to such Award shall mean the
Grantee&rsquo;s Separation from Service.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 3.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Administration</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Committee</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to Article 14, and to Section&nbsp;3.2, the Plan shall be administered by a Committee (the &ldquo;Incentive Plan Committee&rdquo; or the
&ldquo;Committee&rdquo;) of directors of the Company appointed by the Board from time to time. Notwithstanding the foregoing, the Board
may at any time and in one or more instances reserve administrative powers to itself as the Committee or exercise any of the administrative
powers of the Committee. The number of members of the Committee may from time to time be increased or decreased as the Board deems appropriate.
To</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 7 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">the extent the Board considers it desirable
to comply with Rule 16b-3, the Committee shall consist of two or more directors of the Company, all of whom qualify as Section&nbsp;16
Non-Employee Directors.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board or the Incentive Plan Committee may appoint and delegate to another committee (&ldquo;Management Committee&rdquo;), or to the CEO,
any or all of the authority of the Board or the Committee, as applicable, with respect to Awards to Grantees other than Grantees who are
executive officers, Non-Employee Directors, or Section&nbsp;16 Persons at the time any such delegated authority is exercised, provided
that the Board shall fix the terms of the Awards to be granted by the Management Committee for the CEO (including the exercise price of
such Awards) and the maximum number of shares subject to Awards that the Management Committee or the CEO may grant; provided further,
however, that the Management Committee and the CEO shall not be authorized to grant Awards to himself/herself/themselves, or to any other
&ldquo;executive officer&rdquo; of the Company (as defined by Rule 3b-7 under the Exchange Act) or to any other &ldquo;officer&rdquo;
of the Company as defined by Rule 16a-1 under the Exchange Act.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the context requires otherwise, any references herein to &ldquo;Committee&rdquo; include references to the Incentive Plan Committee, or
the Board to the extent the Incentive Plan Committee, or the Board, as applicable, has assumed or exercises administrative powers itself
as the Committee pursuant to subsection (a), and to the Management Committee or the CEO to the extent either has been delegated authority
pursuant to subsection (b), as applicable; provided that (i)&nbsp;for purposes of Awards to Non-Employee Directors, &ldquo;Committee&rdquo;
shall include only the full Board, and (ii)&nbsp;for purposes of Awards intended to comply with Rule 16b-3, the &ldquo;Committee&rdquo;
shall include only the Incentive Plan Committee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Powers
of Committee</U>. Subject to and consistent with the provisions of the Plan (including Article 14), the Committee has full and final authority
and sole discretion as follows; provided that any such authority or discretion exercised with respect to a specific Director shall be
approved by the affirmative vote of a majority of the members of the Board, even if not a quorum, but excluding the Director with respect
to whom such authority or discretion is exercised:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine when, to whom and in what types and amounts Awards should be granted;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
grant Awards to Eligible Persons in any number and to determine the terms and conditions applicable to each Award (including the number
of Shares or the amount of cash or other property to which an Award will relate, any Exercise Price or purchase price, any limitation
or restriction, any schedule for or performance conditions relating to the earning of the Award or the lapse of limitations, forfeiture
restrictions, restrictions on exercisability or transferability, any performance goals including those relating to the Company and/or
an Affiliate and/or any division thereof and/or an individual, and/or vesting based on the passage of time, based in each case on such
considerations as the Committee shall determine);</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the benefit payable under any Award and to determine whether any performance or vesting conditions have been satisfied;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine whether specific Awards shall be granted in connection with other specific Awards, and if so, whether they shall be exercisable
cumulatively with, or alternatively to, such other specific Awards and all other matters to be determined in connection with an Award;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 8 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the Term of any Option or SAR;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the amount, if any, that a Grantee shall pay for Restricted Shares, whether to allow voting rights with respect thereto, or
to permit or require the payment of cash dividends thereon, whether such dividends are to be deferred and the terms related thereto, when
Restricted Shares (including Restricted Shares acquired upon the exercise of an Option) shall be forfeited and whether such shares shall
be held in escrow;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine whether, to what extent and under what circumstances an Award may be settled in, or the exercise price of an Award may be paid
in, cash, Shares, other Awards or other property (including by &ldquo;net&rdquo; exercise), or an Award may be accelerated, vested, canceled,
forfeited or surrendered or any terms of the Award may be waived, and to accelerate the exercisability of, and to accelerate or waive
any or all of the terms and conditions applicable to, any Award or any group of Awards for any reason and at any time;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine with respect to Awards granted to Eligible Persons whether, to what extent and under what circumstances cash, Shares, other
Awards, other property and other amounts payable with respect to an Award will be deferred, either at the election of the Grantee or automatically
pursuant to the terms of the Award Agreement;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
offer to exchange or buy out any previously granted Award for a payment in cash, Shares or other Award;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
construe and interpret the Plan and to make all determinations, including factual determinations, necessary or advisable for the administration
of the Plan;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
make, amend, suspend, waive and rescind rules and regulations relating to the Plan;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
appoint such agents as the Committee may deem necessary or advisable to administer the Plan;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the terms and conditions of all Award Agreements applicable to Eligible Persons (which need not be identical) and, with the
consent of the Grantee, to amend any such Award Agreement at any time, among other things, to permit transfers of such Awards to the extent
permitted by the Plan; provided that the consent of the Grantee shall not be required for any amendment (i)&nbsp;which does not adversely
affect the rights of the Grantee, or (ii)&nbsp;which is necessary or advisable (as determined by the Committee) to carry out the purpose
of the Award as a result of any applicable law or (iii)&nbsp;to the extent the Award Agreement specifically permits amendment without
consent;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
cancel, with the consent of the Grantee, outstanding Awards and to grant new Awards in substitution therefor;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
impose such additional terms and conditions upon the grant, exercise or retention of Awards as the Committee may, before or concurrently
with the grant thereof, deem appropriate, including limiting the percentage of Awards which may from time to time be exercised by a Grantee;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
make adjustments in the terms and conditions of, and the criteria in, Awards in recognition of unusual or nonrecurring events (including
events described in Section&nbsp;4.2)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 9 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">affecting the Company or an Affiliate or
the financial statements of the Company or an Affiliate, or in accordance with applicable laws, regulations or accounting principles;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
correct any defect or supply any omission or reconcile any inconsistency, and to construe and interpret the Plan, rules and regulations
under the Plan, and Award Agreements or any other instruments entered into or relating to an Award under the Plan; and</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
take any other action with respect to any matters relating to the Plan for which it is responsible and to make all other decisions and
determinations as may be required under the terms of the Plan or as the Committee may deem necessary or advisable for the administration
of the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any action of the Committee with
respect to the Plan shall be final, conclusive and binding on all persons, including the Company, its Affiliates, any Grantee, any person
claiming any rights under the Plan from or through any Grantee, and stockholders, except to the extent the Committee may subsequently
modify, or take further action whether or not consistent with, its prior action. If not specified in the Plan, the time at which the Committee
must or may make any determination shall be determined by the Committee, and any such determination may thereafter be modified by the
Committee. The express grant of any specific power to the Committee, and the taking of any action by the Committee, shall not be construed
as limiting any power or authority of the Committee. Subject to Section&nbsp;3.1(b), the Committee may delegate to officers of the Company
or any Affiliate the authority, subject to such terms as the Committee shall determine, to perform specified functions under the Plan.
No Director or member of the Committee, nor any delegate thereof, shall be liable for any act, omission, interpretation, construction
or determination made in good faith in connection with the Plan, and each of the foregoing shall be entitled in all cases to indemnification
and reimbursement by the Company in respect of any claim, loss, damage or expense (including without limitation reasonable attorneys&rsquo;
fees) arising or resulting therefrom to the fullest extent permitted by law and/or under any directors&rsquo; and officers&rsquo; liability
insurance coverage which may be in effect from time to time.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Repricing</U>. Notwithstanding any provision in Section&nbsp;3.2 to the contrary, the terms of any outstanding Option or SAR may not be
amended to reduce the Exercise Price of such Option or SAR or cancel any outstanding Option or SAR in exchange for other Options or SARs
with an Exercise Price that is less than the Exercise Price of the cancelled Option or SAR or for any cash payment (or Shares having with
a Fair Market Value) in an amount that exceeds the excess of the Fair Market Value of the Shares underlying such cancelled Option or SAR
over the aggregate Exercise Price of such Option or SAR or for any other Award, without stockholder approval; provided, however, that
the restrictions set forth in this Section&nbsp;3.3, shall not apply (i)&nbsp;unless the Company has a class of stock that is registered
under Section&nbsp;12 of the Exchange Act or (ii)&nbsp;to any adjustment allowed under to Section&nbsp;4.2.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 4.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Shares Subject to the Plan</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Number
of Shares Available for Grants</U>. Subject to adjustment as provided in Section&nbsp;4.2 and except as provided in Section&nbsp;5.6(b),
the maximum number of Shares hereby reserved for delivery under the Plan shall be one million (1,000,000) Shares. Up to a maximum of one
million ($1,000,000) Shares may be delivered pursuant to the exercise of Incentive Stock Options granted hereunder.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any Shares subject to an Award
granted hereunder (other than a Substitute Award granted pursuant to Section&nbsp;5.6(b)) are forfeited or such Award otherwise terminates
without payment or delivery of such Shares, the Shares subject to such Award, to the extent of any such forfeiture or termination, shall
again be available for grant under the Plan. For avoidance of doubt, however, if any Shares subject to an</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 10 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Award granted hereunder are withheld or applied as
payment in connection with the exercise of an Award or the withholding or payment of taxes related thereto (&ldquo;Returned Shares&rdquo;),
such Returned Shares will be treated as having been delivered for purposes of determining the maximum number of Shares available for grant
under the Plan and shall not again be treated as available for grant under the Plan. Moreover, the number of Shares available for issuance
under the Plan may not be increased through the Company&rsquo;s purchase of Shares on the open market with the proceeds obtained from
the exercise of any Options granted hereunder. Upon settlement of an SAR, the number of Shares underlying the portion of the SAR that
is exercised will be treated as having been delivered for purposes of determining the maximum number of Shares available for grant under
the Plan and shall not again be treated as available for issuance under the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Shares delivered pursuant to the
Plan may be, in whole or in part, authorized and unissued Shares, or treasury Shares, including Shares repurchased by the Company for
purposes of the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments
in Authorized Shares and Awards; Corporate Transaction, Liquidation or Dissolution</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
in Authorized Shares and Awards</U>. In the event that the Committee determines that any dividend or other distribution (whether in the
form of cash, Shares, or other property), recapitalization, forward or reverse stock split, subdivision, consolidation or reduction of
capital, reorganization, merger, consolidation, scheme of arrangement, split-up, spin-off or combination involving the Company or repurchase
or exchange of Shares or other securities of the Company or other rights to purchase Shares or other securities of the Company, or other
similar corporate transaction or event affects the Shares such that any adjustment is determined by the Committee to be appropriate in
order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, then the
Committee shall, in such manner as it may deem equitable, adjust any or all of (i)&nbsp;the number and type of Shares (or other securities
or property) with respect to which Awards may be granted, (ii)&nbsp;the number and type of Shares (or other securities or property) subject
to outstanding Awards, (iii)&nbsp;the Exercise Price with respect to any Option or SAR or, if deemed appropriate, make provision for a
cash payment to the holder of an outstanding Award, and (iv)&nbsp;the number and kind of Shares of outstanding Restricted Shares, or the
Shares underlying any other form of Award. Notwithstanding the foregoing, no such adjustment shall be authorized with respect to any Options
or SARs to the extent that such adjustment would cause the Option or SAR to violate Section&nbsp;424(a) of the Code or otherwise subject
(in the determination of the Committee) any Grantee to taxation under Section&nbsp;409A of the Code; and <I>provided further</I> that
the number of Shares subject to any Award denominated in Shares shall always be a whole number.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Merger,
Consolidation or Similar Corporate Transaction</U>. In the event of a merger or consolidation of the Company with or into another corporation
or a sale of substantially all of the stock of the Company (a &ldquo;Corporate Transaction&rdquo;), unless an outstanding Award is assumed
by the Surviving Company or replaced with an equivalent Award granted by the Surviving Company in substitution for such outstanding Award,
the Committee shall cancel any outstanding Awards that are not vested and nonforfeitable as of the consummation of such Corporate Transaction
(unless the Committee accelerates the vesting of any such Awards) and with respect to any vested and nonforfeitable Awards, the Committee
may either (i)&nbsp;allow all Grantees to exercise such Awards of Options and SARs within a reasonable period prior to the consummation
of the Corporate Transaction and cancel any outstanding Options or SARs that remain unexercised upon consummation of the Corporate Transaction,
or (ii)&nbsp;cancel any or all of such outstanding Awards in exchange for a payment (in cash, or in securities or other property) in an
amount equal to the amount that the Grantee would have received (net of the Exercise Price</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 11 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">with respect to any Options or SARs) if
such vested Awards were settled or distributed or such vested Options and SARs were exercised immediately prior to the consummation of
the Corporate Transaction. Notwithstanding the foregoing, if an Option or SAR is not assumed by the Surviving Company or replaced with
an equivalent Award issued by the Surviving Company and the Exercise Price with respect to any outstanding Option or SAR exceeds the Fair
Market Value of the Shares immediately prior to the consummation of the Corporation Transaction, such Awards shall be cancelled without
any payment to the Grantee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidation
or Dissolution of the Company</U>. In the event of the proposed dissolution or liquidation of the Company, each Award will terminate immediately
prior to the consummation of such proposed action, unless otherwise provided by the Committee. Additionally, the Committee may, in the
exercise of its sole discretion, cause Awards to be vested and non-forfeitable and cause any conditions on any such Award to lapse, as
to all or any part of such Award, including Shares as to which the Award would not otherwise be exercisable or non-forfeitable and allow
all Grantees to exercise such Awards of Options and SARs within a reasonable period prior to the consummation of such proposed action.
Any Awards that remain unexercised upon consummation of such proposed action shall be cancelled.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deferred
Compensation</U>. Notwithstanding the forgoing provisions of this Section&nbsp;4.2, if an Award constitutes deferred compensation within
the meaning of Code Section&nbsp;409A, no payment or settlement of such Award shall be made pursuant to Section&nbsp;4.2(b) or (c), unless
the Corporate Transaction or the dissolution or liquidation of the Company, as applicable, constitutes a Change in Control.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 5.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Eligibility and General Conditions
of Awards</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Eligibility</U>.
The Committee may in its discretion grant Awards to any Eligible Person, whether or not he or she has previously received an Award; provided,
however, that all Awards made to Non-Employee Directors shall be determined by the Board in its sole discretion.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Award
Agreement</U>. To the extent not set forth in the Plan, the terms and conditions of each Award shall be set forth in an Award Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Terms and Termination of Affiliation</U>. The Committee may impose on any Award or the exercise or settlement thereof, at the date of
grant or, subject to the provisions of Section&nbsp;15.2, thereafter, such additional terms and conditions not inconsistent with the provisions
of the Plan as the Committee shall determine, including terms requiring forfeiture, acceleration or pro-rata acceleration of Awards in
the event of a Termination of Affiliation by the Grantee. Except as may be required under applicable state law, Awards may be granted
for no consideration other than prior and future services. Except as set forth in an Award Agreement or as otherwise determined by the
Committee, (a)&nbsp;all Options and SARs that are not vested and exercisable at the time of a Grantee&rsquo;s Termination of Affiliation,
and any other Awards that remain subject to a risk of forfeiture or which are not otherwise vested at the time of the Grantee&rsquo;s
Termination of Affiliation shall be forfeited to the Company and (b)&nbsp;all outstanding Options and SARs not previously exercised shall
expire three months after the Grantee&rsquo;s Termination of Affiliation.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nontransferability
of Awards</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Award and each right under any Award shall be exercisable only by the Grantee during the Grantee&rsquo;s lifetime, or, if permissible
under applicable law, by the Grantee&rsquo;s</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 12 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">guardian or legal representative or by a
transferee receiving such Award pursuant to a domestic relations order.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Award (prior to the time, if applicable, Shares are delivered in respect of such Award), and no right under any Award, may be assigned,
alienated, pledged, attached, sold or otherwise transferred or encumbered by a Grantee otherwise than by will or by the laws of descent
and distribution (or in the case of Restricted Shares, to the Company) or pursuant to a domestic relations order, and any such purported
assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or any Affiliate;
provided that the designation of a beneficiary to receive benefits in the event of the Grantee&rsquo;s death shall not constitute an assignment,
alienation, pledge, attachment, sale, transfer or encumbrance.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
herein shall be construed as requiring the Committee to honor a domestic relations order except to the extent required under applicable
law.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cancellation
and Rescission of Awards</U>. Unless the Award Agreement specifies otherwise, the Committee may cancel, rescind, suspend, withhold, or
otherwise limit or restrict any unexercised Award at any time if the Grantee is not in compliance with all applicable provisions of the
Award Agreement and the Plan or if the Grantee has a Termination of Affiliation.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stand-Alone,
Tandem and Substitute Awards</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awards
granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with, or in substitution
for, any other Award granted under the Plan unless in the determination of the Committee such tandem or substitution Award would subject
the Grantee to a tax imposed under Section&nbsp;409A of the Code. If an Award is granted in substitution for another Award or any non-Plan
award or benefit, the Committee shall require the surrender of such other Award or non-Plan award or benefit in consideration for the
grant of the new Award. Awards granted in addition to or in tandem with other Awards or non-Plan awards or benefits may be granted either
at the same time as or at a different time from the grant of such other Awards or non-Plan awards or benefits; provided, however, that
if any SAR is granted in tandem with an Incentive Stock Option, such SAR and Incentive Stock Option must have the same Grant Date, Term
and the Exercise Price of the SAR may not be less than the Exercise Price of the Incentive Stock Option.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee may, in its discretion and on such terms and conditions as the Committee considers appropriate in the circumstances, grant Awards
under the Plan (&ldquo;Substitute Awards&rdquo;) in substitution for stock and stock-based awards (&ldquo;Acquired Entity Awards&rdquo;)
held by current or former employees or non-employee directors of, or consultants to, another corporation or entity who become Eligible
Persons as the result of a merger or consolidation of the employing corporation or other entity (the &ldquo;Acquired Entity&rdquo;) with
the Company or an Affiliate or the acquisition by the Company or an Affiliate of property or stock of the Acquired Entity immediately
prior to such merger, consolidation or acquisition in order to preserve for the Grantee the economic value of all or a portion of such
Acquired Entity Award at such price as the Committee determines necessary to achieve preservation of economic value.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Rule 16b-3</U>. The provisions of this Section&nbsp;5.7 will not apply unless and until the Company has a class of stock that is
registered under Section&nbsp;12 of the Exchange Act.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 13 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Six-Month
Holding Period Advice</U>. Unless a Grantee could otherwise dispose of or exercise a derivative security or dispose of Shares delivered
under the Plan without incurring liability under Section&nbsp;16(b) of the Exchange Act, the Committee may advise or require a Grantee
to comply with the following in order to avoid incurring liability under Section&nbsp;16(b) of the Exchange Act: (i)&nbsp;at least six
months must elapse from the date of acquisition of a derivative security under the Plan to the date of disposition of the derivative security
(other than upon exercise or conversion) or its underlying equity security, and (ii)&nbsp;Shares granted or awarded under the Plan other
than upon exercise or conversion of a derivative security must be held for at least six months from the date of grant of an Award.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reformation
to Comply with Exchange Act Rules</U>. To the extent the Committee determines that a grant or other transaction by a Section&nbsp;16 Person
should comply with applicable provisions of Rule 16b-3 (except for transactions exempted under alternative Exchange Act rules), the Committee
shall take such actions as necessary to make such grant or other transaction so comply, and if any provision of this Plan or any Award
Agreement relating to a given Award does not comply with the requirements of Rule 16b-3 as then applicable to any such grant or transaction,
such provision will be construed or deemed amended, if the Committee so determines, to the extent necessary to conform to the then applicable
requirements of Rule 16b-3.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rule
16b-3 Administration</U>. Any function relating to a Section&nbsp;16 Person shall be performed solely by the Committee or the Board if
necessary to ensure compliance with applicable requirements of Rule 16b-3, to the extent the Committee determines that such compliance
is desired. Each member of the Committee or person acting on behalf of the Committee shall be entitled to, in good faith, rely or act
upon any report or other information furnished to him by any officer, manager or other employee of the Company or any Affiliate, the Company&rsquo;s
independent certified public accountants or any executive compensation consultant or attorney or other professional retained by the Company
to assist in the administration of the Plan.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deferral
of Award Payouts</U>. The Committee may permit a Grantee to defer, or if and to the extent specified in an Award Agreement require the
Grantee to defer, receipt of the payment of cash or the delivery of Shares that would otherwise be due by virtue of the lapse or waiver
of restrictions with respect to Restricted Stock Units, the satisfaction of any requirements or goals with respect to Performance Units
or Performance Shares, the lapse or waiver of the deferral period for Deferred Stock, or the lapse or waiver of restrictions with respect
to Other Stock-Based Awards or Cash Incentive Awards. If the Committee permits or requires such deferrals, the Committee shall establish
rules and procedures for making such deferral elections and for the payment of such deferrals, which shall conform in the Committee&rsquo;s
determination in form and substance with applicable regulations promulgated under Section&nbsp;409A of the Code so that if the Committee
is correct in such determination the Grantee is not subjected to taxes under Section&nbsp;409A of the Code with respect to such deferrals.
Except as otherwise provided in an Award Agreement, any payment or any Shares that are subject to such deferral shall be made or delivered
to the Grantee as specified in the Award Agreement or pursuant to the Grantee&rsquo;s deferral election.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 6.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Stock Options</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Options</U>. Subject to and consistent with the provisions of the Plan, Options may be granted to any Eligible Person in such number,
and upon such terms, and at any time and from time to time as shall be determined by the Committee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 14 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Award
Agreement</U>. Each Option grant shall be evidenced by an Award Agreement that shall specify the Exercise Price, the Term of the Option,
the number of Shares to which the Option pertains, the time or times at which such Option shall be exercisable and such other provisions
as the Committee shall determine.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
Exercise Price</U>. The Exercise Price of an Option under this Plan shall be determined in the sole discretion of the Committee but may
not be less than 100% of the Fair Market Value of a Share on the Grant Date.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Incentive Stock Options</U>. At the time of the grant of any Option, the Committee may in its discretion designate that such Option
shall be made subject to additional restrictions to permit it to qualify as an Incentive Stock Option. Any Option designated as an Incentive
Stock Option:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
be granted only to an employee of the Company or a Subsidiary Corporation;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
have an Exercise Price of not less than 100% of the Fair Market Value of a Share on the Grant Date, and, if granted to a person who owns
capital stock (including stock treated as owned under Section&nbsp;424(d) of the Code) possessing more than 10% of the total combined
voting power of all classes of capital stock of the Company or any Subsidiary Corporation (a &ldquo;More Than 10% Owner&rdquo;), have
an Exercise Price not less than 110% of the Fair Market Value of a Share on its Grant Date;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
be for a period of not more than 10 years (five years if the Grantee is a More Than 10% Owner) from its Grant Date, and shall be subject
to earlier termination as provided herein or in the applicable Award Agreement;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
not have an aggregate Fair Market Value (as of the Grant Date) of the Shares with respect to which Incentive Stock Options (whether granted
under the Plan or any other plan of the Company or Affiliate (&ldquo;Other Plans&rdquo;)) are exercisable for the first time by such Grantee
during any calendar year (&ldquo;Current Grant&rdquo;), determined in accordance with the provisions of Section&nbsp;422 of the Code,
which exceeds $100,000 (the &ldquo;$100,000 Limit&rdquo;);</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall,
if the aggregate Fair Market Value of the Shares (determined on the Grant Date) with respect to the Current Grant and all Incentive Stock
Options previously granted under the Plan and any Other Plans which are exercisable for the first time during a calendar year (&ldquo;Prior
Grants&rdquo;) would exceed the $100,000 Limit, be, as to the portion in excess of the $100,000 Limit, exercisable as a separate option
that is not an Incentive Stock Option at such date or dates as are provided in the Current Grant;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
require the Grantee to notify the Committee of any disposition of any Shares delivered pursuant to the exercise of the Incentive Stock
Option under the circumstances described in Section&nbsp;421(b) of the Code (relating to holding periods and certain disqualifying dispositions)
(&ldquo;Disqualifying Disposition&rdquo;) within 10 days of such a Disqualifying Disposition;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall
by its terms not be assignable or transferable other than by will or the laws of descent and distribution and may be exercised, during
the Grantee&rsquo;s lifetime, only by the Grantee; provided, however, that the Grantee may, to the extent provided in the Plan in any
manner specified by the Committee, designate in writing a beneficiary to exercise his or her Incentive Stock Option after the Grantee&rsquo;s
death; and</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 15 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall,
if such Option nevertheless fails to meet the foregoing requirements, or otherwise fails to meet the requirements of Section&nbsp;422
of the Code for an Incentive Stock Option, be treated for all purposes of this Plan, except as otherwise provided in subsections (d)&nbsp;and
(e) above, as an Option that is not an Incentive Stock Option.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Exercise Price</U>. Except as otherwise provided in an Award Agreement, Options shall be exercised by the delivery of a written notice
of exercise to the Company, setting forth the number of Shares with respect to which the Option is to be exercised, accompanied by full
payment for the Shares made by any one or more of the following means:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cash,
personal check or wire transfer;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
the approval of the Committee, delivery of Common Stock owned by the Grantee prior to exercise, valued at Fair Market Value on the date
of exercise;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
the approval of the Committee, Shares acquired upon the exercise of such Option, such Shares valued at Fair Market Value on the date of
exercise; or</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
the approval of the Committee, subject to applicable law (including the prohibited loan provisions of Section&nbsp;402 of the Sarbanes
Oxley Act of 2002), through the sale of the Shares acquired on exercise of the Option through a broker-dealer to whom the Grantee has
submitted an irrevocable notice of exercise and irrevocable instructions to deliver promptly to the Company the amount of sale proceeds
sufficient to pay for such Shares, together with, if requested by the Company, the amount of federal, state, local or foreign withholding
taxes payable by Grantee by reason of such exercise.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 7.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Stock Appreciation Rights</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance</U>.
Subject to and consistent with the provisions of the Plan, the Committee, at any time and from time to time, may grant SARs to any Eligible
Person either alone or in addition to other Awards granted under the Plan. Such SARs may, but need not, be granted in connection with
a specific Option granted under Article 6. The Committee may impose such conditions or restrictions on any SAR as it shall deem appropriate.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Award
Agreements</U>. Each SAR grant shall be evidenced by an Award Agreement in such form as the Committee may approve and shall contain such
terms and conditions not inconsistent with other provisions of the Plan as shall be determined from time to time by the Committee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SAR
Exercise Price</U>. The Exercise Price of a SAR shall be determined by the Committee in its sole discretion; provided that the Exercise
Price shall not be less than 100% of the Fair Market Value of a Share on the date of the grant of the SAR.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
and Payment</U>. Upon the exercise of a SAR, a Grantee shall be entitled to receive payment from the Company in an amount determined by
multiplying:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
excess of the Fair Market Value of a Share on the date of exercise over the Exercise Price; by</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of Shares with respect to which the SAR is exercised.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 16 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">SARs shall be deemed exercised
on the date written notice of exercise in a form acceptable to the Committee is received by the Secretary of the Company. The Company
shall make payment in respect of any SAR within five (5)&nbsp;days of the date the SAR is exercised. Any payment by the Company in respect
of a SAR may be made in cash, Shares, other property, or any combination thereof, as the Committee, in its sole discretion, shall determine
or, to the extent permitted under the terms of the applicable Award Agreement, at the election of the Grantee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 8.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Restricted Shares</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Restricted Shares</U>. Subject to and consistent with the provisions of the Plan, the Committee, at any time and from time to time,
may grant Restricted Shares to any Eligible Person in such amounts as the Committee shall determine.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Award
Agreement</U>. Each grant of Restricted Shares shall be evidenced by an Award Agreement that shall specify the Period(s) of Restriction,
the number of Restricted Shares granted, and such other provisions as the Committee shall determine. The Committee may impose such conditions
and/or restrictions on any Restricted Shares granted pursuant to the Plan as it may deem advisable, including restrictions based upon
the achievement of specific performance goals, time-based restrictions on vesting with or without the attainment of the performance goals,
and/or restrictions under applicable securities laws; provided that such conditions and/or restrictions may lapse, if so determined by
the Committee, in the event of the Grantee&rsquo;s Termination of Affiliation due to death, Disability, or involuntary termination by
the Company or an Affiliate without &ldquo;Cause&rdquo;. For purposes of the Plan, &ldquo;<U>Cause&rdquo; means</U> (i) <U>conviction</U>
of, or the entry of a plea of guilty or no contest to, a felony or any other crime that causes the Company or its Affiliates public disgrace
or disrepute, or materially and adversely affects the Company&rsquo;s or its Affiliates&rsquo; operations or financial performance or
the relationship the Company has with its customers, (ii) gross negligence or willful misconduct with respect to the Company or any of
its Affiliates, including, without limitation fraud, embezzlement, theft or dishonesty in the course of his or her employment; (iii) alcohol
abuse or use of controlled drugs other than in accordance with a physician&rsquo;s prescription; (iv) refusal to perform any lawful, material
obligation of fulfill any duty (including any duty or obligation of the type described in clause (vi) below) to the Company or its Affiliates;
(v) material breach of any agreement with or duty owed to the Company or any of its Affiliates; (vi) any breach of any obligation or duty
to the Company or any of its Affiliates (whether arising by statute, common law or agreement) relating to confidentiality, noncompetition,
nonsolicitation or proprietary rights; or (vii) the occurrence of a &ldquo;Forfeiture Event&rdquo; as defined in section 18.5, below.
Notwithstanding the foregoing, if an Eligible Person and the Company (or any of its Affiliates) have entered into an employment agreement,
consulting agreement or other similar agreement that specifically defines &ldquo;cause&rdquo;, then with respect to that Eligible Person
&ldquo;Cause&rdquo; shall have the meaning as defined in such employment, consulting or other agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration
for Restricted Shares</U>. The Committee shall determine the amount, if any, that a Grantee shall pay for Restricted Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect
of Forfeiture</U>. If Restricted Shares are forfeited, and if the Grantee was required to pay for such shares or acquired such Restricted
Shares upon the exercise of an Option, the Grantee shall be deemed to have resold such Restricted Shares to the Company at a price equal
to the lesser of (x)&nbsp;the amount paid by the Grantee for such Restricted Shares, or (y)&nbsp;the Fair Market Value of a Share on the
date of such forfeiture. The Company shall pay to the Grantee the deemed sale price as soon as is administratively practical. Such Restricted
Shares shall cease to be outstanding and shall no longer confer on the Grantee thereof any rights as a stockholder of the Company, from
and after the date of the event</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 17 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">causing the forfeiture, whether or not the Grantee
accepts the Company&rsquo;s tender of payment for such Restricted Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Escrow;
Legends</U>. The Committee may provide that the certificates for any Restricted Shares (x)&nbsp;shall be held (together with a stock power
executed in blank by the Grantee) in escrow by the Secretary of the Company until any applicable conditions or restrictions respecting
such Restricted Shares are satisfied or such Restricted Shares are forfeited and/or (y)&nbsp;shall bear an appropriate legend restricting
the transfer of such Restricted Shares under the Plan. If any applicable conditions or restrictions respecting such Restricted Shares
shall lapse, the Company shall cause certificates for such shares to be delivered without such legend.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 9.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Performance Units and Performance
Shares</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Performance Units and Performance Shares</U>. Subject to and consistent with the provisions of the Plan, Performance Units or Performance
Shares may be granted to any Eligible Person in such amounts and upon such terms, and at any time and from time to time, as shall be determined
by the Committee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Value/Performance
Goals</U>. The Committee shall set performance goals in its discretion which, depending on the extent to which they are met, will determine
the number or value of Performance Units or Performance Shares that will be paid to the Grantee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Performance
Unit</U>. Each Performance Unit shall have an initial value that is established by the Committee at the time of grant.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Performance
Share</U>. Each Performance Share shall have an initial value equal to the Fair Market Value of a Share on the date of grant.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Earning
of Performance Units and Performance Shares</U>. After the applicable Performance Period has ended, the holder of Performance Units or
Performance Shares shall be entitled to payment at the time specified in the Award Agreement based on the level of achievement of performance
goals set by the Committee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the discretion of the Committee,
the settlement of Performance Units or Performance Shares may be in cash, Shares of equivalent value, or in some combination thereof,
as set forth in the Award Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If a Grantee is transferred to
a different business unit of the Company during a Performance Period, then, to the extent the Committee determines that the Award, the
performance goals, or the Performance Period are no longer appropriate, the Committee may adjust, change, eliminate or cancel the Award,
the performance goals, or the applicable Performance Period, as it deems appropriate in order to make them appropriate and comparable
to the initial Award, the performance goals, or the Performance Period.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the discretion of the Committee,
a Grantee may be entitled to receive any dividends or Dividend Equivalents declared with respect to Shares deliverable in connection with
vested Performance Shares which have been earned, but not yet delivered to the Grantee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 18 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 10.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Deferred Stock and Restricted
Stock Units</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Deferred Stock and Restricted Stock Units</U>. Subject to and consistent with the provisions of the Plan, the Committee, at any time
and from time to time, may grant Deferred Stock and/or Restricted Stock Units to any Eligible Person, in such amount and upon such terms
as the Committee shall determine. The Committee may conform such grant(s) in accordance with applicable regulations promulgated under
Section&nbsp;409A of the Code.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Vesting
and Delivery</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
with Respect to Deferred Stock and Restricted Stock Units</U>. Delivery of Shares subject to a Deferred Stock or a Restricted Stock Unit
grant will occur upon expiration of the deferral period or upon the occurrence of one or more of the distribution events described in
Section&nbsp;409A (a) (2) of the Code as specified by the Committee in the Grantee&rsquo;s Award Agreement. Such Award may be subject
to such substantial risk of forfeiture conditions as the Committee may impose, which conditions may lapse at such times or upon the achievement
of such objectives as the Committee shall determine. Unless otherwise determined by the Committee, to the extent that the Grantee has
a Termination of Affiliation while the Deferred Stock remains subject to a substantial risk of forfeiture, such Deferred Shares shall
be forfeited, unless the Committee determines that such substantial risk of forfeiture shall lapse in the event of the Grantee&rsquo;s
Termination of Affiliation due to death, Disability, or involuntary termination by the Company or an Affiliate without &ldquo;Cause.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting
and Dividend Equivalent Rights Attributable to Deferred Stock and Restricted Stock Units</U>. A Grantee awarded Deferred Stock or Restricted
Stock Units will have no voting rights with respect to such Deferred Stock or Restricted Stock Units prior to the delivery of Shares in
settlement of such Deferred Stock and/or Restricted Stock Units. Unless otherwise determined by the Committee, a Grantee will have no
rights to receive Dividend Equivalents in respect of Deferred Stock and/or Restricted Stock Units. Dividend Equivalents, if any, shall
be deemed reinvested in additional Shares of Deferred Stock or Restricted Stock Units, as applicable, which shall remain subject to the
same forfeiture conditions applicable to the Deferred Stock or Restricted Stock Units to which such Dividend Equivalents relate.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 11.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Dividend Equivalents</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee is authorized to
grant Awards of Dividend Equivalents alone or in conjunction with other Awards. The Committee may specify the time or times that Dividend
Equivalents shall be paid or distributed and the extent to which they shall be deemed to have been reinvested in additional Shares or
additional Awards or otherwise reinvested subject to distribution at the same time and subject to the same conditions as the Award to
which they relate; provided, however, that any Dividend Equivalents granted in conjunction with any Award that is subject to forfeiture
conditions shall remain subject to the same forfeiture conditions applicable to the Award to which such Dividend Equivalents relate. The
Committee may determine whether the timing of payment or distribution of Dividend Equivalents should comply with the requirements of Section&nbsp;409A
of the Code.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 19 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 12.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Bonus Shares</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the Plan,
the Committee may grant Bonus Shares to any Eligible Person, in such amount and upon such terms and at any time and from time to time
as shall be determined by the Committee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 13.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Other Stock-Based Awards</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Committee is authorized, subject
to limitations under applicable law, to grant such other Awards that are denominated or payable in, valued in whole or in part by reference
to, or otherwise based on, or related to, Shares, as deemed by the Committee to be consistent with the purposes of the Plan, including
Shares awarded which are not subject to any restrictions or conditions, convertible or exchangeable debt securities or other rights convertible
or exchangeable into Shares, and Awards valued by reference to the value of securities of or the performance of specified Affiliates.
Subject to and consistent with the provisions of the Plan, the Committee shall determine the terms and conditions of such Awards. Except
as provided by the Committee, Shares delivered pursuant to a purchase right granted under this Article 13 shall be purchased for such
consideration, paid for by such methods and in such forms, including cash, Shares, outstanding Awards or other property, as the Committee
shall determine.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 14.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Non-Employee Director Awards</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the Plan,
the Board may grant Awards to any Non-Employee Director, in such amount and upon such terms and at any time and from time to time as shall
be determined by the Board in its sole discretion. Except as otherwise provided in Section&nbsp;5.6(b), Non-Employee Directors may not
be granted Awards with respect to Shares that have a Fair Market Value (determined as of the date of grant) in excess of $750,000 in a
single calendar year.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 15.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Amendment, Modification, and Termination</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment,
Modification, and Termination</U>. Subject to Section&nbsp;15.2, the Board may, at any time and from time to time, alter, amend, suspend,
discontinue or terminate the Plan in whole or in part without the approval of the Company&rsquo;s stockholders, except that (a)&nbsp;any
amendment or alteration shall be subject to the approval of the Company&rsquo;s stockholders if such stockholder approval is required
by any federal or state law or regulation or the rules of any stock exchange or automated quotation system on which the Shares may then
be listed or quoted, and (b)&nbsp;the Board may otherwise, in its discretion, determine to submit other such amendments or alterations
to stockholders for approval.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Awards
Previously Granted</U>. Except as otherwise specifically permitted in the Plan or an Award Agreement, no termination, amendment, or modification
of the Plan shall adversely affect in any material way any Award previously granted under the Plan, without the written consent of the
Grantee of such Award.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 20 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 16.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Section&nbsp;409A</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt">16.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Awards
Subject to Code Section&nbsp;409A</U>. Notwithstanding any provision of the Plan or an Award to the contrary, if any Award or benefit
provided under this Plan is subject to the provisions of Section 409A of the Code (&ldquo;Section 409A&rdquo;), such provision or Award
shall (if the Committee so determines) be administered, interpreted and construed in a manner necessary to comply with Section 409A or
an exception thereto (or disregarded to the extent such provision cannot be so administered, interpreted or construed). In such case,
the following provisions shall apply, as applicable:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 36.05pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of Section 409A, and to the extent the Committee determines applicable to any Award or benefit under the Plan, it is intended
that distribution events qualify as permissible distribution events for purposes of Section 409A and shall be interpreted and construed
accordingly. With respect to payments subject to Section 409A, the Company reserves the right to accelerate and/or defer any payment whether
or not permitted and consistent with Section 409A. Whether a Grantee has separated from service or employment will be determined based
on all of the facts and circumstances and, to the extent the Committee determines applicable to any Award or benefit, in accordance with
the guidance issued under Section 409A.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 36.05pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent the Committee determines applicable, the grant of Non-Qualified Stock Options and other stock rights shall be granted under
terms and conditions consistent with Treas. Reg. &sect; 1.409A-1(b)(5) such that any such Award does not constitute a deferral of compensation
under Section 409A.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 36.05pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
no event shall any member of the Board, the Committee or the Company (or its employees, officers or directors) have any liability to any
Grantee (or any other Person) due to the failure of an Award to satisfy the requirements of Section 409A.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.95pt; text-align: justify; text-indent: 36.05pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything herein or in any Award Agreement to the contrary, to the extent that distribution of a 409A Award is triggered by a Grantee&rsquo;s
Separation from Service, if the Grantee is then a &ldquo;specified employee&rdquo; (as defined in Treasury Regulation Section&nbsp;1.409A-1(i)),
no distribution may be made before the date which is six (6)&nbsp;months after such Grantee&rsquo;s Separation from Service, or, if earlier,
the date of the Grantee&rsquo;s death.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 17.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Withholding</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Required
Withholding</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee in its sole discretion may provide that when taxes are to be withheld in connection with any Award (the &ldquo;Tax Date&rdquo;).
The Grantee may elect to make payment for the withholding of federal, state and local taxes, including Social Security and Medicare (&ldquo;FICA&rdquo;)
taxes by one or a combination of the following methods:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;payment
of an amount in cash equal to the amount to be withheld;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;delivering
part or all of the amount to be withheld in the form of Common Stock valued at its Fair Market Value on the Tax Date;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 21 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requesting
the Company to withhold from those Shares that would otherwise be received pursuant to an Award, a number of Shares having a Fair Market
Value on the Tax Date equal to the amount to be withheld; or</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;withholding
from any compensation otherwise due to the Grantee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The Committee in its
sole discretion may provide that the maximum amount of such tax withholding shall not exceed the minimum amount of taxes, including FICA
taxes, required to be withheld under federal, state and local law. An election by Grantee under this subsection is irrevocable. Any fractional
share amount and any additional withholding not paid by the withholding or surrender of Shares must be paid in cash. If no timely election
is made, the Grantee must deliver cash to satisfy all tax withholding requirements.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Grantee who makes a Disqualifying Disposition (as defined in Section&nbsp;6.4(f)) or an election under Section&nbsp;83(b) of the Code
shall remit to the Company an amount sufficient to satisfy all resulting tax withholding requirements in the same manner as set forth
in subsection (a).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notification
under Code Section&nbsp;83(b)</U>. If the Grantee, in connection with the grant of any publically traded Option, or the grant of Restricted
Shares, makes the election permitted under Section&nbsp;83(b) of the Code to include in such Grantee&rsquo;s gross income in the year
of transfer the amounts specified in Section&nbsp;83(b) of the Code, then such Grantee shall notify the Company of such election within
10 days of filing the notice of the election with the Internal Revenue Service, in addition to any filing and notification required pursuant
to regulations issued under Section&nbsp;83(b) of the Code. The Committee may, in connection with the grant of an Award or at any time
thereafter, prohibit a Grantee from making the election described in this section 17.2.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Article 18.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Additional Provisions</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors</U>.
Subject to Section&nbsp;4.2(b), all obligations of the Company under the Plan with respect to Awards granted hereunder shall be binding
on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation,
or otherwise of all or substantially all of the business and/or assets of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any part of the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity
shall not invalidate any other part of the Plan. Any Section or part of a Section so declared to be unlawful or invalid shall, if possible,
be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while
remaining lawful and valid.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Requirements
of Law</U>. The granting of Awards and the delivery of Shares under the Plan shall be subject to all applicable laws, rules, and regulations,
and to such approvals by any governmental agencies or national securities exchanges as may be required by the same. Notwithstanding any
provision of the Plan or any Award, Grantees shall not be entitled to exercise, or receive benefits under, any Award, and the Company
(and any Affiliate) shall not be obligated to deliver any Shares or deliver benefits to a Grantee, if such exercise or delivery would
constitute a violation by the Grantee or the Company of any applicable law or regulation.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 22 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Law Compliance</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Committee deems it necessary to comply with any applicable securities law, or the requirements of any stock exchange upon which Shares
may be listed, the Committee may impose any restriction on Awards or Shares acquired pursuant to Awards under the Plan as it may deem
advisable. In addition, if requested by the Company or any underwriter engaged by the Company, Shares acquired pursuant to Awards may
not be sold or otherwise transferred or disposed of for such period following the effective date of any registration statement of the
Company filed under the Securities Act as the Company or such underwriter shall specify reasonably and in good faith. All certificates
for Shares delivered under the Plan pursuant to any Award or the exercise thereof shall be subject to such stop transfer orders and other
restrictions as the Committee may deem advisable under the rules, regulations and other requirements of the SEC, any stock exchange upon
which Shares are then listed, any applicable securities or other law, and the Committee may cause a legend or legends to be put on any
such certificates to make appropriate reference to such restrictions. If so requested by the Company, the Grantee shall make a written
representation to the Company that he or she will not sell or offer to sell any Shares unless a registration statement shall be in effect
with respect to such Shares under the Securities Act of 1933, as amended, and any applicable state securities law.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Committee determines that the exercise or nonforfeitability of, or delivery of benefits pursuant to, any Award would violate any applicable
provision of securities or other laws or the listing requirements of any national securities exchange or national market system on which
are listed any of the Company&rsquo;s equity securities, then the Committee may postpone any such exercise, nonforfeitability or delivery,
as applicable, but the Company shall use all reasonable efforts to cause such exercise, nonforfeitability or delivery to comply with all
such provisions at the earliest practicable date.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forfeiture
Events</U>. Notwithstanding any provisions herein to the contrary, the Committee shall have the discretionary authority at any time to
determine that a Grantee&rsquo;s (including his or her estate&rsquo;s, beneficiary&rsquo;s or transferee&rsquo;s) rights , payments and
benefits with respect to any Award shall be subject to reduction, cancellation, forfeiture or recoupment in the event of the Grantee&rsquo;s
serious misconduct; violation of the Company&rsquo;s or an Affiliate&rsquo;s policies; breach of fiduciary duty; unauthorized disclosure
of any trade secret or confidential information of the Company or an Affiliate; breach of applicable noncompetition, nonsolicitation,
confidentiality or other restrictive covenants; or other conduct or activity that is in competition with the business of the Company or
an Affiliate, or otherwise detrimental to the business, reputation or interests of the Company and/or an Affiliate; or upon the Grantee&rsquo;s
termination for Cause or the occurrence of certain events specified in the applicable Award Agreement (in any such case, whether or not
the Grantee is then an Eligible Person). The determination of whether a Grantee&rsquo;s conduct, activities or circumstances are described
in the immediately preceding sentence shall be made by the Committee in its discretion, and pending any such determination, the Committee
shall have the authority to suspend the exercise, payment, delivery or settlement of all or any portion of such Grantee&rsquo;s outstanding
Awards pending any investigation of the matter.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as a Stockholder</U>. No Grantee shall have any rights as a stockholder of the Company with respect to the Shares which may be
deliverable upon exercise or payment of such Award until such Shares have been delivered to him or her, except that Restricted Shares,
whether held by a Grantee or in escrow by the Secretary of the Company, shall confer on the Grantee all rights of a stockholder of the
Company, except as otherwise provided in the Plan or Award Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nature
of Payments</U>. Unless otherwise specified in the Award Agreement, Awards shall be special incentive payments to the Grantee and shall
not be taken into account in computing the amount of salary or compensation of the Grantee for purposes of determining any benefit under
(a)&nbsp;any pension, retirement, profit sharing, bonus, insurance or other employee benefit plan of the Company or any</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 23 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Affiliate, except as such plan shall otherwise expressly
provide, or (b)&nbsp;any agreement between (i)&nbsp;the Company or any Affiliate and (ii)&nbsp;the Grantee, except as such agreement shall
otherwise expressly provide.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Exclusivity
of Plan</U>. Neither the adoption of the Plan by the Board nor its submission to the stockholders of the Company for approval shall be
construed as creating any limitations on the power of the Board to adopt other compensatory arrangements for Eligible Persons as it may
deem desirable.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. The Plan, and all Award Agreements hereunder, shall be construed in accordance with and governed by the laws of the State of
New York, other than its laws respecting choice or conflicts of law rule or principles that might otherwise refer construction or interpretation
of the same to the substantive law of another jurisdiction. Unless otherwise provided in an Award Agreement, all Eligible Persons are
deemed to submit to the exclusive jurisdiction and venue of the federal or state courts of the Eastern District of State of New York,
to resolve any and all issues that may arise out of or relate to the Plan or any related Award Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Unfunded
Status of Awards; Creation of Trusts</U>. The Plan is intended to constitute an &ldquo;unfunded&rdquo; plan for incentive and deferred
compensation. With respect to any payments not yet made to a Grantee pursuant to an Award, nothing contained in the Plan or any Award
Agreement shall give any such Grantee any rights that are greater than those of a general creditor of the Company; provided, however,
that the Committee may authorize the creation of trusts or make other arrangements to meet the Company&rsquo;s obligations under the Plan
to deliver cash, Shares or other property pursuant to any Award which trusts or other arrangements shall be consistent with the &ldquo;unfunded&rdquo;
status of the Plan unless the Committee otherwise determines.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Affiliation</U>.
Nothing in the Plan or an Award Agreement shall interfere with or limit in any way the right of the Company or any Affiliate to terminate
any Grantee&rsquo;s employment or consulting contract at any time, nor confer upon any Grantee the right to continue in the employ of
or as an officer of or as a consultant to, or Director of the Company or any Affiliate.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Participation</U>.
No employee, officer, consultant, director or any other person shall have the right to be selected to receive an Award under this Plan
or, having been so selected, to be selected to receive a future Award.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.13<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Notices</U>.
Any notice to be given to the Company pursuant to the provisions of the Plan will be given by registered or certified mail, postage prepaid,
or by recognized overnight delivery service, and addressed, if to the Company to its Secretary (or such other person as the Company may
designate in writing from time to time) at its principal executive office, and, if to an Eligible Person, to the address given beneath
his or her signature on his or her Award Agreement, or at such other address as such Eligible Person may hereafter designate in writing
to the Company. Any such notice will be deemed duly given on the date and at the time delivered via recognized overnight delivery service
or, if mailed, on the date five (5) days after the date of the mailing.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The following rules of construction will apply to the Plan: (a)&nbsp;the word &ldquo;or&rdquo; is disjunctive but not necessarily exclusive,
and (b)&nbsp;words in the singular include the plural, words in the plural include the singular, and words in the neuter gender include
the masculine and feminine genders and words in the masculine or feminine gender include the neuter gender.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 24 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings of articles and sections are included solely for convenience of reference, and if there is any conflict between such headings
and the text of this Plan, the text shall control.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.16&nbsp;&nbsp;&nbsp;&nbsp;<U>Obligations</U>.
Unless otherwise specified in the Award Agreement, the obligation to deliver, pay or transfer any amount of money or other property pursuant
to Awards under this Plan shall be the sole obligation of a Grantee&rsquo;s employer; provided that the obligation to deliver or transfer
any Shares pursuant to Awards under this Plan shall be the sole obligation of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.17&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Right to Continue as Director</U>. Nothing in the Plan or any Award Agreement shall confer upon any Non-Employee Director the right to
continue to serve as a director of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.18&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder
Approval</U>. All Incentive Stock Options granted on or after the Effective Date and prior to the date the Company&rsquo;s stockholders
approve the Plan are expressly conditioned upon and subject to approval of the Plan by the Company&rsquo;s stockholders.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 25 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>ex_10-3.htm
<DESCRIPTION>FORM OF NON-QUALIFIED/INCENTIVE STOCK OPTION AWARD AGREEMENT
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 12pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 10.3</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NONQUALIFIED STOCK OPTION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AGREEMENT UNDER THE REPRO MED SYSTEMS, INC.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2021 OMNIBUS EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 7in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2.51in"><FONT STYLE="font-size: 12pt"><B>Name of Grantee:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 2.09in"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="width: 2.3in"><FONT STYLE="font-size: 12pt">(the &ldquo;Grantee&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>No. of Shares Underlying Options:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(the &ldquo;Underlying Shares&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>Grant Date:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(the &ldquo;Grant Date&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>Vesting Commencement Date:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(&ldquo;Vesting Commencement Date&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>Expiration Date:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(the &ldquo;Expiration Date&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>Exercise Price/Share:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(the &ldquo;Exercise Price&rdquo;)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Pursuant to the Repro Med Systems, Inc. 2021 Omnibus Equity Incentive Plan
(the &ldquo;Plan&rdquo;), Repro Med Systems, Inc., a New York corporation (together with all successors thereto, the &ldquo;Company&rdquo;),
hereby grants to the Grantee, an Option to purchase, on or prior to the Expiration Date (or such earlier date as provided below), all
or any part of the number of Shares of Common Stock of the Company indicated above (the &ldquo;Underlying Shares,&rdquo; with such Shares
once issued being referred to herein as &ldquo;Option Shares&rdquo;) at the Exercise Price per share indicated above.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Notwithstanding anything in this Nonqualified Stock Option Agreement
(the &ldquo;Agreement&rdquo;) to the contrary, this Option and any Option Shares acquired upon shall be subject to, and governed by,
all the terms and conditions of the Plan. To the extent there is any inconsistency between the terms of the Plan and of this
Agreement, the terms of the Plan shall control.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">All capitalized terms used in this Agreement and not otherwise defined
shall have the respective meanings given such terms in the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Vesting
and Exercisability</U>.</B> Subject to such further limitations as are provided in the Plan and as set forth herein, the Option shall
vest and become exercisable: [with respect to 25% of the Underlying Shares on each of the first (1st), second (2nd), third (3rd) and fourth
(4th) anniversaries of the Vesting Commencement Date until the Option is fully vested and exercisable on the fourth (4th) anniversary
of the Vesting Commencement Date.]</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exercise
of Option</U>.</B> Prior to the Expiration Date (or such earlier date provided below), the Grantee may exercise this Option by delivering
a Option exercise notice (an &ldquo;Exercise Notice&rdquo;) in the form of <U>Appendix A</U> hereto indicating his or her election to
purchase some or all of the Underlying Shares with respect to which this Option is exercisable at the time of such notice and paying the
Exercise Price for the number of Underlying Shares purchased. The Option may not be exercised for any fractional shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Affiliation</U>. Except as the Committee may otherwise expressly provide, or as may otherwise be expressly provided in any agreement
between the Company and the Grantee, if the Grantee has a Termination of Affiliation with the Company and all of its Affiliates, the period
within which the Grantee may exercise this Option may be subject to earlier termination as set forth below:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 1 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Affiliation Due to Death or Disability</U>. If the Grantee&rsquo;s Termination of Affiliation occurs by reason of such Grantee&rsquo;s
death or Disability, this Option may be exercised, to the extent exercisable on the date of such termination, by the Grantee or by the
Grantee&rsquo;s legal representative or legatee for a period of twelve (12) months from the date of such termination or until the Expiration
Date, if earlier.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forfeiture
Event</U>. If the Grantee has a Forfeiture Event, within the meaning of Section 18.5 of the Plan, all Options (unvested and vested) shall
terminate immediately.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Termination</U>. If the Grantee&rsquo;s Termination of Affiliation occurs for any reason other than death or Disability or Cause, this
Option may be exercised, to the extent exercisable on the date of such termination, by the Grantee until the earlier of (i) the date that
is three months from the date of the Grantee&rsquo;s Termination of Affiliation or (ii) the Expiration Date.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Treatment
of Unvested Options on Termination of Affiliation</U>. Any portion of this Option that is not exercisable on the date of the Grantee&rsquo;s
Termination of Affiliation for any reason shall terminate immediately and be null and void and of no further force and effect.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Status
of Option</U>.</B> This Option is intended not to qualify as an &ldquo;incentive stock option&rdquo; as defined in Section 422(b) of
the Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Withholding
Taxes</U>.</B> The Grantee agrees to make appropriate arrangements with the Company (or the appropriate Affiliate that employed the Grantee)
for the satisfaction of all applicable Federal, state, local and foreign income and employment tax withholding requirements, if any, arising
in connection with the exercise of the Option. The Grantee acknowledges and agrees that the Company may refuse to honor the exercise and
refuse to deliver Shares if the Grantee does not deliver or make arrangements to deliver such required withholding amounts to the Company
at the time of exercise.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Miscellaneous
Provisions</U>.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
and Modifications</U>. This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any of its terms
be effective. This Agreement may be changed, modified or terminated only by an agreement in writing signed by the Company and the Grantee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, requests, consents and other communications shall be in writing and be deemed given when delivered personally, by telex or
facsimile transmission or when received if mailed by first class registered or certified mail, postage prepaid. Notices to the Company
or the Grantee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been
furnished by such party in writing to the other.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which shall constitute one and the same document.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Non-assignable</U>.
All Options granted hereunder shall not be assignable or transferable other than by will or the laws of descent and distribution and may
be exercised, during the Grantee&rsquo;s lifetime, only by the Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">The foregoing Agreement is hereby accepted and the terms and conditions
thereof hereby agreed to by the undersigned as of the date first above written.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">REPRO MED SYSYEMS, INC.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">By: _______________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Name:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Title:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">The undersigned hereby acknowledges receiving and reviewing a copy of the
Plan and understands that the Option granted hereby is subject to the terms of the Plan and of this Agreement. This Agreement is hereby
accepted, and the terms and conditions thereof and of the Plan hereby agreed to, by the undersigned as of the date first above written.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">GRANTEE:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">__________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Name:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">DESIGNATION OF BENEFICIARY: _____________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0">Appendix A</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STOCK OPTION<BR>EXERCISE NOTICE</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Repro Med Systems, Inc.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Attention: Corporate Secretary</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the terms of the stock option
agreement between myself and Repro Med Systems, Inc. (the &ldquo;Company&rdquo;) dated ______________ (the &ldquo;Agreement&rdquo;),
under the Company&rsquo;s 2021 Omnibus Equity Incentive Plan, I, [Insert Name], hereby [Circle One] partially/fully exercise such
Option by including herein payment in the amount of $_________________ representing the purchase price for [Fill in number of
Underlying Shares] ___________________ Option Shares. I have chosen the following form(s) of payment:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">[&nbsp;&nbsp;]&nbsp;&nbsp;1.&nbsp;&nbsp;Cash</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">[&nbsp;&nbsp;]&nbsp;&nbsp;2.&nbsp;&nbsp;Personal, certified or bank check
payable to <B>Repro Med Systems, Inc., </B>or</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">[&nbsp;&nbsp;]&nbsp;&nbsp;3.&nbsp;&nbsp;Wire transfer.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Sincerely yours,</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Name:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">__________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Address:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">__________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INCENTIVE STOCK OPTION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AGREEMENT UNDER THE REPRO MED SYSTEMS, INC.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2021 OMNIBUS EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 7in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2.51in"><FONT STYLE="font-size: 12pt"><B>Name of Grantee:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 2.09in"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="width: 2.3in"><FONT STYLE="font-size: 12pt">(the &ldquo;Grantee&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>No. of Shares Underlying Options:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(the &ldquo;Underlying Shares&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>Grant Date:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(the &ldquo;Grant Date&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>Vesting Commencement Date:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(&ldquo;Vesting Commencement Date&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>Expiration Date:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(the &ldquo;Expiration Date&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 12pt"><B>Exercise Price/Share:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 12pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 12pt">(the &ldquo;Exercise Price&rdquo;)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Pursuant to the Repro Med Systems, Inc. 2021 Omnibus Equity Incentive Plan
(the &ldquo;Plan&rdquo;), Repro Med Systems, Inc., a New York corporation (together with all successors thereto, the &ldquo;Company&rdquo;),
hereby grants to the Grantee, an Option to purchase, on or prior to the Expiration Date (or such earlier date as provided below), all
or any part of the number of Shares of Common Stock of the Company indicated above (the &ldquo;Underlying Shares,&rdquo; with such Shares
once issued being referred to herein as &ldquo;Option Shares&rdquo;) at the Exercise Price per share indicated above.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Notwithstanding anything in this Incentive Stock Option Agreement (the
&ldquo;Agreement&rdquo;) to the contrary, this Option and any Option Shares acquired upon shall be subject to, and governed by, all the
terms and conditions of the Plan. To the extent there is any inconsistency between the terms of the Plan and of this Agreement, the terms
of the Plan shall control.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">All capitalized terms used in this Agreement and not otherwise defined
shall have the respective meanings given such terms in the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Vesting
and Exercisability</U>.</B> Subject to such further limitations as are provided in the Plan and as set forth herein, the Option shall
vest and become exercisable: [with respect to 25% of the Underlying Shares on each of the first (1st), second (2nd), third (3rd) and fourth
(4th) anniversaries of the Vesting Commencement Date until the Option is fully vested and exercisable on the fourth (4th) anniversary
of the Vesting Commencement Date.]</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Exercise
of Option</U>.</B> Prior to the Expiration Date (or such earlier date provided below), the Grantee may exercise this Option by delivering
a Option exercise notice (an &ldquo;Exercise Notice&rdquo;) in the form of <U>Appendix A</U> hereto indicating his or her election to
purchase some or all of the Underlying Shares with respect to which this Option is exercisable at the time of such notice and paying the
Exercise Price for the number of Underlying Shares purchased. The Option may not be exercised for any fractional shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Affiliation</U>. Except as the Committee may otherwise expressly provide, or as may otherwise be expressly provided in any agreement
between the Company and the Grantee, if the Grantee has a Termination of Affiliation with the Company and all of its Affiliates, the period
within which the Grantee may exercise this Option may be subject to earlier termination as set forth below:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 1 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Affiliation Due to Death or Disability</U>. If the Grantee&rsquo;s Termination of Affiliation occurs by reason of such Grantee&rsquo;s
death or Disability, this Option may be exercised, to the extent exercisable on the date of such termination, by the Grantee or by the
Grantee&rsquo;s legal representative or legatee for a period of twelve (12) months from the date of such termination or until the Expiration
Date, if earlier.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forfeiture
Event</U>. If the Grantee has a Forfeiture Event, within the meaning of Section 18.5 of the Plan, all Options (unvested and vested) shall
terminate immediately.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Termination</U>. If the Grantee&rsquo;s Termination of Affiliation occurs for any reason other than death or Disability or Cause, this
Option may be exercised, to the extent exercisable on the date of such termination, by the Grantee until the earlier of (i) the date that
is three months from the date of the Grantee&rsquo;s Termination of Affiliation or (ii) the Expiration Date.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Treatment
of Unvested Options on Termination of Affiliation</U>. Any portion of this Option that is not exercisable on the date of the Grantee&rsquo;s
Termination of Affiliation for any reason shall terminate immediately and be null and void and of no further force and effect.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Status
of Option</U>.</B> This Option is intended to qualify as an &ldquo;incentive stock option&rdquo; as defined in Section 422(b) of the Internal
Revenue Code of 1986, as amended. Notwithstanding any provision in this Agreement to the contrary, to the extent that any portion of this
Option exceeds $100,000 Limit (as described in Section 6.4(d) and (e) of the Plan) such portion of the Option shall not qualify as an
&ldquo;incentive stock option.&rdquo; In addition, this Option shall not qualify as an &ldquo;incentive stock option&rdquo; with respect
to the portion of the Option that is exercised more than 3 months after the Grantee ceases to be an employee of the Company or any Subsidiary
for any reason other than the Grantee&rsquo;s death or Disability.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Disqualifying
Dispositions</U>.</B> Within 10 days after any Disqualifying Disposition (as defined in Section 6.4(f) of the Plan) of Option Shares acquired
upon exercise of this Option, the Grantee shall notify the Company of such Disqualifying Disposition.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Withholding
Taxes</U>.</B> The Grantee agrees to make appropriate arrangements with the Company (or the appropriate Affiliate that employed the Grantee)
for the satisfaction of all applicable Federal, state, local and foreign income and employment tax withholding requirements, if any, arising
in connection with the exercise of the Option. The Grantee acknowledges and agrees that the Company may refuse to honor the exercise and
refuse to deliver Shares if the Grantee does not deliver or make arrangements to deliver such required withholding amounts to the Company
at the time of exercise.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Miscellaneous
Provisions</U>.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
and Modifications</U>. This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any of its terms
be effective. This Agreement may be changed, modified or terminated only by an agreement in writing signed by the Company and the Grantee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, requests, consents and other communications shall be in writing and be deemed given when delivered personally, by telex or
facsimile transmission or when received if mailed by first class registered or certified mail, postage prepaid. Notices to the Company
or the Grantee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been
furnished by such party in writing to the other.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which shall constitute one and the same document.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Non-assignable</U>.
All Options granted hereunder shall not be assignable or transferable other than by will or the laws of descent and distribution and may
be exercised, during the Grantee&rsquo;s lifetime, only by the Grantee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">The foregoing Agreement is hereby accepted and the terms and conditions
thereof hereby agreed to by the undersigned as of the date first above written.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">REPRO MED SYSYEMS, INC.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">By: _______________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Name:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Title:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">The undersigned hereby acknowledges receiving and reviewing a copy of the
Plan and understands that the Option granted hereby is subject to the terms of the Plan and of this Agreement. This Agreement is hereby
accepted, and the terms and conditions thereof and of the Plan hereby agreed to, by the undersigned as of the date first above written.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">GRANTEE:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Name:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">DESIGNATION OF BENEFICIARY: _____________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0">Appendix A</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STOCK OPTION<BR>EXERCISE NOTICE</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Repro Med Systems, Inc.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Attention: Corporate Secretary</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the terms of the stock option
agreement between myself and Repro Med Systems, Inc. (the &ldquo;Company&rdquo;) dated ______________ (the &ldquo;Agreement&rdquo;),
under the Company&rsquo;s 2021 Omnibus Equity Incentive Plan, I, [Insert Name], hereby [Circle One] partially/fully exercise such
Option by including herein payment in the amount of $_________________ representing the purchase price for [Fill in number of
Underlying Shares] ___________________ Option Shares. I have chosen the following form(s) of payment:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">[&nbsp;&nbsp;]&nbsp;&nbsp;1.&nbsp;&nbsp;Cash</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">[&nbsp;&nbsp;]&nbsp;&nbsp;2.&nbsp;&nbsp;Personal, certified or bank check
payable to <B>Repro Med Systems, Inc., </B>or</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">[&nbsp;&nbsp;]&nbsp;&nbsp;3.&nbsp;&nbsp;Wire transfer.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Sincerely yours,</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Name:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">__________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">Address:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 4in">__________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>5
<FILENAME>ex_10-4.htm
<DESCRIPTION>FORM OF INDEMNIFICATION AGMT. DIRECTORS & EXECUTIVE OFFICERS
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 12pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7in">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 10.4</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">INDEMNIFICATION AGREEMENT</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Indemnification Agreement
(this &ldquo;Agreement&rdquo;) is made as of _____________ __, 2021 by and between Repro Med Systems, Inc. d/b/a KORU Medical Systems,
a New York corporation (the &ldquo;Company&rdquo;), and ______________________ (&ldquo;Indemnitee&rdquo;).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, highly competent persons
have become more reluctant to serve publicly-held corporations as directors or officers or in other capacities unless they are provided
with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising
out of their service to and activities on behalf of the corporation and due to the fact that such exposure frequently bears no relationship
to compensation paid to such officers and directors;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and Indemnitee
recognize that plaintiffs often seek damages in such large amounts and the costs of litigation may be so enormous (whether or not the
case is meritorious), that the defense and/or settlement of such litigation is often beyond the personal resources of directors and officers;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company&rsquo;s Certificate
of Incorporation and Bylaws require indemnification of the officers and directors of the Company to the maximum extent permitted by the
laws of the State of New York and federal securities laws;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company, after reasonable
investigation, has determined that the liability insurance coverage presently available to the Company may be inadequate in certain circumstances
to cover all possible exposure for which Indemnitee should be protected;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, the uncertainties relating
to such insurance and to indemnification have increased the difficulty of attracting and retaining highly competent persons to serve as
directors and officers, and the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental
to the best interests of the Company&rsquo;s stockholders and that the Company should act to assure such persons that there will be increased
certainty of such protection in the future;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, it is reasonable, prudent
and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the
fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they
will not be so indemnified;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, this Agreement is a supplement
to and in furtherance of the Company&rsquo;s Certificate of Incorporation and Bylaws and any resolutions adopted pursuant thereto, and
shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, Indemnitee does not regard
the protection available under the Company&rsquo;s Certificate of Incorporation, Bylaws and insurance as adequate in the present circumstances,
and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in
such capacity, and Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company
on the condition that he be so indemnified;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and the covenants contained herein, intending to be legally bound, the Company and Indemnitee do hereby covenant and agree
as follows:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Services
to the Company.</U> Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company, as a director,
officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.
Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation
imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such
position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any other corporation,
limited liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving
at the Company&rsquo;s request as a director, officer, employee, agent or fiduciary) and Indemnitee. Indemnitee specifically acknowledges
that Indemnitee&rsquo;s employment with the Company (or any of its subsidiaries or any other corporation, limited liability company, partnership,
joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving at the Company&rsquo;s request as a director,
officer, employee, agent or fiduciary), if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without
cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company (or any of its subsidiaries
or any other corporation, limited liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which
Indemnitee was serving at the Company&rsquo;s request as a director, officer, employee, agent or fiduciary). The foregoing notwithstanding,
this Agreement shall continue in force after Indemnitee has ceased to serve as an officer or director of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions.</U>
As used in this Agreement:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;A &ldquo;Change in
Control&rdquo; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">i.&nbsp;&nbsp;&nbsp;&nbsp;<U>Acquisition
of Stock by Third Party</U>. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly,
of securities of the Company representing thirty-five percent (35%) or more of the combined voting power of the Company&rsquo;s then outstanding
securities;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">ii.&nbsp;&nbsp;&nbsp;<U>Change
in Board</U>. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals
who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered
into an agreement with the Company to effect a transaction described in Sections 2(a)(i), 2(a)(iii) or 2(a)(iv)) whose election by the
Board or nomination for election by the Company&rsquo;s stockholders was approved by a vote of at least two-thirds of the directors then
still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so
approved, cease for any reason to constitute at least a majority of the members of the Board;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">iii.&nbsp;&nbsp;<U>Corporate
Transactions</U>. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to
represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 51% of the
combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and
with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">iv.&nbsp;&nbsp;<U>Liquidation</U>.
The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by
the Company of all or substantially all of the Company&rsquo;s assets; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in">v.&nbsp;&nbsp;&nbsp;<U>Other
Events</U>. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of
Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below),
whether or not the Company is then subject to such reporting requirement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">For purposes of this Section 2(a), the following terms shall have the following
meanings:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(A)&nbsp;&ldquo;Exchange Act&rdquo;
shall mean the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(B)&nbsp;&ldquo;Person&rdquo;
shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude (i)
the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation
owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of
the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(C)&nbsp;&ldquo;Beneficial Owner&rdquo;
shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude
any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another
entity.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&ldquo;Corporate
Status&rdquo; describes the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of any
other corporation, limited liability company, partnership or joint venture, trust, employee benefit plan or other enterprise which such
person is or was serving at the request of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&ldquo;Disinterested
Director&rdquo; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is
sought by Indemnitee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&ldquo;Expenses&rdquo;
shall include all reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses,
duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses
of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or
preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection
with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any
cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii) for purposes of Section 13(d) only, Expenses incurred by
Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&rsquo;s rights under this Agreement, by litigation
or otherwise. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against
Indemnitee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&ldquo;Independent
Counsel&rdquo; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is,
nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party
(other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification
agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing,
the term &ldquo;Independent Counsel&rdquo; shall not include any person who, under the applicable standards of professional conduct then
prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&rsquo;s
rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and
to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement
or its engagement pursuant hereto.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&ldquo;Proceeding&rdquo;
shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry,
administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise
and whether of a civil, criminal, administrative legislative, or investigative nature, including any appeal therefrom, in which Indemnitee
was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was
a director or officer of the Company, by reason of any action taken by him or of any action on his part while acting as director or officer
of the Company, or by reason of the fact that he is or was serving at the request of the Company as a director, officer, employee or agent
of another corporation, limited liability company, partnership, joint venture, trust or other enterprise, in each case whether or not
serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of
expenses can be provided under this Agreement; except one initiated by an Indemnitee to enforce his rights under this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity
in Third-Party Proceedings.</U> The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee
is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company
to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable
law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his behalf
in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably
believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding had no reasonable cause
to believe that his conduct was unlawful.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity
in Proceedings by or in the Right of the Company.</U> The Company shall indemnify Indemnitee in accordance with the provisions of this
Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company
to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable
law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue
or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests
of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which
Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that any court in which
the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances
of the case, Indemnitee is fairly and reasonably entitled to indemnification.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
for Expenses of a Party Who is Wholly or Partly Successful.</U> Notwithstanding any other provisions of this Agreement, to the fullest
extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits
or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify
Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful
in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such
Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection
with each successfully resolved claim, issue or matter. If the Indemnitee is not wholly successful in such Proceeding, the Company also
shall indemnify Indemnitee against all Expenses reasonably incurred in connection with a claim, issue or matter related to any claim,
issue, or matter on which the Indemnitee was successful. For purposes of this Section and without limiting the foregoing, if any Proceeding
is disposed of, on the merits or otherwise (including a disposition without prejudice), without (i) the disposition being adverse to Indemnitee,
(ii) an adjudication that Indemnitee was liable to the Company, (iii) a plea of guilty or nolo contendere by Indemnitee, (iv) an adjudication
that Indemnitee did not act in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests
of the Company and (v) with respect to any criminal proceeding, an adjudication that Indemnitee had reasonable cause to believe Indemnitee&rsquo;s
conduct was unlawful, Indemnitee shall be considered for purposes of this Agreement to have been successful with respect thereto.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
For Expenses of a Witness.</U> Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law
and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise participates in any Proceeding to which
Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection
therewith.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Indemnification.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;Notwithstanding any
limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee
is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure
a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee
in connection with the Proceeding.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;For purposes of Section
7(a), the meaning of the phrase &ldquo;to the fullest extent permitted by applicable law&rdquo; shall include, but not be limited to:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
the fullest extent permitted by the provision of the New York Business Corporation Law (&ldquo;NYBCL&rdquo;) that authorizes or contemplates
additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the NYBCL, and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;to
the fullest extent authorized or permitted by any amendments to or replacements of the NYBCL adopted after the date of this Agreement
that increase the extent to which a corporation may indemnify its officers and directors.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 5 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exclusions.</U>
Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection
with any claim made against Indemnitee:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;for which payment
has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any
excess beyond the amount paid under any insurance policy or other indemnity provision; or</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;for any Proceedings
with respect to which final judgment is rendered against Indemnitee for payment of (i) an accounting of profits made from the purchase
and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as
defined in Section 2(a) hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by
the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the
sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from
an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;),
or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of
the Sarbanes-Oxley Act), or</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;any Proceeding involving
the enforcement of non-compete and/or non- disclosure agreements or the non-compete and/or non-disclosure provisions of employment, consulting
or similar agreements the Indemnitee may be a party to with the Company or any subsidiary of the Company or any other applicable foreign
or domestic corporation, partnership, joint venture, trust or other enterprise, if any; or</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;except as provided
in Section 13(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including
any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other
indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company
provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Advances
of Expenses.</U> The Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with
any Proceeding, and such advancement shall be made within thirty (30) days after receipt by the Corporation of (i) a statement or statements
from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of any Proceeding,
and (ii) an undertaking by or on behalf of Indemnitee to repay such amount or amounts, only if, and to the extent that, it shall ultimately
be determined that Indemnitee is not entitled to be indemnified by the Corporation as authorized by this Agreement or otherwise. Such
undertaking shall be accepted without reference to the financial ability of Indemnitee to make such repayment. Advances shall be unsecured
and interest free. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement,
including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. This Section 9 shall not
apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 8 or to any Proceeding for which the Company
has assumed the defense thereof in accordance with Section 10(b) of this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 6 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure
for Notification and Defense of Claim.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;Indemnitee shall
notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses
hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to
the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification
under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and
information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is
entitled to indemnification following the final disposition of such action, suit or proceeding. The omission by Indemnitee to notify the
Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this
Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The
Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee
has requested indemnification.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;In the event the
Company shall be obligated to pay the Expenses of Indemnitee with respect to a Proceeding, as provided in this Agreement, the Company
shall be entitled to assume the defense of such Proceeding, with counsel reasonably acceptable to Indemnitee, upon delivery of written
notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and retention of such counsel by
the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee
with respect to the same Proceeding, provided that (1) Indemnitee shall have the right to employ Indemnitee&rsquo;s own counsel in such
Proceeding at Indemnitee&rsquo;s expense and (2) if (i) the employment of counsel by Indemnitee has been previously authorized in writing
by the Company, (ii) counsel to the Company or Indemnitee shall have reasonably concluded that there may be a conflict of interest or
position, or reasonably believes that a conflict is likely to arise, on any significant issue between the Company and the Indemnitee in
the conduct of such defense or (iii) the Company shall not, in fact, have employed counsel to assume the defense of such Proceeding, then
the fees and expenses of Indemnitee&rsquo;s counsel shall be at the expense of the Company, except as otherwise expressly provided by
this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;The Company will
be entitled to participate in the Proceeding at its own expense.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure
Upon Application for Indemnification.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;Upon written request
by Indemnitee for indemnification pursuant to Section 10(a), a determination, if required by applicable law, with respect to Indemnitee&rsquo;s
entitlement thereto shall be made in the specific case: (i) if a Change in Control shall have occurred after the date of this Agreement,
by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control
shall not have occurred after the date of this Agreement, (A) by a majority vote of the Disinterested Directors, even though less than
a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even
though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct,
by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the
Disinterested Directors, by the stockholders of the Company; and, if it is so determined that Indemnitee is entitled to</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 7 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">indemnification, payment to Indemnitee
shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such
determination with respect to Indemnitee&rsquo;s entitlement to indemnification, including providing to such person, persons or entity
upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which
is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys&rsquo;
fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be
borne by the Company (irrespective of the determination as to Indemnitee&rsquo;s entitlement to indemnification) and the Company hereby
indemnifies and agrees to hold Indemnitee harmless therefrom.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;In the event the
determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 11(a) hereof, the Independent
Counsel shall be selected as provided in this Section 11(b). If a Change in Control shall not have occurred after the date of this Agreement,
the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising him of the identity
of the Independent Counsel so selected. If a Change in Control shall have occurred after the date of this Agreement, the Independent Counsel
shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding
sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel
so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection
shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; <U>provided</U>,
<U>however</U>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements
of &ldquo;Independent Counsel&rdquo; as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the
factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such
written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until
such objection is withdrawn or a court has determined that such objection is without merit. If, within twenty (20) days after the submission
by Indemnitee or the Company, as the case may be, of a written objection, no Independent Counsel shall have been selected and not objected
to, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been
made by the Company or Indemnitee to the other&rsquo;s selection of Independent Counsel and/or for the appointment as Independent Counsel
of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom all objections
are so resolved or the person so appointed shall act as Independent Counsel under Section 11(a) hereof. Upon the due commencement of any
judicial proceeding or arbitration pursuant to Section 13(a) of this Agreement, Independent Counsel shall be discharged and relieved of
any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Presumptions
and Effect of Certain Proceedings.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;In making a determination
with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest
extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted
a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company shall, to the fullest extent not prohibited
by law, have the burden of proof to overcome that</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 8 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">presumption in connection with the
making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including
by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement
that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination
by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct,
shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;Subject to Section
13(e), if the person, persons or entity empowered or selected under Section 11 of this Agreement to determine whether Indemnitee is entitled
to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the
requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made
and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of
a material fact necessary to make Indemnitee&rsquo;s statement not materially misleading, in connection with the request for indemnification,
or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable
time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement
to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating
thereto; and provided, further, that the foregoing provisions of this Section 12(b) shall not apply (i) if the determination of entitlement
to indemnification is to be made by the stockholders pursuant to Section 11(a) of this Agreement and if (A) within fifteen (15) days after
receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for
their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is
made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making
such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is
made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section
11(a) of this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;The termination of
any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of <U>nolo contendere</U>
or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee
to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be
in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause
to believe that his conduct was unlawful.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;<U>Reliance as Safe
Harbor</U>. For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee&rsquo;s
action is based on the records or books of account of the Company or other corporation, limited liability company, partnership, joint
venture, trust employee benefit plan or other enterprise of which Indemnitee was serving as a director, officer, employee, agent or fiduciary,
including financial statements, or on information supplied to Indemnitee by the officers of the Company or other corporation, limited
liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving as a</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 9 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">director, officer, employee, agent
or fiduciary in the course of their duties, or on the advice of legal counsel for the enterprise or on information or records given or
reports made to the Company or other corporation, limited liability company, partnership, joint venture, trust employee benefit plan or
other enterprise of which Indemnitee was serving as a director, officer, employee, agent or fiduciary by an independent certified public
accountant or by an appraiser or other expert selected with the reasonable care by the Company or other corporation, limited liability
company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving as a director, officer,
employee, agent or fiduciary. The provisions of this Section 12(d) shall not be deemed to be exclusive or to limit in any way the other
circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;<U>Actions of Others</U>.
The knowledge and/or actions, or failure to act, of any other director, officer, agent or employee of the Company or other corporation,
limited liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving
as a director, officer, employee, agent or fiduciary shall not be imputed to Indemnitee for purposes of determining the right to indemnification
under this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies
of Indemnitee.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;Subject to Section
13(e), in the event that (i) a determination is made pursuant to Section 11 of this Agreement that Indemnitee is not entitled to indemnification
under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 9 of this Agreement, (iii) no determination
of entitlement to indemnification shall have been made pursuant to Section 11(a) of this Agreement within ninety (90) days after receipt
by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5 or 6 or the last
sentence of Section 11(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment
of indemnification pursuant to Section 3, 4 or 7 of this Agreement is not made within ten (10) days after a determination has been made
that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any
action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or
to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled
to an adjudication by a court of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his
option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American
Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days
following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 13(a); <U>provided</U>,
<U>however</U>, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under
Section 5 of this Agreement. The Company shall not oppose Indemnitee&rsquo;s right to seek any such adjudication or award in arbitration.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;In the event that
a determination shall have been made pursuant to Section 11(a) of this Agreement that Indemnitee is not entitled to indemnification, any
judicial proceeding or arbitration commenced pursuant to this Section 13 shall be conducted in all respects as a <U>de novo</U> trial,
or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding
or arbitration commenced pursuant to this Section 13 the Company shall have the burden of proving Indemnitee is not entitled to indemnification
or advancement of Expenses, as the case may be.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 10 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;If a determination
shall have been made pursuant to Section 11(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be
bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 13, absent (i) a misstatement
by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s statement not materially misleading,
in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;The Company shall,
to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant
to this Section 13 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in
any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the
Company that the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense
of Indemnitee&rsquo;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially
detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall indemnify Indemnitee against any and
all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor)
advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action
brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors&rsquo; and
officers&rsquo; liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be
entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;Notwithstanding anything
in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be
made prior to the final disposition of the Proceeding.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-exclusivity;
Survival of Rights; Insurance; Subrogation.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;The rights of indemnification
and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee
may at any time be entitled under applicable law, the Company&rsquo;s Certificate of Incorporation, the Company&rsquo;s By-laws, any agreement,
a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision
hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee
in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in New York law, whether by statute
or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company&rsquo;s
Certificate of Incorporation, the Company&rsquo;s By-laws and this Agreement, it is the intent of the parties hereto that Indemnitee shall
enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive
of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given
hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder,
or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 11 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;To the extent that
the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the
Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves
at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum
extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the
receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company
shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective
policies. The Company and the Indemnitee shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf
of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;In the event of any
payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee
with respect to any insurance policy, who shall execute all papers required and take all action necessary to secure such rights, including
execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;The Company shall
not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder)
hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement
or otherwise.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;The Company&rsquo;s
obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director,
officer, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan
or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from
such other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability.</U>
If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)
the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of
any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid,
illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted
by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the
maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including,
without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable,
that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforcement</U>.
The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon
this Agreement in serving as a director or officer of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 12 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement. Supersedes Prior Agreements</U>. This Agreement constitutes the entire agreement between the parties hereto with respect to
the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto
with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate
of Incorporation of the Company and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights
of Indemnitee thereunder.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification
and Waiver.</U> No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties
thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of
this Agreement nor shall any waiver constitute a continuing waiver.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
by Indemnitee.</U> Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena,
complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement
of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which
it may have to the Indemnitee under this Agreement or otherwise except to the extent the Corporation is prejudiced in its defense of such
action, suit or proceeding as a result of such failure.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices.</U>
All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly
given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b)
mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed
by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d)
sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;If to Indemnitee,
to such address as Indemnitee shall provide to the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;If to the Company,
to Repro Med Systems, Inc., 24 Carpenter Road, Chester NY 10918, Attention: Chairman of the Board, or to any other address as may have
been furnished to Indemnitee by the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution.</U>
To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee
for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether
for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim
relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances
of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or
transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees
and agents) and Indemnitee in connection with such event(s) and/or transaction(s).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable
Law and Consent to Jurisdiction.</U> This Agreement and the legal relations among the parties shall be governed by, and construed and
enforced in accordance with, the laws of the</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 13 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">State of New York, without regard to its conflict
of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 13(a) of this Agreement, the Company
and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this
Agreement shall be brought in a New York state court or federal court sitting in New York, (ii) consent to submit to the exclusive jurisdiction
of such court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection
to the laying of venue of any such action or proceeding in such court, and (iv) waive, and agree not to plead or to make, any claim that
any such action or proceeding brought in such court has been brought in an improper or inconvenient forum.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Identical
Counterparts.</U> This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an
original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against
whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous.</U>
Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs
of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction
thereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 14 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

<P STYLE="break-before: always"></P><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have caused this Indemnification
Agreement to be signed as of the day and year first above written.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">THE COMPANY:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">REPRO MED SYSTEMS, INC.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">By: ____________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Name:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Title:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">INDEMNITEE:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">________________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Name:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 14 -</P> <HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>ex_31-1.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Linda Tharby, Principal Executive Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 7.5in">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2">I have reviewed this Quarterly Report on Form 10-Q of Repro Med Systems, Inc. (the &ldquo;Report&rdquo;);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
        necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
        to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
        all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
        in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
        and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in
        Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 7in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
        to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
        within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
        our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
        for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
        about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
        and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
        most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
        or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
        over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
        persons performing this equivalent function):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
        reasonably likely to adversely affect registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
        internal control over financial reporting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: August 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>7
<FILENAME>ex_31-2.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL FINANCIAL OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Karen Fisher, Principal Financial Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 7.5in">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2">I have reviewed this Quarterly Report on Form 10-Q of Repro Med Systems, Inc. (the &ldquo;Report&rdquo;);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
        necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
        to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
        all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
        in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
        and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in
        Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 7in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
        to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
        within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
        our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
        for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
        about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
        and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
        most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
        or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
        over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
        persons performing this equivalent function):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
        reasonably likely to adversely affect registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
        internal control over financial reporting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: August 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Karen Fisher</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Karen Fisher</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>ex_32-1.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Quarterly Report of Repro Med Systems, Inc. (the
&ldquo;Company&rdquo;) on Form 10-Q (the &ldquo;Report&rdquo;) for the quarter ended June 30, 2021 as filed with the Securities and Exchange
Commission, I, Linda Tharby, Principal Executive Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 7.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD STYLE="width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
        the Company.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: August 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>9
<FILENAME>ex_32-2.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Quarterly Report of Repro Med Systems, Inc. (the
&ldquo;Company&rdquo;) on Form 10-Q (the &ldquo;Report&rdquo;) for the quarter ended June 30, 2021 as filed with the Securities and Exchange
Commission, I, Karen Fisher, Principal Financial Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 7.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD STYLE="width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
        the Company.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: August 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Karen Fisher</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Karen Fisher</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="width: 100%">

</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>krmd-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6I5w7xRiXgen8uPa3csWaCIGaPtzJZyOekxvmx6Hcn6ryMqnwNV3C4rCmp2caEK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:krmd="http://repro-med.com/20210630" elementFormDefault="qualified" targetNamespace="http://repro-med.com/20210630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://repro-med.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - BALANCE SHEETS (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000008 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000009 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000010 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/DebtObligations" id="DebtObligations">
	  <link:definition>00000011 - Disclosure - DEBT OBLIGATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/Leases" id="Leases">
	  <link:definition>00000012 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/Equity" id="Equity">
	  <link:definition>00000013 - Disclosure - EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000014 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000019 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" id="BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails">
	  <link:definition>00000020 - Disclosure - Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" id="FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details">
	  <link:definition>00000021 - Disclosure - The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000022 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" id="PropertyAndEquipmentConsistsOfFollowingAtDetails">
	  <link:definition>00000023 - Disclosure - Property and equipment consists of the following at: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000024 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/Stock-basedCompensationDetails" id="Stock-basedCompensationDetails">
	  <link:definition>00000025 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" id="FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails">
	  <link:definition>00000026 - Disclosure - The following table summarizes the status of the Plan with respect to time based stock options: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" id="FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details">
	  <link:definition>00000027 - Disclosure - The following table presents information pertaining to options outstanding at June 30, 2021: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" id="FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails">
	  <link:definition>00000028 - Disclosure - The following table summarizes the status of the Plan with respect to performance-based stock options: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" id="FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details">
	  <link:definition>00000029 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000030 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/DebtObligationsDetailsNarrative" id="DebtObligationsDetailsNarrative">
	  <link:definition>00000031 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" id="ComponentsOfLeaseExpenseWereAsFollowsDetails">
	  <link:definition>00000032 - Disclosure - The components of lease expense were as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" id="SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails">
	  <link:definition>00000033 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" id="SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails">
	  <link:definition>00000034 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" id="MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails">
	  <link:definition>00000035 - Disclosure - Maturities of lease liabilities are as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000036 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://repro-med.com/role/EquityDetailsNarrative" id="EquityDetailsNarrative">
	  <link:definition>00000037 - Disclosure - EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="krmd-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="krmd-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="krmd-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="krmd-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="krmd_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ManufacturingEquipmentAndToolingMember" name="ManufacturingEquipmentAndToolingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlan2015Member" name="StockOptionPlan2015Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ChiefExecutiveOfficerJamesMBeckMember" name="ChiefExecutiveOfficerJamesMBeckMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ChiefExecutiveOfficerLindaTharbyMember" name="ChiefExecutiveOfficerLindaTharbyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EmployeesAndConsultantsUnderThePlanMember" name="EmployeesAndConsultantsUnderThePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonEmployeeDirectorMember" name="NonEmployeeDirectorMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonEmployeeDirectorAndBoardAdvisorMember" name="NonEmployeeDirectorAndBoardAdvisorMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SettlementAgreementMember" name="SettlementAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EMEDTechnologiesCorporationMember" name="EMEDTechnologiesCorporationMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ChiefExecutiveOfficerDonaldPettigrewMember" name="ChiefExecutiveOfficerDonaldPettigrewMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TimeBasedSharesOptionsMember" name="TimeBasedSharesOptionsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExercisePrice1Member" name="ExercisePrice1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_KeyBankNationalAssociationMember" name="KeyBankNationalAssociationMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PromissoryNoteMember" name="PromissoryNoteMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_KeyEquipmentFinanceMember" name="KeyEquipmentFinanceMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ProgressPaymentLoanAndSecurityAgreementMember" name="ProgressPaymentLoanAndSecurityAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PurchaseAgreementMember" name="PurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PiperSandlerCoAndCanaccordGenuityLLCMember" name="PiperSandlerCoAndCanaccordGenuityLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockbasedLitigationSettlementExpense" name="StockbasedLitigationSettlementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_BorrowingsFromIndebtedness" name="BorrowingsFromIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CommonStockIssuanceAsSettlementForLitigation" name="CommonStockIssuanceAsSettlementForLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IssuanceOfCommonStockCompensation" name="IssuanceOfCommonStockCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LitigationSettlementOptions" name="LitigationSettlementOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" name="AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NewIssuanceLitigationSettlementAmountIssuance" name="NewIssuanceLitigationSettlementAmountIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NewIssuanceLitigationSettlementShareIssuance" name="NewIssuanceLitigationSettlementShareIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NewIssuanceOfCapitalRaiseAmount" name="NewIssuanceOfCapitalRaiseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NewIssuanceOfCapitalRaiseShares" name="NewIssuanceOfCapitalRaiseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AccountingPronouncementsNotYetAdopted" name="AccountingPronouncementsNotYetAdopted" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfNetSalesByGeography" name="ScheduleOfNetSalesByGeography" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonemployeeServicesTransactionCost" name="NonemployeeServicesTransactionCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AmountForChairingBoardCommittee" name="AmountForChairingBoardCommittee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" name="StockIssuedDuringPeriodSharesStockOptionsExercised1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DebtInstrumentPrepaidTerms" name="DebtInstrumentPrepaidTerms" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PrincipalAndInterestPayableTerms" name="PrincipalAndInterestPayableTerms" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost1Abstract" name="FinanceLeaseCost1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" name="AssetsAndLiabilitiesOperatingLesseeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" name="AssetsAndLiabilitiesLesseeFinanceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseImputedInterest" name="LesseeOperatingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseImputedInterest" name="LesseeFinancingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LessorOperatingLeaseOptionToTerminate1" name="LessorOperatingLeaseOptionToTerminate1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NumberOfSharesIssued" name="NumberOfSharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AdditionalNumberOfSharesIssued" name="AdditionalNumberOfSharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AmortizationOfIntangibleAssets1" name="AmortizationOfIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_BoardOfDirectorsMember" name="BoardOfDirectorsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CancellationOfCommonStock" name="CancellationOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CancellationOfCommonStockShares" name="CancellationOfCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CertificateOfDepositMaturedDate" name="CertificateOfDepositMaturedDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ChiefExecutiveOfficerMrGoldbergerMember" name="ChiefExecutiveOfficerMrGoldbergerMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EmploymentAgreementMember" name="EmploymentAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EquipmentAndToolingMember" name="EquipmentAndToolingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExchangeAmountForTransitionServices" name="ExchangeAmountForTransitionServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExercisePrice2Member" name="ExercisePrice2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IndependentDirectorsMember" name="IndependentDirectorsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_InterestRateOnCertificatesOfDeposit" name="InterestRateOnCertificatesOfDeposit" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LoanAgreementMember" name="LoanAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LoansFundedDate" name="LoansFundedDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_MrBeckMember" name="MrBeckMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NoncashExpense" name="NoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RelatedPartyTransactionAmountsOfTransaction1" name="RelatedPartyTransactionAmountsOfTransaction1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockAward1Member" name="RestrictedStockAward1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockAwardMember" name="RestrictedStockAwardMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfShareBasedCompensationSharesAuthorizedUnderPerformanceBaseStockOptionPlansByExercisePriceRangeTextBlock" name="ScheduleOfShareBasedCompensationSharesAuthorizedUnderPerformanceBaseStockOptionPlansByExercisePriceRangeTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TransitionServicesAgreementMember" name="TransitionServicesAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>krmd-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://repro-med.com/role/Cover" xlink:href="krmd-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BalanceSheets" xlink:href="krmd-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfOperations" xlink:href="krmd-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfCashFlows" xlink:href="krmd-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20210630.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipment" xlink:href="krmd-20210630.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/CommitmentsAndContingencies" xlink:href="krmd-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensation" xlink:href="krmd-20210630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/DebtObligations" xlink:href="krmd-20210630.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Leases" xlink:href="krmd-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Equity" xlink:href="krmd-20210630.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SubsequentEvents" xlink:href="krmd-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationTables" xlink:href="krmd-20210630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/LeasesTables" xlink:href="krmd-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:href="krmd-20210630.xsd#BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationDetails" xlink:href="krmd-20210630.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:href="krmd-20210630.xsd#FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20210630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20210630.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20210630.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20210630.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20210630.xsd#SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20210630.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/LeasesDetailsNarrative" xlink:href="krmd-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/EquityDetailsNarrative" xlink:href="krmd-20210630.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockbasedLitigationSettlementExpense" xlink:label="loc_krmdStockbasedLitigationSettlementExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_krmdStockbasedLitigationSettlementExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedTaxesPayable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="loc_krmdBorrowingsFromIndebtedness" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdBorrowingsFromIndebtedness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:label="loc_krmdCommonStockIssuanceAsSettlementForLitigation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdCommonStockIssuanceAsSettlementForLitigation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/CommitmentsAndContingencies" xlink:title="00000009 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/DebtObligations" xlink:title="00000011 - Disclosure - DEBT OBLIGATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Leases" xlink:title="00000012 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Equity" xlink:title="00000013 - Disclosure - EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentTables" xlink:title="00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationTables" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:title="00000020 - Disclosure - Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:title="00000021 - Disclosure - The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000023 - Disclosure - Property and equipment consists of the following at: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000024 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationDetails" xlink:title="00000025 - Disclosure - STOCK-BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:title="00000026 - Disclosure - The following table summarizes the status of the Plan with respect to time based stock options: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:title="00000027 - Disclosure - The following table presents information pertaining to options outstanding at June 30, 2021: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:title="00000028 - Disclosure - The following table summarizes the status of the Plan with respect to performance-based stock options: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:title="00000029 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000030 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/DebtObligationsDetailsNarrative" xlink:title="00000031 - Disclosure - DEBT OBLIGATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="00000032 - Disclosure - The components of lease expense were as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000033 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000034 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentOtherNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentOtherNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiability" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiability" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="00000035 - Disclosure - Maturities of lease liabilities are as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/LeasesDetailsNarrative" xlink:title="00000036 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://repro-med.com/role/EquityDetailsNarrative" xlink:title="00000037 - Disclosure - EQUITY (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>krmd-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://repro-med.com/role/Cover" xlink:href="krmd-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BalanceSheets" xlink:href="krmd-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfOperations" xlink:href="krmd-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfCashFlows" xlink:href="krmd-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20210630.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipment" xlink:href="krmd-20210630.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/CommitmentsAndContingencies" xlink:href="krmd-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensation" xlink:href="krmd-20210630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/DebtObligations" xlink:href="krmd-20210630.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Leases" xlink:href="krmd-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Equity" xlink:href="krmd-20210630.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SubsequentEvents" xlink:href="krmd-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationTables" xlink:href="krmd-20210630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/LeasesTables" xlink:href="krmd-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:href="krmd-20210630.xsd#BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationDetails" xlink:href="krmd-20210630.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:href="krmd-20210630.xsd#FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20210630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20210630.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20210630.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20210630.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20210630.xsd#SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20210630.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/LeasesDetailsNarrative" xlink:href="krmd-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/EquityDetailsNarrative" xlink:href="krmd-20210630.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LitigationSettlementOptions" xlink:label="loc_krmdLitigationSettlementOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdLitigationSettlementOptions_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" xlink:label="loc_krmdAdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdAdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:label="loc_krmdNewIssuanceLitigationSettlementAmountIssuance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceLitigationSettlementAmountIssuance_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:label="loc_krmdNewIssuanceLitigationSettlementShareIssuance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceLitigationSettlementShareIssuance_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceOfCapitalRaiseAmount" xlink:label="loc_krmdNewIssuanceOfCapitalRaiseAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceOfCapitalRaiseAmount_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceOfCapitalRaiseShares" xlink:label="loc_krmdNewIssuanceOfCapitalRaiseShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceOfCapitalRaiseShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/CommitmentsAndContingencies" xlink:title="00000009 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/DebtObligations" xlink:title="00000011 - Disclosure - DEBT OBLIGATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/Leases" xlink:title="00000012 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/Equity" xlink:title="00000013 - Disclosure - EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentTables" xlink:title="00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationTables" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:title="00000020 - Disclosure - Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_60" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_60" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_60" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_60" xlink:to="loc_us-gaapEarningsPerShareBasic_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_60" xlink:to="loc_us-gaapEarningsPerShareDiluted_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:title="00000021 - Disclosure - The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="loc_srtMortgageLoansOnRealEstateLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapRevenues_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000023 - Disclosure - Property and equipment consists of the following at: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000024 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationDetails" xlink:title="00000025 - Disclosure - STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:title="00000026 - Disclosure - The following table summarizes the status of the Plan with respect to time based stock options: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:title="00000027 - Disclosure - The following table presents information pertaining to options outstanding at June 30, 2021: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:title="00000028 - Disclosure - The following table summarizes the status of the Plan with respect to performance-based stock options: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:title="00000029 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000030 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_EmployeesAndConsultantsUnderThePlanMember" xlink:label="loc_krmdEmployeesAndConsultantsUnderThePlanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdEmployeesAndConsultantsUnderThePlanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerJamesMBeckMember" xlink:label="loc_krmdChiefExecutiveOfficerJamesMBeckMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdChiefExecutiveOfficerJamesMBeckMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:label="loc_krmdChiefExecutiveOfficerLindaTharbyMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdChiefExecutiveOfficerLindaTharbyMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerDonaldPettigrewMember" xlink:label="loc_krmdChiefExecutiveOfficerDonaldPettigrewMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdChiefExecutiveOfficerDonaldPettigrewMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonEmployeeDirectorMember" xlink:label="loc_krmdNonEmployeeDirectorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_SettlementAgreementMember" xlink:label="loc_krmdSettlementAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdSettlementAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_EMEDTechnologiesCorporationMember" xlink:label="loc_krmdEMEDTechnologiesCorporationMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdEMEDTechnologiesCorporationMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPSharesContributedToESOP_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPSharesContributedToESOP_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ExercisePrice" xlink:label="loc_krmdExercisePrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdExercisePrice_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AmountForChairingBoardCommittee" xlink:label="loc_krmdAmountForChairingBoardCommittee_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdAmountForChairingBoardCommittee_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_250" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_250" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_250" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_250" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_250" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/DebtObligationsDetailsNarrative" xlink:title="00000031 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_KeyBankNationalAssociationMember" xlink:label="loc_krmdKeyBankNationalAssociationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdKeyBankNationalAssociationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_KeyEquipmentFinanceMember" xlink:label="loc_krmdKeyEquipmentFinanceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdKeyEquipmentFinanceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PromissoryNoteMember" xlink:label="loc_krmdPromissoryNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_krmdPromissoryNoteMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapLineOfCreditMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_KeyBankNationalAssociationMember" xlink:label="loc_krmdKeyBankNationalAssociationMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_krmdKeyBankNationalAssociationMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ProgressPaymentLoanAndSecurityAgreementMember" xlink:label="loc_krmdProgressPaymentLoanAndSecurityAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdProgressPaymentLoanAndSecurityAgreementMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_DebtInstrumentPrepaidTerms" xlink:label="loc_krmdDebtInstrumentPrepaidTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_krmdDebtInstrumentPrepaidTerms_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapProceedsFromLoans_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PrincipalAndInterestPayableTerms" xlink:label="loc_krmdPrincipalAndInterestPayableTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_krmdPrincipalAndInterestPayableTerms_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="00000032 - Disclosure - The components of lease expense were as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000033 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000034 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="00000035 - Disclosure - Maturities of lease liabilities are as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/LeasesDetailsNarrative" xlink:title="00000036 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://repro-med.com/role/EquityDetailsNarrative" xlink:title="00000037 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PurchaseAgreementMember" xlink:label="loc_krmdPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PiperSandlerCoAndCanaccordGenuityLLCMember" xlink:label="loc_krmdPiperSandlerCoAndCanaccordGenuityLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdPiperSandlerCoAndCanaccordGenuityLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NumberOfSharesIssued" xlink:label="loc_krmdNumberOfSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_krmdNumberOfSharesIssued_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AdditionalNumberOfSharesIssued" xlink:label="loc_krmdAdditionalNumberOfSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_krmdAdditionalNumberOfSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="8" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>krmd-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">Non-US [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="krmd_FurnitureAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="krmd_ManufacturingEquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_lbl" xml:lang="en-US">Manufacturing Equipment And Tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="krmd_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Stock Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerJamesMBeckMember" xlink:label="krmd_ChiefExecutiveOfficerJamesMBeckMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerJamesMBeckMember" xlink:to="krmd_ChiefExecutiveOfficerJamesMBeckMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ChiefExecutiveOfficerJamesMBeckMember_lbl" xml:lang="en-US">James M. Beck [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:label="krmd_ChiefExecutiveOfficerLindaTharbyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:to="krmd_ChiefExecutiveOfficerLindaTharbyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ChiefExecutiveOfficerLindaTharbyMember_lbl" xml:lang="en-US">Linda Tharby [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_EmployeesAndConsultantsUnderThePlanMember" xlink:label="krmd_EmployeesAndConsultantsUnderThePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EmployeesAndConsultantsUnderThePlanMember" xlink:to="krmd_EmployeesAndConsultantsUnderThePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_EmployeesAndConsultantsUnderThePlanMember_lbl" xml:lang="en-US">Employees and Consultants under the Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonEmployeeDirectorMember" xlink:label="krmd_NonEmployeeDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorMember" xlink:to="krmd_NonEmployeeDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonEmployeeDirectorMember_lbl" xml:lang="en-US">Non-Employee Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xml:lang="en-US">Non-Employee Director and Board Advisor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_SettlementAgreementMember" xlink:label="krmd_SettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SettlementAgreementMember" xlink:to="krmd_SettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Series [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_EMEDTechnologiesCorporationMember" xlink:label="krmd_EMEDTechnologiesCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EMEDTechnologiesCorporationMember" xlink:to="krmd_EMEDTechnologiesCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_EMEDTechnologiesCorporationMember_lbl" xml:lang="en-US">EMED Technologies Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerDonaldPettigrewMember" xlink:label="krmd_ChiefExecutiveOfficerDonaldPettigrewMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerDonaldPettigrewMember" xlink:to="krmd_ChiefExecutiveOfficerDonaldPettigrewMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ChiefExecutiveOfficerDonaldPettigrewMember_lbl" xml:lang="en-US">Donald Pettigrew [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="krmd_TimeBasedSharesOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsMember" xlink:to="krmd_TimeBasedSharesOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TimeBasedSharesOptionsMember_lbl" xml:lang="en-US">Time Based Shares Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ExercisePrice1Member" xlink:label="krmd_ExercisePrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExercisePrice1Member_lbl" xml:lang="en-US">$ 0.38 - 3.15 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_RestrictedStockAwardsMember" xlink:label="krmd_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_KeyBankNationalAssociationMember" xlink:label="krmd_KeyBankNationalAssociationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_KeyBankNationalAssociationMember" xlink:to="krmd_KeyBankNationalAssociationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_KeyBankNationalAssociationMember_lbl" xml:lang="en-US">KeyBank National Association [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PromissoryNoteMember" xlink:label="krmd_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PromissoryNoteMember" xlink:to="krmd_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US">Line of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_KeyEquipmentFinanceMember" xlink:label="krmd_KeyEquipmentFinanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_KeyEquipmentFinanceMember" xlink:to="krmd_KeyEquipmentFinanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_KeyEquipmentFinanceMember_lbl" xml:lang="en-US">Key Equipment Finance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ProgressPaymentLoanAndSecurityAgreementMember" xlink:label="krmd_ProgressPaymentLoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ProgressPaymentLoanAndSecurityAgreementMember" xlink:to="krmd_ProgressPaymentLoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ProgressPaymentLoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Progress Payment Loan and Security Agreement And Master Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PurchaseAgreementMember" xlink:label="krmd_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PurchaseAgreementMember" xlink:to="krmd_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PiperSandlerCoAndCanaccordGenuityLLCMember" xlink:label="krmd_PiperSandlerCoAndCanaccordGenuityLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PiperSandlerCoAndCanaccordGenuityLLCMember" xlink:to="krmd_PiperSandlerCoAndCanaccordGenuityLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PiperSandlerCoAndCanaccordGenuityLLCMember_lbl" xml:lang="en-US">Piper Sandler &amp; Co. and Canaccord Genuity LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable less allowance for doubtful accounts of $24,469 for June 30, 2021, and December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $232,820 and $199,899 at June 30, 2021 and December 31, 2020, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Refer to Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value, 75,000,000 shares authorized, 47,910,676 and 46,680,119 shares issued 44,490,174 and 43,259,617 shares outstanding at June 30, 2021, and December 31, 2020, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 3,420,502 shares at June 30, 2021 and December 31, 2020, respectively, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained earnings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivable, allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Patents, accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">NET SALES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Litigation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Net Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Non-Operating Income/(Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Gain/(Loss) on currency exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">(Loss)/Gain on disposal of fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER INCOME/(EXPENSE)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Benefit/(Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockbasedLitigationSettlementExpense" xlink:label="krmd_StockbasedLitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockbasedLitigationSettlementExpense" xlink:to="krmd_StockbasedLitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockbasedLitigationSettlementExpense_lbl" xml:lang="en-US">Stock-based litigation settlement expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US">Deferred income taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">(Gain)/Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">(Increase)/Decrease in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Decrease/(Increase) in prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase in accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">(Decrease)/Increase in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl" xml:lang="en-US">Increase in accrued tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="krmd_BorrowingsFromIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BorrowingsFromIndebtedness" xlink:to="krmd_BorrowingsFromIndebtedness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_BorrowingsFromIndebtedness_lbl" xml:lang="en-US">Borrowings from indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:label="krmd_CommonStockIssuanceAsSettlementForLitigation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:to="krmd_CommonStockIssuanceAsSettlementForLitigation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CommonStockIssuanceAsSettlementForLitigation_lbl" xml:lang="en-US">Common stock issuance as settlement for litigation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAbstract_lbl" xml:lang="en-US">Cash paid during the periods for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Non-Cash Operating, Investing and Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_IssuanceOfCommonStockCompensation" xlink:label="krmd_IssuanceOfCommonStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IssuanceOfCommonStockCompensation" xlink:to="krmd_IssuanceOfCommonStockCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IssuanceOfCommonStockCompensation_lbl" xml:lang="en-US">Issuance of common stock as compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of common stock as settlement for litigation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of stock-based compensation (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense related to stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LitigationSettlementOptions" xlink:label="krmd_LitigationSettlementOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LitigationSettlementOptions" xlink:to="krmd_LitigationSettlementOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LitigationSettlementOptions_lbl" xml:lang="en-US">Litigation settlement options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" xlink:label="krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" xlink:to="krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards_lbl" xml:lang="en-US">Compensation expense related to restricted stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:label="krmd_NewIssuanceLitigationSettlementAmountIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:to="krmd_NewIssuanceLitigationSettlementAmountIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NewIssuanceLitigationSettlementAmountIssuance_lbl" xml:lang="en-US">Litigation settlement share issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:label="krmd_NewIssuanceLitigationSettlementShareIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:to="krmd_NewIssuanceLitigationSettlementShareIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NewIssuanceLitigationSettlementShareIssuance_lbl" xml:lang="en-US">Litigation settlement share issuance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance upon options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance upon options exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceOfCapitalRaiseAmount" xlink:label="krmd_NewIssuanceOfCapitalRaiseAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceOfCapitalRaiseAmount" xlink:to="krmd_NewIssuanceOfCapitalRaiseAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NewIssuanceOfCapitalRaiseAmount_lbl" xml:lang="en-US">Capital raise</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceOfCapitalRaiseShares" xlink:label="krmd_NewIssuanceOfCapitalRaiseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceOfCapitalRaiseShares" xlink:to="krmd_NewIssuanceOfCapitalRaiseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NewIssuanceOfCapitalRaiseShares_lbl" xml:lang="en-US">Capital raise (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT OBLIGATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">PATENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">PROPERTY, EQUIPMENT, AND DEPRECIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">NET INCOME PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AccountingPronouncementsNotYetAdopted" xlink:label="krmd_AccountingPronouncementsNotYetAdopted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AccountingPronouncementsNotYetAdopted" xlink:to="krmd_AccountingPronouncementsNotYetAdopted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AccountingPronouncementsNotYetAdopted_lbl" xml:lang="en-US">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">IMPAIRMENT OF LONG-LIVED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">RECLASSIFICATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and consultant stock options. See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ScheduleOfNetSalesByGeography" xlink:label="krmd_ScheduleOfNetSalesByGeography" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetSalesByGeography" xlink:to="krmd_ScheduleOfNetSalesByGeography_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfNetSalesByGeography_lbl" xml:lang="en-US">The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and equipment consists of the following at:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the status of the Plan with respect to time based stock options:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">The following table presents information pertaining to options outstanding at June 30, 2021:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the status of the Plan with respect to performance-based stock options:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">The components of lease expense were as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Supplemental cash flow information related to leases was as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Supplemental balance sheet information related to leases was as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Maturities of lease liabilities are as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted Average Outstanding Shares:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Option shares includable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="srt_MortgageLoansOnRealEstateLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateLineItems" xlink:to="srt_MortgageLoansOnRealEstateLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MortgageLoansOnRealEstateLineItems_lbl" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">FDIC cash uninsured amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Anti-dilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Weighted-average volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_lbl" xml:lang="en-US">Number of stock option shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Number of stock option shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ExercisePrice" xlink:label="krmd_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice" xlink:to="krmd_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of shares vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Description of vesting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Number of stock option shares issued, value</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="krmd_NonemployeeServicesTransactionCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonemployeeServicesTransactionCost_lbl" xml:lang="en-US">Nonemployee services transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AmountForChairingBoardCommittee" xlink:label="krmd_AmountForChairingBoardCommittee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmountForChairingBoardCommittee" xlink:to="krmd_AmountForChairingBoardCommittee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AmountForChairingBoardCommittee_lbl" xml:lang="en-US">Amount for chairing board committee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction_lbl" xml:lang="en-US">Description of non employee services transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xml:lang="en-US">Number of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Cash received from option exercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xml:lang="en-US">Tax benefits associated with stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average period (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Total fair value of shares vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Allocated stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Interest rate terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt instrument, principal and unpaid interest due</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_DebtInstrumentPrepaidTerms" xlink:label="krmd_DebtInstrumentPrepaidTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DebtInstrumentPrepaidTerms" xlink:to="krmd_DebtInstrumentPrepaidTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DebtInstrumentPrepaidTerms_lbl" xml:lang="en-US">Debt instrument, prepaid terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Loans, principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PrincipalAndInterestPayableTerms" xlink:label="krmd_PrincipalAndInterestPayableTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PrincipalAndInterestPayableTerms" xlink:to="krmd_PrincipalAndInterestPayableTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PrincipalAndInterestPayableTerms_lbl" xml:lang="en-US">Principal and interest payable terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="krmd_FinanceLeaseCost1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost1Abstract_lbl" xml:lang="en-US">Finance lease cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_FinanceLeaseCost" xlink:label="krmd_FinanceLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Financing cash flows from finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease long term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_lbl" xml:lang="en-US">Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Property and equipment, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Finance lease current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease long term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Total finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US">Finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021 (excluding the six months ended June 30, 2021)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021 (excluding the six months ended June 30, 2021)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted finance lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="krmd_LesseeOperatingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="krmd_LesseeFinancingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Total finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LessorOperatingLeaseOptionToTerminate1" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LessorOperatingLeaseOptionToTerminate1" xlink:to="krmd_LessorOperatingLeaseOptionToTerminate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1_lbl" xml:lang="en-US">Operating lease, options to terminate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NumberOfSharesIssued" xlink:label="krmd_NumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NumberOfSharesIssued" xlink:to="krmd_NumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NumberOfSharesIssued_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Option excercise period</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AdditionalNumberOfSharesIssued" xlink:label="krmd_AdditionalNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AdditionalNumberOfSharesIssued" xlink:to="krmd_AdditionalNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AdditionalNumberOfSharesIssued_lbl" xml:lang="en-US">Option to purchase additional number of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Option excercise date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US">Maximum amount of stock repurchase program</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares repurchased</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Aggregate amount stock repurchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AccountingPronouncementsNotYetAdopted" xlink:to="krmd_AccountingPronouncementsNotYetAdopted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AccountingPronouncementsNotYetAdopted_doc" xml:lang="en-US">The entire disclosure for accounting pronouncements not yet adopted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AdditionalNumberOfSharesIssued" xlink:to="krmd_AdditionalNumberOfSharesIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AdditionalNumberOfSharesIssued_doc" xml:lang="en-US">Represents additional number of shares issued.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="krmd_AmortizationOfIntangibleAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmortizationOfIntangibleAssets1" xlink:to="krmd_AmortizationOfIntangibleAssets1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AmortizationOfIntangibleAssets1_doc" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmountForChairingBoardCommittee" xlink:to="krmd_AmountForChairingBoardCommittee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AmountForChairingBoardCommittee_doc" xml:lang="en-US">Amount rerpesent for chairing board committee.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_BoardOfDirectorsMember" xlink:label="krmd_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BoardOfDirectorsMember" xlink:to="krmd_BoardOfDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_BoardOfDirectorsMember_doc" xml:lang="en-US">Represents member of board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BorrowingsFromIndebtedness" xlink:to="krmd_BorrowingsFromIndebtedness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_BorrowingsFromIndebtedness_doc" xml:lang="en-US">The amount of borrowings from indebtedness.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_CancellationOfCommonStock" xlink:label="krmd_CancellationOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CancellationOfCommonStock" xlink:to="krmd_CancellationOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CancellationOfCommonStock_doc" xml:lang="en-US">Repreents amount related to cancellations of common stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_CancellationOfCommonStockShares" xlink:label="krmd_CancellationOfCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CancellationOfCommonStockShares" xlink:to="krmd_CancellationOfCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CancellationOfCommonStockShares_doc" xml:lang="en-US">Repreents amount related to cancellations of common stock share.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_CertificateOfDepositMaturedDate" xlink:label="krmd_CertificateOfDepositMaturedDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CertificateOfDepositMaturedDate" xlink:to="krmd_CertificateOfDepositMaturedDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CertificateOfDepositMaturedDate_doc" xml:lang="en-US">Represent the certificate of deposit matured date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerDonaldPettigrewMember" xlink:to="krmd_ChiefExecutiveOfficerDonaldPettigrewMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ChiefExecutiveOfficerDonaldPettigrewMember_doc" xml:lang="en-US">Member represent donald pettigrew.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerJamesMBeckMember" xlink:to="krmd_ChiefExecutiveOfficerJamesMBeckMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ChiefExecutiveOfficerJamesMBeckMember_doc" xml:lang="en-US">Member represent james M beck.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:to="krmd_ChiefExecutiveOfficerLindaTharbyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ChiefExecutiveOfficerLindaTharbyMember_doc" xml:lang="en-US">Member linda thar by.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerMrGoldbergerMember" xlink:label="krmd_ChiefExecutiveOfficerMrGoldbergerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerMrGoldbergerMember" xlink:to="krmd_ChiefExecutiveOfficerMrGoldbergerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ChiefExecutiveOfficerMrGoldbergerMember_doc" xml:lang="en-US">Represents member of chief executive officer Mr Goldberger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:to="krmd_CommonStockIssuanceAsSettlementForLitigation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CommonStockIssuanceAsSettlementForLitigation_doc" xml:lang="en-US">Amount rerpesent common stock issuance as settlement for litigation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DebtInstrumentPrepaidTerms" xlink:to="krmd_DebtInstrumentPrepaidTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DebtInstrumentPrepaidTerms_doc" xml:lang="en-US">Description of dent instrument prepaid terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EMEDTechnologiesCorporationMember" xlink:to="krmd_EMEDTechnologiesCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_EMEDTechnologiesCorporationMember_doc" xml:lang="en-US">Information pertaining to EMED technologies corporation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EmployeesAndConsultantsUnderThePlanMember" xlink:to="krmd_EmployeesAndConsultantsUnderThePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_EmployeesAndConsultantsUnderThePlanMember_doc" xml:lang="en-US">Member represent employees and consultant under the plan.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_EmploymentAgreementMember" xlink:label="krmd_EmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EmploymentAgreementMember" xlink:to="krmd_EmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_EmploymentAgreementMember_doc" xml:lang="en-US">Represents member of employment agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_EquipmentAndToolingMember" xlink:label="krmd_EquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EquipmentAndToolingMember" xlink:to="krmd_EquipmentAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_EquipmentAndToolingMember_doc" xml:lang="en-US">Represents member of equipment and tooling.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ExchangeAmountForTransitionServices" xlink:label="krmd_ExchangeAmountForTransitionServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExchangeAmountForTransitionServices" xlink:to="krmd_ExchangeAmountForTransitionServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExchangeAmountForTransitionServices_doc" xml:lang="en-US">Amount rerpesent exchange amount for transition services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice" xlink:to="krmd_ExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExercisePrice_doc" xml:lang="en-US">Exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExercisePrice1Member_doc" xml:lang="en-US">Information pertaining to exercise price.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ExercisePrice2Member" xlink:label="krmd_ExercisePrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice2Member" xlink:to="krmd_ExercisePrice2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExercisePrice2Member_doc" xml:lang="en-US">Infformation pertaining to exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost_doc" xml:lang="en-US">The amount of finance lease cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_doc" xml:lang="en-US">Represents member of furniture and office equipment.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_IndependentDirectorsMember" xlink:label="krmd_IndependentDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IndependentDirectorsMember" xlink:to="krmd_IndependentDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_IndependentDirectorsMember_doc" xml:lang="en-US">Leader of the entity's board of directors who does not have a material or pecuniary relationship with company or related persons, except sitting fees.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_InterestRateOnCertificatesOfDeposit" xlink:label="krmd_InterestRateOnCertificatesOfDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_InterestRateOnCertificatesOfDeposit" xlink:to="krmd_InterestRateOnCertificatesOfDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_InterestRateOnCertificatesOfDeposit_doc" xml:lang="en-US">It refers the percentage of interest rate on certificate of deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IssuanceOfCommonStockCompensation" xlink:to="krmd_IssuanceOfCommonStockCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_IssuanceOfCommonStockCompensation_doc" xml:lang="en-US">Amount represent issuance of common stock compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_KeyBankNationalAssociationMember" xlink:to="krmd_KeyBankNationalAssociationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_KeyBankNationalAssociationMember_doc" xml:lang="en-US">The memmber represent key bank national association.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_KeyEquipmentFinanceMember" xlink:to="krmd_KeyEquipmentFinanceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_KeyEquipmentFinanceMember_doc" xml:lang="en-US">The member represent key equipment finance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_doc" xml:lang="en-US">Amount of lessee financing lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_doc" xml:lang="en-US">Represents lessee operating lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LitigationSettlementOptions" xlink:to="krmd_LitigationSettlementOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LitigationSettlementOptions_doc" xml:lang="en-US">Repreents amount related to litigation settlement options.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LoanAgreementMember" xlink:label="krmd_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LoanAgreementMember" xlink:to="krmd_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LoanAgreementMember_doc" xml:lang="en-US">The member represent loan agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LoansFundedDate" xlink:label="krmd_LoansFundedDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LoansFundedDate" xlink:to="krmd_LoansFundedDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LoansFundedDate_doc" xml:lang="en-US">Date which loans funded is set to expire, in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_doc" xml:lang="en-US">Represents the manufacturing equipment and tooling.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_MrBeckMember" xlink:label="krmd_MrBeckMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_MrBeckMember" xlink:to="krmd_MrBeckMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_MrBeckMember_doc" xml:lang="en-US">It is represent the mr beck.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:to="krmd_NewIssuanceLitigationSettlementAmountIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NewIssuanceLitigationSettlementAmountIssuance_doc" xml:lang="en-US">Represents amouont related to new issuance of litigation settlement amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:to="krmd_NewIssuanceLitigationSettlementShareIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NewIssuanceLitigationSettlementShareIssuance_doc" xml:lang="en-US">Repreents amount related to litigation settlement share in issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceOfCapitalRaiseAmount" xlink:to="krmd_NewIssuanceOfCapitalRaiseAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NewIssuanceOfCapitalRaiseAmount_doc" xml:lang="en-US">Represents amount related to new issuance of capital raise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceOfCapitalRaiseShares" xlink:to="krmd_NewIssuanceOfCapitalRaiseShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NewIssuanceOfCapitalRaiseShares_doc" xml:lang="en-US">The amount of capital raise in shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xml:lang="en-US">Member represent non employee director and board advisor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorMember" xlink:to="krmd_NonEmployeeDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonEmployeeDirectorMember_doc" xml:lang="en-US">Member represent non employee director.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NoncashExpense" xlink:label="krmd_NoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NoncashExpense" xlink:to="krmd_NoncashExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NoncashExpense_doc" xml:lang="en-US">Represents no cash expense amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonemployeeServicesTransactionCost_doc" xml:lang="en-US">Amount non employee services transaction cost.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PatentsAndTrademarksMember" xlink:label="krmd_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PatentsAndTrademarksMember" xlink:to="krmd_PatentsAndTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PatentsAndTrademarksMember_doc" xml:lang="en-US">Represents member of patents and trademarks.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PiperSandlerCoAndCanaccordGenuityLLCMember" xlink:to="krmd_PiperSandlerCoAndCanaccordGenuityLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PiperSandlerCoAndCanaccordGenuityLLCMember_doc" xml:lang="en-US">Represents member related to piper sandler Co and Canaaccord Genuity LLC.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PrincipalAndInterestPayableTerms" xlink:to="krmd_PrincipalAndInterestPayableTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PrincipalAndInterestPayableTerms_doc" xml:lang="en-US">The description of principal and interest payment terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ProgressPaymentLoanAndSecurityAgreementMember" xlink:to="krmd_ProgressPaymentLoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ProgressPaymentLoanAndSecurityAgreementMember_doc" xml:lang="en-US">The member represent progress payment loan and security agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PromissoryNoteMember" xlink:to="krmd_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PromissoryNoteMember_doc" xml:lang="en-US">The member represent promissory note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PurchaseAgreementMember" xlink:to="krmd_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PurchaseAgreementMember_doc" xml:lang="en-US">Represents purchase agreement member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_RelatedPartyTransactionAmountsOfTransaction1" xlink:label="krmd_RelatedPartyTransactionAmountsOfTransaction1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RelatedPartyTransactionAmountsOfTransaction1" xlink:to="krmd_RelatedPartyTransactionAmountsOfTransaction1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RelatedPartyTransactionAmountsOfTransaction1_doc" xml:lang="en-US">Amount of transactions with related party during the financial reporting period.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_RestrictedStockAward1Member" xlink:label="krmd_RestrictedStockAward1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAward1Member" xlink:to="krmd_RestrictedStockAward1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RestrictedStockAward1Member_doc" xml:lang="en-US">The information of restricted stock award.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_RestrictedStockAwardMember" xlink:label="krmd_RestrictedStockAwardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardMember" xlink:to="krmd_RestrictedStockAwardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RestrictedStockAwardMember_doc" xml:lang="en-US">The information of restricted stock award.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetSalesByGeography" xlink:to="krmd_ScheduleOfNetSalesByGeography_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfNetSalesByGeography_doc" xml:lang="en-US">Tabular disclosure of net sales by geography.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ScheduleOfShareBasedCompensationSharesAuthorizedUnderPerformanceBaseStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="krmd_ScheduleOfShareBasedCompensationSharesAuthorizedUnderPerformanceBaseStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationSharesAuthorizedUnderPerformanceBaseStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationSharesAuthorizedUnderPerformanceBaseStockOptionPlansByExercisePriceRangeTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfShareBasedCompensationSharesAuthorizedUnderPerformanceBaseStockOptionPlansByExercisePriceRangeTextBlock_doc" xml:lang="en-US">Tabular disclosure of performance base option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SettlementAgreementMember" xlink:to="krmd_SettlementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_SettlementAgreementMember_doc" xml:lang="en-US">Represents member of settlement agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">it refers the amount of share based payment award grants in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="krmd_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="krmd_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Number of shares of stock issued during the period pursuant to warrants exercised.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="krmd_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="krmd_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Value of stock issued pursuant to warrants exercised during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlan2015Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsMember" xlink:to="krmd_TimeBasedSharesOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TimeBasedSharesOptionsMember_doc" xml:lang="en-US">Information pertaining to time based shares options.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_TransitionServicesAgreementMember" xlink:label="krmd_TransitionServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TransitionServicesAgreementMember" xlink:to="krmd_TransitionServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TransitionServicesAgreementMember_doc" xml:lang="en-US">Member represent transition services agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockbasedLitigationSettlementExpense" xlink:to="krmd_StockbasedLitigationSettlementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockbasedLitigationSettlementExpense_doc" xml:lang="en-US">The amount of stock based litigation settlement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" xlink:to="krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards_doc" xml:lang="en-US">The amount of compensation expense related to restricted stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xml:lang="en-US">The shares represent unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">Represent unvested per shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xml:lang="en-US">Gross number of share options (or share units) granted during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Represent vested per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xml:lang="en-US">Represent vested shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xml:lang="en-US">The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LessorOperatingLeaseOptionToTerminate1" xlink:to="krmd_LessorOperatingLeaseOptionToTerminate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1_doc" xml:lang="en-US">Represent operating lease, options to terminate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NumberOfSharesIssued" xlink:to="krmd_NumberOfSharesIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NumberOfSharesIssued_doc" xml:lang="en-US">Number of shares issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_3_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xml:lang="en-US">Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xml:lang="en-US">Unvested (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xml:lang="en-US">Granted (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Granted (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Vested [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Forfeited [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_2_lbl" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xml:lang="en-US">Less: imputed interest [Default Label]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>krmd-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://repro-med.com/role/Cover" xlink:href="krmd-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BalanceSheets" xlink:href="krmd-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfOperations" xlink:href="krmd-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfCashFlows" xlink:href="krmd-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20210630.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipment" xlink:href="krmd-20210630.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/CommitmentsAndContingencies" xlink:href="krmd-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensation" xlink:href="krmd-20210630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/DebtObligations" xlink:href="krmd-20210630.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Leases" xlink:href="krmd-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Equity" xlink:href="krmd-20210630.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SubsequentEvents" xlink:href="krmd-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationTables" xlink:href="krmd-20210630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/LeasesTables" xlink:href="krmd-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:href="krmd-20210630.xsd#BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20210630.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="krmd-20210630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationDetails" xlink:href="krmd-20210630.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:href="krmd-20210630.xsd#FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:href="krmd-20210630.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20210630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20210630.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20210630.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20210630.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20210630.xsd#SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20210630.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/LeasesDetailsNarrative" xlink:href="krmd-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://repro-med.com/role/EquityDetailsNarrative" xlink:href="krmd-20210630.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockbasedLitigationSettlementExpense" xlink:label="loc_krmdStockbasedLitigationSettlementExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_krmdStockbasedLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedTaxesPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="loc_krmdBorrowingsFromIndebtedness" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdBorrowingsFromIndebtedness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:label="loc_krmdCommonStockIssuanceAsSettlementForLitigation" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdCommonStockIssuanceAsSettlementForLitigation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapAdditionalCashFlowElementsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_IssuanceOfCommonStockCompensation" xlink:label="loc_krmdIssuanceOfCommonStockCompensation" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_krmdIssuanceOfCommonStockCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LitigationSettlementOptions" xlink:label="loc_krmdLitigationSettlementOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdLitigationSettlementOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" xlink:label="loc_krmdAdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdAdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:label="loc_krmdNewIssuanceLitigationSettlementAmountIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceLitigationSettlementAmountIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:label="loc_krmdNewIssuanceLitigationSettlementShareIssuance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceLitigationSettlementShareIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceOfCapitalRaiseAmount" xlink:label="loc_krmdNewIssuanceOfCapitalRaiseAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceOfCapitalRaiseAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NewIssuanceOfCapitalRaiseShares" xlink:label="loc_krmdNewIssuanceOfCapitalRaiseShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceOfCapitalRaiseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/CommitmentsAndContingencies" xlink:title="00000009 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/DebtObligations" xlink:title="00000011 - Disclosure - DEBT OBLIGATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Leases" xlink:title="00000012 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Equity" xlink:title="00000013 - Disclosure - EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/SubsequentEvents" xlink:title="00000014 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AccountingPronouncementsNotYetAdopted" xlink:label="loc_krmdAccountingPronouncementsNotYetAdopted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdAccountingPronouncementsNotYetAdopted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ScheduleOfNetSalesByGeography" xlink:label="loc_krmdScheduleOfNetSalesByGeography" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdScheduleOfNetSalesByGeography" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentTables" xlink:title="00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationTables" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails" xlink:title="00000020 - Disclosure - Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details" xlink:title="00000021 - Disclosure - The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="loc_srtMortgageLoansOnRealEstateLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtMortgageLoansOnRealEstateLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000023 - Disclosure - Property and equipment consists of the following at: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000024 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationDetails" xlink:title="00000025 - Disclosure - STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails" xlink:title="00000026 - Disclosure - The following table summarizes the status of the Plan with respect to time based stock options: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details" xlink:title="00000027 - Disclosure - The following table presents information pertaining to options outstanding at June 30, 2021: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails" xlink:title="00000028 - Disclosure - The following table summarizes the status of the Plan with respect to performance-based stock options: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details" xlink:title="00000029 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000030 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_EmployeesAndConsultantsUnderThePlanMember" xlink:label="loc_krmdEmployeesAndConsultantsUnderThePlanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdEmployeesAndConsultantsUnderThePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerJamesMBeckMember" xlink:label="loc_krmdChiefExecutiveOfficerJamesMBeckMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdChiefExecutiveOfficerJamesMBeckMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:label="loc_krmdChiefExecutiveOfficerLindaTharbyMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdChiefExecutiveOfficerLindaTharbyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ChiefExecutiveOfficerDonaldPettigrewMember" xlink:label="loc_krmdChiefExecutiveOfficerDonaldPettigrewMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdChiefExecutiveOfficerDonaldPettigrewMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonEmployeeDirectorMember" xlink:label="loc_krmdNonEmployeeDirectorMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_SettlementAgreementMember" xlink:label="loc_krmdSettlementAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_EMEDTechnologiesCorporationMember" xlink:label="loc_krmdEMEDTechnologiesCorporationMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdEMEDTechnologiesCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPSharesContributedToESOP" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ExercisePrice" xlink:label="loc_krmdExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AmountForChairingBoardCommittee" xlink:label="loc_krmdAmountForChairingBoardCommittee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdAmountForChairingBoardCommittee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/DebtObligationsDetailsNarrative" xlink:title="00000031 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_KeyBankNationalAssociationMember" xlink:label="loc_krmdKeyBankNationalAssociationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdKeyBankNationalAssociationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_KeyEquipmentFinanceMember" xlink:label="loc_krmdKeyEquipmentFinanceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdKeyEquipmentFinanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PromissoryNoteMember" xlink:label="loc_krmdPromissoryNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_krmdPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapLineOfCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_KeyBankNationalAssociationMember" xlink:label="loc_krmdKeyBankNationalAssociationMember_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_krmdKeyBankNationalAssociationMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_ProgressPaymentLoanAndSecurityAgreementMember" xlink:label="loc_krmdProgressPaymentLoanAndSecurityAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdProgressPaymentLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_DebtInstrumentPrepaidTerms" xlink:label="loc_krmdDebtInstrumentPrepaidTerms" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_krmdDebtInstrumentPrepaidTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PrincipalAndInterestPayableTerms" xlink:label="loc_krmdPrincipalAndInterestPayableTerms" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_krmdPrincipalAndInterestPayableTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="00000032 - Disclosure - The components of lease expense were as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="loc_krmdFinanceLeaseCost1Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdFinanceLeaseCost1Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_FinanceLeaseCost" xlink:label="loc_krmdFinanceLeaseCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_krmdFinanceLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000033 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="00000034 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:label="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:label="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="00000035 - Disclosure - Maturities of lease liabilities are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="loc_krmdLesseeOperatingLeaseImputedInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="loc_krmdLesseeFinancingLeaseImputedInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/LeasesDetailsNarrative" xlink:title="00000036 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_LessorOperatingLeaseOptionToTerminate1" xlink:label="loc_krmdLessorOperatingLeaseOptionToTerminate1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLessorOperatingLeaseOptionToTerminate1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://repro-med.com/role/EquityDetailsNarrative" xlink:title="00000037 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PurchaseAgreementMember" xlink:label="loc_krmdPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_PiperSandlerCoAndCanaccordGenuityLLCMember" xlink:label="loc_krmdPiperSandlerCoAndCanaccordGenuityLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdPiperSandlerCoAndCanaccordGenuityLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_NumberOfSharesIssued" xlink:label="loc_krmdNumberOfSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_krmdNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20210630.xsd#krmd_AdditionalNumberOfSharesIssued" xlink:label="loc_krmdAdditionalNumberOfSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_krmdAdditionalNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>krmd-20210630_form10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krmd="http://repro-med.com/20210630"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krmd-20210630.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="From2021-08-102021-08-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2019-04-222019-04-23_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-22</startDate>
            <endDate>2019-04-23</endDate>
        </period>
    </context>
    <context id="From2021-02-132021-02-15_custom_ChiefExecutiveOfficerJamesMBeckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerJamesMBeckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-13</startDate>
            <endDate>2021-02-15</endDate>
        </period>
    </context>
    <context id="From2021-03-212021-03-22_custom_ChiefExecutiveOfficerJamesMBeckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerJamesMBeckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-21</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="From2021-03-142021-03-15_custom_ChiefExecutiveOfficerLindaTharbyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerLindaTharbyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-14</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerLindaTharbyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-11</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_EmployeesAndConsultantsUnderThePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:EmployeesAndConsultantsUnderThePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2018-12-302019-01-02_custom_NonEmployeeDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-30</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="From2019-09-292019-10-01_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-29</startDate>
            <endDate>2019-10-01</endDate>
        </period>
    </context>
    <context id="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2021-01-02</endDate>
        </period>
    </context>
    <context id="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2021-01-02</endDate>
        </period>
    </context>
    <context id="From2020-05-172021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-17</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="From2020-05-172021-05-18_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-17</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="From2020-05-192020-05-20_custom_SettlementAgreementMember_custom_EMEDTechnologiesCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:EMEDTechnologiesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-19</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="From2021-02-132021-02-16_custom_ChiefExecutiveOfficerDonaldPettigrewMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerDonaldPettigrewMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-13</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="AsOf2020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="From2020-04-132020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="From2020-06-232020-06-24_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-23</startDate>
            <endDate>2020-06-24</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PromissoryNoteMember_custom_KeyBankNationalAssociationMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">krmd:KeyBankNationalAssociationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2020-04-262020-04-27_custom_KeyEquipmentFinanceMember_custom_ProgressPaymentLoanAndSecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:KeyEquipmentFinanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:ProgressPaymentLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-26</startDate>
            <endDate>2020-04-27</endDate>
        </period>
    </context>
    <context id="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:PiperSandlerCoAndCanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:PiperSandlerCoAndCanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-18</instant>
        </period>
    </context>
    <context id="From2020-11-152020-11-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2020-11-15</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>krmd:Segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-06-30">0000704440</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-06-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-06-30">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2021-04-012021-06-30"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-04-012021-06-30"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockbasedLitigationSettlementExpense
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:BorrowingsFromIndebtedness
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:CommonStockIssuanceAsSettlementForLitigation
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:LitigationSettlementOptions
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:LitigationSettlementOptions
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:LitigationSettlementOptions
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:NewIssuanceOfCapitalRaiseAmount
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:NewIssuanceOfCapitalRaiseAmount
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl0903"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl0914"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl0915"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      id="xdx2ixbrl0955"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl1071"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-01-01to2021-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-01-01to2021-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-06-30">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-06-30">0-12305</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-06-30">REPRO MED SYSTEMS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-06-30">NY</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-06-30">13-3044880</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-06-30">24 Carpenter Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-06-30">Chester</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-06-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-06-30">10918</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-06-30">845</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-06-30">469-2042</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-01-01to2021-06-30">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-01-01to2021-06-30">KRMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-01-01to2021-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-08-11" decimals="INF" unitRef="Shares">44511162</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2021-08-102021-08-11"
      decimals="INF"
      unitRef="USDPShares">0.01</dei:EntityListingParValuePerShare>
    <us-gaap:TreasuryStockCommonShares contextRef="AsOf2021-08-11" decimals="INF" unitRef="Shares">3420502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">26538478</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">27315286</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">24469</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24469</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2577400</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2572954</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">7562750</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">6829772</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">461553</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">807780</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">37140181</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">37525792</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1110550</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1167623</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">232820</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">199899</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">834644</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">843587</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">166483</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">236846</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1327230</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">125274</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">19812</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">19812</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">40598900</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">39918934</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1005653</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">624920</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1771666</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2610413</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">390326</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">287130</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1030</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2646</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">142450</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">141293</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3311125</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3666402</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">24033</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">95553</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3335158</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3761955</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">47910676</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">46680119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">44490174</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">43259617</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">479106</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">466801</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">39376131</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">35880986</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">3420502</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">3420502</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1252067</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3652754</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">37263742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">36156979</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">40598900</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">39918934</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">5528174</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">7708904</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">10959125</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">14038913</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2317990</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">2799024</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">4517087</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">5340823</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">3210184</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">4909880</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">6442038</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">8698090</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">4085945</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">3201831</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">9078774</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">5964811</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">2346914</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">2446072</us-gaap:LitigationSettlementExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">386878</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">298196</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">723719</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">554221</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">118415</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">94940</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">233888</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">182164</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">4591238</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">5941881</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">10036381</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">9147268</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-1381054</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1032001</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-3594343</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-449178</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1239</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-2594</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-14478</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-13091</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-5522</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">736</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-5522</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">9950</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-5002</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">19721</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">14028</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">11189</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-13118</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">5979</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-4585</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-1369865</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1045119</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-3588364</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-453763</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-245316</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">30919</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-1187677</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">172847</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-1124549</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1076038</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-2400687</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-626610</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">44489853</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">40361924</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">44226936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">40018559</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">44489853</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">40361924</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">44226936</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">40018559</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-2400687</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-626610</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1339356</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">784821</us-gaap:ShareBasedCompensation>
    <krmd:StockbasedLitigationSettlementExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1285102</krmd:StockbasedLitigationSettlementExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">233888</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">182164</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-1201956</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-145770</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">736</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-5522</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">4446</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-268619</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">732978</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1278811</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-346227</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">156316</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">380733</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">347350</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">103196</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">333272</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-838747</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1389588</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">318618</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-2776150</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">2707549</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">152223</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">363750</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">9065</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">23978</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">149523</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-167136</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-513273</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <krmd:BorrowingsFromIndebtedness
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">3500000</krmd:BorrowingsFromIndebtedness>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1230000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">26567861</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <krmd:CommonStockIssuanceAsSettlementForLitigation
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">938094</krmd:CommonStockIssuanceAsSettlementForLitigation>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1616</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">3717</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">2166478</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">30064144</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-776808</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">32258420</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">27315286</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5870929</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">26538478</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">38129349</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">47</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">13554</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">850</us-gaap:IncomeTaxesPaidNet>
    <krmd:IssuanceOfCommonStockCompensation
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">153446</krmd:IssuanceOfCommonStockCompensation>
    <krmd:IssuanceOfCommonStockCompensation
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">120004</krmd:IssuanceOfCommonStockCompensation>
    <us-gaap:StockIssued1
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">938094</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">938094</us-gaap:StockIssued1>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">46680119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">466801</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">35880986</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">3652754</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">36156979</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10124</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">101</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">56149</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">56250</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">677934</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">677934</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:NewIssuanceLitigationSettlementShareIssuance
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">95238</krmd:NewIssuanceLitigationSettlementShareIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">952</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">937142</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">938094</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1110580</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">11106</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1218894</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1230000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1276138</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-1276138</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">47896061</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">478960</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38771105</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">2376616</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">37783119</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14615</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">146</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">97050</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">97196</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">441841</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">441841</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">66135</krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards>
    <krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">66135</krmd:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1124549</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-1124549</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">47910676</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">479106</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">39376131</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">1252067</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">37263742</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">42239788</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">422398</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6293069</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">4864817</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-344204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11236080</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9189</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">92</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">59910</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">60002</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">300966</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">300966</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">175000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1750</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">83750</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">85500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">449428</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">449428</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">42423977</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">424240</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6737695</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">5314245</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-344204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">12131976</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7999</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">80</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">59922</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">60002</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">363851</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">363851</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:LitigationSettlementOptions
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">347008</krmd:LitigationSettlementOptions>
    <krmd:LitigationSettlementOptions
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">347008</krmd:LitigationSettlementOptions>
    <krmd:NewIssuanceLitigationSettlementShareIssuance
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">95238</krmd:NewIssuanceLitigationSettlementShareIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">952</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">937142</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">938094</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">519156</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5192</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5189</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">10381</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <krmd:NewIssuanceOfCapitalRaiseShares
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3593750</krmd:NewIssuanceOfCapitalRaiseShares>
    <krmd:NewIssuanceOfCapitalRaiseAmount
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">35937</krmd:NewIssuanceOfCapitalRaiseAmount>
    <krmd:NewIssuanceOfCapitalRaiseAmount
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">26436043</krmd:NewIssuanceOfCapitalRaiseAmount>
    <krmd:NewIssuanceOfCapitalRaiseAmount
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">26471980</krmd:NewIssuanceOfCapitalRaiseAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1076038</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1076038</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">46640120</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">466401</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">34886850</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">4238207</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-344204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">39247254</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zszxjvrooL89" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_828_z49aNUozAF67"&gt;NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--NatureOfOperations_zzLB9l9CxQBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_zLuydB9ob6Th"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;REPRO MED SYSTEMS, INC. d/b/a KORU Medical Systems (the &#x201c;Company,&#x201d;
&#x201c;KORU Medical,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#x201c;FDA&#x201d;) quality and regulatory system and international standards for quality system management. The Company operates
as one segment.&lt;/p&gt;

&lt;p id="xdx_850_zIB7fjaFPui8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zidEruAYtJTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_zgP7U5inoSBg"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The accompanying financial statements should be read in conjunction with
the Company&#x2019;s annual report on Form&#160;10-K for the year ended December 31, 2020 (&#x201c;Annual Report&#x201d;). &#160;Certain
information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally
accepted accounting principles (&#x201c;GAAP&#x201d;) have been condensed or omitted from the accompanying financial statements. &#160;The
accompanying year-end balance sheet was derived from the audited financial statements included in the Annual Report. &#160;The accompanying
interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement
of the Company&#x2019;s financial position, results of operations, and cash flows for the periods presented. &#160;All such adjustments
are of a normal, recurring nature. &#160;The Company&#x2019;s results of operations and cash flows for the interim periods are not necessarily
indicative of the results of operations and cash flows that it may achieve in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyj3kqJ33Zp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zDJ1Jd74IAN6"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $&lt;span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20210630_zZrT2AXjEXk3" title="FDIC cash uninsured amount"&gt;250,000&lt;/span&gt; at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.&lt;/p&gt;

&lt;p id="xdx_853_zmJ7VtTm6Jzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_za3kvhmAk2Y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86B_zBZoxYJedvue"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.&lt;/p&gt;

&lt;p id="xdx_857_zMT0PW4qIhic" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zdcRLTdRdq47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zdDUt6WKworh"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Costs incurred in obtaining patents have been capitalized and are being
amortized over the legal life of the patents.&lt;/p&gt;

&lt;p id="xdx_851_z1RjFihRrXcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zHPeWf7pGDT" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_869_zyL6O3yBD6ea"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment. &#160;Generally, tax years starting with 2018 are subject to examination by income tax authorities.&lt;/p&gt;

&lt;p id="xdx_855_zVnSX2BqyXq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSysJqjHW94b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_864_zdX1YVAMTI4l"&gt;PROPERTY, EQUIPMENT, AND DEPRECIATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment is stated at cost and is depreciated using the straight-line
method over the estimated useful lives of the respective assets.&lt;/p&gt;

&lt;p id="xdx_852_zKAiMgdkzQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zHUIHD9awjtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_z8WVD7yOvUPh"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains a stock option plan under which it grants stock options
to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using
the Black-Scholes option-pricing model. &#160;All options are charged against income at their fair value. &#160;The entire compensation
expense of the award is recognized over the vesting period. Shares of stock granted for director fees are recorded at the fair value of
the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company also maintains an omnibus equity incentive plan. There have
been no awards made pursuant to this plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company issues restricted&#160;stock awards. Restricted stock awards&#160;are
equity classified and measured at the fair market value of the underlying&#160;stock&#160;at the grant date. The fair value of restricted
stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo
lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.&lt;/p&gt;

&lt;p id="xdx_85F_zkL4bwS17Q29" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z1xCcSeSHM86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_864_zsuvcyuQVtEf"&gt;NET INCOME PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjTTKoQ7UOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share include only an increase in the weighted average shares by the common
shares issuable upon exercise of employee and consultant stock options. &#160;See &#x201c;NOTE 4 &#x2014; STOCK-BASED COMPENSATION&#x201d;
for further detail.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
    &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20210401__20210630_zQGpNyK9f178" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200401__20200630_z1o6TJSbzC97" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20210101__20210630_zPCyGKWfTrf4" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20200101__20200630_zGwHFnUPduSh" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 194.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.6pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.9pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.6pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.65pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.95pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLoss_zv4fw3nRSP6k" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(1,124,549&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(1,076,038&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(2,400,687&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(626,610&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_z837ovkF5Vqd" style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pii_z7NebrhraI44" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Outstanding shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,489,853&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,361,924&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,226,936&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,018,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pii_d0_zNTiRV7g9ts6" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Option shares includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2F_zilqoIZ4MFU4" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F27_zJzr4rPhUo91"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F25_zRtY9rwURta6" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F2A_zWUKTiWZY6Pi"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2D_zkJ3yzTZ3V1c" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F23_z5t9VBxHgvUc"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2F_zFIcI8Lh1XKj" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F27_zQuAXOll0kba"&gt;(a)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pii_zX1oRbwIfiv9" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,489,853&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;40,361,924&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,226,936&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;40,018,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zzOtlyrYekO4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EarningsPerShareBasic_i01_pii_z8Y5gvNjHD0k" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.02&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i01_pii_zTw8efKpAh0f" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.02&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;__________&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F0A_ztv2jJQ0taD2" style="width: 0.25in"&gt;(a)&lt;/td&gt;
    &lt;td id="xdx_F1C_zx8BqlIVozUe" style="width: 7.25in"&gt;For the three months ended June 30, 2021, and 2020, option shares of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDdwHQpAnyRe" title="Anti-dilutive shares"&gt;224,336&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWXY5olwk3nh" title="Anti-dilutive shares"&gt;162,831&lt;/span&gt; respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the six months ended June 30, 2021, and 2020, option shares of &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoemU54MKHC4"&gt;214,132&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw5OpqlCcwXb"&gt;182,575&lt;/span&gt; respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the three and six months ended June 30, 2021 and 2020, restricted shares of 1,000,000 and zero respectively, were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zcoJ6QJOJ6S" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_85E_zomDJNCqFr9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zGpQguJGkmX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86C_zVsp7TWsxiw4"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. Important estimates include but are not limited to asset lives, valuation allowances, inventory
valuation, and accruals.&lt;/p&gt;

&lt;p id="xdx_85F_zQ8xgN9P1Wve" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zuHcfhzK17b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_zZ1sOI6AFsCi"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting
Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers. &#160;We adopted this ASU effective January
1, 2018, on a full retrospective basis. &#160;Adoption of this standard did not result in significant changes to our accounting policies,
business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or
related disclosures. &#160;As such, prior period financial statements were not recast.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&#x2019;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and
pricing specified to select customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfNetSalesByGeography_z7cjsz1nWk08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes net sales by geography for the three and
six months ended June 30, 2021, and 2020:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 94.75pt"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 8.65pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Domestic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__country--US_zdxC0DKEPdY" style="text-align: right" title="Net sales"&gt;4,645,770&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__country--US_z0szl53PSM2f" style="text-align: right"&gt;6,745,810&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__country--US_z5wwga36DHFk" style="text-align: right"&gt;9,092,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__country--US_zFSqCuy1yHse" style="text-align: right"&gt;12,086,676&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zsFa8rlwk9Nc" style="border-bottom: black 0.5pt solid; text-align: right" title="Net sales"&gt;882,404&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvK6NueSLZua" style="border-bottom: black 0.5pt solid; text-align: right"&gt;963,094&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zIL5FPFBKHb9" style="border-bottom: black 0.5pt solid; text-align: right"&gt;1,866,566&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zR3hTpRPSqaa" style="border-bottom: black 0.5pt solid; text-align: right"&gt;1,952,237&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20210401__20210630_z0NvtAvZ1vvg" style="border-bottom: black 2.25pt double; text-align: right" title="Net sales"&gt;5,528,174&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--Revenues_c20200401__20200630_zZX9c8JkcSfi" style="border-bottom: black 2.25pt double; text-align: right"&gt;7,708,904&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--Revenues_c20210101__20210630_zu1g9YmAAPxh" style="border-bottom: black 2.25pt double; text-align: right"&gt;10,959,125&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630_z9ufXfC3UwQ5" style="border-bottom: black 2.25pt double; text-align: right"&gt;14,038,913&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zQalavPH0Wyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_85F_zCDQyBK52ygl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zElmttjoLqif" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_865_zGTMgFRdrB2"&gt;LEASES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#x201c;NOTE 6 &lt;b&gt;&#x2014; &lt;/b&gt;LEASES&#x201d; for further detail.&lt;/p&gt;

&lt;p id="xdx_850_zKzoVBYfEnN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwFwhCjIm43k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zjMfPKRiyNhd"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes (Topic
740): &#160;Simplifying the Accounting for Income Taxes&lt;/i&gt;. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.&lt;/p&gt;

&lt;p id="xdx_857_z4N2lKm2RrWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--AccountingPronouncementsNotYetAdopted_zwRZjiUm8616" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_z2ABr3nPvare"&gt;ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;i&gt;Reference Rate Reform
(Topic 848)&lt;/i&gt;, which provided elective amendments for entities that have contracts, hedging relationships and other transactions that
reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. &#160;The amendments may be applied
to impacted contracts and hedges prospectively through December 31, 2022. &#160;The Company is currently evaluating the impact this guidance
will have on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

&lt;p id="xdx_85B_z92b69M12Eme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyhjpzhOBLu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86B_zuc97anlv0p7"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the six months ended June
30, 2021.&lt;/p&gt;

&lt;p id="xdx_853_z1BKo310pO57" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ziw9pFqYLzgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_zpfOF3NqbFAi"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through June 30, 2021.&lt;/p&gt;

&lt;p id="xdx_85C_zDkFyPzM8sTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPXNVb7D2Dz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zveEKIQEFp0i"&gt;RECLASSIFICATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain reclassifications have been made to conform prior period data to
the current presentation. &#160;These reclassifications had no effect on reported net income.&lt;/p&gt;

&lt;p id="xdx_851_zDB18J3oGJGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_843_eus-gaap--NatureOfOperations_zzLB9l9CxQBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_zLuydB9ob6Th"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;REPRO MED SYSTEMS, INC. d/b/a KORU Medical Systems (the &#x201c;Company,&#x201d;
&#x201c;KORU Medical,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#x201c;FDA&#x201d;) quality and regulatory system and international standards for quality system management. The Company operates
as one segment.&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zidEruAYtJTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_zgP7U5inoSBg"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The accompanying financial statements should be read in conjunction with
the Company&#x2019;s annual report on Form&#160;10-K for the year ended December 31, 2020 (&#x201c;Annual Report&#x201d;). &#160;Certain
information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally
accepted accounting principles (&#x201c;GAAP&#x201d;) have been condensed or omitted from the accompanying financial statements. &#160;The
accompanying year-end balance sheet was derived from the audited financial statements included in the Annual Report. &#160;The accompanying
interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement
of the Company&#x2019;s financial position, results of operations, and cash flows for the periods presented. &#160;All such adjustments
are of a normal, recurring nature. &#160;The Company&#x2019;s results of operations and cash flows for the interim periods are not necessarily
indicative of the results of operations and cash flows that it may achieve in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyj3kqJ33Zp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zDJ1Jd74IAN6"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $&lt;span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20210630_zZrT2AXjEXk3" title="FDIC cash uninsured amount"&gt;250,000&lt;/span&gt; at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">250000</us-gaap:CashUninsuredAmount>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_za3kvhmAk2Y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86B_zBZoxYJedvue"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zdcRLTdRdq47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zdDUt6WKworh"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Costs incurred in obtaining patents have been capitalized and are being
amortized over the legal life of the patents.&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zHPeWf7pGDT" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_869_zyL6O3yBD6ea"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment. &#160;Generally, tax years starting with 2018 are subject to examination by income tax authorities.&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSysJqjHW94b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_864_zdX1YVAMTI4l"&gt;PROPERTY, EQUIPMENT, AND DEPRECIATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment is stated at cost and is depreciated using the straight-line
method over the estimated useful lives of the respective assets.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zHUIHD9awjtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_z8WVD7yOvUPh"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains a stock option plan under which it grants stock options
to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using
the Black-Scholes option-pricing model. &#160;All options are charged against income at their fair value. &#160;The entire compensation
expense of the award is recognized over the vesting period. Shares of stock granted for director fees are recorded at the fair value of
the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company also maintains an omnibus equity incentive plan. There have
been no awards made pursuant to this plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company issues restricted&#160;stock awards. Restricted stock awards&#160;are
equity classified and measured at the fair market value of the underlying&#160;stock&#160;at the grant date. The fair value of restricted
stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo
lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z1xCcSeSHM86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_864_zsuvcyuQVtEf"&gt;NET INCOME PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjTTKoQ7UOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share include only an increase in the weighted average shares by the common
shares issuable upon exercise of employee and consultant stock options. &#160;See &#x201c;NOTE 4 &#x2014; STOCK-BASED COMPENSATION&#x201d;
for further detail.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
    &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20210401__20210630_zQGpNyK9f178" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200401__20200630_z1o6TJSbzC97" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20210101__20210630_zPCyGKWfTrf4" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20200101__20200630_zGwHFnUPduSh" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 194.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.6pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.9pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.6pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.65pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.95pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLoss_zv4fw3nRSP6k" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(1,124,549&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(1,076,038&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(2,400,687&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(626,610&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_z837ovkF5Vqd" style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pii_z7NebrhraI44" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Outstanding shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,489,853&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,361,924&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,226,936&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,018,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pii_d0_zNTiRV7g9ts6" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Option shares includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2F_zilqoIZ4MFU4" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F27_zJzr4rPhUo91"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F25_zRtY9rwURta6" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F2A_zWUKTiWZY6Pi"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2D_zkJ3yzTZ3V1c" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F23_z5t9VBxHgvUc"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2F_zFIcI8Lh1XKj" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F27_zQuAXOll0kba"&gt;(a)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pii_zX1oRbwIfiv9" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,489,853&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;40,361,924&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,226,936&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;40,018,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zzOtlyrYekO4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EarningsPerShareBasic_i01_pii_z8Y5gvNjHD0k" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.02&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i01_pii_zTw8efKpAh0f" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.02&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;__________&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F0A_ztv2jJQ0taD2" style="width: 0.25in"&gt;(a)&lt;/td&gt;
    &lt;td id="xdx_F1C_zx8BqlIVozUe" style="width: 7.25in"&gt;For the three months ended June 30, 2021, and 2020, option shares of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDdwHQpAnyRe" title="Anti-dilutive shares"&gt;224,336&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWXY5olwk3nh" title="Anti-dilutive shares"&gt;162,831&lt;/span&gt; respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the six months ended June 30, 2021, and 2020, option shares of &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoemU54MKHC4"&gt;214,132&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw5OpqlCcwXb"&gt;182,575&lt;/span&gt; respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the three and six months ended June 30, 2021 and 2020, restricted shares of 1,000,000 and zero respectively, were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zcoJ6QJOJ6S" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjTTKoQ7UOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share include only an increase in the weighted average shares by the common
shares issuable upon exercise of employee and consultant stock options. &#160;See &#x201c;NOTE 4 &#x2014; STOCK-BASED COMPENSATION&#x201d;
for further detail.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
    &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20210401__20210630_zQGpNyK9f178" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200401__20200630_z1o6TJSbzC97" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_499_20210101__20210630_zPCyGKWfTrf4" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20200101__20200630_zGwHFnUPduSh" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 194.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.6pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.9pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.6pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.65pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.95pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLoss_zv4fw3nRSP6k" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(1,124,549&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(1,076,038&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(2,400,687&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(626,610&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_z837ovkF5Vqd" style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pii_z7NebrhraI44" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Outstanding shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,489,853&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,361,924&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,226,936&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,018,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pii_d0_zNTiRV7g9ts6" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Option shares includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2F_zilqoIZ4MFU4" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F27_zJzr4rPhUo91"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F25_zRtY9rwURta6" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F2A_zWUKTiWZY6Pi"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2D_zkJ3yzTZ3V1c" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F23_z5t9VBxHgvUc"&gt;(a)&lt;/sup&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F2F_zFIcI8Lh1XKj" style="border-bottom: black 0.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&lt;sup id="xdx_F27_zQuAXOll0kba"&gt;(a)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pii_zX1oRbwIfiv9" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,489,853&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;40,361,924&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,226,936&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;40,018,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zzOtlyrYekO4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EarningsPerShareBasic_i01_pii_z8Y5gvNjHD0k" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(0.02&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i01_pii_zTw8efKpAh0f" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.03&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.05&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.02&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;__________&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F0A_ztv2jJQ0taD2" style="width: 0.25in"&gt;(a)&lt;/td&gt;
    &lt;td id="xdx_F1C_zx8BqlIVozUe" style="width: 7.25in"&gt;For the three months ended June 30, 2021, and 2020, option shares of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDdwHQpAnyRe" title="Anti-dilutive shares"&gt;224,336&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWXY5olwk3nh" title="Anti-dilutive shares"&gt;162,831&lt;/span&gt; respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the six months ended June 30, 2021, and 2020, option shares of &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoemU54MKHC4"&gt;214,132&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw5OpqlCcwXb"&gt;182,575&lt;/span&gt; respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the three and six months ended June 30, 2021 and 2020, restricted shares of 1,000,000 and zero respectively, were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-1124549</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1076038</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-2400687</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-626610</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">44489853</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">40361924</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">44226936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">40018559</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">44489853</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">40361924</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">44226936</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">40018559</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012021-06-30_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">224336</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012020-06-30_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">162831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">214132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-06-30_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">182575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zGpQguJGkmX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86C_zVsp7TWsxiw4"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. Important estimates include but are not limited to asset lives, valuation allowances, inventory
valuation, and accruals.&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zuHcfhzK17b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_zZ1sOI6AFsCi"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting
Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers. &#160;We adopted this ASU effective January
1, 2018, on a full retrospective basis. &#160;Adoption of this standard did not result in significant changes to our accounting policies,
business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or
related disclosures. &#160;As such, prior period financial statements were not recast.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&#x2019;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and
pricing specified to select customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfNetSalesByGeography_z7cjsz1nWk08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes net sales by geography for the three and
six months ended June 30, 2021, and 2020:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 94.75pt"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 8.65pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Domestic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__country--US_zdxC0DKEPdY" style="text-align: right" title="Net sales"&gt;4,645,770&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__country--US_z0szl53PSM2f" style="text-align: right"&gt;6,745,810&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__country--US_z5wwga36DHFk" style="text-align: right"&gt;9,092,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__country--US_zFSqCuy1yHse" style="text-align: right"&gt;12,086,676&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zsFa8rlwk9Nc" style="border-bottom: black 0.5pt solid; text-align: right" title="Net sales"&gt;882,404&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvK6NueSLZua" style="border-bottom: black 0.5pt solid; text-align: right"&gt;963,094&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zIL5FPFBKHb9" style="border-bottom: black 0.5pt solid; text-align: right"&gt;1,866,566&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zR3hTpRPSqaa" style="border-bottom: black 0.5pt solid; text-align: right"&gt;1,952,237&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20210401__20210630_z0NvtAvZ1vvg" style="border-bottom: black 2.25pt double; text-align: right" title="Net sales"&gt;5,528,174&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--Revenues_c20200401__20200630_zZX9c8JkcSfi" style="border-bottom: black 2.25pt double; text-align: right"&gt;7,708,904&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--Revenues_c20210101__20210630_zu1g9YmAAPxh" style="border-bottom: black 2.25pt double; text-align: right"&gt;10,959,125&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630_z9ufXfC3UwQ5" style="border-bottom: black 2.25pt double; text-align: right"&gt;14,038,913&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zQalavPH0Wyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <krmd:ScheduleOfNetSalesByGeography contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_892_ecustom--ScheduleOfNetSalesByGeography_z7cjsz1nWk08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes net sales by geography for the three and
six months ended June 30, 2021, and 2020:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 94.75pt"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 8.65pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 66.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Domestic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__country--US_zdxC0DKEPdY" style="text-align: right" title="Net sales"&gt;4,645,770&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__country--US_z0szl53PSM2f" style="text-align: right"&gt;6,745,810&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__country--US_z5wwga36DHFk" style="text-align: right"&gt;9,092,559&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__country--US_zFSqCuy1yHse" style="text-align: right"&gt;12,086,676&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zsFa8rlwk9Nc" style="border-bottom: black 0.5pt solid; text-align: right" title="Net sales"&gt;882,404&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvK6NueSLZua" style="border-bottom: black 0.5pt solid; text-align: right"&gt;963,094&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zIL5FPFBKHb9" style="border-bottom: black 0.5pt solid; text-align: right"&gt;1,866,566&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zR3hTpRPSqaa" style="border-bottom: black 0.5pt solid; text-align: right"&gt;1,952,237&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20210401__20210630_z0NvtAvZ1vvg" style="border-bottom: black 2.25pt double; text-align: right" title="Net sales"&gt;5,528,174&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--Revenues_c20200401__20200630_zZX9c8JkcSfi" style="border-bottom: black 2.25pt double; text-align: right"&gt;7,708,904&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--Revenues_c20210101__20210630_zu1g9YmAAPxh" style="border-bottom: black 2.25pt double; text-align: right"&gt;10,959,125&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630_z9ufXfC3UwQ5" style="border-bottom: black 2.25pt double; text-align: right"&gt;14,038,913&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfNetSalesByGeography>
    <us-gaap:Revenues
      contextRef="From2021-04-012021-06-30_country_US"
      decimals="0"
      unitRef="USD">4645770</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-012020-06-30_country_US"
      decimals="0"
      unitRef="USD">6745810</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-06-30_country_US"
      decimals="0"
      unitRef="USD">9092559</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-06-30_country_US"
      decimals="0"
      unitRef="USD">12086676</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-04-012021-06-30_us-gaap_NonUsMember"
      decimals="0"
      unitRef="USD">882404</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-012020-06-30_us-gaap_NonUsMember"
      decimals="0"
      unitRef="USD">963094</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-06-30_us-gaap_NonUsMember"
      decimals="0"
      unitRef="USD">1866566</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-06-30_us-gaap_NonUsMember"
      decimals="0"
      unitRef="USD">1952237</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">5528174</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">7708904</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">10959125</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">14038913</us-gaap:Revenues>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zElmttjoLqif" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_865_zGTMgFRdrB2"&gt;LEASES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#x201c;NOTE 6 &lt;b&gt;&#x2014; &lt;/b&gt;LEASES&#x201d; for further detail.&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwFwhCjIm43k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zjMfPKRiyNhd"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes (Topic
740): &#160;Simplifying the Accounting for Income Taxes&lt;/i&gt;. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <krmd:AccountingPronouncementsNotYetAdopted contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84F_ecustom--AccountingPronouncementsNotYetAdopted_zwRZjiUm8616" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_z2ABr3nPvare"&gt;ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;i&gt;Reference Rate Reform
(Topic 848)&lt;/i&gt;, which provided elective amendments for entities that have contracts, hedging relationships and other transactions that
reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. &#160;The amendments may be applied
to impacted contracts and hedges prospectively through December 31, 2022. &#160;The Company is currently evaluating the impact this guidance
will have on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

</krmd:AccountingPronouncementsNotYetAdopted>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyhjpzhOBLu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86B_zuc97anlv0p7"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the six months ended June
30, 2021.&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ziw9pFqYLzgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_zpfOF3NqbFAi"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through June 30, 2021.&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPXNVb7D2Dz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zveEKIQEFp0i"&gt;RECLASSIFICATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain reclassifications have been made to conform prior period data to
the current presentation. &#160;These reclassifications had no effect on reported net income.&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRmG5e9KkgJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_82E_zZuPcu0NaFHb"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zs1rgbK88Cv" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment consists of the following at:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 208.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zJmgTQZf9Zqd" style="text-align: right" title="Total property and equipment"&gt;787,694&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zHYJE7kIrEt4" style="text-align: right"&gt;753,536&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQ8BUBXeDZ28" style="text-align: right" title="Total property and equipment"&gt;556,907&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8u4zmdSWoNg" style="text-align: right"&gt;542,796&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_z4TYy83udBY5" style="border-bottom: black 0.5pt solid; text-align: right" title="Total property and equipment"&gt;1,922,196&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zr9USlS4alu3" style="border-bottom: black 0.5pt solid; text-align: right"&gt;1,856,909&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630_zh4r3Zz9VNvf" style="text-align: right" title="Total property and equipment"&gt;3,266,797&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zfpe2OFnicPj" style="text-align: right"&gt;3,153,241&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20210630_zm8TwX9TYpcj" style="border-bottom: black 0.5pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,156,247&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zBjXcDBMxh97" style="border-bottom: black 0.5pt solid; text-align: right"&gt;(1,985,618&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20210630_zVPRp1qh0RU5" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;1,110,550&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20201231_zKSGcoxr2816" style="border-bottom: black 2.25pt double; text-align: right"&gt;1,167,623&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_z7c96ycr1Txe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Depreciation expense was $&lt;span id="xdx_900_eus-gaap--Depreciation_c20210401__20210630_z4yAt88WdzK6" title="Depreciation expense"&gt;100,564&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--Depreciation_c20200401__20200630_zGJBJcX5PcOj"&gt;79,245&lt;/span&gt; for the three months ended
June 30, 2021 and 2020, respectively, and $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20210101__20210630_zGkyfkOey4ui"&gt;200,967&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--Depreciation_c20200101__20200630_zzeciJNFrJXh"&gt;152,013&lt;/span&gt; for the six months ended June 30, 2021 and 2020, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zs1rgbK88Cv" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment consists of the following at:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 208.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zJmgTQZf9Zqd" style="text-align: right" title="Total property and equipment"&gt;787,694&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zHYJE7kIrEt4" style="text-align: right"&gt;753,536&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQ8BUBXeDZ28" style="text-align: right" title="Total property and equipment"&gt;556,907&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8u4zmdSWoNg" style="text-align: right"&gt;542,796&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_z4TYy83udBY5" style="border-bottom: black 0.5pt solid; text-align: right" title="Total property and equipment"&gt;1,922,196&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zr9USlS4alu3" style="border-bottom: black 0.5pt solid; text-align: right"&gt;1,856,909&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630_zh4r3Zz9VNvf" style="text-align: right" title="Total property and equipment"&gt;3,266,797&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zfpe2OFnicPj" style="text-align: right"&gt;3,153,241&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20210630_zm8TwX9TYpcj" style="border-bottom: black 0.5pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,156,247&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zBjXcDBMxh97" style="border-bottom: black 0.5pt solid; text-align: right"&gt;(1,985,618&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20210630_zVPRp1qh0RU5" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;1,110,550&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20201231_zKSGcoxr2816" style="border-bottom: black 2.25pt double; text-align: right"&gt;1,167,623&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      unitRef="USD">787694</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      unitRef="USD">753536</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">556907</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">542796</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      unitRef="USD">1922196</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      unitRef="USD">1856909</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3266797</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3153241</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2156247</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1985618</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1110550</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1167623</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">100564</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">79245</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">200967</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">152013</us-gaap:Depreciation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zb0KtrLyEQbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_82B_zUClJXyOeNv4"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;LEGAL PROCEEDINGS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On July 12, 2021, the lead plaintiff filed a notice of voluntary dismissal
without prejudice of the claims in the previously disclosed putative class action lawsuit filed in the United States District Court for
the Southern District of New York against the Company and its Chief Financial Officer and former Chief Executive Officer, alleging they
made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company&#x2019;s business,
operations and prospects, in the Company&#x2019;s earnings communications and Form 10-Q filed during the period August 4, 2020 and January
25, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;OTHER&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#x201c;Command&#x201d;), pursuant to which Command has agreed to manufacture and supply
the Company&#x2019;s subassemblies, needle sets and tubing products pursuant to the Company&#x2019;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#x201c;Effective
Date&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement. &#160;If the Company terminates the Manufacturing and Supply Agreement other than for those reasons within the first three
years from the Effective Date, the Company is obligated to pay an early termination fee to Command.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zLZHQnhRfSM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 4 &#x2014; &lt;span id="xdx_82A_z86Bm7GmEt5"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On June 29, 2016, the Board of Directors amended the Company&#x2019;s 2015
Stock Option Plan (as amended, the &#x201c;Plan&#x201d;)&#160;authorizing the Company to grant awards to certain executives, key employees,
and consultants under the Plan, which was approved by shareholders at the Annual Meeting of Shareholders held on September 6, 2016. &#160;The
total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, may not exceed &lt;span id="xdx_902_eus-gaap--EmployeeStockOwnershipPlanESOPSharesContributedToESOP_pii_c20190422__20190423__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zV2sjZVKZZz8" title="Number of stock option shares"&gt;6,000,000&lt;/span&gt; pursuant
to an amendment to the Plan approved by shareholders at their annual meeting on April 23, 2019.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On February 15, 2021, under the Plan, the Company issued to James M. Beck,
its Interim Chief Executive Officer, a non-qualified option to purchase up to &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zTil1egajmA6" title="Number of stock option shares issued"&gt;150,000&lt;/span&gt; shares of the Company&#x2019;s common stock at an
exercise price of $&lt;span id="xdx_900_ecustom--ExercisePrice_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zvnzsXOGRDQa" title="Exercise price"&gt;4.37&lt;/span&gt; per share, of which &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pii_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zqPIste0Jgk6" title="Number of shares vested"&gt;100,000&lt;/span&gt; vested on February 15, 2021 and &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pii_c20210321__20210322__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zUzFCWDIvNIk"&gt;50,000&lt;/span&gt; vested on March 22, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On March 15, 2021, under the Plan, the Company issued to Linda Tharby,
its incoming President and Chief Executive Officer, a non-qualified stock option to purchase up to &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zVkS1LdQibmk" title="Number of stock option shares issued"&gt;1,000,000&lt;/span&gt; shares of the Company&#x2019;s
common stock at an exercise price of $&lt;span id="xdx_900_ecustom--ExercisePrice_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zkaftxGOdFK5"&gt;3.875&lt;/span&gt; per share, subject to vesting as follows: &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zxGh16ONFaa8" title="Description of vesting rights"&gt;25% on March 15, 2022 and 25% each twelve months
thereafter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#x2019;s President and Chief Executive Officer, the Company issued three restricted stock
awards for an aggregate &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zsg6xIpq7C4d"&gt;1,000,000&lt;/span&gt; shares of common stock for an aggregate stock price of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_pid_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zf50zmUo7Gvf" title="Number of stock option shares issued, value"&gt;3,310,000&lt;/span&gt; and each vesting subject to employment
on the respective vesting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of June 30, 2021, the Company had options to purchase &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--EmployeesAndConsultantsUnderThePlanMember_zQpJrfmAab72" title="Number of stock option shares issued"&gt;3,072,494&lt;/span&gt; shares
of Common Stock outstanding to certain executives, key employees and consultants under the Plan, of which &lt;span id="xdx_90D_eus-gaap--EmployeeStockOwnershipPlanESOPSharesContributedToESOP_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--EmployeesAndConsultantsUnderThePlanMember_zkL70w1j48Y2" title="Number of stock option shares"&gt;1,150,000&lt;/span&gt; were issued during
the six months ended June 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Prior to January 1, 2021, each non-employee director of the Company was
eligible to receive $&lt;span id="xdx_90C_ecustom--NonemployeeServicesTransactionCost_c20181230__20190102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember_zlutGgmrYSGh" title="Nonemployee services transaction cost"&gt;50,000&lt;/span&gt; annually (effective January 1, 2019), plus $&lt;span id="xdx_907_ecustom--AmountForChairingBoardCommittee_c20181230__20190102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember_zj6yAk6K7KAd" title="Amount for chairing board committee"&gt;10,000&lt;/span&gt; for chairing a Board committee (effective February 20,
2019), all to be paid quarterly half in cash and half in common stock. &#160;The Chairman of the Board was eligible to receive an additional
$&lt;span id="xdx_909_ecustom--NonemployeeServicesTransactionCost_c20190929__20191001__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zZfBmWpP0ob7" title="Nonemployee services transaction cost"&gt;50,000&lt;/span&gt; annually (effective October 1, 2019), all to be paid in common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Effective January 1, 2021, each non-employee director of the Company (other
than the Chairman of the Board) and Board advisor are eligible to receive of $&lt;span id="xdx_904_ecustom--NonemployeeServicesTransactionCost_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zdFvSJ0LlIve"&gt;75,000&lt;/span&gt; annually, &lt;span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zYSvTkrTE0Nd" title="Description of non employee services transaction"&gt;to be paid quarterly $12,500 in cash and
$6,250 in common stock.&lt;/span&gt; &#160;The Chairman of the Board is eligible to receive $&lt;span id="xdx_90B_ecustom--NonemployeeServicesTransactionCost_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zovzgh9BnFjb" title="Nonemployee services transaction cost"&gt;100,000&lt;/span&gt; annually, &lt;span id="xdx_905_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zsuAlWmnmsk7" title="Description of non employee services transaction"&gt;to be paid quarterly $12,500 in cash
and $12,500 in common stock.&lt;/span&gt; &#160; Effective May 18, 2021, each non-employee director of the Company (other than the Chairman of the
Board) and Board advisor are eligible to receive of $&lt;span id="xdx_906_ecustom--NonemployeeServicesTransactionCost_c20200517__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zI0NheSvSwI"&gt;110,000&lt;/span&gt; annually, &lt;span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20200517__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zIS71i90yZF7"&gt;to be paid quarterly $12,500 in cash and $15,000 in common stock.&lt;/span&gt;
&#160;The Chairman of the Board is eligible to receive $&lt;span id="xdx_90D_ecustom--NonemployeeServicesTransactionCost_c20200517__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z8nwhWts5fF1"&gt;140,000&lt;/span&gt; annually, &lt;span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20200517__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zHWsKEPZC938"&gt;to be paid quarterly $12,500 in cash and $22,500 in common stock&lt;/span&gt;.
All payments were and are pro-rated for partial service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On May 20, 2020, the Company entered into a Settlement Agreement with EMED
Technologies Corporation (&#x201c;EMED&#x201d;) to settle all claims in connection with all pending litigation matters between them. &#160;Pursuant
to the Settlement Agreement, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200519__20200520__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--EMEDTechnologiesCorporationMember_zjEBEgRlulS4" title="Description of vesting rights"&gt;the Company issued to EMED (i) 95,238 restricted stock units, which vested on May 21, 2020, and 95,238 restricted
stock units, which vested on January 1, 2021, and (ii) an option to purchase up to 400,000 shares of the Company&#x2019;s common stock
at an exercise price of $11.21 per share prior to February 1, 2021, which was not exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On February 16, 2021, Donald Pettigrew, the Company&#x2019;s former Chief
Executive Officer, exercised options held by him for an aggregate &lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_c20210213__20210216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerDonaldPettigrewMember_zX3wm6WjsQe9" title="Number of options exercised"&gt;1,000,000&lt;/span&gt; shares of common stock for an aggregate exercise price of
$&lt;span id="xdx_904_eus-gaap--ProceedsFromStockOptionsExercised_c20210213__20210216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerDonaldPettigrewMember_zCY0FxLqmOhg" title="Cash received from option exercises"&gt;1,230,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On March 18, 2021, our shareholders approved the Company&#x2019;s 2021 Omnibus
Equity Incentive Plan (the &#x201c;2021 Equity Plan&#x201d;). There have been no awards made pursuant to the 2021 Equity Plan to date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2015 STOCK OPTION PLAN, as amended&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Time Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The per share weighted average fair value of stock options granted during
the six months ended June 30, 2021 and June 30, 2020 was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSpOnHAF6bBh" title="Weighted average grant date fair value of stock options"&gt;3.06&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUC7u8WoiMNf"&gt;6.68&lt;/span&gt;, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
six months ended June 30, 2021 and June 30, 2020. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $&lt;span id="xdx_90D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5E5tBDLPBT1" title="Tax benefits associated with stock-based compensation"&gt;9,817&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLzs4vneJ0K5"&gt;31,196&lt;/span&gt; for the six months ended June 30, 2021 and 2020, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmyu4wT6pbBa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 136.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 71.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 72.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zA6qLtvmNho5" style="text-align: right" title="Dividend yield"&gt;0.00%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zTvnuPh4j5h4" style="text-align: right"&gt;0.00%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zHIqnKC8RgH9" title="Expected Volatility"&gt;74.01&lt;/span&gt;%-&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zfJu2yK49WC8" title="Expected Volatility"&gt;74.28&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVRIJdFXiTY6" title="Expected Volatility"&gt;62.1&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z6vwKr4PyTGl" style="text-align: right" title="Weighted-average volatility"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlQ9IAIXVwel" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvK0LmrvMbtg" style="text-align: right" title="Expected dividends"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrRf4DJKBAf4" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zy19u1GF5Zfl" style="text-align: right" title="Expected term (in years)"&gt;10&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJswur0xwyhi" style="text-align: right"&gt;10&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zksXkYHvgxDg" title="Risk-free rate"&gt;1.20&lt;/span&gt;%-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z8nYOJtIoEC2" title="Risk-free rate"&gt;1.62&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlx3KzqaaXEk" title="Risk-free rate"&gt;0.63&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zigQswkQPBLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGxmR11YK5ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the Plan with respect to time
based stock options:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 226pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zo2vXiwdPqsa" style="width: 51.8pt; text-align: right" title="Outstanding at beginning"&gt;2,922,494&lt;/td&gt;
    &lt;td style="width: 23.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQApE92Scpol" style="width: 52.1pt; text-align: right" title="Outstanding at beginning"&gt;2.46&lt;/td&gt;
    &lt;td style="width: 23.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQfPU7YTCzof" style="width: 51.8pt; text-align: right"&gt;3,647,000&lt;/td&gt;
    &lt;td style="width: 23.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJkYbqhcN6Qc" style="width: 52.4pt; text-align: right"&gt;1.32&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zP63Rjb8h23b" style="text-align: right" title="Granted"&gt;1,250,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zphz7pXf69i2" style="text-align: right" title="Granted"&gt;3.94&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYqLhyOdZxaj" style="text-align: right"&gt;60,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1UGvet7fAha" style="text-align: right"&gt;9.76&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1EsMWu5DKBi" style="text-align: right" title="Exercised"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1jOtwBme6r6" style="text-align: right" title="Exercised"&gt;1.23&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKXkGafFSas5" style="text-align: right"&gt;722,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVBcqz6Bvpw8" style="text-align: right"&gt;0.58&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHYItV16tNib" style="text-align: right" title="Forfeited"&gt;100,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdgUGvPyBta4" style="text-align: right" title="Forfeited"&gt;3.94&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zmZ3LHDClJb" style="text-align: right"&gt;200,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzqhQhrr3H9i" style="text-align: right"&gt;2.09&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z18kgkoI4bX2" style="text-align: right" title="Outstanding at ending"&gt;3,072,494&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zp0CJdBzpM8e" style="text-align: right" title="Outstanding at ending"&gt;3.41&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjYuBCmwaEna" style="text-align: right"&gt;2,785,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyqxKOs4PKMa" style="text-align: right"&gt;1.64&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_ziQra1t9VNk5" style="text-align: right" title="Options exercisable at ending"&gt;871,244&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKguv4s32AMj" style="text-align: right" title="Options exercisable at ending"&gt;2.18&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQTj58kGXVc" style="text-align: right"&gt;812,760&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlo7npOo25Kj" style="text-align: right"&gt;1.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zpnaRxRZU1h1" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;3.06&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zd3BUCz4ZTN1" style="text-align: right"&gt;6.68&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zakrN2qX9gC1" style="text-align: right" title="Stock-based compensation expense"&gt;1,528,522&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvigHFTvguyb" style="text-align: right"&gt;290,991&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zo5FV1GXVCta" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total stock-based compensation expense was $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zeUFfOVmOM0c" title="Stock-based compensation expense"&gt;1,528,522&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_znNVxqFE0u4i"&gt;290,991&lt;/span&gt; for
the six months ended June 30, 2021, and 2020, respectively. Cash received from option exercises for the six months ended June 30, 2021,
and 2020 was $&lt;span id="xdx_907_eus-gaap--ProceedsFromStockOptionsExercised_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zNBcsHiSJJng" title="Cash received from option exercises"&gt;1,230,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ProceedsFromStockOptionsExercised_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxasnBV60dl5"&gt;95,880&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The weighted-average grant-date fair value of options granted during the
six months ended June 30, 2021, and 2020 was $&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_dm_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUTiWLkSNQ3d" title="Weighted-average grant-date fair value options granted"&gt;3.8&lt;/span&gt; million and $&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_dm_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zakQjRChLDWh"&gt;0.4&lt;/span&gt; million, respectively. &#160;There were &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_dm_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlgB5WqFlHVe" title="Number of options exercised"&gt;1.0 million&lt;/span&gt; options exercised
during the six months ended June 30, 2021, and &lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zx83yZBoebma"&gt;722,000&lt;/span&gt; during the six months ended June 30, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z2rniEiNvszl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to options outstanding
at June 30, 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 131.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 55.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15.1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$0.50-$9.76&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zCwt6XNE6DMe" style="text-align: right" title="Number Outstanding"&gt;3,072,494&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmTzMyWYowhb" title="Weighted Average Remaining Contractual Term"&gt;7.7&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zYYDYXQlocm9" style="text-align: right" title="Weighted Average Exercise Price"&gt;3.41&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmZI3iZxahba" style="text-align: right" title="Number Exercisable"&gt;871,244&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmhDWEtPXzjl" style="text-align: right" title="Weighted Average Exercise Price"&gt;2.18&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zL3tDKeuG7oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of June 30, 2021, there was $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_dm_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJOc14ILmpQ6"&gt;5.4&lt;/span&gt; million of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the Plan. &#160;That cost is expected to be recognized
over a weighted-average period of &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtM_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZNdUYsFUQgb" title="Weighted-average period (in years)"&gt;46&lt;/span&gt; months. &#160;The total fair value of shares vested as of June 30, 2021, and June 30, 2020, was $&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z4FAoOM072bi" title="Total fair value of shares vested"&gt;1,378,220&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoFINabZD55a"&gt;1,110,068&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Performance Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;There were no stock options granted during the six months ended June 30,
2021, and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zqNVn5RWIKKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the Plan with respect to performance-based
stock options:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 272.95pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 10.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zbuKzGTmHC9" style="width: 46.6pt; text-align: right" title="Outstanding at beginning"&gt;1,000,000&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMOlabXcllm2" style="width: 43.6pt; text-align: right" title="Outstanding at beginning"&gt;1.70&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6QbTuusZIMe" style="width: 46.65pt; text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsmdBEHNcf64" style="width: 45.15pt; text-align: right"&gt;1.70&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zUTMUOXN6NLh" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztZty21pGmc4" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7QfgIKCHST2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zHh4YCMASza6" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzaxM9dSfHo" style="text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNahtaB1VSmc" style="text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7h4oPnjqgLb" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyMJU0ac8wlj" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKSA5S4n7u6a" style="text-align: right" title="Forfeited"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMffMehLbIWj" style="text-align: right" title="Forfeited"&gt;1.70&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_za8vA2gSyQY3" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeceIHP9Dnhi" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2Hfpq2hfGV9" style="text-align: right" title="Outstanding at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zZMlo3MrKwr6" style="text-align: right" title="Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zBDwzzKqzcSf" style="text-align: right" title="Outstanding at ending"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zPE6sbTlZmnl" style="text-align: right" title="Outstanding at ending"&gt;1.70&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zF6NIYePdcXb" style="text-align: right" title="Options exercisable at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQqf0CJaYwwg" style="text-align: right" title="Options exercisable at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmcimHmi9TV6" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="background-color: #E6E6E6"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNgbyNxvXz98" style="background-color: #E6E6E6; text-align: right" title="Weighted average fair value of options granted during the period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #E0E0E0; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="background-color: #E0E0E0"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #E0E0E0"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zULar0RDbqVl" style="background-color: #E0E0E0; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0915"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zr1hSJTIGdl2" style="text-align: right" title="Stock-based compensation expense"&gt;(408,747&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z4Pa2bpS9TXk" style="text-align: right"&gt;373,826&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_z2PZ4hSWMR84" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total performance stock-based compensation expense totaled ($&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zvTVgpnknN79" title="Allocated stock-based compensation expense"&gt;408,747&lt;/span&gt;) and
$&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zG0rI9y4oUva"&gt;373,826&lt;/span&gt; for the six months ended June 30, 2021, and 2020, respectively. All performance-based stock options were forfeited as of June
30, 2021, and there was &lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zAHSYShJYz16" title="Total unrecognized compensation cost"&gt;no&lt;/span&gt; unrecognized compensation cost remaining.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted Stock Awards&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zC3grbogC7bf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the activities for our unvested restricted
stock awards for the six months ended June 30, 2021, and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 272.95pt"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 10.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwtfJaMxqiR6" style="width: 46.6pt; text-align: right" title="Outstanding at beginning"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zqUzQfmBNsod" style="width: 43.6pt; text-align: right" title="Outstanding at beginning"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zpiFG5GWMlag" style="width: 46.65pt; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8BgLBjeFPn9" style="width: 45.15pt; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkgHYELz1ITl" style="text-align: right" title="Granted"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zOhSOSLY25x8" style="text-align: right" title="Granted"&gt;3.01&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zT6tzxTQ67tc" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxob1AAVAqR1" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zHLSy0xR69Ph" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zPMRwi7W6cJh" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zaHKowckP4M2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zZjsCcCGJKJ2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfBWwYu5fpkj" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkjGU85rRiSl" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfAERmVq9E89" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwDa3ocCpnT6" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zq28dRJMU5u4" style="text-align: right" title="Outstanding at ending"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z6UN4qMwz8Bc" style="text-align: right" title="Outstanding at ending"&gt;3.01&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zbJ4Qb6uFM2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z1Kg27uxR9h8" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0955"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zZGMqMIqxmX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of June 30, 2021, there was $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8kjUKaC0UF1" title="Total unrecognized compensation cost"&gt;2,458,451&lt;/span&gt; of unrecognized compensation cost
related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtM_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zcbjjUrgf0T5"&gt;21&lt;/span&gt; months.
We have recognized tax benefits associated with restricted stock award compensation of $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zpaeGnSXdoda"&gt;13,888&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_dc_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zLyyxaFwCWtd"&gt;zero&lt;/span&gt; for the six months ended June
30, 2021 and 2020, respectively.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP
      contextRef="From2019-04-222019-04-23_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2021-02-132021-02-15_custom_ChiefExecutiveOfficerJamesMBeckMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <krmd:ExercisePrice
      contextRef="From2021-02-132021-02-15_custom_ChiefExecutiveOfficerJamesMBeckMember"
      decimals="INF"
      unitRef="USDPShares">4.37</krmd:ExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-02-132021-02-15_custom_ChiefExecutiveOfficerJamesMBeckMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-03-212021-03-22_custom_ChiefExecutiveOfficerJamesMBeckMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2021-03-142021-03-15_custom_ChiefExecutiveOfficerLindaTharbyMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <krmd:ExercisePrice
      contextRef="From2021-03-142021-03-15_custom_ChiefExecutiveOfficerLindaTharbyMember"
      decimals="INF"
      unitRef="USDPShares">3.875</krmd:ExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2021-03-142021-03-15_custom_ChiefExecutiveOfficerLindaTharbyMember">25% on March 15, 2022 and 25% each twelve months
thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember"
      decimals="0"
      unitRef="USD">3310000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndConsultantsUnderThePlanMember"
      decimals="INF"
      unitRef="Shares">3072494</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndConsultantsUnderThePlanMember"
      decimals="INF"
      unitRef="Shares">1150000</us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2018-12-302019-01-02_custom_NonEmployeeDirectorMember"
      decimals="0"
      unitRef="USD">50000</krmd:NonemployeeServicesTransactionCost>
    <krmd:AmountForChairingBoardCommittee
      contextRef="From2018-12-302019-01-02_custom_NonEmployeeDirectorMember"
      decimals="0"
      unitRef="USD">10000</krmd:AmountForChairingBoardCommittee>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2019-09-292019-10-01_srt_BoardOfDirectorsChairmanMember"
      decimals="0"
      unitRef="USD">50000</krmd:NonemployeeServicesTransactionCost>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      decimals="0"
      unitRef="USD">75000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction contextRef="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember">to be paid quarterly $12,500 in cash and
$6,250 in common stock.</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember"
      decimals="0"
      unitRef="USD">100000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction contextRef="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember">to be paid quarterly $12,500 in cash
and $12,500 in common stock.</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2020-05-172021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      decimals="0"
      unitRef="USD">110000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction contextRef="From2020-05-172021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember">to be paid quarterly $12,500 in cash and $15,000 in common stock.</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2020-05-172021-05-18_srt_BoardOfDirectorsChairmanMember"
      decimals="0"
      unitRef="USD">140000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction contextRef="From2020-05-172021-05-18_srt_BoardOfDirectorsChairmanMember">to be paid quarterly $12,500 in cash and $22,500 in common stock</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2020-05-192020-05-20_custom_SettlementAgreementMember_custom_EMEDTechnologiesCorporationMember">the Company issued to EMED (i) 95,238 restricted stock units, which vested on May 21, 2020, and 95,238 restricted
stock units, which vested on January 1, 2021, and (ii) an option to purchase up to 400,000 shares of the Company&#x2019;s common stock
at an exercise price of $11.21 per share prior to February 1, 2021, which was not exercised.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2021-02-132021-02-16_custom_ChiefExecutiveOfficerDonaldPettigrewMember"
      decimals="INF"
      unitRef="Shares">1000000</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-02-132021-02-16_custom_ChiefExecutiveOfficerDonaldPettigrewMember"
      decimals="0"
      unitRef="USD">1230000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="USDPShares">3.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="USDPShares">6.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">9817</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">31196</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmyu4wT6pbBa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 136.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 71.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 72.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zA6qLtvmNho5" style="text-align: right" title="Dividend yield"&gt;0.00%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zTvnuPh4j5h4" style="text-align: right"&gt;0.00%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zHIqnKC8RgH9" title="Expected Volatility"&gt;74.01&lt;/span&gt;%-&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zfJu2yK49WC8" title="Expected Volatility"&gt;74.28&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVRIJdFXiTY6" title="Expected Volatility"&gt;62.1&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z6vwKr4PyTGl" style="text-align: right" title="Weighted-average volatility"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlQ9IAIXVwel" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvK0LmrvMbtg" style="text-align: right" title="Expected dividends"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrRf4DJKBAf4" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zy19u1GF5Zfl" style="text-align: right" title="Expected term (in years)"&gt;10&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJswur0xwyhi" style="text-align: right"&gt;10&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zksXkYHvgxDg" title="Risk-free rate"&gt;1.20&lt;/span&gt;%-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z8nYOJtIoEC2" title="Risk-free rate"&gt;1.62&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlx3KzqaaXEk" title="Risk-free rate"&gt;0.63&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.7401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.7428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGxmR11YK5ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the Plan with respect to time
based stock options:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 226pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zo2vXiwdPqsa" style="width: 51.8pt; text-align: right" title="Outstanding at beginning"&gt;2,922,494&lt;/td&gt;
    &lt;td style="width: 23.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQApE92Scpol" style="width: 52.1pt; text-align: right" title="Outstanding at beginning"&gt;2.46&lt;/td&gt;
    &lt;td style="width: 23.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQfPU7YTCzof" style="width: 51.8pt; text-align: right"&gt;3,647,000&lt;/td&gt;
    &lt;td style="width: 23.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJkYbqhcN6Qc" style="width: 52.4pt; text-align: right"&gt;1.32&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zP63Rjb8h23b" style="text-align: right" title="Granted"&gt;1,250,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zphz7pXf69i2" style="text-align: right" title="Granted"&gt;3.94&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYqLhyOdZxaj" style="text-align: right"&gt;60,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1UGvet7fAha" style="text-align: right"&gt;9.76&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1EsMWu5DKBi" style="text-align: right" title="Exercised"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1jOtwBme6r6" style="text-align: right" title="Exercised"&gt;1.23&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKXkGafFSas5" style="text-align: right"&gt;722,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVBcqz6Bvpw8" style="text-align: right"&gt;0.58&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHYItV16tNib" style="text-align: right" title="Forfeited"&gt;100,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdgUGvPyBta4" style="text-align: right" title="Forfeited"&gt;3.94&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zmZ3LHDClJb" style="text-align: right"&gt;200,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzqhQhrr3H9i" style="text-align: right"&gt;2.09&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z18kgkoI4bX2" style="text-align: right" title="Outstanding at ending"&gt;3,072,494&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zp0CJdBzpM8e" style="text-align: right" title="Outstanding at ending"&gt;3.41&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjYuBCmwaEna" style="text-align: right"&gt;2,785,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyqxKOs4PKMa" style="text-align: right"&gt;1.64&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_ziQra1t9VNk5" style="text-align: right" title="Options exercisable at ending"&gt;871,244&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKguv4s32AMj" style="text-align: right" title="Options exercisable at ending"&gt;2.18&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQTj58kGXVc" style="text-align: right"&gt;812,760&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlo7npOo25Kj" style="text-align: right"&gt;1.37&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zpnaRxRZU1h1" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;3.06&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zd3BUCz4ZTN1" style="text-align: right"&gt;6.68&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zakrN2qX9gC1" style="text-align: right" title="Stock-based compensation expense"&gt;1,528,522&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvigHFTvguyb" style="text-align: right"&gt;290,991&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">2922494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">3647000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">9.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">722000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">0.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">3072494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">2785000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">871244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">812760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">6.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">1528522</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">290991</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">1528522</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">290991</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">1230000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">95880</us-gaap:ProceedsFromStockOptionsExercised>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">3800</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">400</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Shares">1000000.0</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Shares">722000</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z2rniEiNvszl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to options outstanding
at June 30, 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 131.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 55.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15.1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$0.50-$9.76&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zCwt6XNE6DMe" style="text-align: right" title="Number Outstanding"&gt;3,072,494&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmTzMyWYowhb" title="Weighted Average Remaining Contractual Term"&gt;7.7&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zYYDYXQlocm9" style="text-align: right" title="Weighted Average Exercise Price"&gt;3.41&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmZI3iZxahba" style="text-align: right" title="Number Exercisable"&gt;871,244&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmhDWEtPXzjl" style="text-align: right" title="Weighted Average Exercise Price"&gt;2.18&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="Shares">3072494</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">3.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="Shares">871244</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">5400</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">P46M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">1378220</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">1110068</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89B_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zqNVn5RWIKKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the Plan with respect to performance-based
stock options:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 272.95pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 10.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zbuKzGTmHC9" style="width: 46.6pt; text-align: right" title="Outstanding at beginning"&gt;1,000,000&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMOlabXcllm2" style="width: 43.6pt; text-align: right" title="Outstanding at beginning"&gt;1.70&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6QbTuusZIMe" style="width: 46.65pt; text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsmdBEHNcf64" style="width: 45.15pt; text-align: right"&gt;1.70&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zUTMUOXN6NLh" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztZty21pGmc4" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7QfgIKCHST2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zHh4YCMASza6" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzaxM9dSfHo" style="text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNahtaB1VSmc" style="text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7h4oPnjqgLb" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyMJU0ac8wlj" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKSA5S4n7u6a" style="text-align: right" title="Forfeited"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMffMehLbIWj" style="text-align: right" title="Forfeited"&gt;1.70&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_za8vA2gSyQY3" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeceIHP9Dnhi" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2Hfpq2hfGV9" style="text-align: right" title="Outstanding at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zZMlo3MrKwr6" style="text-align: right" title="Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zBDwzzKqzcSf" style="text-align: right" title="Outstanding at ending"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zPE6sbTlZmnl" style="text-align: right" title="Outstanding at ending"&gt;1.70&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zF6NIYePdcXb" style="text-align: right" title="Options exercisable at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQqf0CJaYwwg" style="text-align: right" title="Options exercisable at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmcimHmi9TV6" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="background-color: #E6E6E6"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNgbyNxvXz98" style="background-color: #E6E6E6; text-align: right" title="Weighted average fair value of options granted during the period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #E0E0E0; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="background-color: #E0E0E0"&gt;&#160;&lt;/td&gt;
    &lt;td style="background-color: #E0E0E0"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zULar0RDbqVl" style="background-color: #E0E0E0; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0915"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="background-color: #E6E6E6"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zr1hSJTIGdl2" style="text-align: right" title="Stock-based compensation expense"&gt;(408,747&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z4Pa2bpS9TXk" style="text-align: right"&gt;373,826&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="0"
      unitRef="USD">-408747</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="0"
      unitRef="USD">373826</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="0"
      unitRef="USD">-408747</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="0"
      unitRef="USD">373826</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zC3grbogC7bf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the activities for our unvested restricted
stock awards for the six months ended June 30, 2021, and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 272.95pt"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 10.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwtfJaMxqiR6" style="width: 46.6pt; text-align: right" title="Outstanding at beginning"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zqUzQfmBNsod" style="width: 43.6pt; text-align: right" title="Outstanding at beginning"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zpiFG5GWMlag" style="width: 46.65pt; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8BgLBjeFPn9" style="width: 45.15pt; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkgHYELz1ITl" style="text-align: right" title="Granted"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zOhSOSLY25x8" style="text-align: right" title="Granted"&gt;3.01&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zT6tzxTQ67tc" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxob1AAVAqR1" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zHLSy0xR69Ph" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zPMRwi7W6cJh" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zaHKowckP4M2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zZjsCcCGJKJ2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfBWwYu5fpkj" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkjGU85rRiSl" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfAERmVq9E89" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwDa3ocCpnT6" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at June 30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zq28dRJMU5u4" style="text-align: right" title="Outstanding at ending"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z6UN4qMwz8Bc" style="text-align: right" title="Outstanding at ending"&gt;3.01&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zbJ4Qb6uFM2" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z1Kg27uxR9h8" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0955"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2019-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">1000000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">3.01</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">1000000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">3.01</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="USD">2458451</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember">P21M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="USD">13888</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zWuPEnWVlbVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_82B_znfyO8NFxJka"&gt;DEBT OBLIGATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On April 14, 2020, the Company issued a promissory note to KeyBank in the
aggregate principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zxXGZ2WONxsf" title="Face amount"&gt;3.5 million&lt;/span&gt; (the &#x201c;Note&#x201d;) as an extension of its line of credit, replacing its then current
line of credit agreement. &#160;The $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zfz9TNBQKtsh" title="Face amount"&gt;3.5 million&lt;/span&gt; Note is in the form of a variable rate non-disclosable revolving line of credit with
an interest rate of &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zGwHNv8DPn7c" title="Interest rate terms"&gt;Prime Rate announced by the Bank minus 0.75%&lt;/span&gt;. &#160;The Note was renewed on June 24, 2021, in the same form with an
interest rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateTerms_c20200623__20200624__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_znDD1E6hWY78"&gt;Prime Rate announced by the Bank minus 1.50%&lt;/span&gt;. Interest is due monthly, and all principal and unpaid interest is due on
&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zXe7EzbOPXC8" title="Debt instrument, principal and unpaid interest due"&gt;June 1, 2022&lt;/span&gt;. &#160;The $3.5 million Note may be prepaid at &lt;span id="xdx_908_ecustom--DebtInstrumentPrepaidTerms_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_z682Pd5xJ8cb" title="Debt instrument, prepaid terms"&gt;any time prior to maturity with no prepayment penalties.&lt;/span&gt; &#160;The $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20210630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--LineOfCreditFacilityAxis__custom--KeyBankNationalAssociationMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z3kvbYLhMMVa" title="Face amount"&gt;3.5 million&lt;/span&gt;
Note contains events of default and other provisions customary for a loan of this type.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In connection with the Note, the Company entered into a Commercial Security
Agreement with the Bank dated April 14, 2020 (the &#x201c;Security Agreement&#x201d;), pursuant to which the Company granted a security
interest in substantially all assets of the Company to secure the obligations of the Company under the Note. &#160;The Security Agreement
contains terms and conditions typical for the granting of security interests of this kind.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company had no amount outstanding against the line of credit as of
June 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On April 27, 2020, the Company entered into a Progress Payment Loan and
Security Agreement (&#x201c;PPLSA&#x201d;) and a Master Security Agreement (the &#x201c;MSA&#x201d;), each dated as of April 20, 2020, with
Key Equipment Finance, a division of the Bank (&#x201c;KEF&#x201d;), to provide up to $&lt;span id="xdx_90A_eus-gaap--ProceedsFromLoans_dm_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_zx72ED2NU07j" title="Loans, principal amount"&gt;2.5 million&lt;/span&gt; in financing for equipment purchases
from third party vendors.&#160; The PPLSA allows the Company to make draws with KEF to make certain payments to the equipment suppliers
prior to the commencement of periodic payments under a term loan. Each draw under the PPLSA will bear interest at a variable rate equal
to the then-current Prime Rate and will be secured by the financed equipment under the MSA.&#160; At the end of each calendar quarter
or year, the advances made under the PPLSA will be converted to term loans, subject to KEF&#x2019;s approval of the equipment and certain
other closing conditions being met.&#160; Once the draws under the PPLSA are converted into a term loan, each promissory note will bear
interest at a &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateTerms_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_z1qTYyDElNB7" title="Interest rate terms"&gt;fixed rate of 4.07% per annum&lt;/span&gt;, subject to adjustment based on KEF&#x2019;s cost of funds, with principal and interest payable
in &lt;span id="xdx_904_ecustom--PrincipalAndInterestPayableTerms_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_zI7VaEQoTY91" title="Principal and interest payable terms"&gt;84 equal consecutive monthly installments.&lt;/span&gt;&#160; Each fixed rate installment promissory note may be prepaid, subject to a penalty if
prepaid before the fifth anniversary of its issuance. &#160;As of June 30, 2021, the Company had no amount outstanding against the PPLSA.&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2020-04-132020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">Prime Rate announced by the Bank minus 0.75%</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2020-06-232020-06-24_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">Prime Rate announced by the Bank minus 1.50%</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-04-132020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">2022-06-01</us-gaap:DebtInstrumentMaturityDate>
    <krmd:DebtInstrumentPrepaidTerms contextRef="From2020-04-132020-04-14_custom_KeyBankNationalAssociationMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">any time prior to maturity with no prepayment penalties.</krmd:DebtInstrumentPrepaidTerms>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-06-30_custom_PromissoryNoteMember_custom_KeyBankNationalAssociationMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromLoans
      contextRef="From2020-04-262020-04-27_custom_KeyEquipmentFinanceMember_custom_ProgressPaymentLoanAndSecurityAgreementMember"
      decimals="0"
      unitRef="USD">2500000</us-gaap:ProceedsFromLoans>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2020-04-262020-04-27_custom_KeyEquipmentFinanceMember_custom_ProgressPaymentLoanAndSecurityAgreementMember">fixed rate of 4.07% per annum</us-gaap:DebtInstrumentInterestRateTerms>
    <krmd:PrincipalAndInterestPayableTerms contextRef="From2020-04-262020-04-27_custom_KeyEquipmentFinanceMember_custom_ProgressPaymentLoanAndSecurityAgreementMember">84 equal consecutive monthly installments.</krmd:PrincipalAndInterestPayableTerms>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80E_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zrDYIyOQ8E5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_827_zff4px4vL5Ak"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our leases have remaining lease terms of one year, some of which include options to extend the leases
monthly and annually and some with options to terminate the leases within &lt;span id="xdx_900_ecustom--LessorOperatingLeaseOptionToTerminate1_dtY_c20210101__20210630_zrnqCAMOgl19" title="Operating lease, options to terminate"&gt;1&lt;/span&gt; year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zwGa4UfmjYgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of lease expense were as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
    &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20210401__20210630_zZaWvnSpX8yf" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200401__20200630_zLHKQfG7ngf6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20210101__20210630_z1dFLYflUgC4" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20200101__20200630_zueWJemDhqng" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 194.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 65pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 65.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseCost_maLCzFzn_zPKw9zV4yZnh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;37,369&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;37,921&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;75,290&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;75,843&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShortTermLeaseCost_maLCzFzn_zdlf8ws9Idwe" style="vertical-align: bottom"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;33,548&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;8,231&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;68,437&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;13,688&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LeaseCost_iT_mtLCzFzn_zmwTf74rHzT5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;70,917&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;46,152&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;143,727&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;89,531&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--FinanceLeaseCost1Abstract_iB_ziRIVCloueh9" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_zmIFK3XXlJuh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;794&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,855&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,589&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,711&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseInterestExpense_i01_zGtiDov6Svxh" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;19&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;65&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;47&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;152&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zxM3Mq5HgEz8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;813&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,920&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,636&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,863&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zLp4ym2YvjY" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHL5nnqh0Om2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
    &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20210101__20210630_ziH3O5baTcyj" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20200101__20200630_zp2e2G5j2rL7" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zsR7d49S9s85" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 190.85pt; padding-left: 8.25pt; text-indent: -8.25pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td style="width: 7.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeasePayments_i01_z7FiJ4aeNLwc" style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;70,363&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;67,633&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeasePrincipalPayments_i01_z9AN3VAMTJFk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,616&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,717&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zJcO7zFlV5Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zQiNaXNJlm76" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210630_zXM0qlgUIPEb" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20201231_z2gCExGJxlWa" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 191.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_z8Xv4V1ELMSd" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z0BtnOKeqzih" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;166,483&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;236,846&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maOLLzUcW_zlW0iahbKple" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,450&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;141,293&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maOLLzUcW_zHfSi4es3vs7" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease long term liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;24,033&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;95,553&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLzUcW_z4XYNXlvjBzc" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;166,483&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;236,846&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zTsqDG9fm3c3" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentOther_i01I_maPPAEOzWRu_zN3CAHfvhIBb" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Property and equipment, at cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;12,725&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;12,725&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_msPPAEOzWRu_zvFKBnOKYQSl" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(11,729&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(10,139&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01TI_mtPPAEOzWRu_z4FTBdWN2Cvj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;996&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,586&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maFLLzWBu_zdkTQzPiG4ve" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Finance lease current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,646&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_maFLLzWBu_zFy6rVbdwz82" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Finance lease long term liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1071"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iTI_mtFLLzWBu_zYWZ33KOnXh7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Total finance lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,646&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 191.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom; width: 70pt; text-align: center"&gt;&lt;b&gt;June 30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 12.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 70.75pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 7.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20210630_zusuzvdfX3Ea" title="Operating leases"&gt;0.9&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20201231_zArj6Ze92ou9" title="Operating leases"&gt;1.4&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20210630_zwamrVGEYzz4" title="Finance leases"&gt;0.4&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20201231_zmqe0wmYDxa5" title="Finance leases"&gt;0.7&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20210630_zItnF8QQVqq1" title="Operating leases"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20201231_zyiJBszJBDxh"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20210630_zwoj4sguvkyi" title="Finance leases"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20201231_zLRHQoTe2769"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zOhQlNTD2Sij" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3pqKhlt91G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Maturities of lease liabilities are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 261.6pt"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 9.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_z5Jyuh1OOA9" style="vertical-align: bottom; width: 78.95pt; text-align: right" title="2021 (excluding the six months ended June 30, 2021)"&gt;74,185&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_zggtra8KoDAd" style="vertical-align: bottom; width: 78.95pt; text-align: right" title="2021 (excluding the six months ended June 30, 2021)"&gt;1,042&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20210630_zi6VZGlUJ7Md" style="text-align: right" title="2022"&gt;97,257&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_d0_c20210630_zEzzAZL36opf" style="text-align: right" title="2022"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2023&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEOac3n1nbGe" style="vertical-align: bottom; text-align: right" title="2023"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEpT69EtF7rj" style="vertical-align: bottom; text-align: right" title="2023"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;2024&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_z77X5Crra5sa" style="vertical-align: bottom; text-align: right" title="2024"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_zxg5aSROj5li" style="vertical-align: bottom; text-align: right" title="2024"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zzFmgow3Njr6" style="vertical-align: bottom; text-align: right" title="2025"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zoFMAd54HSj1" style="vertical-align: bottom; text-align: right" title="2025"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zvok11nADIeg" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Thereafter"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zCMQnUjkpQek" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Thereafter"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20210630_znsBgzsFRobe" style="vertical-align: bottom; text-align: right" title="Total undiscounted operating lease payments"&gt;171,442&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20210630_zgCMfRA6jxO1" style="vertical-align: bottom; text-align: right" title="Total undiscounted finance lease payments"&gt;1,042&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 16.45pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20210630_zr3ss6kxZFL3" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest"&gt;(4,959&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20210630_zOrjha7HuQL4" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest"&gt;(12&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_c20210630_z0xWEDw4gZAb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total operating lease liabilities"&gt;166,483&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_c20210630_zyVgjaS92qKb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total finance lease liabilities"&gt;1,030&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zdMkoDHIcjt" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <krmd:LessorOperatingLeaseOptionToTerminate1 contextRef="From2021-01-01to2021-06-30">P1Y</krmd:LessorOperatingLeaseOptionToTerminate1>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zwGa4UfmjYgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of lease expense were as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
    &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20210401__20210630_zZaWvnSpX8yf" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200401__20200630_zLHKQfG7ngf6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20210101__20210630_z1dFLYflUgC4" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20200101__20200630_zueWJemDhqng" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 194.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 65pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 65.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseCost_maLCzFzn_zPKw9zV4yZnh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;37,369&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;37,921&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;75,290&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;75,843&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShortTermLeaseCost_maLCzFzn_zdlf8ws9Idwe" style="vertical-align: bottom"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;33,548&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;8,231&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;68,437&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;13,688&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LeaseCost_iT_mtLCzFzn_zmwTf74rHzT5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;70,917&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;46,152&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;143,727&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;89,531&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--FinanceLeaseCost1Abstract_iB_ziRIVCloueh9" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_zmIFK3XXlJuh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;794&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,855&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,589&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,711&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseInterestExpense_i01_zGtiDov6Svxh" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;19&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;65&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;47&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;152&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zxM3Mq5HgEz8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;813&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,920&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,636&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,863&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">37369</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">37921</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">75290</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">75843</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">33548</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">8231</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">68437</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">13688</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">70917</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">46152</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">143727</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">89531</us-gaap:LeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">794</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1855</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1589</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">3711</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">19</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">65</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">47</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">152</us-gaap:FinanceLeaseInterestExpense>
    <krmd:FinanceLeaseCost
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">813</krmd:FinanceLeaseCost>
    <krmd:FinanceLeaseCost
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1920</krmd:FinanceLeaseCost>
    <krmd:FinanceLeaseCost
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1636</krmd:FinanceLeaseCost>
    <krmd:FinanceLeaseCost
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">3863</krmd:FinanceLeaseCost>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89B_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHL5nnqh0Om2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
    &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20210101__20210630_ziH3O5baTcyj" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20200101__20200630_zp2e2G5j2rL7" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zsR7d49S9s85" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 190.85pt; padding-left: 8.25pt; text-indent: -8.25pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td style="width: 7.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeasePayments_i01_z7FiJ4aeNLwc" style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;70,363&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;67,633&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeasePrincipalPayments_i01_z9AN3VAMTJFk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,616&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,717&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">70363</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">67633</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1616</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">3717</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89F_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zQiNaXNJlm76" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210630_zXM0qlgUIPEb" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;June 30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20201231_z2gCExGJxlWa" style="border-bottom: black 0.5pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 191.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_z8Xv4V1ELMSd" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z0BtnOKeqzih" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;166,483&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;236,846&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maOLLzUcW_zlW0iahbKple" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,450&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;141,293&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maOLLzUcW_zHfSi4es3vs7" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Operating lease long term liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;24,033&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;95,553&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLzUcW_z4XYNXlvjBzc" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;166,483&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;236,846&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zTsqDG9fm3c3" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentOther_i01I_maPPAEOzWRu_zN3CAHfvhIBb" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Property and equipment, at cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;12,725&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;12,725&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_msPPAEOzWRu_zvFKBnOKYQSl" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(11,729&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;(10,139&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01TI_mtPPAEOzWRu_z4FTBdWN2Cvj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;996&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,586&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maFLLzWBu_zdkTQzPiG4ve" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Finance lease current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,646&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_maFLLzWBu_zFy6rVbdwz82" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 24.7pt; text-indent: -8.25pt"&gt;Finance lease long term liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1071"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iTI_mtFLLzWBu_zYWZ33KOnXh7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 7.95pt; text-indent: -7.95pt"&gt;Total finance lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,646&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 191.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom; width: 70pt; text-align: center"&gt;&lt;b&gt;June 30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 12.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 70.75pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 7.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20210630_zusuzvdfX3Ea" title="Operating leases"&gt;0.9&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20201231_zArj6Ze92ou9" title="Operating leases"&gt;1.4&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20210630_zwamrVGEYzz4" title="Finance leases"&gt;0.4&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20201231_zmqe0wmYDxa5" title="Finance leases"&gt;0.7&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20210630_zItnF8QQVqq1" title="Operating leases"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20201231_zyiJBszJBDxh"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 0.2in"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20210630_zwoj4sguvkyi" title="Finance leases"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20201231_zLRHQoTe2769"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">166483</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">236846</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">142450</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">141293</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">24033</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">95553</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">166483</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">236846</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">12725</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">12725</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">11729</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">10139</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">996</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2586</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1030</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2646</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1030</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2646</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2021-06-30">P0Y10M24D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2020-12-31">P1Y4M24D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2021-06-30">P0Y4M24D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2020-12-31">P0Y8M12D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="AsOf2021-06-30" decimals="INF" unitRef="Pure">0.0475</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="AsOf2020-12-31" decimals="INF" unitRef="Pure">0.0475</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="AsOf2021-06-30" decimals="INF" unitRef="Pure">0.0475</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="AsOf2020-12-31" decimals="INF" unitRef="Pure">0.0475</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3pqKhlt91G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Maturities of lease liabilities are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 261.6pt"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 9.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_z5Jyuh1OOA9" style="vertical-align: bottom; width: 78.95pt; text-align: right" title="2021 (excluding the six months ended June 30, 2021)"&gt;74,185&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_zggtra8KoDAd" style="vertical-align: bottom; width: 78.95pt; text-align: right" title="2021 (excluding the six months ended June 30, 2021)"&gt;1,042&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 9.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20210630_zi6VZGlUJ7Md" style="text-align: right" title="2022"&gt;97,257&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_d0_c20210630_zEzzAZL36opf" style="text-align: right" title="2022"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2023&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEOac3n1nbGe" style="vertical-align: bottom; text-align: right" title="2023"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEpT69EtF7rj" style="vertical-align: bottom; text-align: right" title="2023"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;2024&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_z77X5Crra5sa" style="vertical-align: bottom; text-align: right" title="2024"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_zxg5aSROj5li" style="vertical-align: bottom; text-align: right" title="2024"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zzFmgow3Njr6" style="vertical-align: bottom; text-align: right" title="2025"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zoFMAd54HSj1" style="vertical-align: bottom; text-align: right" title="2025"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zvok11nADIeg" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Thereafter"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zCMQnUjkpQek" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Thereafter"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20210630_znsBgzsFRobe" style="vertical-align: bottom; text-align: right" title="Total undiscounted operating lease payments"&gt;171,442&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20210630_zgCMfRA6jxO1" style="vertical-align: bottom; text-align: right" title="Total undiscounted finance lease payments"&gt;1,042&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 16.45pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20210630_zr3ss6kxZFL3" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest"&gt;(4,959&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 0.5pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20210630_zOrjha7HuQL4" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest"&gt;(12&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_c20210630_z0xWEDw4gZAb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total operating lease liabilities"&gt;166,483&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_c20210630_zyVgjaS92qKb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total finance lease liabilities"&gt;1,030&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">74185</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1042</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">97257</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">171442</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1042</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <krmd:LesseeOperatingLeaseImputedInterest contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4959</krmd:LesseeOperatingLeaseImputedInterest>
    <krmd:LesseeFinancingLeaseImputedInterest contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">12</krmd:LesseeFinancingLeaseImputedInterest>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">166483</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1030</us-gaap:FinanceLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgjpf35xkIic" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_826_zdAOnzWMeMY3"&gt;EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On June 18, 2020, the Company entered into a Purchase Agreement with
Piper Sandler &amp;amp; Co. and Canaccord Genuity LLC, as representatives of the several underwriters named therein (the
&#x201c;Underwriters&#x201d;), pursuant to which the Company agreed to issue and sel&lt;span id="xdx_90B_ecustom--NumberOfSharesIssued_pid_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8PCG71Fjdw" title="Number of shares issued"&gt;l
3,125,000&lt;/span&gt; shares of its common stock. &#160;Under the terms of the Purchase Agreement, the Company granted to the
Underwriters an option, exercisable for a period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtD_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyXZ7QDBB0pa" title="Option excercise period"&gt;30&lt;/span&gt;
days, to purchase up to an additional &lt;span id="xdx_90A_ecustom--AdditionalNumberOfSharesIssued_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1qwrTjSKofb" title="Option to purchase additional number of shares"&gt;468,750&lt;/span&gt;
shares of the Company&#x2019;s common stock, which the Underwriters exercised in full on &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBvoxzpk8fxl" title="Option excercise date"&gt;June
19, 2020&lt;/span&gt;. &#160;The Underwriters purchased the shares pursuant to the Purchase Agreement, including the shares subject to the
option, at a price of $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2dMfslqanpc" title="Share price (in dollars per share)"&gt;7.52&lt;/span&gt;
per share. &#160;Proceeds to the Company, net of discounts, commissions, fees and expenses, were $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_dm_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6xjXZgtNOq1" title="Proceeds from issuance"&gt;26.6 million&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On November 16, 2020, the Company announced that its Board of Directors&#160;had
authorized a stock repurchase program under which the Company may purchase up to $&lt;span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pp5d_dm_c20201115__20201116_zDQwJnWnrwm" title="Maximum amount of stock repurchase program"&gt;10.0 million&lt;/span&gt; of its outstanding common stock through
December 31, 2021. &#160;As of June 30, 2021, the Company had purchased &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210630_zwHO69BD8Q0h" title="Number of shares repurchased"&gt;683,271&lt;/span&gt; shares for an aggregate $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210630_zht3Nx4JcKMi" title="Aggregate amount stock repurchase"&gt;3,499,358&lt;/span&gt; pursuant to this program.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <krmd:NumberOfSharesIssued
      contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3125000</krmd:NumberOfSharesIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember">P30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <krmd:AdditionalNumberOfSharesIssued
      contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">468750</krmd:AdditionalNumberOfSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember">2020-06-19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharePrice
      contextRef="AsOf2020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">7.52</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2020-06-012020-06-18_custom_PurchaseAgreementMember_custom_PiperSandlerCoAndCanaccordGenuityLLCMember_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">26600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2020-11-152020-11-16"
      decimals="5"
      unitRef="USD">10000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">683271</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">3499358</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zfMIFgnPV3gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_821_zDvOHFamnNef"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On July 12, 2021, the lead plaintiff filed a notice of voluntary dismissal
without prejudice of the claims in the previously disclosed putative class action lawsuit filed in the United States District Court for
the Southern District of New York against the Company and its Chief Financial Officer and former Chief Executive Officer, alleging they
made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company&#x2019;s business,
operations and prospects, in the Company&#x2019;s earnings communications and Form 10-Q filed during the period August 4, 2020 and January
25, 2021.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227523794264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10-Q<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0-12305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">REPRO MED SYSTEMS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0000704440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13-3044880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 Carpenter Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Chester<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">469-2042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">KRMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">44,511,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="nump">3,420,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227521721704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,538,478<span></span>
</td>
<td class="nump">$ 27,315,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable less allowance for doubtful accounts of $24,469 for June 30, 2021, and December 31, 2020</a></td>
<td class="nump">2,577,400<span></span>
</td>
<td class="nump">2,572,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,562,750<span></span>
</td>
<td class="nump">6,829,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">461,553<span></span>
</td>
<td class="nump">807,780<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">37,140,181<span></span>
</td>
<td class="nump">37,525,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,110,550<span></span>
</td>
<td class="nump">1,167,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization of $232,820 and $199,899 at June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">834,644<span></span>
</td>
<td class="nump">843,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">166,483<span></span>
</td>
<td class="nump">236,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets, net</a></td>
<td class="nump">1,327,230<span></span>
</td>
<td class="nump">125,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">19,812<span></span>
</td>
<td class="nump">19,812<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">40,598,900<span></span>
</td>
<td class="nump">39,918,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,005,653<span></span>
</td>
<td class="nump">624,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,771,666<span></span>
</td>
<td class="nump">2,610,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related taxes</a></td>
<td class="nump">390,326<span></span>
</td>
<td class="nump">287,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability &#8211; current</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current</a></td>
<td class="nump">142,450<span></span>
</td>
<td class="nump">141,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">3,311,125<span></span>
</td>
<td class="nump">3,666,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">24,033<span></span>
</td>
<td class="nump">95,553<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">3,335,158<span></span>
</td>
<td class="nump">3,761,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Refer to Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 75,000,000 shares authorized, 47,910,676 and 46,680,119 shares issued 44,490,174 and 43,259,617 shares outstanding at June 30, 2021, and December 31, 2020, respectively</a></td>
<td class="nump">479,106<span></span>
</td>
<td class="nump">466,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">39,376,131<span></span>
</td>
<td class="nump">35,880,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 3,420,502 shares at June 30, 2021 and December 31, 2020, respectively, at cost</a></td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,252,067<span></span>
</td>
<td class="nump">3,652,754<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">37,263,742<span></span>
</td>
<td class="nump">36,156,979<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 40,598,900<span></span>
</td>
<td class="nump">$ 39,918,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524699944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for doubtful accounts</a></td>
<td class="nump">$ 24,469<span></span>
</td>
<td class="nump">$ 24,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Patents, accumulated amortization</a></td>
<td class="nump">$ 232,820<span></span>
</td>
<td class="nump">$ 199,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">47,910,676<span></span>
</td>
<td class="nump">46,680,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">44,490,174<span></span>
</td>
<td class="nump">43,259,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock</a></td>
<td class="nump">3,420,502<span></span>
</td>
<td class="nump">3,420,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524300600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET SALES</a></td>
<td class="nump">$ 5,528,174<span></span>
</td>
<td class="nump">$ 7,708,904<span></span>
</td>
<td class="nump">$ 10,959,125<span></span>
</td>
<td class="nump">$ 14,038,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">2,317,990<span></span>
</td>
<td class="nump">2,799,024<span></span>
</td>
<td class="nump">4,517,087<span></span>
</td>
<td class="nump">5,340,823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">3,210,184<span></span>
</td>
<td class="nump">4,909,880<span></span>
</td>
<td class="nump">6,442,038<span></span>
</td>
<td class="nump">8,698,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">4,085,945<span></span>
</td>
<td class="nump">3,201,831<span></span>
</td>
<td class="nump">9,078,774<span></span>
</td>
<td class="nump">5,964,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,346,914<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,446,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">386,878<span></span>
</td>
<td class="nump">298,196<span></span>
</td>
<td class="nump">723,719<span></span>
</td>
<td class="nump">554,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">118,415<span></span>
</td>
<td class="nump">94,940<span></span>
</td>
<td class="nump">233,888<span></span>
</td>
<td class="nump">182,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">4,591,238<span></span>
</td>
<td class="nump">5,941,881<span></span>
</td>
<td class="nump">10,036,381<span></span>
</td>
<td class="nump">9,147,268<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net Operating Loss</a></td>
<td class="num">(1,381,054)<span></span>
</td>
<td class="num">(1,032,001)<span></span>
</td>
<td class="num">(3,594,343)<span></span>
</td>
<td class="num">(449,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-Operating Income/(Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain/(Loss) on currency exchange</a></td>
<td class="nump">1,239<span></span>
</td>
<td class="num">(2,594)<span></span>
</td>
<td class="num">(14,478)<span></span>
</td>
<td class="num">(13,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Loss)/Gain on disposal of fixed assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,522)<span></span>
</td>
<td class="nump">736<span></span>
</td>
<td class="num">(5,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income, net</a></td>
<td class="nump">9,950<span></span>
</td>
<td class="num">(5,002)<span></span>
</td>
<td class="nump">19,721<span></span>
</td>
<td class="nump">14,028<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME/(EXPENSE)</a></td>
<td class="nump">11,189<span></span>
</td>
<td class="num">(13,118)<span></span>
</td>
<td class="nump">5,979<span></span>
</td>
<td class="num">(4,585)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(1,369,865)<span></span>
</td>
<td class="num">(1,045,119)<span></span>
</td>
<td class="num">(3,588,364)<span></span>
</td>
<td class="num">(453,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit/(Expense)</a></td>
<td class="nump">245,316<span></span>
</td>
<td class="num">(30,919)<span></span>
</td>
<td class="nump">1,187,677<span></span>
</td>
<td class="num">(172,847)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (1,124,549)<span></span>
</td>
<td class="num">$ (1,076,038)<span></span>
</td>
<td class="num">$ (2,400,687)<span></span>
</td>
<td class="num">$ (626,610)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">44,489,853<span></span>
</td>
<td class="nump">40,361,924<span></span>
</td>
<td class="nump">44,226,936<span></span>
</td>
<td class="nump">40,018,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">44,489,853<span></span>
</td>
<td class="nump">40,361,924<span></span>
</td>
<td class="nump">44,226,936<span></span>
</td>
<td class="nump">40,018,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524318776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (2,400,687)<span></span>
</td>
<td class="num">$ (626,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,339,356<span></span>
</td>
<td class="nump">784,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_StockbasedLitigationSettlementExpense', window );">Stock-based litigation settlement expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,285,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">233,888<span></span>
</td>
<td class="nump">182,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(1,201,956)<span></span>
</td>
<td class="num">(145,770)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain)/Loss on disposal of fixed assets</a></td>
<td class="num">(736)<span></span>
</td>
<td class="nump">5,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase)/Decrease in accounts receivable</a></td>
<td class="num">(4,446)<span></span>
</td>
<td class="nump">268,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(732,978)<span></span>
</td>
<td class="num">(1,278,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease/(Increase) in prepaid expenses and other assets</a></td>
<td class="nump">346,227<span></span>
</td>
<td class="num">(156,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">380,733<span></span>
</td>
<td class="nump">347,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase in accrued payroll and related taxes</a></td>
<td class="nump">103,196<span></span>
</td>
<td class="nump">333,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">(Decrease)/Increase in accrued expenses</a></td>
<td class="num">(838,747)<span></span>
</td>
<td class="nump">1,389,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Increase in accrued tax liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">318,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="num">(2,776,150)<span></span>
</td>
<td class="nump">2,707,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(152,223)<span></span>
</td>
<td class="num">(363,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">9,065<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(23,978)<span></span>
</td>
<td class="num">(149,523)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(167,136)<span></span>
</td>
<td class="num">(513,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_BorrowingsFromIndebtedness', window );">Borrowings from indebtedness</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of equity</a></td>
<td class="nump">1,230,000<span></span>
</td>
<td class="nump">26,567,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_CommonStockIssuanceAsSettlementForLitigation', window );">Common stock issuance as settlement for litigation</a></td>
<td class="nump">938,094<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease liability</a></td>
<td class="num">(1,616)<span></span>
</td>
<td class="num">(3,717)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">2,166,478<span></span>
</td>
<td class="nump">30,064,144<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(776,808)<span></span>
</td>
<td class="nump">32,258,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">27,315,286<span></span>
</td>
<td class="nump">5,870,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">26,538,478<span></span>
</td>
<td class="nump">38,129,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAbstract', window );"><strong>Cash paid during the periods for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">13,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes</a></td>
<td class="nump">850<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Schedule of Non-Cash Operating, Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_IssuanceOfCommonStockCompensation', window );">Issuance of common stock as compensation</a></td>
<td class="nump">153,446<span></span>
</td>
<td class="nump">120,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock as settlement for litigation</a></td>
<td class="nump">$ 938,094<span></span>
</td>
<td class="nump">$ 938,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_BorrowingsFromIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings from indebtedness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_BorrowingsFromIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CommonStockIssuanceAsSettlementForLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount rerpesent common stock issuance as settlement for litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CommonStockIssuanceAsSettlementForLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IssuanceOfCommonStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represent issuance of common stock compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IssuanceOfCommonStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockbasedLitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock based litigation settlement expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockbasedLitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227522099608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 422,398<span></span>
</td>
<td class="nump">$ 6,293,069<span></span>
</td>
<td class="nump">$ 4,864,817<span></span>
</td>
<td class="num">$ (344,204)<span></span>
</td>
<td class="nump">$ 11,236,080<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2019</a></td>
<td class="nump">42,239,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock-based compensation</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">59,910<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock-based compensation (in shares)</a></td>
<td class="nump">9,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">300,966<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">300,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon options exercised</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="nump">83,750<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">85,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance upon options exercised (in shares)</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">449,428<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">449,428<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 424,240<span></span>
</td>
<td class="nump">6,737,695<span></span>
</td>
<td class="nump">5,314,245<span></span>
</td>
<td class="num">(344,204)<span></span>
</td>
<td class="nump">12,131,976<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending (in shares) at Mar. 31, 2020</a></td>
<td class="nump">42,423,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 422,398<span></span>
</td>
<td class="nump">6,293,069<span></span>
</td>
<td class="nump">4,864,817<span></span>
</td>
<td class="num">(344,204)<span></span>
</td>
<td class="nump">11,236,080<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2019</a></td>
<td class="nump">42,239,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,610)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 466,401<span></span>
</td>
<td class="nump">34,886,850<span></span>
</td>
<td class="nump">4,238,207<span></span>
</td>
<td class="num">(344,204)<span></span>
</td>
<td class="nump">39,247,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending (in shares) at Jun. 30, 2020</a></td>
<td class="nump">46,640,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 424,240<span></span>
</td>
<td class="nump">6,737,695<span></span>
</td>
<td class="nump">5,314,245<span></span>
</td>
<td class="num">(344,204)<span></span>
</td>
<td class="nump">12,131,976<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning (in shares) at Mar. 31, 2020</a></td>
<td class="nump">42,423,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock-based compensation</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">59,922<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock-based compensation (in shares)</a></td>
<td class="nump">7,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">363,851<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">363,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_LitigationSettlementOptions', window );">Litigation settlement options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">347,008<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">347,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NewIssuanceLitigationSettlementAmountIssuance', window );">Litigation settlement share issuance</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">937,142<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">938,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NewIssuanceLitigationSettlementShareIssuance', window );">Litigation settlement share issuance (in shares)</a></td>
<td class="nump">95,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon options exercised</a></td>
<td class="nump">$ 5,192<span></span>
</td>
<td class="nump">5,189<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance upon options exercised (in shares)</a></td>
<td class="nump">519,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NewIssuanceOfCapitalRaiseAmount', window );">Capital raise</a></td>
<td class="nump">$ 35,937<span></span>
</td>
<td class="nump">26,436,043<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,471,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NewIssuanceOfCapitalRaiseShares', window );">Capital raise (in shares)</a></td>
<td class="nump">3,593,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,076,038)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,076,038)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 466,401<span></span>
</td>
<td class="nump">34,886,850<span></span>
</td>
<td class="nump">4,238,207<span></span>
</td>
<td class="num">(344,204)<span></span>
</td>
<td class="nump">39,247,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending (in shares) at Jun. 30, 2020</a></td>
<td class="nump">46,640,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 466,801<span></span>
</td>
<td class="nump">35,880,986<span></span>
</td>
<td class="nump">3,652,754<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">36,156,979<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">46,680,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock-based compensation</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">56,149<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock-based compensation (in shares)</a></td>
<td class="nump">10,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">677,934<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">677,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NewIssuanceLitigationSettlementAmountIssuance', window );">Litigation settlement share issuance</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">937,142<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">938,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NewIssuanceLitigationSettlementShareIssuance', window );">Litigation settlement share issuance (in shares)</a></td>
<td class="nump">95,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon options exercised</a></td>
<td class="nump">$ 11,106<span></span>
</td>
<td class="nump">1,218,894<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,230,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance upon options exercised (in shares)</a></td>
<td class="nump">1,110,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,276,138)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,276,138)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 478,960<span></span>
</td>
<td class="nump">38,771,105<span></span>
</td>
<td class="nump">2,376,616<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">37,783,119<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending (in shares) at Mar. 31, 2021</a></td>
<td class="nump">47,896,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 466,801<span></span>
</td>
<td class="nump">35,880,986<span></span>
</td>
<td class="nump">3,652,754<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">36,156,979<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">46,680,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,400,687)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 479,106<span></span>
</td>
<td class="nump">39,376,131<span></span>
</td>
<td class="nump">1,252,067<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">37,263,742<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending (in shares) at Jun. 30, 2021</a></td>
<td class="nump">47,910,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 478,960<span></span>
</td>
<td class="nump">38,771,105<span></span>
</td>
<td class="nump">2,376,616<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">37,783,119<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning (in shares) at Mar. 31, 2021</a></td>
<td class="nump">47,896,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock-based compensation</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">97,050<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">97,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock-based compensation (in shares)</a></td>
<td class="nump">14,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">441,841<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">441,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards', window );">Compensation expense related to restricted stock awards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">66,135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">66,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,124,549)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,124,549)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 479,106<span></span>
</td>
<td class="nump">$ 39,376,131<span></span>
</td>
<td class="nump">$ 1,252,067<span></span>
</td>
<td class="num">$ (3,843,562)<span></span>
</td>
<td class="nump">$ 37,263,742<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending (in shares) at Jun. 30, 2021</a></td>
<td class="nump">47,910,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation expense related to restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LitigationSettlementOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repreents amount related to litigation settlement options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LitigationSettlementOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NewIssuanceLitigationSettlementAmountIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amouont related to new issuance of litigation settlement amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NewIssuanceLitigationSettlementAmountIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NewIssuanceLitigationSettlementShareIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repreents amount related to litigation settlement share in issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NewIssuanceLitigationSettlementShareIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NewIssuanceOfCapitalRaiseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to new issuance of capital raise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NewIssuanceOfCapitalRaiseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NewIssuanceOfCapitalRaiseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of capital raise in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NewIssuanceOfCapitalRaiseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524122104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zszxjvrooL89" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_828_z49aNUozAF67">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_843_eus-gaap--NatureOfOperations_zzLB9l9CxQBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_zLuydB9ob6Th">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">REPRO MED SYSTEMS, INC. d/b/a KORU Medical Systems (the &#8220;Company,&#8221;
&#8220;KORU Medical,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management. The Company operates
as one segment.</p>

<p id="xdx_850_zIB7fjaFPui8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zidEruAYtJTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_zgP7U5inoSBg">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying financial statements should be read in conjunction with
the Company&#8217;s annual report on Form&#160;10-K for the year ended December 31, 2020 (&#8220;Annual Report&#8221;). &#160;Certain
information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted from the accompanying financial statements. &#160;The
accompanying year-end balance sheet was derived from the audited financial statements included in the Annual Report. &#160;The accompanying
interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement
of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. &#160;All such adjustments
are of a normal, recurring nature. &#160;The Company&#8217;s results of operations and cash flows for the interim periods are not necessarily
indicative of the results of operations and cash flows that it may achieve in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyj3kqJ33Zp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zDJ1Jd74IAN6">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20210630_zZrT2AXjEXk3" title="FDIC cash uninsured amount">250,000</span> at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.</p>

<p id="xdx_853_zmJ7VtTm6Jzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_za3kvhmAk2Y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zBZoxYJedvue">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p id="xdx_857_zMT0PW4qIhic" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zdcRLTdRdq47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zdDUt6WKworh">PATENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Costs incurred in obtaining patents have been capitalized and are being
amortized over the legal life of the patents.</p>

<p id="xdx_851_z1RjFihRrXcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zHPeWf7pGDT" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_zyL6O3yBD6ea">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment. &#160;Generally, tax years starting with 2018 are subject to examination by income tax authorities.</p>

<p id="xdx_855_zVnSX2BqyXq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSysJqjHW94b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_864_zdX1YVAMTI4l">PROPERTY, EQUIPMENT, AND DEPRECIATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment is stated at cost and is depreciated using the straight-line
method over the estimated useful lives of the respective assets.</p>

<p id="xdx_852_zKAiMgdkzQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zHUIHD9awjtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_z8WVD7yOvUPh">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan under which it grants stock options
to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using
the Black-Scholes option-pricing model. &#160;All options are charged against income at their fair value. &#160;The entire compensation
expense of the award is recognized over the vesting period. Shares of stock granted for director fees are recorded at the fair value of
the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company also maintains an omnibus equity incentive plan. There have
been no awards made pursuant to this plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted&#160;stock awards. Restricted stock awards&#160;are
equity classified and measured at the fair market value of the underlying&#160;stock&#160;at the grant date. The fair value of restricted
stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo
lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.</p>

<p id="xdx_85F_zkL4bwS17Q29" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z1xCcSeSHM86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_864_zsuvcyuQVtEf">NET INCOME PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjTTKoQ7UOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share include only an increase in the weighted average shares by the common
shares issuable upon exercise of employee and consultant stock options. &#160;See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221;
for further detail.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20210401__20210630_zQGpNyK9f178" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20200401__20200630_z1o6TJSbzC97" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_499_20210101__20210630_zPCyGKWfTrf4" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20200630_zGwHFnUPduSh" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 194.55pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.6pt; text-align: right">&#160;</td>
    <td style="width: 13.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.9pt; text-align: right">&#160;</td>
    <td style="width: 13.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.6pt; text-align: right">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.65pt; text-align: right">&#160;</td>
    <td style="width: 7.95pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zv4fw3nRSP6k" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(1,124,549</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(1,076,038</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(2,400,687</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(626,610</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_z837ovkF5Vqd" style="vertical-align: bottom">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pii_z7NebrhraI44" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Outstanding shares</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,489,853</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">40,361,924</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,226,936</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">40,018,559</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pii_d0_zNTiRV7g9ts6" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Option shares includable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2F_zilqoIZ4MFU4" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F27_zJzr4rPhUo91">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F25_zRtY9rwURta6" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F2A_zWUKTiWZY6Pi">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2D_zkJ3yzTZ3V1c" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F23_z5t9VBxHgvUc">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2F_zFIcI8Lh1XKj" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F27_zQuAXOll0kba">(a)</sup></td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pii_zX1oRbwIfiv9" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,489,853</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">40,361,924</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,226,936</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">40,018,559</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zzOtlyrYekO4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_i01_pii_z8Y5gvNjHD0k" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.03</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.03</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.05</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.02</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i01_pii_zTw8efKpAh0f" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.03</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.03</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.02</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F0A_ztv2jJQ0taD2" style="width: 0.25in">(a)</td>
    <td id="xdx_F1C_zx8BqlIVozUe" style="width: 7.25in">For the three months ended June 30, 2021, and 2020, option shares of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDdwHQpAnyRe" title="Anti-dilutive shares">224,336</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWXY5olwk3nh" title="Anti-dilutive shares">162,831</span> respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the six months ended June 30, 2021, and 2020, option shares of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoemU54MKHC4">214,132</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw5OpqlCcwXb">182,575</span> respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the three and six months ended June 30, 2021 and 2020, restricted shares of 1,000,000 and zero respectively, were not included as the impact is anti-dilutive.</td></tr>
  </table>
<p id="xdx_8AD_zcoJ6QJOJ6S" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_85E_zomDJNCqFr9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_846_eus-gaap--UseOfEstimates_zGpQguJGkmX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zVsp7TWsxiw4">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. Important estimates include but are not limited to asset lives, valuation allowances, inventory
valuation, and accruals.</p>

<p id="xdx_85F_zQ8xgN9P1Wve" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zuHcfhzK17b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zZ1sOI6AFsCi">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers. &#160;We adopted this ASU effective January
1, 2018, on a full retrospective basis. &#160;Adoption of this standard did not result in significant changes to our accounting policies,
business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or
related disclosures. &#160;As such, prior period financial statements were not recast.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and
pricing specified to select customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_892_ecustom--ScheduleOfNetSalesByGeography_z7cjsz1nWk08" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes net sales by geography for the three and
six months ended June 30, 2021, and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Three Months Ended June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 94.75pt"><b>Sales</b></td>
    <td style="width: 8.65pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 18.8pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 18.8pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 8.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Domestic</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__country--US_zdxC0DKEPdY" style="text-align: right" title="Net sales">4,645,770</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__country--US_z0szl53PSM2f" style="text-align: right">6,745,810</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__country--US_z5wwga36DHFk" style="text-align: right">9,092,559</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__country--US_zFSqCuy1yHse" style="text-align: right">12,086,676</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zsFa8rlwk9Nc" style="border-bottom: black 0.5pt solid; text-align: right" title="Net sales">882,404</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvK6NueSLZua" style="border-bottom: black 0.5pt solid; text-align: right">963,094</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zIL5FPFBKHb9" style="border-bottom: black 0.5pt solid; text-align: right">1,866,566</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zR3hTpRPSqaa" style="border-bottom: black 0.5pt solid; text-align: right">1,952,237</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20210401__20210630_z0NvtAvZ1vvg" style="border-bottom: black 2.25pt double; text-align: right" title="Net sales">5,528,174</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--Revenues_c20200401__20200630_zZX9c8JkcSfi" style="border-bottom: black 2.25pt double; text-align: right">7,708,904</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98A_eus-gaap--Revenues_c20210101__20210630_zu1g9YmAAPxh" style="border-bottom: black 2.25pt double; text-align: right">10,959,125</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630_z9ufXfC3UwQ5" style="border-bottom: black 2.25pt double; text-align: right">14,038,913</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AA_zQalavPH0Wyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_85F_zCDQyBK52ygl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zElmttjoLqif" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_865_zGTMgFRdrB2">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 6 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

<p id="xdx_850_zKzoVBYfEnN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwFwhCjIm43k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zjMfPKRiyNhd">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes (Topic
740): &#160;Simplifying the Accounting for Income Taxes</i>. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.</p>

<p id="xdx_857_z4N2lKm2RrWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_ecustom--AccountingPronouncementsNotYetAdopted_zwRZjiUm8616" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_z2ABr3nPvare">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2020, the FASB issued ASU No. 2020-04, <i>Reference Rate Reform
(Topic 848)</i>, which provided elective amendments for entities that have contracts, hedging relationships and other transactions that
reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. &#160;The amendments may be applied
to impacted contracts and hedges prospectively through December 31, 2022. &#160;The Company is currently evaluating the impact this guidance
will have on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<p id="xdx_85B_z92b69M12Eme" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyhjpzhOBLu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zuc97anlv0p7">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the six months ended June
30, 2021.</p>

<p id="xdx_853_z1BKo310pO57" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ziw9pFqYLzgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zpfOF3NqbFAi">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through June 30, 2021.</p>

<p id="xdx_85C_zDkFyPzM8sTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPXNVb7D2Dz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zveEKIQEFp0i">RECLASSIFICATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain reclassifications have been made to conform prior period data to
the current presentation. &#160;These reclassifications had no effect on reported net income.</p>

<p id="xdx_851_zDB18J3oGJGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227520597656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRmG5e9KkgJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_82E_zZuPcu0NaFHb">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zs1rgbK88Cv" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment consists of the following at:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30, 2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>December 31, 2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 208.35pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zJmgTQZf9Zqd" style="text-align: right" title="Total property and equipment">787,694</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zHYJE7kIrEt4" style="text-align: right">753,536</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQ8BUBXeDZ28" style="text-align: right" title="Total property and equipment">556,907</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8u4zmdSWoNg" style="text-align: right">542,796</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_z4TYy83udBY5" style="border-bottom: black 0.5pt solid; text-align: right" title="Total property and equipment">1,922,196</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zr9USlS4alu3" style="border-bottom: black 0.5pt solid; text-align: right">1,856,909</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630_zh4r3Zz9VNvf" style="text-align: right" title="Total property and equipment">3,266,797</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zfpe2OFnicPj" style="text-align: right">3,153,241</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20210630_zm8TwX9TYpcj" style="border-bottom: black 0.5pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,156,247</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zBjXcDBMxh97" style="border-bottom: black 0.5pt solid; text-align: right">(1,985,618</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20210630_zVPRp1qh0RU5" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">1,110,550</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20201231_zKSGcoxr2816" style="border-bottom: black 2.25pt double; text-align: right">1,167,623</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A8_z7c96ycr1Txe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Depreciation expense was $<span id="xdx_900_eus-gaap--Depreciation_c20210401__20210630_z4yAt88WdzK6" title="Depreciation expense">100,564</span> and $<span id="xdx_902_eus-gaap--Depreciation_c20200401__20200630_zGJBJcX5PcOj">79,245</span> for the three months ended
June 30, 2021 and 2020, respectively, and $<span id="xdx_90D_eus-gaap--Depreciation_c20210101__20210630_zGkyfkOey4ui">200,967</span> and $<span id="xdx_901_eus-gaap--Depreciation_c20200101__20200630_zzeciJNFrJXh">152,013</span> for the six months ended June 30, 2021 and 2020, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227535325576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zb0KtrLyEQbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_82B_zUClJXyOeNv4">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 12, 2021, the lead plaintiff filed a notice of voluntary dismissal
without prejudice of the claims in the previously disclosed putative class action lawsuit filed in the United States District Court for
the Southern District of New York against the Company and its Chief Financial Officer and former Chief Executive Officer, alleging they
made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company&#8217;s business,
operations and prospects, in the Company&#8217;s earnings communications and Form 10-Q filed during the period August 4, 2020 and January
25, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OTHER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), pursuant to which Command has agreed to manufacture and supply
the Company&#8217;s subassemblies, needle sets and tubing products pursuant to the Company&#8217;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#8220;Effective
Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement. &#160;If the Company terminates the Manufacturing and Supply Agreement other than for those reasons within the first three
years from the Effective Date, the Company is obligated to pay an early termination fee to Command.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227520565496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zLZHQnhRfSM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8212; <span id="xdx_82A_z86Bm7GmEt5">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 29, 2016, the Board of Directors amended the Company&#8217;s 2015
Stock Option Plan (as amended, the &#8220;Plan&#8221;)&#160;authorizing the Company to grant awards to certain executives, key employees,
and consultants under the Plan, which was approved by shareholders at the Annual Meeting of Shareholders held on September 6, 2016. &#160;The
total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, may not exceed <span id="xdx_902_eus-gaap--EmployeeStockOwnershipPlanESOPSharesContributedToESOP_pii_c20190422__20190423__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zV2sjZVKZZz8" title="Number of stock option shares">6,000,000</span> pursuant
to an amendment to the Plan approved by shareholders at their annual meeting on April 23, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On February 15, 2021, under the Plan, the Company issued to James M. Beck,
its Interim Chief Executive Officer, a non-qualified option to purchase up to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zTil1egajmA6" title="Number of stock option shares issued">150,000</span> shares of the Company&#8217;s common stock at an
exercise price of $<span id="xdx_900_ecustom--ExercisePrice_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zvnzsXOGRDQa" title="Exercise price">4.37</span> per share, of which <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pii_c20210213__20210215__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zqPIste0Jgk6" title="Number of shares vested">100,000</span> vested on February 15, 2021 and <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pii_c20210321__20210322__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerJamesMBeckMember_zUzFCWDIvNIk">50,000</span> vested on March 22, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 15, 2021, under the Plan, the Company issued to Linda Tharby,
its incoming President and Chief Executive Officer, a non-qualified stock option to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zVkS1LdQibmk" title="Number of stock option shares issued">1,000,000</span> shares of the Company&#8217;s
common stock at an exercise price of $<span id="xdx_900_ecustom--ExercisePrice_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zkaftxGOdFK5">3.875</span> per share, subject to vesting as follows: <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zxGh16ONFaa8" title="Description of vesting rights">25% on March 15, 2022 and 25% each twelve months
thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#8217;s President and Chief Executive Officer, the Company issued three restricted stock
awards for an aggregate <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zsg6xIpq7C4d">1,000,000</span> shares of common stock for an aggregate stock price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_pid_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zf50zmUo7Gvf" title="Number of stock option shares issued, value">3,310,000</span> and each vesting subject to employment
on the respective vesting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2021, the Company had options to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--EmployeesAndConsultantsUnderThePlanMember_zQpJrfmAab72" title="Number of stock option shares issued">3,072,494</span> shares
of Common Stock outstanding to certain executives, key employees and consultants under the Plan, of which <span id="xdx_90D_eus-gaap--EmployeeStockOwnershipPlanESOPSharesContributedToESOP_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--EmployeesAndConsultantsUnderThePlanMember_zkL70w1j48Y2" title="Number of stock option shares">1,150,000</span> were issued during
the six months ended June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to January 1, 2021, each non-employee director of the Company was
eligible to receive $<span id="xdx_90C_ecustom--NonemployeeServicesTransactionCost_c20181230__20190102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember_zlutGgmrYSGh" title="Nonemployee services transaction cost">50,000</span> annually (effective January 1, 2019), plus $<span id="xdx_907_ecustom--AmountForChairingBoardCommittee_c20181230__20190102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember_zj6yAk6K7KAd" title="Amount for chairing board committee">10,000</span> for chairing a Board committee (effective February 20,
2019), all to be paid quarterly half in cash and half in common stock. &#160;The Chairman of the Board was eligible to receive an additional
$<span id="xdx_909_ecustom--NonemployeeServicesTransactionCost_c20190929__20191001__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zZfBmWpP0ob7" title="Nonemployee services transaction cost">50,000</span> annually (effective October 1, 2019), all to be paid in common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Effective January 1, 2021, each non-employee director of the Company (other
than the Chairman of the Board) and Board advisor are eligible to receive of $<span id="xdx_904_ecustom--NonemployeeServicesTransactionCost_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zdFvSJ0LlIve">75,000</span> annually, <span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zYSvTkrTE0Nd" title="Description of non employee services transaction">to be paid quarterly $12,500 in cash and
$6,250 in common stock.</span> &#160;The Chairman of the Board is eligible to receive $<span id="xdx_90B_ecustom--NonemployeeServicesTransactionCost_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zovzgh9BnFjb" title="Nonemployee services transaction cost">100,000</span> annually, <span id="xdx_905_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zsuAlWmnmsk7" title="Description of non employee services transaction">to be paid quarterly $12,500 in cash
and $12,500 in common stock.</span> &#160; Effective May 18, 2021, each non-employee director of the Company (other than the Chairman of the
Board) and Board advisor are eligible to receive of $<span id="xdx_906_ecustom--NonemployeeServicesTransactionCost_c20200517__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zI0NheSvSwI">110,000</span> annually, <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20200517__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zIS71i90yZF7">to be paid quarterly $12,500 in cash and $15,000 in common stock.</span>
&#160;The Chairman of the Board is eligible to receive $<span id="xdx_90D_ecustom--NonemployeeServicesTransactionCost_c20200517__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z8nwhWts5fF1">140,000</span> annually, <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20200517__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zHWsKEPZC938">to be paid quarterly $12,500 in cash and $22,500 in common stock</span>.
All payments were and are pro-rated for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 20, 2020, the Company entered into a Settlement Agreement with EMED
Technologies Corporation (&#8220;EMED&#8221;) to settle all claims in connection with all pending litigation matters between them. &#160;Pursuant
to the Settlement Agreement, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20200519__20200520__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--EMEDTechnologiesCorporationMember_zjEBEgRlulS4" title="Description of vesting rights">the Company issued to EMED (i) 95,238 restricted stock units, which vested on May 21, 2020, and 95,238 restricted
stock units, which vested on January 1, 2021, and (ii) an option to purchase up to 400,000 shares of the Company&#8217;s common stock
at an exercise price of $11.21 per share prior to February 1, 2021, which was not exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On February 16, 2021, Donald Pettigrew, the Company&#8217;s former Chief
Executive Officer, exercised options held by him for an aggregate <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_c20210213__20210216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerDonaldPettigrewMember_zX3wm6WjsQe9" title="Number of options exercised">1,000,000</span> shares of common stock for an aggregate exercise price of
$<span id="xdx_904_eus-gaap--ProceedsFromStockOptionsExercised_c20210213__20210216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerDonaldPettigrewMember_zCY0FxLqmOhg" title="Cash received from option exercises">1,230,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 18, 2021, our shareholders approved the Company&#8217;s 2021 Omnibus
Equity Incentive Plan (the &#8220;2021 Equity Plan&#8221;). There have been no awards made pursuant to the 2021 Equity Plan to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2015 STOCK OPTION PLAN, as amended</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the six months ended June 30, 2021 and June 30, 2020 was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSpOnHAF6bBh" title="Weighted average grant date fair value of stock options">3.06</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUC7u8WoiMNf">6.68</span>, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
six months ended June 30, 2021 and June 30, 2020. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5E5tBDLPBT1" title="Tax benefits associated with stock-based compensation">9,817</span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLzs4vneJ0K5">31,196</span> for the six months ended June 30, 2021 and 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmyu4wT6pbBa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 136.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 71.6pt">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 72.35pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zA6qLtvmNho5" style="text-align: right" title="Dividend yield">0.00%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zTvnuPh4j5h4" style="text-align: right">0.00%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zHIqnKC8RgH9" title="Expected Volatility">74.01</span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zfJu2yK49WC8" title="Expected Volatility">74.28</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVRIJdFXiTY6" title="Expected Volatility">62.1</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z6vwKr4PyTGl" style="text-align: right" title="Weighted-average volatility">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlQ9IAIXVwel" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvK0LmrvMbtg" style="text-align: right" title="Expected dividends">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrRf4DJKBAf4" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zy19u1GF5Zfl" style="text-align: right" title="Expected term (in years)">10</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJswur0xwyhi" style="text-align: right">10</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zksXkYHvgxDg" title="Risk-free rate">1.20</span>%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z8nYOJtIoEC2" title="Risk-free rate">1.62</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlx3KzqaaXEk" title="Risk-free rate">0.63</span>%</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A5_zigQswkQPBLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGxmR11YK5ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Plan with respect to time
based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 226pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zo2vXiwdPqsa" style="width: 51.8pt; text-align: right" title="Outstanding at beginning">2,922,494</td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQApE92Scpol" style="width: 52.1pt; text-align: right" title="Outstanding at beginning">2.46</td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQfPU7YTCzof" style="width: 51.8pt; text-align: right">3,647,000</td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJkYbqhcN6Qc" style="width: 52.4pt; text-align: right">1.32</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zP63Rjb8h23b" style="text-align: right" title="Granted">1,250,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zphz7pXf69i2" style="text-align: right" title="Granted">3.94</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYqLhyOdZxaj" style="text-align: right">60,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1UGvet7fAha" style="text-align: right">9.76</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1EsMWu5DKBi" style="text-align: right" title="Exercised">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1jOtwBme6r6" style="text-align: right" title="Exercised">1.23</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKXkGafFSas5" style="text-align: right">722,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVBcqz6Bvpw8" style="text-align: right">0.58</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHYItV16tNib" style="text-align: right" title="Forfeited">100,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdgUGvPyBta4" style="text-align: right" title="Forfeited">3.94</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zmZ3LHDClJb" style="text-align: right">200,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzqhQhrr3H9i" style="text-align: right">2.09</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at June 30</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z18kgkoI4bX2" style="text-align: right" title="Outstanding at ending">3,072,494</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zp0CJdBzpM8e" style="text-align: right" title="Outstanding at ending">3.41</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjYuBCmwaEna" style="text-align: right">2,785,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyqxKOs4PKMa" style="text-align: right">1.64</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at June 30</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_ziQra1t9VNk5" style="text-align: right" title="Options exercisable at ending">871,244</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKguv4s32AMj" style="text-align: right" title="Options exercisable at ending">2.18</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQTj58kGXVc" style="text-align: right">812,760</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlo7npOo25Kj" style="text-align: right">1.37</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zpnaRxRZU1h1" style="text-align: right" title="Weighted average fair value of options granted during the period">3.06</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zd3BUCz4ZTN1" style="text-align: right">6.68</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zakrN2qX9gC1" style="text-align: right" title="Stock-based compensation expense">1,528,522</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvigHFTvguyb" style="text-align: right">290,991</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A6_zo5FV1GXVCta" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense was $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zeUFfOVmOM0c" title="Stock-based compensation expense">1,528,522</span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_znNVxqFE0u4i">290,991</span> for
the six months ended June 30, 2021, and 2020, respectively. Cash received from option exercises for the six months ended June 30, 2021,
and 2020 was $<span id="xdx_907_eus-gaap--ProceedsFromStockOptionsExercised_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zNBcsHiSJJng" title="Cash received from option exercises">1,230,000</span> and $<span id="xdx_90D_eus-gaap--ProceedsFromStockOptionsExercised_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxasnBV60dl5">95,880</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average grant-date fair value of options granted during the
six months ended June 30, 2021, and 2020 was $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_dm_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zUTiWLkSNQ3d" title="Weighted-average grant-date fair value options granted">3.8</span> million and $<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_dm_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zakQjRChLDWh">0.4</span> million, respectively. &#160;There were <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_dm_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlgB5WqFlHVe" title="Number of options exercised">1.0 million</span> options exercised
during the six months ended June 30, 2021, and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zx83yZBoebma">722,000</span> during the six months ended June 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z2rniEiNvszl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
at June 30, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 0.5pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 63.35pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="width: 55.8pt">&#160;</td>
    <td style="width: 15.1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$0.50-$9.76</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zCwt6XNE6DMe" style="text-align: right" title="Number Outstanding">3,072,494</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmTzMyWYowhb" title="Weighted Average Remaining Contractual Term">7.7</span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zYYDYXQlocm9" style="text-align: right" title="Weighted Average Exercise Price">3.41</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmZI3iZxahba" style="text-align: right" title="Number Exercisable">871,244</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmhDWEtPXzjl" style="text-align: right" title="Weighted Average Exercise Price">2.18</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AA_zL3tDKeuG7oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2021, there was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_dm_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJOc14ILmpQ6">5.4</span> million of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the Plan. &#160;That cost is expected to be recognized
over a weighted-average period of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtM_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZNdUYsFUQgb" title="Weighted-average period (in years)">46</span> months. &#160;The total fair value of shares vested as of June 30, 2021, and June 30, 2020, was $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z4FAoOM072bi" title="Total fair value of shares vested">1,378,220</span>
and $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoFINabZD55a">1,110,068</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Performance Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There were no stock options granted during the six months ended June 30,
2021, and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89B_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zqNVn5RWIKKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Plan with respect to performance-based
stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 272.95pt">Outstanding at January 1</td>
    <td style="width: 10.5pt">&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zbuKzGTmHC9" style="width: 46.6pt; text-align: right" title="Outstanding at beginning">1,000,000</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMOlabXcllm2" style="width: 43.6pt; text-align: right" title="Outstanding at beginning">1.70</td>
    <td style="width: 14.3pt">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6QbTuusZIMe" style="width: 46.65pt; text-align: right">1,000,000</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsmdBEHNcf64" style="width: 45.15pt; text-align: right">1.70</td>
    <td style="width: 10.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zUTMUOXN6NLh" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztZty21pGmc4" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7QfgIKCHST2" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zHh4YCMASza6" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzaxM9dSfHo" style="text-align: right" title="Exercised">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNahtaB1VSmc" style="text-align: right" title="Exercised">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7h4oPnjqgLb" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyMJU0ac8wlj" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKSA5S4n7u6a" style="text-align: right" title="Forfeited">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMffMehLbIWj" style="text-align: right" title="Forfeited">1.70</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_za8vA2gSyQY3" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeceIHP9Dnhi" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at June 30</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2Hfpq2hfGV9" style="text-align: right" title="Outstanding at ending">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zZMlo3MrKwr6" style="text-align: right" title="Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0903">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zBDwzzKqzcSf" style="text-align: right" title="Outstanding at ending">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zPE6sbTlZmnl" style="text-align: right" title="Outstanding at ending">1.70</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at June 30</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zF6NIYePdcXb" style="text-align: right" title="Options exercisable at ending">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQqf0CJaYwwg" style="text-align: right" title="Options exercisable at ending">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmcimHmi9TV6" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="background-color: #E6E6E6">Weighted average fair value of options granted during the period</td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E6E6E6; text-align: right">&#8212;</td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E6E6E6">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNgbyNxvXz98" style="background-color: #E6E6E6; text-align: right" title="Weighted average fair value of options granted during the period"><span style="-sec-ix-hidden: xdx2ixbrl0914">&#8212;</span></td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E0E0E0; text-align: right">&#8212;</td>
    <td style="background-color: #E0E0E0">&#160;</td>
    <td style="background-color: #E0E0E0">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zULar0RDbqVl" style="background-color: #E0E0E0; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">&#8212;</span></td>
    <td style="background-color: #E6E6E6">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zr1hSJTIGdl2" style="text-align: right" title="Stock-based compensation expense">(408,747</td>
    <td>)</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z4Pa2bpS9TXk" style="text-align: right">373,826</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AD_z2PZ4hSWMR84" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total performance stock-based compensation expense totaled ($<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zvTVgpnknN79" title="Allocated stock-based compensation expense">408,747</span>) and
$<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zG0rI9y4oUva">373,826</span> for the six months ended June 30, 2021, and 2020, respectively. All performance-based stock options were forfeited as of June
30, 2021, and there was <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zAHSYShJYz16" title="Total unrecognized compensation cost">no</span> unrecognized compensation cost remaining.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Awards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zC3grbogC7bf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the activities for our unvested restricted
stock awards for the six months ended June 30, 2021, and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 272.95pt">Unvested at January 1</td>
    <td style="width: 10.5pt">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwtfJaMxqiR6" style="width: 46.6pt; text-align: right" title="Outstanding at beginning">&#8212;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zqUzQfmBNsod" style="width: 43.6pt; text-align: right" title="Outstanding at beginning">&#8212;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zpiFG5GWMlag" style="width: 46.65pt; text-align: right">&#8212;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8BgLBjeFPn9" style="width: 45.15pt; text-align: right">&#8212;</td>
    <td style="width: 10.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkgHYELz1ITl" style="text-align: right" title="Granted">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zOhSOSLY25x8" style="text-align: right" title="Granted">3.01</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zT6tzxTQ67tc" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxob1AAVAqR1" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zHLSy0xR69Ph" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zPMRwi7W6cJh" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zaHKowckP4M2" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zZjsCcCGJKJ2" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfBWwYu5fpkj" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkjGU85rRiSl" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfAERmVq9E89" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwDa3ocCpnT6" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at June 30</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zq28dRJMU5u4" style="text-align: right" title="Outstanding at ending">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z6UN4qMwz8Bc" style="text-align: right" title="Outstanding at ending">3.01</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zbJ4Qb6uFM2" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z1Kg27uxR9h8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A8_zZGMqMIqxmX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2021, there was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8kjUKaC0UF1" title="Total unrecognized compensation cost">2,458,451</span> of unrecognized compensation cost
related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtM_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zcbjjUrgf0T5">21</span> months.
We have recognized tax benefits associated with restricted stock award compensation of $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zpaeGnSXdoda">13,888</span> and <span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_dc_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zLyyxaFwCWtd">zero</span> for the six months ended June
30, 2021 and 2020, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227551926488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT OBLIGATIONS</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zWuPEnWVlbVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_82B_znfyO8NFxJka">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 14, 2020, the Company issued a promissory note to KeyBank in the
aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zxXGZ2WONxsf" title="Face amount">3.5 million</span> (the &#8220;Note&#8221;) as an extension of its line of credit, replacing its then current
line of credit agreement. &#160;The $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zfz9TNBQKtsh" title="Face amount">3.5 million</span> Note is in the form of a variable rate non-disclosable revolving line of credit with
an interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zGwHNv8DPn7c" title="Interest rate terms">Prime Rate announced by the Bank minus 0.75%</span>. &#160;The Note was renewed on June 24, 2021, in the same form with an
interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateTerms_c20200623__20200624__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_znDD1E6hWY78">Prime Rate announced by the Bank minus 1.50%</span>. Interest is due monthly, and all principal and unpaid interest is due on
<span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zXe7EzbOPXC8" title="Debt instrument, principal and unpaid interest due">June 1, 2022</span>. &#160;The $3.5 million Note may be prepaid at <span id="xdx_908_ecustom--DebtInstrumentPrepaidTerms_c20200413__20200414__srt--TitleOfIndividualAxis__custom--KeyBankNationalAssociationMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_z682Pd5xJ8cb" title="Debt instrument, prepaid terms">any time prior to maturity with no prepayment penalties.</span> &#160;The $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_dm_c20210630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--LineOfCreditFacilityAxis__custom--KeyBankNationalAssociationMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z3kvbYLhMMVa" title="Face amount">3.5 million</span>
Note contains events of default and other provisions customary for a loan of this type.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Note, the Company entered into a Commercial Security
Agreement with the Bank dated April 14, 2020 (the &#8220;Security Agreement&#8221;), pursuant to which the Company granted a security
interest in substantially all assets of the Company to secure the obligations of the Company under the Note. &#160;The Security Agreement
contains terms and conditions typical for the granting of security interests of this kind.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company had no amount outstanding against the line of credit as of
June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 27, 2020, the Company entered into a Progress Payment Loan and
Security Agreement (&#8220;PPLSA&#8221;) and a Master Security Agreement (the &#8220;MSA&#8221;), each dated as of April 20, 2020, with
Key Equipment Finance, a division of the Bank (&#8220;KEF&#8221;), to provide up to $<span id="xdx_90A_eus-gaap--ProceedsFromLoans_dm_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_zx72ED2NU07j" title="Loans, principal amount">2.5 million</span> in financing for equipment purchases
from third party vendors.&#160; The PPLSA allows the Company to make draws with KEF to make certain payments to the equipment suppliers
prior to the commencement of periodic payments under a term loan. Each draw under the PPLSA will bear interest at a variable rate equal
to the then-current Prime Rate and will be secured by the financed equipment under the MSA.&#160; At the end of each calendar quarter
or year, the advances made under the PPLSA will be converted to term loans, subject to KEF&#8217;s approval of the equipment and certain
other closing conditions being met.&#160; Once the draws under the PPLSA are converted into a term loan, each promissory note will bear
interest at a <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateTerms_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_z1qTYyDElNB7" title="Interest rate terms">fixed rate of 4.07% per annum</span>, subject to adjustment based on KEF&#8217;s cost of funds, with principal and interest payable
in <span id="xdx_904_ecustom--PrincipalAndInterestPayableTerms_c20200426__20200427__srt--TitleOfIndividualAxis__custom--KeyEquipmentFinanceMember__us-gaap--TypeOfArrangementAxis__custom--ProgressPaymentLoanAndSecurityAgreementMember_zI7VaEQoTY91" title="Principal and interest payable terms">84 equal consecutive monthly installments.</span>&#160; Each fixed rate installment promissory note may be prepaid, subject to a penalty if
prepaid before the fifth anniversary of its issuance. &#160;As of June 30, 2021, the Company had no amount outstanding against the PPLSA.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227520898088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zrDYIyOQ8E5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_827_zff4px4vL5Ak">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our leases have remaining lease terms of one year, some of which include options to extend the leases
monthly and annually and some with options to terminate the leases within <span id="xdx_900_ecustom--LessorOperatingLeaseOptionToTerminate1_dtY_c20210101__20210630_zrnqCAMOgl19" title="Operating lease, options to terminate">1</span> year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zwGa4UfmjYgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_492_20210401__20210630_zZaWvnSpX8yf" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20200401__20200630_zLHKQfG7ngf6" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_497_20210101__20210630_z1dFLYflUgC4" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_493_20200101__20200630_zueWJemDhqng" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 194.9pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.7pt">&#160;</td>
    <td style="width: 13.55pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 65pt">&#160;</td>
    <td style="width: 13.55pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 64.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 65.45pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_maLCzFzn_zPKw9zV4yZnh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">37,369</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">37,921</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">75,290</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">75,843</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShortTermLeaseCost_maLCzFzn_zdlf8ws9Idwe" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">33,548</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">8,231</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">68,437</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">13,688</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LeaseCost_iT_mtLCzFzn_zmwTf74rHzT5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">70,917</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">46,152</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">143,727</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">89,531</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--FinanceLeaseCost1Abstract_iB_ziRIVCloueh9" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_zmIFK3XXlJuh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">794</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">1,855</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">1,589</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,711</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseInterestExpense_i01_zGtiDov6Svxh" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">19</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">65</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">47</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">152</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zxM3Mq5HgEz8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">813</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,920</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,636</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,863</td>
    <td>&#160;</td></tr>
  </table>

<p id="xdx_8AB_zLp4ym2YvjY" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89B_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHL5nnqh0Om2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20210101__20210630_ziH3O5baTcyj" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20200101__20200630_zp2e2G5j2rL7" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zsR7d49S9s85" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 190.85pt; padding-left: 8.25pt; text-indent: -8.25pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.1pt">&#160;</td>
    <td style="width: 12.75pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 64.45pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeasePayments_i01_z7FiJ4aeNLwc" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">70,363</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">67,633</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeasePrincipalPayments_i01_z9AN3VAMTJFk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,616</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">3,717</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A6_zJcO7zFlV5Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89F_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zQiNaXNJlm76" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49A_20210630_zXM0qlgUIPEb" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,<br/>
2021</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20201231_z2gCExGJxlWa" style="border-bottom: black 0.5pt solid; text-align: center"><b>December 31,<br/>
2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 191.5pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.1pt">&#160;</td>
    <td style="width: 12.75pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.85pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_z8Xv4V1ELMSd" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Operating Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z0BtnOKeqzih" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">166,483</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">236,846</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maOLLzUcW_zlW0iahbKple" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,450</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">141,293</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maOLLzUcW_zHfSi4es3vs7" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">24,033</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">95,553</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLzUcW_z4XYNXlvjBzc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">166,483</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">236,846</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zTsqDG9fm3c3" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentOther_i01I_maPPAEOzWRu_zN3CAHfvhIBb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">12,725</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">12,725</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_msPPAEOzWRu_zvFKBnOKYQSl" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(11,729</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(10,139</td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01TI_mtPPAEOzWRu_z4FTBdWN2Cvj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">996</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">2,586</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maFLLzWBu_zdkTQzPiG4ve" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,030</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,646</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_maFLLzWBu_zFy6rVbdwz82" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iTI_mtFLLzWBu_zYWZ33KOnXh7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,030</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">2,646</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 191.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 7.25pt">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom; width: 70pt; text-align: center"><b>June 30,<br/>
2021</b></td>
    <td style="vertical-align: bottom; width: 12.8pt">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 70.75pt; text-align: center"><b>December 31,<br/>
2020</b></td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 7.25pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20210630_zusuzvdfX3Ea" title="Operating leases">0.9</span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20201231_zArj6Ze92ou9" title="Operating leases">1.4</span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20210630_zwamrVGEYzz4" title="Finance leases">0.4</span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20201231_zmqe0wmYDxa5" title="Finance leases">0.7</span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20210630_zItnF8QQVqq1" title="Operating leases">4.75</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20201231_zyiJBszJBDxh">4.75</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20210630_zwoj4sguvkyi" title="Finance leases">4.75</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20201231_zLRHQoTe2769">4.75</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8A1_zOhQlNTD2Sij" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3pqKhlt91G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom"><b>Year Ending December 31, </b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 261.6pt">2021 (excluding the six months ended June 30, 2021)</td>
    <td style="vertical-align: top; width: 0.1in">&#160;</td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_z5Jyuh1OOA9" style="vertical-align: bottom; width: 78.95pt; text-align: right" title="2021 (excluding the six months ended June 30, 2021)">74,185</td>
    <td style="vertical-align: bottom; width: 14.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 7.5pt">&#160;</td>
    <td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_zggtra8KoDAd" style="vertical-align: bottom; width: 78.95pt; text-align: right" title="2021 (excluding the six months ended June 30, 2021)">1,042</td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>2022</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20210630_zi6VZGlUJ7Md" style="text-align: right" title="2022">97,257</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_d0_c20210630_zEzzAZL36opf" style="text-align: right" title="2022">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2023</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEOac3n1nbGe" style="vertical-align: bottom; text-align: right" title="2023">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEpT69EtF7rj" style="vertical-align: bottom; text-align: right" title="2023">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2024</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_z77X5Crra5sa" style="vertical-align: bottom; text-align: right" title="2024">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_zxg5aSROj5li" style="vertical-align: bottom; text-align: right" title="2024">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zzFmgow3Njr6" style="vertical-align: bottom; text-align: right" title="2025">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zoFMAd54HSj1" style="vertical-align: bottom; text-align: right" title="2025">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zvok11nADIeg" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Thereafter">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zCMQnUjkpQek" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Thereafter">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20210630_znsBgzsFRobe" style="vertical-align: bottom; text-align: right" title="Total undiscounted operating lease payments">171,442</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20210630_zgCMfRA6jxO1" style="vertical-align: bottom; text-align: right" title="Total undiscounted finance lease payments">1,042</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 16.45pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20210630_zr3ss6kxZFL3" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest">(4,959</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_986_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20210630_zOrjha7HuQL4" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest">(12</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_c20210630_z0xWEDw4gZAb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total operating lease liabilities">166,483</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_c20210630_zyVgjaS92qKb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total finance lease liabilities">1,030</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p id="xdx_8A1_zdMkoDHIcjt" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524649928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgjpf35xkIic" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_826_zdAOnzWMeMY3">EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 18, 2020, the Company entered into a Purchase Agreement with
Piper Sandler &amp; Co. and Canaccord Genuity LLC, as representatives of the several underwriters named therein (the
&#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sel<span id="xdx_90B_ecustom--NumberOfSharesIssued_pid_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8PCG71Fjdw" title="Number of shares issued">l
3,125,000</span> shares of its common stock. &#160;Under the terms of the Purchase Agreement, the Company granted to the
Underwriters an option, exercisable for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtD_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyXZ7QDBB0pa" title="Option excercise period">30</span>
days, to purchase up to an additional <span id="xdx_90A_ecustom--AdditionalNumberOfSharesIssued_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1qwrTjSKofb" title="Option to purchase additional number of shares">468,750</span>
shares of the Company&#8217;s common stock, which the Underwriters exercised in full on <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBvoxzpk8fxl" title="Option excercise date">June
19, 2020</span>. &#160;The Underwriters purchased the shares pursuant to the Purchase Agreement, including the shares subject to the
option, at a price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2dMfslqanpc" title="Share price (in dollars per share)">7.52</span>
per share. &#160;Proceeds to the Company, net of discounts, commissions, fees and expenses, were $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_dm_c20200601__20200618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PiperSandlerCoAndCanaccordGenuityLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6xjXZgtNOq1" title="Proceeds from issuance">26.6 million</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 16, 2020, the Company announced that its Board of Directors&#160;had
authorized a stock repurchase program under which the Company may purchase up to $<span id="xdx_90B_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_pp5d_dm_c20201115__20201116_zDQwJnWnrwm" title="Maximum amount of stock repurchase program">10.0 million</span> of its outstanding common stock through
December 31, 2021. &#160;As of June 30, 2021, the Company had purchased <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210630_zwHO69BD8Q0h" title="Number of shares repurchased">683,271</span> shares for an aggregate $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210630_zht3Nx4JcKMi" title="Aggregate amount stock repurchase">3,499,358</span> pursuant to this program.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227519322472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zfMIFgnPV3gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_821_zDvOHFamnNef">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 12, 2021, the lead plaintiff filed a notice of voluntary dismissal
without prejudice of the claims in the previously disclosed putative class action lawsuit filed in the United States District Court for
the Southern District of New York against the Company and its Chief Financial Officer and former Chief Executive Officer, alleging they
made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company&#8217;s business,
operations and prospects, in the Company&#8217;s earnings communications and Form 10-Q filed during the period August 4, 2020 and January
25, 2021.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524450344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_843_eus-gaap--NatureOfOperations_zzLB9l9CxQBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_zLuydB9ob6Th">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">REPRO MED SYSTEMS, INC. d/b/a KORU Medical Systems (the &#8220;Company,&#8221;
&#8220;KORU Medical,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) designs, manufactures and markets proprietary portable
and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management. The Company operates
as one segment.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zidEruAYtJTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_zgP7U5inoSBg">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying financial statements should be read in conjunction with
the Company&#8217;s annual report on Form&#160;10-K for the year ended December 31, 2020 (&#8220;Annual Report&#8221;). &#160;Certain
information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted from the accompanying financial statements. &#160;The
accompanying year-end balance sheet was derived from the audited financial statements included in the Annual Report. &#160;The accompanying
interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement
of the Company&#8217;s financial position, results of operations, and cash flows for the periods presented. &#160;All such adjustments
are of a normal, recurring nature. &#160;The Company&#8217;s results of operations and cash flows for the interim periods are not necessarily
indicative of the results of operations and cash flows that it may achieve in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyj3kqJ33Zp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zDJ1Jd74IAN6">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20210630_zZrT2AXjEXk3" title="FDIC cash uninsured amount">250,000</span> at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_za3kvhmAk2Y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zBZoxYJedvue">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">PATENTS</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zdcRLTdRdq47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zdDUt6WKworh">PATENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Costs incurred in obtaining patents have been capitalized and are being
amortized over the legal life of the patents.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zHPeWf7pGDT" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_zyL6O3yBD6ea">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment. &#160;Generally, tax years starting with 2018 are subject to examination by income tax authorities.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY, EQUIPMENT, AND DEPRECIATION</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSysJqjHW94b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_864_zdX1YVAMTI4l">PROPERTY, EQUIPMENT, AND DEPRECIATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment is stated at cost and is depreciated using the straight-line
method over the estimated useful lives of the respective assets.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zHUIHD9awjtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_z8WVD7yOvUPh">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan under which it grants stock options
to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using
the Black-Scholes option-pricing model. &#160;All options are charged against income at their fair value. &#160;The entire compensation
expense of the award is recognized over the vesting period. Shares of stock granted for director fees are recorded at the fair value of
the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company also maintains an omnibus equity incentive plan. There have
been no awards made pursuant to this plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted&#160;stock awards. Restricted stock awards&#160;are
equity classified and measured at the fair market value of the underlying&#160;stock&#160;at the grant date. The fair value of restricted
stock awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo
lattice model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">NET INCOME PER COMMON SHARE</a></td>
<td class="text"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_z1xCcSeSHM86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_864_zsuvcyuQVtEf">NET INCOME PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjTTKoQ7UOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share include only an increase in the weighted average shares by the common
shares issuable upon exercise of employee and consultant stock options. &#160;See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221;
for further detail.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20210401__20210630_zQGpNyK9f178" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20200401__20200630_z1o6TJSbzC97" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_499_20210101__20210630_zPCyGKWfTrf4" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20200630_zGwHFnUPduSh" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 194.55pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.6pt; text-align: right">&#160;</td>
    <td style="width: 13.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.9pt; text-align: right">&#160;</td>
    <td style="width: 13.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.6pt; text-align: right">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.65pt; text-align: right">&#160;</td>
    <td style="width: 7.95pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zv4fw3nRSP6k" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(1,124,549</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(1,076,038</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(2,400,687</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(626,610</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_z837ovkF5Vqd" style="vertical-align: bottom">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pii_z7NebrhraI44" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Outstanding shares</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,489,853</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">40,361,924</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,226,936</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">40,018,559</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pii_d0_zNTiRV7g9ts6" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Option shares includable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2F_zilqoIZ4MFU4" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F27_zJzr4rPhUo91">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F25_zRtY9rwURta6" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F2A_zWUKTiWZY6Pi">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2D_zkJ3yzTZ3V1c" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F23_z5t9VBxHgvUc">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2F_zFIcI8Lh1XKj" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F27_zQuAXOll0kba">(a)</sup></td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pii_zX1oRbwIfiv9" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,489,853</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">40,361,924</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,226,936</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">40,018,559</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zzOtlyrYekO4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_i01_pii_z8Y5gvNjHD0k" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.03</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.03</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.05</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.02</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i01_pii_zTw8efKpAh0f" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.03</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.03</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.02</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F0A_ztv2jJQ0taD2" style="width: 0.25in">(a)</td>
    <td id="xdx_F1C_zx8BqlIVozUe" style="width: 7.25in">For the three months ended June 30, 2021, and 2020, option shares of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDdwHQpAnyRe" title="Anti-dilutive shares">224,336</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWXY5olwk3nh" title="Anti-dilutive shares">162,831</span> respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the six months ended June 30, 2021, and 2020, option shares of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoemU54MKHC4">214,132</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw5OpqlCcwXb">182,575</span> respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the three and six months ended June 30, 2021 and 2020, restricted shares of 1,000,000 and zero respectively, were not included as the impact is anti-dilutive.</td></tr>
  </table>
<p id="xdx_8AD_zcoJ6QJOJ6S" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</a></td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_zGpQguJGkmX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zVsp7TWsxiw4">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. Important estimates include but are not limited to asset lives, valuation allowances, inventory
valuation, and accruals.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zuHcfhzK17b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zZ1sOI6AFsCi">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers. &#160;We adopted this ASU effective January
1, 2018, on a full retrospective basis. &#160;Adoption of this standard did not result in significant changes to our accounting policies,
business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or
related disclosures. &#160;As such, prior period financial statements were not recast.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and
pricing specified to select customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_892_ecustom--ScheduleOfNetSalesByGeography_z7cjsz1nWk08" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes net sales by geography for the three and
six months ended June 30, 2021, and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Three Months Ended June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 94.75pt"><b>Sales</b></td>
    <td style="width: 8.65pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 18.8pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 18.8pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 8.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Domestic</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__country--US_zdxC0DKEPdY" style="text-align: right" title="Net sales">4,645,770</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__country--US_z0szl53PSM2f" style="text-align: right">6,745,810</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__country--US_z5wwga36DHFk" style="text-align: right">9,092,559</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__country--US_zFSqCuy1yHse" style="text-align: right">12,086,676</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zsFa8rlwk9Nc" style="border-bottom: black 0.5pt solid; text-align: right" title="Net sales">882,404</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvK6NueSLZua" style="border-bottom: black 0.5pt solid; text-align: right">963,094</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zIL5FPFBKHb9" style="border-bottom: black 0.5pt solid; text-align: right">1,866,566</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zR3hTpRPSqaa" style="border-bottom: black 0.5pt solid; text-align: right">1,952,237</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20210401__20210630_z0NvtAvZ1vvg" style="border-bottom: black 2.25pt double; text-align: right" title="Net sales">5,528,174</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--Revenues_c20200401__20200630_zZX9c8JkcSfi" style="border-bottom: black 2.25pt double; text-align: right">7,708,904</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98A_eus-gaap--Revenues_c20210101__20210630_zu1g9YmAAPxh" style="border-bottom: black 2.25pt double; text-align: right">10,959,125</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630_z9ufXfC3UwQ5" style="border-bottom: black 2.25pt double; text-align: right">14,038,913</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AA_zQalavPH0Wyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zElmttjoLqif" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_865_zGTMgFRdrB2">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 6 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwFwhCjIm43k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zjMfPKRiyNhd">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes (Topic
740): &#160;Simplifying the Accounting for Income Taxes</i>. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_AccountingPronouncementsNotYetAdopted', window );">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</a></td>
<td class="text"><p id="xdx_84F_ecustom--AccountingPronouncementsNotYetAdopted_zwRZjiUm8616" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_z2ABr3nPvare">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2020, the FASB issued ASU No. 2020-04, <i>Reference Rate Reform
(Topic 848)</i>, which provided elective amendments for entities that have contracts, hedging relationships and other transactions that
reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. &#160;The amendments may be applied
to impacted contracts and hedges prospectively through December 31, 2022. &#160;The Company is currently evaluating the impact this guidance
will have on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyhjpzhOBLu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zuc97anlv0p7">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the six months ended June
30, 2021.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">IMPAIRMENT OF LONG-LIVED ASSETS</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ziw9pFqYLzgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zpfOF3NqbFAi">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through June 30, 2021.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">RECLASSIFICATION</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPXNVb7D2Dz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zveEKIQEFp0i">RECLASSIFICATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain reclassifications have been made to conform prior period data to
the current presentation. &#160;These reclassifications had no effect on reported net income.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AccountingPronouncementsNotYetAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AccountingPronouncementsNotYetAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227532747496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and consultant stock options. See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjTTKoQ7UOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share include only an increase in the weighted average shares by the common
shares issuable upon exercise of employee and consultant stock options. &#160;See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221;
for further detail.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20210401__20210630_zQGpNyK9f178" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20200401__20200630_z1o6TJSbzC97" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_499_20210101__20210630_zPCyGKWfTrf4" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20200630_zGwHFnUPduSh" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 194.55pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.6pt; text-align: right">&#160;</td>
    <td style="width: 13.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.9pt; text-align: right">&#160;</td>
    <td style="width: 13.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.6pt; text-align: right">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.65pt; text-align: right">&#160;</td>
    <td style="width: 7.95pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zv4fw3nRSP6k" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(1,124,549</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(1,076,038</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(2,400,687</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(626,610</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_z837ovkF5Vqd" style="vertical-align: bottom">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pii_z7NebrhraI44" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Outstanding shares</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,489,853</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">40,361,924</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,226,936</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">40,018,559</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pii_d0_zNTiRV7g9ts6" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Option shares includable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2F_zilqoIZ4MFU4" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F27_zJzr4rPhUo91">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F25_zRtY9rwURta6" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F2A_zWUKTiWZY6Pi">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2D_zkJ3yzTZ3V1c" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F23_z5t9VBxHgvUc">(a)</sup></td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_F2F_zFIcI8Lh1XKj" style="border-bottom: black 0.5pt solid; text-align: right">&#8212;</td>
    <td><sup id="xdx_F27_zQuAXOll0kba">(a)</sup></td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pii_zX1oRbwIfiv9" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,489,853</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">40,361,924</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,226,936</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">40,018,559</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zzOtlyrYekO4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_i01_pii_z8Y5gvNjHD0k" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.03</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.03</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.05</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">$</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(0.02</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i01_pii_zTw8efKpAh0f" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.03</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.03</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.05</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.02</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F0A_ztv2jJQ0taD2" style="width: 0.25in">(a)</td>
    <td id="xdx_F1C_zx8BqlIVozUe" style="width: 7.25in">For the three months ended June 30, 2021, and 2020, option shares of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDdwHQpAnyRe" title="Anti-dilutive shares">224,336</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWXY5olwk3nh" title="Anti-dilutive shares">162,831</span> respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the six months ended June 30, 2021, and 2020, option shares of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoemU54MKHC4">214,132</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIE5BVFVSRSBPRiBPUEVSQVRJT05TIEFORCBTVU1NQVJZIE9GIFNJR05JRklDQU5UIEFDQ09VTlRJTkcgUE9MSUNJRVMgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zw5OpqlCcwXb">182,575</span> respectively, were not included as the impact is anti-dilutive.&#160;&#160;For the three and six months ended June 30, 2021 and 2020, restricted shares of 1,000,000 and zero respectively, were not included as the impact is anti-dilutive.</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ScheduleOfNetSalesByGeography', window );">The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020:</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfNetSalesByGeography_z7cjsz1nWk08" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes net sales by geography for the three and
six months ended June 30, 2021, and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Three Months Ended June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 94.75pt"><b>Sales</b></td>
    <td style="width: 8.65pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 18.8pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 18.8pt">&#160;</td>
    <td style="width: 8.6pt">&#160;</td>
    <td style="width: 66.5pt; text-align: right">&#160;</td>
    <td style="width: 8.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Domestic</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__country--US_zdxC0DKEPdY" style="text-align: right" title="Net sales">4,645,770</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__country--US_z0szl53PSM2f" style="text-align: right">6,745,810</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__country--US_z5wwga36DHFk" style="text-align: right">9,092,559</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__country--US_zFSqCuy1yHse" style="text-align: right">12,086,676</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.2in">International</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--Revenues_c20210401__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zsFa8rlwk9Nc" style="border-bottom: black 0.5pt solid; text-align: right" title="Net sales">882,404</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--Revenues_c20200401__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zvK6NueSLZua" style="border-bottom: black 0.5pt solid; text-align: right">963,094</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--Revenues_c20210101__20210630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zIL5FPFBKHb9" style="border-bottom: black 0.5pt solid; text-align: right">1,866,566</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zR3hTpRPSqaa" style="border-bottom: black 0.5pt solid; text-align: right">1,952,237</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20210401__20210630_z0NvtAvZ1vvg" style="border-bottom: black 2.25pt double; text-align: right" title="Net sales">5,528,174</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--Revenues_c20200401__20200630_zZX9c8JkcSfi" style="border-bottom: black 2.25pt double; text-align: right">7,708,904</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98A_eus-gaap--Revenues_c20210101__20210630_zu1g9YmAAPxh" style="border-bottom: black 2.25pt double; text-align: right">10,959,125</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98E_eus-gaap--Revenues_c20200101__20200630_z9ufXfC3UwQ5" style="border-bottom: black 2.25pt double; text-align: right">14,038,913</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfNetSalesByGeography">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net sales by geography.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfNetSalesByGeography</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227534789944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consists of the following at:</a></td>
<td class="text"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zs1rgbK88Cv" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment consists of the following at:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30, 2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>December 31, 2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 208.35pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zJmgTQZf9Zqd" style="text-align: right" title="Total property and equipment">787,694</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zHYJE7kIrEt4" style="text-align: right">753,536</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQ8BUBXeDZ28" style="text-align: right" title="Total property and equipment">556,907</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8u4zmdSWoNg" style="text-align: right">542,796</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_z4TYy83udBY5" style="border-bottom: black 0.5pt solid; text-align: right" title="Total property and equipment">1,922,196</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zr9USlS4alu3" style="border-bottom: black 0.5pt solid; text-align: right">1,856,909</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20210630_zh4r3Zz9VNvf" style="text-align: right" title="Total property and equipment">3,266,797</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zfpe2OFnicPj" style="text-align: right">3,153,241</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20210630_zm8TwX9TYpcj" style="border-bottom: black 0.5pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,156,247</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zBjXcDBMxh97" style="border-bottom: black 0.5pt solid; text-align: right">(1,985,618</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20210630_zVPRp1qh0RU5" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">1,110,550</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20201231_zKSGcoxr2816" style="border-bottom: black 2.25pt double; text-align: right">1,167,623</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227519390040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmyu4wT6pbBa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 136.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 71.6pt">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 72.35pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zA6qLtvmNho5" style="text-align: right" title="Dividend yield">0.00%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zTvnuPh4j5h4" style="text-align: right">0.00%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zHIqnKC8RgH9" title="Expected Volatility">74.01</span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zfJu2yK49WC8" title="Expected Volatility">74.28</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVRIJdFXiTY6" title="Expected Volatility">62.1</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z6vwKr4PyTGl" style="text-align: right" title="Weighted-average volatility">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlQ9IAIXVwel" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zvK0LmrvMbtg" style="text-align: right" title="Expected dividends">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zrRf4DJKBAf4" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zy19u1GF5Zfl" style="text-align: right" title="Expected term (in years)">10</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJswur0xwyhi" style="text-align: right">10</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zksXkYHvgxDg" title="Risk-free rate">1.20</span>%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z8nYOJtIoEC2" title="Risk-free rate">1.62</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlx3KzqaaXEk" title="Risk-free rate">0.63</span>%</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">The following table summarizes the status of the Plan with respect to time based stock options:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGxmR11YK5ia" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Plan with respect to time
based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 226pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zo2vXiwdPqsa" style="width: 51.8pt; text-align: right" title="Outstanding at beginning">2,922,494</td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQApE92Scpol" style="width: 52.1pt; text-align: right" title="Outstanding at beginning">2.46</td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQfPU7YTCzof" style="width: 51.8pt; text-align: right">3,647,000</td>
    <td style="width: 23.3pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJkYbqhcN6Qc" style="width: 52.4pt; text-align: right">1.32</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zP63Rjb8h23b" style="text-align: right" title="Granted">1,250,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zphz7pXf69i2" style="text-align: right" title="Granted">3.94</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYqLhyOdZxaj" style="text-align: right">60,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1UGvet7fAha" style="text-align: right">9.76</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1EsMWu5DKBi" style="text-align: right" title="Exercised">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1jOtwBme6r6" style="text-align: right" title="Exercised">1.23</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKXkGafFSas5" style="text-align: right">722,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVBcqz6Bvpw8" style="text-align: right">0.58</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHYItV16tNib" style="text-align: right" title="Forfeited">100,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdgUGvPyBta4" style="text-align: right" title="Forfeited">3.94</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zmZ3LHDClJb" style="text-align: right">200,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzqhQhrr3H9i" style="text-align: right">2.09</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at June 30</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z18kgkoI4bX2" style="text-align: right" title="Outstanding at ending">3,072,494</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zp0CJdBzpM8e" style="text-align: right" title="Outstanding at ending">3.41</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjYuBCmwaEna" style="text-align: right">2,785,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyqxKOs4PKMa" style="text-align: right">1.64</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at June 30</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_ziQra1t9VNk5" style="text-align: right" title="Options exercisable at ending">871,244</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKguv4s32AMj" style="text-align: right" title="Options exercisable at ending">2.18</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQTj58kGXVc" style="text-align: right">812,760</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlo7npOo25Kj" style="text-align: right">1.37</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zpnaRxRZU1h1" style="text-align: right" title="Weighted average fair value of options granted during the period">3.06</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zd3BUCz4ZTN1" style="text-align: right">6.68</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zakrN2qX9gC1" style="text-align: right" title="Stock-based compensation expense">1,528,522</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvigHFTvguyb" style="text-align: right">290,991</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">The following table presents information pertaining to options outstanding at June 30, 2021:</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z2rniEiNvszl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
at June 30, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 0.5pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 63.35pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="width: 55.8pt">&#160;</td>
    <td style="width: 15.1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$0.50-$9.76</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zCwt6XNE6DMe" style="text-align: right" title="Number Outstanding">3,072,494</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmTzMyWYowhb" title="Weighted Average Remaining Contractual Term">7.7</span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zYYDYXQlocm9" style="text-align: right" title="Weighted Average Exercise Price">3.41</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmZI3iZxahba" style="text-align: right" title="Number Exercisable">871,244</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zmhDWEtPXzjl" style="text-align: right" title="Weighted Average Exercise Price">2.18</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">The following table summarizes the status of the Plan with respect to performance-based stock options:</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zqNVn5RWIKKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Plan with respect to performance-based
stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 272.95pt">Outstanding at January 1</td>
    <td style="width: 10.5pt">&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zbuKzGTmHC9" style="width: 46.6pt; text-align: right" title="Outstanding at beginning">1,000,000</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMOlabXcllm2" style="width: 43.6pt; text-align: right" title="Outstanding at beginning">1.70</td>
    <td style="width: 14.3pt">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6QbTuusZIMe" style="width: 46.65pt; text-align: right">1,000,000</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsmdBEHNcf64" style="width: 45.15pt; text-align: right">1.70</td>
    <td style="width: 10.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zUTMUOXN6NLh" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztZty21pGmc4" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7QfgIKCHST2" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zHh4YCMASza6" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzaxM9dSfHo" style="text-align: right" title="Exercised">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNahtaB1VSmc" style="text-align: right" title="Exercised">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7h4oPnjqgLb" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyMJU0ac8wlj" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKSA5S4n7u6a" style="text-align: right" title="Forfeited">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMffMehLbIWj" style="text-align: right" title="Forfeited">1.70</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_za8vA2gSyQY3" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeceIHP9Dnhi" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at June 30</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2Hfpq2hfGV9" style="text-align: right" title="Outstanding at ending">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zZMlo3MrKwr6" style="text-align: right" title="Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0903">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zBDwzzKqzcSf" style="text-align: right" title="Outstanding at ending">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zPE6sbTlZmnl" style="text-align: right" title="Outstanding at ending">1.70</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable at June 30</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zF6NIYePdcXb" style="text-align: right" title="Options exercisable at ending">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQqf0CJaYwwg" style="text-align: right" title="Options exercisable at ending">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmcimHmi9TV6" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="background-color: #E6E6E6">Weighted average fair value of options granted during the period</td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E6E6E6; text-align: right">&#8212;</td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E6E6E6">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNgbyNxvXz98" style="background-color: #E6E6E6; text-align: right" title="Weighted average fair value of options granted during the period"><span style="-sec-ix-hidden: xdx2ixbrl0914">&#8212;</span></td>
    <td style="background-color: #E6E6E6">&#160;</td>
    <td style="background-color: #E0E0E0; text-align: right">&#8212;</td>
    <td style="background-color: #E0E0E0">&#160;</td>
    <td style="background-color: #E0E0E0">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zULar0RDbqVl" style="background-color: #E0E0E0; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">&#8212;</span></td>
    <td style="background-color: #E6E6E6">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zr1hSJTIGdl2" style="text-align: right" title="Stock-based compensation expense">(408,747</td>
    <td>)</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z4Pa2bpS9TXk" style="text-align: right">373,826</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020.</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zC3grbogC7bf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the activities for our unvested restricted
stock awards for the six months ended June 30, 2021, and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 0.5pt solid; text-align: center"><b>Six Months Ended June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 272.95pt">Unvested at January 1</td>
    <td style="width: 10.5pt">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwtfJaMxqiR6" style="width: 46.6pt; text-align: right" title="Outstanding at beginning">&#8212;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zqUzQfmBNsod" style="width: 43.6pt; text-align: right" title="Outstanding at beginning">&#8212;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zpiFG5GWMlag" style="width: 46.65pt; text-align: right">&#8212;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 10.55pt">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8BgLBjeFPn9" style="width: 45.15pt; text-align: right">&#8212;</td>
    <td style="width: 10.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkgHYELz1ITl" style="text-align: right" title="Granted">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zOhSOSLY25x8" style="text-align: right" title="Granted">3.01</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zT6tzxTQ67tc" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxob1AAVAqR1" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zHLSy0xR69Ph" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zPMRwi7W6cJh" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zaHKowckP4M2" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zZjsCcCGJKJ2" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfBWwYu5fpkj" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zkjGU85rRiSl" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zfAERmVq9E89" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zwDa3ocCpnT6" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at June 30</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zq28dRJMU5u4" style="text-align: right" title="Outstanding at ending">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20210101__20210630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z6UN4qMwz8Bc" style="text-align: right" title="Outstanding at ending">3.01</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pii_d0_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zbJ4Qb6uFM2" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_c20200101__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z1Kg27uxR9h8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524888328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">The components of lease expense were as follows:</a></td>
<td class="text"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zwGa4UfmjYgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_492_20210401__20210630_zZaWvnSpX8yf" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20200401__20200630_zLHKQfG7ngf6" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_497_20210101__20210630_z1dFLYflUgC4" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_493_20200101__20200630_zueWJemDhqng" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 194.9pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 64.7pt">&#160;</td>
    <td style="width: 13.55pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 65pt">&#160;</td>
    <td style="width: 13.55pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 64.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 65.45pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_maLCzFzn_zPKw9zV4yZnh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">37,369</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">37,921</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">75,290</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">75,843</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShortTermLeaseCost_maLCzFzn_zdlf8ws9Idwe" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">33,548</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">8,231</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">68,437</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">13,688</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LeaseCost_iT_mtLCzFzn_zmwTf74rHzT5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">70,917</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">46,152</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">143,727</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">89,531</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--FinanceLeaseCost1Abstract_iB_ziRIVCloueh9" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_zmIFK3XXlJuh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.2in">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">794</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">1,855</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">1,589</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,711</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseInterestExpense_i01_zGtiDov6Svxh" style="vertical-align: bottom">
    <td style="padding-left: 0.2in">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">19</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">65</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">47</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">152</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zxM3Mq5HgEz8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">813</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,920</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,636</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,863</td>
    <td>&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Supplemental cash flow information related to leases was as follows:</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHL5nnqh0Om2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_493_20210101__20210630_ziH3O5baTcyj" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20200101__20200630_zp2e2G5j2rL7" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Six Months Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; text-align: center"><b>2020</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zsR7d49S9s85" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 190.85pt; padding-left: 8.25pt; text-indent: -8.25pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.1pt">&#160;</td>
    <td style="width: 12.75pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 64.45pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeasePayments_i01_z7FiJ4aeNLwc" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">70,363</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">67,633</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeasePrincipalPayments_i01_z9AN3VAMTJFk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,616</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">3,717</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Supplemental balance sheet information related to leases was as follows:</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zQiNaXNJlm76" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49A_20210630_zXM0qlgUIPEb" style="border-bottom: black 0.5pt solid; text-align: center"><b>June 30,<br/>
2021</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20201231_z2gCExGJxlWa" style="border-bottom: black 0.5pt solid; text-align: center"><b>December 31,<br/>
2020</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 191.5pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.1pt">&#160;</td>
    <td style="width: 12.75pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 63.85pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_z8Xv4V1ELMSd" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Operating Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_z0BtnOKeqzih" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">166,483</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">236,846</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maOLLzUcW_zlW0iahbKple" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,450</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">141,293</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maOLLzUcW_zHfSi4es3vs7" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">24,033</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">95,553</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLzUcW_z4XYNXlvjBzc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">166,483</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">236,846</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_zTsqDG9fm3c3" style="vertical-align: bottom">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentOther_i01I_maPPAEOzWRu_zN3CAHfvhIBb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">12,725</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">12,725</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_msPPAEOzWRu_zvFKBnOKYQSl" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(11,729</td>
    <td>)</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right">(10,139</td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01TI_mtPPAEOzWRu_z4FTBdWN2Cvj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">996</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">2,586</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maFLLzWBu_zdkTQzPiG4ve" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease current liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,030</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,646</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_maFLLzWBu_zFy6rVbdwz82" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease long term liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 0.5pt solid">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iTI_mtFLLzWBu_zYWZ33KOnXh7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.95pt; text-indent: -7.95pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,030</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">2,646</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 191.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 7.25pt">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom; width: 70pt; text-align: center"><b>June 30,<br/>
2021</b></td>
    <td style="vertical-align: bottom; width: 12.8pt">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 70.75pt; text-align: center"><b>December 31,<br/>
2020</b></td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: top; width: 7.25pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20210630_zusuzvdfX3Ea" title="Operating leases">0.9</span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20201231_zArj6Ze92ou9" title="Operating leases">1.4</span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20210630_zwamrVGEYzz4" title="Finance leases">0.4</span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20201231_zmqe0wmYDxa5" title="Finance leases">0.7</span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 0.2in">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20210630_zItnF8QQVqq1" title="Operating leases">4.75</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20201231_zyiJBszJBDxh">4.75</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 0.2in">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20210630_zwoj4sguvkyi" title="Finance leases">4.75</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_dp_c20201231_zLRHQoTe2769">4.75</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liabilities are as follows:</a></td>
<td class="text"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3pqKhlt91G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom"><b>Year Ending December 31, </b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 261.6pt">2021 (excluding the six months ended June 30, 2021)</td>
    <td style="vertical-align: top; width: 0.1in">&#160;</td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_z5Jyuh1OOA9" style="vertical-align: bottom; width: 78.95pt; text-align: right" title="2021 (excluding the six months ended June 30, 2021)">74,185</td>
    <td style="vertical-align: bottom; width: 14.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 7.5pt">&#160;</td>
    <td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210630_zggtra8KoDAd" style="vertical-align: bottom; width: 78.95pt; text-align: right" title="2021 (excluding the six months ended June 30, 2021)">1,042</td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>2022</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20210630_zi6VZGlUJ7Md" style="text-align: right" title="2022">97,257</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_d0_c20210630_zEzzAZL36opf" style="text-align: right" title="2022">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2023</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEOac3n1nbGe" style="vertical-align: bottom; text-align: right" title="2023">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_d0_c20210630_zEpT69EtF7rj" style="vertical-align: bottom; text-align: right" title="2023">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2024</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_z77X5Crra5sa" style="vertical-align: bottom; text-align: right" title="2024">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_d0_c20210630_zxg5aSROj5li" style="vertical-align: bottom; text-align: right" title="2024">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zzFmgow3Njr6" style="vertical-align: bottom; text-align: right" title="2025">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_d0_c20210630_zoFMAd54HSj1" style="vertical-align: bottom; text-align: right" title="2025">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zvok11nADIeg" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Thereafter">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_d0_c20210630_zCMQnUjkpQek" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Thereafter">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20210630_znsBgzsFRobe" style="vertical-align: bottom; text-align: right" title="Total undiscounted operating lease payments">171,442</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20210630_zgCMfRA6jxO1" style="vertical-align: bottom; text-align: right" title="Total undiscounted finance lease payments">1,042</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 16.45pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20210630_zr3ss6kxZFL3" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest">(4,959</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 0.5pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_986_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20210630_zOrjha7HuQL4" style="border-bottom: black 0.5pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest">(12</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_c20210630_z0xWEDw4gZAb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total operating lease liabilities">166,483</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_c20210630_zyVgjaS92qKb" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total finance lease liabilities">1,030</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227521255752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,124,549)<span></span>
</td>
<td class="num">$ (1,276,138)<span></span>
</td>
<td class="num">$ (1,076,038)<span></span>
</td>
<td class="nump">$ 449,428<span></span>
</td>
<td class="num">$ (2,400,687)<span></span>
</td>
<td class="num">$ (626,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Outstanding Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Outstanding shares</a></td>
<td class="nump">44,489,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,361,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,226,936<span></span>
</td>
<td class="nump">40,018,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">&#160;</a></td>
<td class="nump">44,489,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,361,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,226,936<span></span>
</td>
<td class="nump">40,018,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">224,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,132<span></span>
</td>
<td class="nump">182,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227528250776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 5,528,174<span></span>
</td>
<td class="nump">$ 7,708,904<span></span>
</td>
<td class="nump">$ 10,959,125<span></span>
</td>
<td class="nump">$ 14,038,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">4,645,770<span></span>
</td>
<td class="nump">6,745,810<span></span>
</td>
<td class="nump">9,092,559<span></span>
</td>
<td class="nump">12,086,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 882,404<span></span>
</td>
<td class="nump">$ 963,094<span></span>
</td>
<td class="nump">$ 1,866,566<span></span>
</td>
<td class="nump">$ 1,952,237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227535061304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">FDIC cash uninsured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">224,336<span></span>
</td>
<td class="nump">162,831<span></span>
</td>
<td class="nump">214,132<span></span>
</td>
<td class="nump">182,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227534889256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment consists of the following at: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 3,266,797<span></span>
</td>
<td class="nump">$ 3,153,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,156,247)<span></span>
</td>
<td class="num">(1,985,618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,110,550<span></span>
</td>
<td class="nump">1,167,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">787,694<span></span>
</td>
<td class="nump">753,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">556,907<span></span>
</td>
<td class="nump">542,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember', window );">Manufacturing Equipment And Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,922,196<span></span>
</td>
<td class="nump">$ 1,856,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524147576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 100,564<span></span>
</td>
<td class="nump">$ 79,245<span></span>
</td>
<td class="nump">$ 200,967<span></span>
</td>
<td class="nump">$ 152,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524902952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details) - 2015 Stock Option Plan [Member] - Time Based Shares Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.63%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">74.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">74.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227535637976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the status of the Plan with respect to time based stock options: (Details) - 2015 Stock Option Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">2,922,494<span></span>
</td>
<td class="nump">3,647,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">3,072,494<span></span>
</td>
<td class="nump">2,785,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at ending</a></td>
<td class="nump">871,244<span></span>
</td>
<td class="nump">812,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at ending</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="nump">$ 6.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,528,522<span></span>
</td>
<td class="nump">$ 290,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227520582456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table presents information pertaining to options outstanding at June 30, 2021: (Details) - 2015 Stock Option Plan [Member] - Time Based Shares Options [Member] - $ 0.38 - 3.15 [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding | shares</a></td>
<td class="nump">3,072,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">871,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227517954872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the status of the Plan with respect to performance-based stock options: (Details) - 2015 Stock Option Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">2,922,494<span></span>
</td>
<td class="nump">3,647,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">3,072,494<span></span>
</td>
<td class="nump">2,785,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at ending</a></td>
<td class="nump">871,244<span></span>
</td>
<td class="nump">812,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at ending</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="nump">$ 6.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,528,522<span></span>
</td>
<td class="nump">$ 290,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="num">$ (408,747)<span></span>
</td>
<td class="nump">$ 373,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524749464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details) - 2015 Stock Option Plan [Member] - Restricted Stock Awards [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested', window );">Granted</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested', window );">Granted</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross', window );">Vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice', window );">Vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested', window );">Forfeited/canceled</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested', window );">Forfeited/canceled</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at ending</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at ending</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares represent unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent unvested per shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent vested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent vested per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227444040840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 12, 2021</div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Feb. 15, 2021</div></th>
<th class="th"><div>Jan. 02, 2021</div></th>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Apr. 23, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 18, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=krmd_SettlementAgreementMember', window );">Settlement Agreement [Member] | EMED Technologies Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Description of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company issued to EMED (i) 95,238 restricted stock units, which vested on May 21, 2020, and 95,238 restricted
stock units, which vested on January 1, 2021, and (ii) an option to purchase up to 400,000 shares of the Company&#8217;s common stock
at an exercise price of $11.21 per share prior to February 1, 2021, which was not exercised.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorMember', window );">Non-Employee Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_AmountForChairingBoardCommittee', window );">Amount for chairing board committee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction', window );">Description of non employee services transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to be paid quarterly $12,500 in cash
and $12,500 in common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to be paid quarterly $12,500 in cash and $22,500 in common stock<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember', window );">Non-Employee Director and Board Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction', window );">Description of non employee services transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to be paid quarterly $12,500 in cash and
$6,250 in common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to be paid quarterly $12,500 in cash and $15,000 in common stock.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerJamesMBeckMember', window );">James M. Beck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Number of stock option shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerLindaTharbyMember', window );">Linda Tharby [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Number of stock option shares issued</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Description of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25% on March 15, 2022 and 25% each twelve months
thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Number of stock option shares issued, value</a></td>
<td class="nump">$ 3,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerDonaldPettigrewMember', window );">Donald Pettigrew [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">2015 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP', window );">Number of stock option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="nump">$ 6.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,528,522<span></span>
</td>
<td class="nump">$ 290,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,528,522)<span></span>
</td>
<td class="num">$ (290,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">2015 Stock Option Plan [Member] | Time Based Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,230,000<span></span>
</td>
<td class="nump">$ 95,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="nump">$ 6.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Tax benefits associated with stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,817<span></span>
</td>
<td class="nump">$ 31,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,528,522<span></span>
</td>
<td class="nump">290,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">46 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,378,220<span></span>
</td>
<td class="nump">1,110,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,528,522)<span></span>
</td>
<td class="num">$ (290,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">2015 Stock Option Plan [Member] | Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (408,747)<span></span>
</td>
<td class="nump">$ 373,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,747<span></span>
</td>
<td class="num">(373,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">2015 Stock Option Plan [Member] | Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,888<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,458,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,888)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_EmployeesAndConsultantsUnderThePlanMember', window );">Employees and Consultants under the Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP', window );">Number of stock option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Number of stock option shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,072,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AmountForChairingBoardCommittee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount rerpesent for chairing board committee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AmountForChairingBoardCommittee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NonemployeeServicesTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount non employee services transaction cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NonemployeeServicesTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>it refers the amount of share based payment award grants in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the number of shares provided to the Employee Stock Ownership Plan (ESOP) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of transactions in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting method used for valuing the transaction, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=krmd_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=krmd_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krmd_EMEDTechnologiesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krmd_EMEDTechnologiesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerJamesMBeckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerJamesMBeckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerLindaTharbyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerLindaTharbyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerDonaldPettigrewMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerDonaldPettigrewMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_EmployeesAndConsultantsUnderThePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_EmployeesAndConsultantsUnderThePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524068312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT OBLIGATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 24, 2020</div></th>
<th class="th"><div>Apr. 27, 2020</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember', window );">Promissory Note [Member] | Revolving Credit Facility [Member] | KeyBank National Association [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_KeyBankNationalAssociationMember', window );">KeyBank National Association [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_KeyBankNationalAssociationMember', window );">KeyBank National Association [Member] | Promissory Note [Member] | Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Interest rate terms</a></td>
<td class="text">Prime Rate announced by the Bank minus 1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prime Rate announced by the Bank minus 0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, principal and unpaid interest due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_DebtInstrumentPrepaidTerms', window );">Debt instrument, prepaid terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">any time prior to maturity with no prepayment penalties.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_KeyEquipmentFinanceMember', window );">Key Equipment Finance [Member] | Progress Payment Loan and Security Agreement And Master Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Interest rate terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">fixed rate of 4.07% per annum<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Loans, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_PrincipalAndInterestPayableTerms', window );">Principal and interest payable terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">84 equal consecutive monthly installments.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DebtInstrumentPrepaidTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of dent instrument prepaid terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DebtInstrumentPrepaidTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_PrincipalAndInterestPayableTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of principal and interest payment terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_PrincipalAndInterestPayableTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=krmd_KeyBankNationalAssociationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=krmd_KeyBankNationalAssociationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_KeyBankNationalAssociationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_KeyBankNationalAssociationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_KeyEquipmentFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_KeyEquipmentFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=krmd_ProgressPaymentLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=krmd_ProgressPaymentLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227546109160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The components of lease expense were as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 37,369<span></span>
</td>
<td class="nump">$ 37,921<span></span>
</td>
<td class="nump">$ 75,290<span></span>
</td>
<td class="nump">$ 75,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">33,548<span></span>
</td>
<td class="nump">8,231<span></span>
</td>
<td class="nump">68,437<span></span>
</td>
<td class="nump">13,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">70,917<span></span>
</td>
<td class="nump">46,152<span></span>
</td>
<td class="nump">143,727<span></span>
</td>
<td class="nump">89,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_FinanceLeaseCost1Abstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">3,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">$ 1,920<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
<td class="nump">$ 3,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance lease cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524790120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental cash flow information related to leases was as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 70,363<span></span>
</td>
<td class="nump">$ 67,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 1,616<span></span>
</td>
<td class="nump">$ 3,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227523876968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental balance sheet information related to leases was as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_AssetsAndLiabilitiesOperatingLesseeAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 166,483<span></span>
</td>
<td class="nump">$ 236,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">142,450<span></span>
</td>
<td class="nump">141,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease long term liabilities</a></td>
<td class="nump">24,033<span></span>
</td>
<td class="nump">95,553<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">166,483<span></span>
</td>
<td class="nump">236,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_AssetsAndLiabilitiesLesseeFinanceAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Property and equipment, at cost</a></td>
<td class="nump">12,725<span></span>
</td>
<td class="nump">12,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="num">(11,729)<span></span>
</td>
<td class="num">(10,139)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and equipment, net</a></td>
<td class="nump">996<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease current liabilities</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease long term liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 1,030<span></span>
</td>
<td class="nump">$ 2,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leases</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance leases</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating leases</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance leases</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AssetsAndLiabilitiesLesseeFinanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AssetsAndLiabilitiesLesseeFinanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AssetsAndLiabilitiesOperatingLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AssetsAndLiabilitiesOperatingLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524729512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Maturities of lease liabilities are as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021 (excluding the six months ended June 30, 2021)</a></td>
<td class="nump">$ 74,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021 (excluding the six months ended June 30, 2021)</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">97,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">171,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted finance lease payments</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(4,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">166,483<span></span>
</td>
<td class="nump">$ 236,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 1,030<span></span>
</td>
<td class="nump">$ 2,646<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee financing lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents lessee operating lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227520901416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_LessorOperatingLeaseOptionToTerminate1', window );">Operating lease, options to terminate</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LessorOperatingLeaseOptionToTerminate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent operating lease, options to terminate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LessorOperatingLeaseOptionToTerminate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140227524329336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Jun. 18, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Maximum amount of stock repurchase program</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate amount stock repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,499,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=krmd_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Piper Sandler &amp; Co. and Canaccord Genuity LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option excercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krmd_AdditionalNumberOfSharesIssued', window );">Option to purchase additional number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Option excercise date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 19,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AdditionalNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents additional number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AdditionalNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=krmd_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=krmd_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_PiperSandlerCoAndCanaccordGenuityLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_PiperSandlerCoAndCanaccordGenuityLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MA6G@+IQ#0_B!NS6..=0+'9_P%YPJ=0%#]=+40W<D'CBLOCT3T[Y\NASX=I7
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MM7Z6ZZ-8M3$B;JM8=XGDBH5$<5&,S:*X9D?P;=W] J@S&V.#L0DCODN-+@3
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M \@&SE!.F#.4$^3</7J#O^7IJOATDJ&YV">R?)U[N'KX/-,O/DIHUP?D8DB
MZR-R$90?7^KTY;>@ARA=Q4F&-GRIAL+GKKK=M/R\4IY(L2N^'SP+*<6V.%SS
M:,'3'*!^7PHAWT_R 0X?N7I_ U!+ P04    " #LB M30[E[QY('  "B'0
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MP7PR_8$&P_GD>3*?C&>&:9S=-$XQC=,QS102^J?(<]T"E"/]8J3*VK>;"^)
M%@?^E?76](Q&T".>A^V=W!XV=X?--;I@$/T7XA126^9("LCM4*1AG'"4 N@$
M0*NOZCED^1*=;7(>H3@]M]:9>(LA*-#+)X*RE#$9IZ]E7L<RYOFEP6_>#IMG
M]-M,BO#WA<KS"(5B!<4O9T7YX!_JF>O\66IT&V["E/:IZQVXLRWG!TZ@@E+G
M37^'V#\9<0)^>"WQYES*A"LGFZ ;52M&N,S7+.37/2CY.<_>>.\&Z7+(;[N
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M9?W=15ULVI?+;XJZ+E;MQWN1+439",CO;XNB?KIHWE<__,F$R_\#4$L#!!0
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M>&RI"G$*>BB879C5#26WM]]"QIOK"]A8R!CT&8GN]'1FDYSK@B3L,B^B></
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M8=(HX/>U$'KW8C;H?Q7-_P=02P,$%     @ [(@+4_[14%X, P  -08  !D
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M):VG,L_@QCU#<NLH=^,@H7R.,9(W^TQ5ES*#1H!V@'%R3=]$M0>#68#V.L%
MOY_/H]%UI;.K"+8TDY)E.D?LQ70(1Z>J($J+7*?6F/[HE%A+@]8PDNX^I(L@
MFC#W%G4\0'/G,H<1-^F7<][41F$TA4:#6R?2>:%% 9N92C<3@U1%F?GUK*TN
M"#(("%%$\]\0@NW(AY6*5SS>K:O7< ,X9KUHF*?(H#G&D*\BM8K$(E)YO6"
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M*J'8RSSB[*8QS@10.Z_G\A$XC40"(/!=/@G83J*?I+-7@@, 3U$5K!EVVJ
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M%H@^D/2VZG)#C_G]1WB-3.%0+C03HNHC!!GEB0Z2J"A4++TZ[V*[+4>.&6!
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MF,M2N_^PV\OZ'<BWVLAJKXP15(5HOMGCO@ZO4:![!>KB;ARY*&^885<72NY
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M5F%,"L%I6%%VCXWEO](4[W_1%.\_;XIWI"G>8J/0WG/X0U8\OCCP$,W<H?E
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M@^N@(S>X?W-E!?!^):4Y,-9!N]%?_0E02P,$%     @ [(@+4\O8QYGR @
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M#B?N<8WS(RAK@.]+*<WMPDXH_40Z_PE02P,$%     @ [(@+4Y^/.6B# @
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M8536@-XOI#0/'3M!4V%/?@%02P,$%     @ [(@+4QO?FO-""0  US$  !D
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M'31>9#*-2V'P( Z3XI,]EA.Q)8"]&@%2"I"V FXIX.X(^+A&P"L%O+86:"E
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ML>$^F"3\]41O4>C]C (O\$?6LWI]N#<FY_]EW_SG[!=FA%U-A(8OO,+WFZX
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M1E=C$J;;AM1.K*K]G5XK2QW"#TOJX:A= .T72MG=Q!W0?Q7FKU!+ P04
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M9A/RL7*_WNPT?:[*. WS5<:D5SSQ;I /M+('QL7MD?>$N3<%#\+85R\ 5RM
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ME,1QFOH1P/P*XAA#X&G$$4P!:,"0.&[.P:/S*.S.J7#W[X?9;U!+ P04
M" #LB M3EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M]99WZNW#HW1^['FN\?QW4AWZ;]UX_+!\;D[8&7"V< V]_P502P,$%     @
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #LB M3O*/Y#NT    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #L
MB M3F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( .R("U.3]WY_/@4  -X5   8
M  " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #L
MB M3#[X)4YP&  #?%P  &               @(& #0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ [(@+4SK@(6(; P  HP@  !@
M         ("!4A0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( .R("U.5B_)>T 8  / :   8              " @:,7  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #LB M30[E[QY('  "B'0
M&               @(&I'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ [(@+4_I[>4)]"0  /D$  !@              ("!<28  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .R("U.>\Z 4[!,
M /LQ   8              " @20P  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " #LB M3X.,9] L#  !*!@  &               @(%&
M1   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ [(@+4S6=
MYUL9!@  B0T  !@              ("!AT<  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( .R("U-3RZZ33 D  -4:   9
M  " @=9-  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M[(@+4T.)Q$87!   "@D  !D              ("!65<  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " #LB M3P^= >V@%   A#0  &0
M            @(&G6P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( .R("U/^T5!># ,  #4&   9              " @49A  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ [(@+4Y3X$PM0 P
MVP8  !D              ("!B60  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " #LB M3V4NE\@P5  "H.@  &0              @($0
M:   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .R("U,H
M_I)*H00  -T+   9              " @5-]  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ [(@+4\O8QYGR @  )P8  !D
M     ("!*X(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .R("U-QGZE<[0(  #0(   9              "
M@4"8  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ [(@+
M4]-P?M<W P  G0H  !D              ("!9)L  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " #LB M3GX\Y:(,"  ":!@  &0
M        @('2G@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( .R("U,1"(68> ,  .<,   9              " @8RA  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ [(@+4UM3C[0.!   %@X
M !D              ("!.Z4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " #LB M36L7.+P0#  ";!P  &0              @(& J0
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .R("U/&[@#C
M004  $H8   9              " @;NL  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ [(@+4X)SS$=I P  ;0L  !D
M ("!,[(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #L
MB M3&]^:\T()  #7,0  &0              @('3M0  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .R("U-X'DIS_0,  $\.   9
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M970S-2YX;6Q02P$"% ,4    " #LB M3V2F;P/X!  !7!   &0
M    @(%YT0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M .R("U-(XNQ!B@,  '4*   9              " @:[3  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ [(@+4_QE)<D* P  BQ    T
M             ( !;]<  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #LB M3
MEXJ[',     3 @  "P              @ &DV@  7W)E;',O+G)E;'-02P$"
M% ,4    " #LB M3IFP#[N(#   .&0  #P              @ &-VP  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ [(@+4YD^HH1\ 0  EA8  !H
M         ( !G-\  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ [(@+4ZIG%&&8 0  "Q<  !,              ( !4.$  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     "T +0 R#   &>,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>121</ContextCount>
  <ElementCount>325</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - DEBT OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/DebtObligations</Role>
      <ShortName>DEBT OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/Equity</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://repro-med.com/role/PropertyAndEquipment</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://repro-med.com/role/Stock-basedCompensation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://repro-med.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails</Role>
      <ShortName>Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details</Role>
      <ShortName>The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Property and equipment consists of the following at: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails</Role>
      <ShortName>Property and equipment consists of the following at: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://repro-med.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/Stock-basedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://repro-med.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - The following table summarizes the status of the Plan with respect to time based stock options: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails</Role>
      <ShortName>The following table summarizes the status of the Plan with respect to time based stock options: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - The following table presents information pertaining to options outstanding at June 30, 2021: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details</Role>
      <ShortName>The following table presents information pertaining to options outstanding at June 30, 2021: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - The following table summarizes the status of the Plan with respect to performance-based stock options: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails</Role>
      <ShortName>The following table summarizes the status of the Plan with respect to performance-based stock options: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details</Role>
      <ShortName>The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://repro-med.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/DebtObligationsDetailsNarrative</Role>
      <ShortName>DEBT OBLIGATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://repro-med.com/role/DebtObligations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - The components of lease expense were as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails</Role>
      <ShortName>The components of lease expense were as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails</Role>
      <ShortName>Supplemental cash flow information related to leases was as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails</Role>
      <ShortName>Supplemental balance sheet information related to leases was as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Maturities of lease liabilities are as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails</Role>
      <ShortName>Maturities of lease liabilities are as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://repro-med.com/role/LeasesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="krmd-20210630_form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://repro-med.com/role/EquityDetailsNarrative</Role>
      <ShortName>EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://repro-med.com/role/Equity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="krmd-20210630_form10q.htm">krmd-20210630_form10q.htm</File>
    <File>ex_10-1.htm</File>
    <File>ex_10-2.htm</File>
    <File>ex_10-3.htm</File>
    <File>ex_10-4.htm</File>
    <File>ex_31-1.htm</File>
    <File>ex_31-2.htm</File>
    <File>ex_32-1.htm</File>
    <File>ex_32-2.htm</File>
    <File>krmd-20210630.xsd</File>
    <File>krmd-20210630_cal.xml</File>
    <File>krmd-20210630_def.xml</File>
    <File>krmd-20210630_lab.xml</File>
    <File>krmd-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "krmd-20210630_form10q.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 121,
   "dts": {
    "calculationLink": {
     "local": [
      "krmd-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krmd-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "krmd-20210630_form10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "krmd-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krmd-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "krmd-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 401,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 55,
    "http://repro-med.com/20210630": 16,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 76
   },
   "keyCustom": 33,
   "keyStandard": 292,
   "memberCustom": 20,
   "memberStandard": 14,
   "nsprefix": "krmd",
   "nsuri": "http://repro-med.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://repro-med.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://repro-med.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - DEBT OBLIGATIONS",
     "role": "http://repro-med.com/role/DebtObligations",
     "shortName": "DEBT OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - LEASES",
     "role": "http://repro-med.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - EQUITY",
     "role": "http://repro-med.com/role/Equity",
     "shortName": "EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://repro-med.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://repro-med.com/role/PropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://repro-med.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - LEASES (Tables)",
     "role": "http://repro-med.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - BALANCE SHEETS (UNAUDITED)",
     "role": "http://repro-med.com/role/BalanceSheets",
     "shortName": "BALANCE SHEETS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details)",
     "role": "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
     "shortName": "Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and con (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details)",
     "role": "http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details",
     "shortName": "The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfNetSalesByGeography",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30_country_US",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Property and equipment consists of the following at: (Details)",
     "role": "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails",
     "shortName": "Property and equipment consists of the following at: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "role": "http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "role": "http://repro-med.com/role/Stock-basedCompensationDetails",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-012021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2020-12-31_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - The following table summarizes the status of the Plan with respect to time based stock options: (Details)",
     "role": "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
     "shortName": "The following table summarizes the status of the Plan with respect to time based stock options: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - The following table presents information pertaining to options outstanding at June 30, 2021: (Details)",
     "role": "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
     "shortName": "The following table presents information pertaining to options outstanding at June 30, 2021: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2020-12-31_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - The following table summarizes the status of the Plan with respect to performance-based stock options: (Details)",
     "role": "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
     "shortName": "The following table summarizes the status of the Plan with respect to performance-based stock options: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2020-12-31_custom_StockOptionPlan2015Member_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details)",
     "role": "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
     "shortName": "The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_RestrictedStockAwardsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "role": "http://repro-med.com/role/BalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2020-05-192020-05-20_custom_SettlementAgreementMember_custom_EMEDTechnologiesCorporationMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "role": "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2020-05-192020-05-20_custom_SettlementAgreementMember_custom_EMEDTechnologiesCorporationMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30_custom_PromissoryNoteMember_custom_KeyBankNationalAssociationMember_us-gaap_RevolvingCreditFacilityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - DEBT OBLIGATIONS (Details Narrative)",
     "role": "http://repro-med.com/role/DebtObligationsDetailsNarrative",
     "shortName": "DEBT OBLIGATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30_custom_PromissoryNoteMember_custom_KeyBankNationalAssociationMember_us-gaap_RevolvingCreditFacilityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - The components of lease expense were as follows: (Details)",
     "role": "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails",
     "shortName": "The components of lease expense were as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)",
     "role": "http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails",
     "shortName": "Supplemental cash flow information related to leases was as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Supplemental balance sheet information related to leases was as follows: (Details)",
     "role": "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails",
     "shortName": "Supplemental balance sheet information related to leases was as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Maturities of lease liabilities are as follows: (Details)",
     "role": "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails",
     "shortName": "Maturities of lease liabilities are as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krmd:LessorOperatingLeaseOptionToTerminate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - LEASES (Details Narrative)",
     "role": "http://repro-med.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krmd:LessorOperatingLeaseOptionToTerminate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2020-11-152020-11-16",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - EQUITY (Details Narrative)",
     "role": "http://repro-med.com/role/EquityDetailsNarrative",
     "shortName": "EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2020-11-152020-11-16",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://repro-med.com/role/StatementsOfOperations",
     "shortName": "STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://repro-med.com/role/StatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://repro-med.com/role/StatementsOfStockholdersEquity",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2020-01-012020-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://repro-med.com/role/PropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://repro-med.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "krmd-20210630_form10q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 35,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r442",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingParValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.",
        "label": "Entity Listing, Par Value Per Share"
       }
      }
     },
     "localname": "EntityListingParValuePerShare",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Series [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "krmd_AccountingPronouncementsNotYetAdopted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounting pronouncements not yet adopted.",
        "label": "ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED"
       }
      }
     },
     "localname": "AccountingPronouncementsNotYetAdopted",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krmd_AdditionalNumberOfSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents additional number of shares issued.",
        "label": "Option to purchase additional number of shares"
       }
      }
     },
     "localname": "AdditionalNumberOfSharesIssued",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation expense related to restricted stock awards.",
        "label": "Compensation expense related to restricted stock awards"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToRestrictedStockAwards",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_AmountForChairingBoardCommittee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount rerpesent for chairing board committee.",
        "label": "Amount for chairing board committee"
       }
      }
     },
     "localname": "AmountForChairingBoardCommittee",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_AssetsAndLiabilitiesLesseeFinanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeFinanceAbstract",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_AssetsAndLiabilitiesOperatingLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesOperatingLesseeAbstract",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_BorrowingsFromIndebtedness": {
     "auth_ref": [],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of borrowings from indebtedness.",
        "label": "Borrowings from indebtedness"
       }
      }
     },
     "localname": "BorrowingsFromIndebtedness",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_ChiefExecutiveOfficerDonaldPettigrewMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member represent donald pettigrew.",
        "label": "Donald Pettigrew [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerDonaldPettigrewMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_ChiefExecutiveOfficerJamesMBeckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member represent james M beck.",
        "label": "James M. Beck [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerJamesMBeckMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_ChiefExecutiveOfficerLindaTharbyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member linda thar by.",
        "label": "Linda Tharby [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerLindaTharbyMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_CommonStockIssuanceAsSettlementForLitigation": {
     "auth_ref": [],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount rerpesent common stock issuance as settlement for litigation.",
        "label": "Common stock issuance as settlement for litigation"
       }
      }
     },
     "localname": "CommonStockIssuanceAsSettlementForLitigation",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_DebtInstrumentPrepaidTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of dent instrument prepaid terms.",
        "label": "Debt instrument, prepaid terms"
       }
      }
     },
     "localname": "DebtInstrumentPrepaidTerms",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_EMEDTechnologiesCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to EMED technologies corporation.",
        "label": "EMED Technologies Corporation [Member]"
       }
      }
     },
     "localname": "EMEDTechnologiesCorporationMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_EmployeesAndConsultantsUnderThePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member represent employees and consultant under the plan.",
        "label": "Employees and Consultants under the Plan [Member]"
       }
      }
     },
     "localname": "EmployeesAndConsultantsUnderThePlanMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price.",
        "label": "Exercise price"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ExercisePrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to exercise price.",
        "label": "$ 0.38 - 3.15 [Member]"
       }
      }
     },
     "localname": "ExercisePrice1Member",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_FinanceLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of finance lease cost.",
        "label": "Total finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_FinanceLeaseCost1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease cost:"
       }
      }
     },
     "localname": "FinanceLeaseCost1Abstract",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member of furniture and office equipment.",
        "label": "Furniture and Office Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_IssuanceOfCommonStockCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represent issuance of common stock compensation.",
        "label": "Issuance of common stock as compensation"
       }
      }
     },
     "localname": "IssuanceOfCommonStockCompensation",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_KeyBankNationalAssociationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The memmber represent key bank national association.",
        "label": "KeyBank National Association [Member]"
       }
      }
     },
     "localname": "KeyBankNationalAssociationMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_KeyEquipmentFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent key equipment finance.",
        "label": "Key Equipment Finance [Member]"
       }
      }
     },
     "localname": "KeyEquipmentFinanceMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_LesseeFinancingLeaseImputedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee financing lease imputed interest.",
        "label": "Less: imputed interest [Default Label]",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeFinancingLeaseImputedInterest",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_LesseeOperatingLeaseImputedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents lessee operating lease imputed interest.",
        "label": "Less: imputed interest",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterest",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_LessorOperatingLeaseOptionToTerminate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent operating lease, options to terminate.",
        "label": "Operating lease, options to terminate"
       }
      }
     },
     "localname": "LessorOperatingLeaseOptionToTerminate1",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "krmd_LitigationSettlementOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repreents amount related to litigation settlement options.",
        "label": "Litigation settlement options"
       }
      }
     },
     "localname": "LitigationSettlementOptions",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_ManufacturingEquipmentAndToolingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the manufacturing equipment and tooling.",
        "label": "Manufacturing Equipment And Tooling [Member]"
       }
      }
     },
     "localname": "ManufacturingEquipmentAndToolingMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_NewIssuanceLitigationSettlementAmountIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amouont related to new issuance of litigation settlement amount.",
        "label": "Litigation settlement share issuance"
       }
      }
     },
     "localname": "NewIssuanceLitigationSettlementAmountIssuance",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_NewIssuanceLitigationSettlementShareIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repreents amount related to litigation settlement share in issuance.",
        "label": "Litigation settlement share issuance (in shares)"
       }
      }
     },
     "localname": "NewIssuanceLitigationSettlementShareIssuance",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_NewIssuanceOfCapitalRaiseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount related to new issuance of capital raise.",
        "label": "Capital raise"
       }
      }
     },
     "localname": "NewIssuanceOfCapitalRaiseAmount",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_NewIssuanceOfCapitalRaiseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of capital raise in shares.",
        "label": "Capital raise (in shares)"
       }
      }
     },
     "localname": "NewIssuanceOfCapitalRaiseShares",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_NonEmployeeDirectorAndBoardAdvisorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member represent non employee director and board advisor.",
        "label": "Non-Employee Director and Board Advisor [Member]"
       }
      }
     },
     "localname": "NonEmployeeDirectorAndBoardAdvisorMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_NonEmployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member represent non employee director.",
        "label": "Non-Employee Director [Member]"
       }
      }
     },
     "localname": "NonEmployeeDirectorMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_NonemployeeServicesTransactionCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount non employee services transaction cost.",
        "label": "Nonemployee services transaction cost"
       }
      }
     },
     "localname": "NonemployeeServicesTransactionCost",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_NumberOfSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued.",
        "label": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_PiperSandlerCoAndCanaccordGenuityLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member related to piper sandler Co and Canaaccord Genuity LLC.",
        "label": "Piper Sandler &amp; Co. and Canaccord Genuity LLC [Member]"
       }
      }
     },
     "localname": "PiperSandlerCoAndCanaccordGenuityLLCMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_PrincipalAndInterestPayableTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of principal and interest payment terms.",
        "label": "Principal and interest payable terms"
       }
      }
     },
     "localname": "PrincipalAndInterestPayableTerms",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_ProgressPaymentLoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent progress payment loan and security agreement.",
        "label": "Progress Payment Loan and Security Agreement And Master Security Agreement [Member]"
       }
      }
     },
     "localname": "ProgressPaymentLoanAndSecurityAgreementMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_PromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent promissory note.",
        "label": "Promissory Note [Member]"
       }
      }
     },
     "localname": "PromissoryNoteMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents purchase agreement member.",
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_RestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockAwardsMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_ScheduleOfNetSalesByGeography": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net sales by geography.",
        "label": "The following table summarizes net sales by geography for the three and six months ended June 30, 2021, and 2020:"
       }
      }
     },
     "localname": "ScheduleOfNetSalesByGeography",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krmd_SettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member of settlement agreement.",
        "label": "Settlement Agreement [Member]"
       }
      }
     },
     "localname": "SettlementAgreementMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it refers the amount of share based payment award grants in period.",
        "label": "Weighted-average grant-date fair value options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period",
        "label": "Granted (in shares)",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares represent unvested.",
        "label": "Unvested",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent unvested per shares.",
        "label": "Unvested (in dollars per share)",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent vested shares.",
        "label": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Forfeited [Default Label]",
        "verboseLabel": "Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted (in dollars per share)",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent vested per share.",
        "label": "Vested [Default Label]",
        "verboseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Number of options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "2015 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_StockbasedLitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of stock based litigation settlement expense.",
        "label": "Stock-based litigation settlement expense"
       }
      }
     },
     "localname": "StockbasedLitigationSettlementExpense",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_TimeBasedSharesOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to time based shares options.",
        "label": "Time Based Shares Options [Member]"
       }
      }
     },
     "localname": "TimeBasedSharesOptionsMember",
     "nsuri": "http://repro-med.com/20210630",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
      "http://repro-med.com/role/Stock-basedCompensationDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r188",
      "r218",
      "r248",
      "r249",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r408",
      "r410",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r188",
      "r218",
      "r248",
      "r249",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r408",
      "r410",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r188",
      "r218",
      "r246",
      "r248",
      "r249",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r408",
      "r410",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r188",
      "r218",
      "r246",
      "r248",
      "r249",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r408",
      "r410",
      "r430",
      "r431"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r243",
      "r244",
      "r409",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r243",
      "r244",
      "r409",
      "r416",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r146",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r361"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r19",
      "r147",
      "r148"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable less allowance for doubtful accounts of $24,469 for June 30, 2021, and December 31, 2020"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r48",
      "r49",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the periods for:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r281",
      "r282",
      "r283",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Compensation expense related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r251",
      "r277",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedLabel": "Allocated stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r25",
      "r149",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts receivable, allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative",
      "http://repro-med.com/role/EquityDetailsNarrative",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r131",
      "r134",
      "r140",
      "r151",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r310",
      "r312",
      "r319",
      "r359",
      "r361",
      "r390",
      "r400"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r44",
      "r83",
      "r151",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r310",
      "r312",
      "r319",
      "r359",
      "r361"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r26",
      "r71"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets",
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r324"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Non-Cash Operating, Investing and Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "FDIC cash uninsured amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r171",
      "r394",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Refer to Note 3)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r172",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative",
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r361"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.01 par value, 75,000,000 shares authorized, 47,910,676 and 46,680,119 shares issued 44,490,174 and 43,259,617 shares outstanding at June 30, 2021, and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r55",
      "r376"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r202",
      "r209",
      "r210",
      "r211",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "DEBT OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r82",
      "r85",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r212",
      "r213",
      "r214",
      "r215",
      "r332",
      "r391",
      "r392",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r185",
      "r212",
      "r213",
      "r331",
      "r332",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.",
        "label": "Interest rate terms"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r37",
      "r188",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt instrument, principal and unpaid interest due"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38",
      "r82",
      "r85",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r212",
      "r213",
      "r214",
      "r215",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred income tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Tax benefits associated with stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r69",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r69",
      "r129"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows",
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r101",
      "r103",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r316",
      "r317",
      "r396",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r103",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r316",
      "r317",
      "r396",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "NET INCOME PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the number of shares provided to the Employee Stock Ownership Plan (ESOP) during the period.",
        "label": "Number of stock option shares"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPSharesContributedToESOP",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r48",
      "r49",
      "r50",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r117",
      "r152",
      "r230",
      "r231",
      "r281",
      "r282",
      "r283",
      "r302",
      "r303",
      "r315",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r411",
      "r412",
      "r413",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative",
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r341",
      "r347",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r340",
      "r352"
     ],
     "calculation": {
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Total finance lease liabilities",
        "totalLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails",
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance lease liability \u2013 current",
        "verboseLabel": "Finance lease current liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets",
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease long term liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Total undiscounted finance lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2021 (excluding the six months ended June 30, 2021)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r342",
      "r350"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Financing cash flows from finance leases",
        "negatedLabel": "Payments on finance lease liability"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows",
      "http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r341",
      "r347",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Patents, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r160",
      "r377"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Intangible assets, net of accumulated amortization of $232,820 and $199,899 at June 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Gain/(Loss) on currency exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "(Loss)/Gain on disposal of fixed assets, net",
        "negatedLabel": "(Gain)/Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows",
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r54",
      "r83",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141",
      "r151",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r319"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross Profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r161",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "IMPAIRMENT OF LONG-LIVED ASSETS"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r131",
      "r133",
      "r136",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "LOSS BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r98",
      "r99",
      "r130",
      "r295",
      "r304",
      "r305",
      "r407"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income Tax Benefit/(Expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r291",
      "r292",
      "r296",
      "r297",
      "r298",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "(Increase)/Decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "(Decrease)/Increase in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.",
        "label": "Increase in accrued tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase in accrued payroll and related taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease/(Increase) in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Option shares includable"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r77",
      "r159",
      "r373",
      "r374",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "PATENTS"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r63",
      "r66",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r42",
      "r361"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r43",
      "r78",
      "r115",
      "r154",
      "r155",
      "r156",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "INVENTORY"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r351",
      "r353"
     ],
     "calculation": {
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "The components of lease expense were as follows:"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments.",
        "label": "Lessee, Finance Lease, Discount Rate",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance leases"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Maturities of lease liabilities are as follows:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2021 (excluding the six months ended June 30, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r83",
      "r135",
      "r151",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r311",
      "r312",
      "r313",
      "r319",
      "r359",
      "r360"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r83",
      "r151",
      "r319",
      "r361",
      "r393",
      "r402"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r83",
      "r151",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r311",
      "r312",
      "r313",
      "r319",
      "r359",
      "r360",
      "r361"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r32",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r32",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r32",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r118",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r45",
      "r46",
      "r50",
      "r52",
      "r70",
      "r83",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r107",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141",
      "r151",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r317",
      "r319",
      "r395",
      "r405"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/StatementsOfCashFlows",
      "http://repro-med.com/role/StatementsOfOperations",
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "TOTAL OTHER INCOME/(EXPENSE)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Operating Income/(Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r131",
      "r133",
      "r136",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Net Operating Loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r348",
      "r353"
     ],
     "calculation": {
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r116",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Supplemental cash flow information related to leases was as follows:"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails",
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability \u2013 current",
        "verboseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets",
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease long term liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets",
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r343",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets",
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Supplemental balance sheet information related to leases was as follows:"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86",
      "r100",
      "r126",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r60",
      "r306",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "RECLASSIFICATION"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoans": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from principal payments made on loans related to operating activities.",
        "label": "Loans, principal amount"
       }
      }
     },
     "localname": "ProceedsFromLoans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from disposal of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Cash received from option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r165",
      "r361",
      "r398",
      "r403"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets",
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SupplementalBalanceSheetInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r165",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY, EQUIPMENT, AND DEPRECIATION"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property and equipment consists of the following at:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r247",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r247",
      "r355",
      "r358",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r290",
      "r372",
      "r432"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r231",
      "r284",
      "r361",
      "r401",
      "r414",
      "r415"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r152",
      "r281",
      "r282",
      "r283",
      "r302",
      "r303",
      "r315",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r51",
      "r83",
      "r127",
      "r128",
      "r132",
      "r137",
      "r138",
      "r142",
      "r143",
      "r145",
      "r151",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r319",
      "r397"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "NET SALES",
        "verboseLabel": "Net sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details",
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and consultant stock options. See \u201cNOTE 4 \u2014 STOCK-BASED COMPENSATION\u201d for further detail."
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "The following table presents information pertaining to options outstanding at June 30, 2021:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r259",
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "The following table summarizes the status of the Plan with respect to time based stock options:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "The following table summarizes the activities for our unvested restricted stock awards for the six months ended June 30, 2021, and 2020."
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://repro-med.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Description of vesting rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.",
        "label": "Option excercise date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Weighted-average volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Options exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Options exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average fair value of options granted during the period",
        "verboseLabel": "Weighted average grant date fair value of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r261",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r250",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details",
      "http://repro-med.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForSixMonthsEndedJune302021And2020.Details",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetails",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r253",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "The following table summarizes the status of the Plan with respect to performance-based stock options:"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Number Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Number Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of transactions in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting method used for valuing the transaction, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.",
        "label": "Description of non employee services transaction"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Option excercise period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r272",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Total fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTablePresentsInformationPertainingToOptionsOutstandingAtJune302021Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance ending (in shares)",
        "periodStartLabel": "Balance beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r349",
      "r353"
     ],
     "calculation": {
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r41",
      "r48",
      "r49",
      "r50",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r117",
      "r152",
      "r230",
      "r231",
      "r281",
      "r282",
      "r283",
      "r302",
      "r303",
      "r315",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r411",
      "r412",
      "r413",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative",
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r117",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesNetSalesByGeographyForThreeAndSixMonthsEndedJune302021And2020Details",
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Issuance of common stock as settlement for litigation"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Number of stock option shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares repurchased"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Issuance of stock-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuance upon options exercised (in shares)",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToPerformance-basedStockOptionsDetails",
      "http://repro-med.com/role/FollowingTableSummarizesStatusOfPlanWithRespectToTimeBasedStockOptionsDetails",
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Number of stock option shares issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Aggregate amount stock repurchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r231",
      "r252",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Issuance of stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuance upon options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Maximum amount of stock repurchase program"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r83",
      "r150",
      "r151",
      "r319",
      "r361"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets",
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r40",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r40",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r40",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://repro-med.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, 3,420,502 shares at June 30, 2021 and December 31, 2020, respectively, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/DebtObligationsDetailsNarrative",
      "http://repro-med.com/role/EquityDetailsNarrative",
      "http://repro-med.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "USE OF ESTIMATES IN THE FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r102",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r101",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Outstanding shares",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails",
      "http://repro-med.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Outstanding Shares:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://repro-med.com/role/BasicEarningsPerShareAreComputedOnWeightedAverageOfCommonSharesOutstandingDuringEachYear.DilutedEarningsPerShareIncludeOnlyIncreaseInWeightedAverageSharesByCommonSharesIssuableUponExerciseOfEmployeeAndConDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r433": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r437": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r438": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r441": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r442": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r443": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r444": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r445": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r446": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r447": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r448": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r449": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r450": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r451": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001161697-21-000374-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001161697-21-000374-xbrl.zip
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M9T/B=' IXL!TR"ZAQU)NJ.<I4U_14-FB&IR10%F^:*,SI?>Z.*W15DI%_EM
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M[,+O#:P9"8G;'CUL!B=D!#$H80TQS5(;_MSZN4GPV-80P?<!RFF ->]'YX<
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M;37?;*P.4%!_OA+2+[?T'[D,V;EH_57XT*)D)B'=:_?M[8?*D/N/EB!7.EY
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M8PJDJA3ZW.0F\HCBQ9H\=_CV."[('6$+[(KIF'80F,V0,^TDXXVB-N2&OGD
MTNS1/M@?1%KQ[RAVY.1R+XMSBOPHAP^3.1C6%"$H2FT/A7>8^2YA9;P0+]'F
MQ[/@+:8_UKF)&/NZ?DV'RGWQ)*F,8/@#3VU.0E1:,KNAK.C(; Q0'VPB1CY7
M&W ($B2$0L<I&@47Q5EA>RF2^042I-/E)BAH)<OGKG8DA=WS>2/$7QBB]NS+
M /&]F?+&P6EV*$C\;.,@\>EZAFBINF&&IP"K%L+4#HZH$H9"(:[A<.LWG_;X
MLKB87A6,%,=H;ASW%__"I<W/"LF-U96FN'F T6&?!H03^7M*H\\\:M;_KA#
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MJ^<L:Z.*C%TO( >VF_-H52-78V2[MJK/<)?W\D2BTV]R@P(W:<G(GXC@ ,[
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M??OBY=]YA-_^\OK%/^BCO[W[_;>?_W]02P,$%     @ [(@+4XZXDF 1$0
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MLRQOO3@+&NFC8/[+48'1QJA-6&X_K+@=0ZSS(UKREN!>N+8(<&P&]K",P"C
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M6FMUI:VLKE56URJK:ZTSAY;5M<KJ6AM33J>LKK6VJ"FK:Y75M<KJ6F5UK;]
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M$SS$M=QMMM_97\?=YH<C_/%V<'YV]']02P,$%     @ [(@+4VJBG#PR/
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MVV^8\%SW/<A($)Y$)?1&>?:L1^8%_[ R$5\Q4Z5JX9@[-1U:9D/XT X?*:@
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M[N^YZ7S^(_Q2E),B'2 :OL<8[., "Q/(*]@>BI@L\1QT4]+>7C?9P:-#\BS
M!O9X2DM*MSA #5W7TVHHH\= _K)KDN[]!WK,Q'W]"T[61JE!)0&C!52&Z\O&
M".6)@M52R,8&/WALG(?SA/+T<^MHK6'[K P\8)4 M-C:-S!+,JP*XXP7UWV&
M+T<92QH$QE] ^4#[BLW5M+(+/U"S&9IB!:@G1=UQ<@R^8MKJ"4N/,R49,X^
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M2S2EQRQG%9=0#A6]C/+62+;;]^5>M,AD*!,G+R2=5S)5AWENM%(JX> S,F(
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MT'-GC6Q^8<M<GTWD$GLXB--X^RO"FI0Z%%O=0 .)!=3;FN, HJ"82D;&1=,
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M5#@F1&;A/C"&TBVT%'_0K#U40:?)3@9ZZY4&9B:9E\340V Y4U=4H#(=6CE
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M/8#>JLBA9W)%J'(5R\1MH DVO":,*5L+%6\:N3<,@"(KGO<S<U7<NP:"22<
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M@:16T\AO@XPCZUMMU0S!':GFF,-5DO!K,Y5M>#4J=8O0$")]U.;L''2'LI/
MGE "LDZ+'X/J0\ C7%G8Q/-\9DZ JH:#R<T*[S6V[0]Y;OQN/\F<2#;Y.2GR
M,%Y%XGAI5M%2LG EN\+#MNQ)>&09T?[>SQ(H [[6B:/M/[TVI&P)GX^C!GC
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M/S[^]U_K)I3X!Z7&/X>P?O[UJY/_XAE^_<.;5[_11S^=O_[YQ?\'4$L#!!0
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M^W#B.>L6DP+$UVH%[/3DM/4:K]C;'SI-V]RX9F\W/^SK9Y7-9?>RY"T:0QQ
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M[Y>J/>O\7_4^*"5U'1V[LSI'JB?(W5QQZ< O0>]K)N@62[]2]_3]VGL$N2W
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MKG=WV1ZV+O_T)E[9QP(8FQ)%@=P"66?;W8(_+RUX]%UFW -51"HKV1OWYCJ
M '2QP6]H<RO@^S4%#(;>L'73ZH+P>U>HUV_=>L-VKZM5P7 44$6"-]&/FUA.
MKT+^4"#Y99-;\.^<@F]Z@Q_05:?WY<WY9 0_4-S_.N5A )%QZY>(JD5> P4P
M;E6\=ZIB,.PU?_JAU[ELW0[^#[7^>=<>_OPV&[J0%0BRZF@\%@RBV0R+!:B
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M4HQ^>G.SVI4*K9XVI%O/N?VZ+;&4]I/2T)%X34T->@!RD+#T(,61 HJ0,3V
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M7)4CIZX7H5]TX4&8Z>E+T%*O3XMZO7:"O8%@\_9Q5RXW=JKL/DD^F=D0OI4
M?&7/\?'$UGZ"C_\%4$L#!!0    ( .R("U/$W=#YUA$  %W"   5    :W)M
M9"TR,#(Q,#8S,%]C86PN>&UL[5UM<^.V$?[>F?X'UIWII#.57\YYNTNN'5F2
M':6VI%IRW'SJT"1D84(1"D#:5GY]=T%2(D42!&U1A--F)F=;P@*[^RQV%U@0
M_/X?+TO/>B)<4.9_/CH[/CVRB.\PE_J/GX_NIIWNM#<<'EDBL'W7]IA//A_Y
M[.@??__C'RSX[_L_=3K6)26>^\GJ,Z<S].?L.VMD+\DGZXKXA-L!X]]9/]E>
MB)^P2^H1;O78<N61@, 7T<"?K*^./SY8G8Y&MS\1WV7\[G:XZ781!"OQZ>3D
M^?GYV&=/]C/COXACARWU.IP&=A"*36^G+Z?Q?Q'Y]Q[U?_F$_SS8@EB@+E]\
M>A'T\Q&.&P_[?'[,^./)A]/3LY-_WUQ/G059VAWJH]H<<I1082]%=&<?/WX\
MD=\F37,M7QZXEXQQ?I*PL^D9OJ6*]BE.!/TD)'O7S+$#B7KE,%9I"_RKDS3K
MX$>=LP^=\[/C%^$>)<J7&N3,([=D;N%/0&\S*B<KSCI+XB)B)_CM28^!00*K
MDF[!R?SST2]\Z4+W'\Y.OSX_Q<[_G&D4K%=@F(*B71U9)Z\=^,+V4$O3!2&!
MJ&*@L'$3C$QL3OQ@00+JV%XMK@HI]\0B3ANRA.[%>#Y>X4P'6ZI4FIJJ =9Z
MMEA<>NRY%F<YH@88FP;,^67!/!=<X.#7D ;K.AR64^^)U1$X14[2('5]=QHN
MES9?P_#TT:=SL"H_Z#H."_T XL6$>=2AI%+3>^AZ3T).. ,>@C6,CTI<H7*K
MN%?1[(DMB(]+&DBD890>DRJ J*RA6PW2O=DR6& 'W;Z+\9SX0F)9;<1*LCTQ
MUR</P?C!HX]Z7JFD^9Z8N28@;24/V59[&EK/L33B0*;A@R"_AF")@R<TQTK#
M*&G?OC\[@%]KR+^]@:.9_> U*G)V@ 8=NIXDU93-^DT]+K6(]^JV]/@J:KNW
M5%A09V!S'VQ'3 B?+B"I[7*"\H<!<<?^/:&/"_BM"PL"^Q&L$8,@\V5#,0X#
MN78%ZG[(X=^![2Q^)C8_[E,/Z7>['OJ.%[ID['MK^)6C8,/=(:*N+];I@89"
MA"C_W8KY@Q?"'2J E0%(S]:$1,&X3P*;>AHKB]^MR'LRBDOF07H.,DB3BQP.
M_8V($0FFMH=\7A'VR.W58GW)^ P4C>Q,Z<L-9$0+,?!=XOX8^N3\%!4/7\&/
M4TUT#C%V^_X_9FAD<Z1\(@U&@K*A&HP)8)B""EQ(;=#L!IKXO[:_!L6I"U:=
M/IH->YHZUZ-NV+E$&X7C^<2S_7L:+&Z)6!$GF+$979(+Y$VR.5Y)\W^C-WG3
M8(TH8@(>'Q-SW#OE2ZE_"" P+L:2&8LY206?;K!U<Z_2QCY';,LV@&')O.^0
MR'X/82-U!FU8,5T'G D-P,U#,!R'_,Y_(@+2"N UX-0)8MZZSS9WL4E%G#Q^
MH\H:9N<@SE+;S=?LIIF]E[I,:Y+O;ZL-DM=H3U4N8@8OJ"=R3R#C%I$5Z4[3
MU_2UM\V6%72 8=SVDLWKE->\)9X-ICUCT3KMWA9U9=O;  T(G"YY-";TFP?9
MD^ WF&=+!Q8;V36U'Z@G/^G6M]E7=K?7+8:Z'D)-M=>=T[JLJ:E4K#FVYX2>
MM*EK^#M#05X"@N$GZ0<9U*Z?!C3 UG%-^\SJ8 $\1*.&7^.6S;%27"3-L/0!
M^-B4MN#WB^YU=]0;6-,?!H/9U/KB;M2]ZP]G@_Y?DX)RPJC'G QS'E:TV4[E
M.#D=(.O6<UL\R.)U*#J/MKTZ0?1.B!>(Y!.)9^?T+*YA_SG^^#]=(4""7LAY
MJM[CV0_$D^/^)VZWT^RD18[13>,>#/Q LWRR/5D5"GI@EFO(C.1YAW))-,EW
M)4P93Y<[%N,NX9^/SI)Q;.YD3"9_HB!N<2(P9\-N.A1,(Z&?<[94*3Q6+GN-
M*&E@@(LCZUEN@4GNVP0RWC$1M\0AP#SDLR,25%NBDDH/M@^MPJ8CMWEH#7TL
M7S&^!F;+T<FVTD/CO%4TBN0R3_L3B$$V=>/,NW*2E#37P^/+5O%02FH>,)%(
M58'3E'A2YI$*<3%.U\GV+NX+!>D]7J5+4E.9$3!*YT*UP.;!=$E]$/D:%@CN
M$):8_B.%$!?)J02JBLZ,:%("E9[0YH$5U[7\1[GZO$6>QO,[$;%>CE4%F1F!
MI@0J+9'-0ZI/Y@0<-)@7K$+)S'[1F%(J&CV,OFH'HVIAS0-H'"P(C_EDOE.5
MHY4TUX/EZY:FCDI$\Q!);?I5ILQ%;4U8'4_L-2X1M=?%N^W;3CS+,2A9%A<+
M;)YQ ;\\)&X=&U.0M)V'UH%)+;9Y2"4GM^*B1AW$-$C;3DNUD=-6@WD(0G:-
MV^V92LZZ$CPU5=LYJC9N.L*;!UDVR]8'K8JN[;15&S8]!9@'7$I K6S)J!2C
M!(OWY.M*[$9K25%-:E">46_>O(?U1OG3BWFLBMJV6E:-#L C5U45U%S+MAV
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M^C#/85Q#)A,]U34E01 ]6%,)HI*H;9>ABYR&Y.;!=4L$ 7[PY'P?@I''5EJ
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M11VMDO6V>7/EO.1 T&$W=Z/3F'HLYVIHR2'T,I9C2\-_<&L?/ODO4$L#!!0
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MZK8E!E=96VFF<!)X'3>.L.PD-R >3K!1VXH!P7^.@-^/OH/@88)_:^$#@?N
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M<_K P068Q< +J \$_QX"2NN(^,MB%/Q)/V<BRO$V29IAYX1"*N*&JE<FT#W
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M;&^-%H6L,2](='-<BYANIJVVG$R/X:-21J1)8Q6'=L5ZVAUQ--EVVFF1;=0
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M;%4H8&.C=D=[$@#R<)XW)QZ4_G@<>"#^#6N0Y/H<>#^XVE"HKP+F"6E"SO*
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MS87)\]AB4<0"ZKY^DO?_5+V357L@/5Y*/G?@=BB9ZJW4Q60CK53U@M#L/2M
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M0%@PZCTW5#)4P9!_&!EQ'D73T,@:J[+U+&1KJ*N-'ZJL0/VICR& #F0.& %
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M!Q$WCJPQ9P@D+#>.Z,&M(3KV?PA3FWT^VY_)L_T$*'@A&RCN051D!1"0-KI
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MMV[U:_@&Q,NIYP_&$-(]G$9W! +<FB'$VX1$DAR*/@1GG^CKVILY<'X[@\L
M&#()]&05IQ/@:!)RG!GJ7PP?!&9E0OP[_:_SW,8'?*%SGD.2W'[6!U;[R:]?
M9-5B3FCWG3*.=G*KI'CR'=+O;ZT]E:11?K+7&8>7>W)R?NU-B03.REGW.GJY
MX/M:7.<RZX]$D%37BW#ZOJ9/O&58Q<B5KVXN'LIJ=-=CQ1[%D^,%B_;D7I'V
M!>B@+^?%P>MEWK)L7T).RX^Y" ]3?C'W!;]Z,3:@EVGX&"_W/7$LW8[9ER&=
M9":J!SR;LE"3.OF;?UGV%D4;SGZ<MR[Q2T7K'6_D-F_OKZ9J^;HJ1D_'#I)V
MMP:P=9EWZ?>)%@,K3V/#E'MP2=4>U"A^6@\%?[U4-50M/2\K$YN6D%-5#5N&
M8\-2F7!>@/-[/5+QH,I%DRD3-/N;#.=&9*/"Y6B(3U]E W,^NH@O"PJ2NRA)
M CV,[L-)J,0C=([0H9SD%V1DOPG_>&H_2_A^"/O(&$#M.N.Z;W OL)V"[/V-
M5L _9RZ+$9J5Q$8+>5&IM-#<:YE7JC8'C1Y=SS1WP;QN>) 6\679].U\ =N4
MA7$?LB=!TU9>^.H)>F;1P9[?6K6[MXY-S!R02SIRU=Z2'$UWIK]S@T>%$MO-
MYOPPKJ);MW97'><UXYXL[-N\ED_NE*87]TH=#R7-E( H0XUU0M@?C/].JK7*
M"8&NF>$AG&N&'$=FX,)I?G8TYL W4_76Y3V$*'$QC+D^'?(:,@R$O"'H?U"4
MLP%T/.<,/91-L1A1Y?)S]:'VP#\TF,V(\AGYQ(>V(8ZH+;'EOIB)@K>^N)H%
M=7$$R4(=2;P!'1#:?#=).SP.WM%1'\2MQ\T<^XXT"M_B"X,33!@VC6!0EFBM
M,!Y?4F).SK[G_% XN\CN-V1B9,:2'$.1&2H(E9DV=!:=)>0S#68VF>WFV&X#
MU-O0S='T'\2E+DR@$R2(SU!)CU7I=.'[ ;"R-)G1^[^$X]E0U/\Z(;Z?SR'M
MPJ4\GW8!Q!STGP3E39A 9*1/$OIF+/CF$B=]31+?)K3N[>U@*GSM:WY?K%%N
M5NLEHEPKP87_NJN577>&DH:F7;BX+J.['\5ZK5VNM>.[%GO@<0,*9]8&"AWP
M9TS01ZD8#D$;A<MRV//-J)[?NO.Q[7)$X2ZA)?QWPIZLFZ0!F82HGA&5:JU0
M*U8+UU @(&8MM/'UZ8-:OI=X_Q]E'OWCAJX*!1]!GRV!5YDY2;-J)P;Q[4X5
MQI(,G;(0N6WLQT2;)W07@H)JO!'0:0 07P+6^ O7,MTXQ-'7$A"M0C.L9:!3
M1\QZ0>>B0HC2^@A8DFJ!)F='C.9 !P!CUY#?G>,?*VBPN!GHD7 XYSXMSHN"
M,2 JBO;FC?/8,9WYM)C&CLM 4Z *-NQ42L(J-;5K:N<_T1Z@.K<&"O5YJ;[@
M0&<_)LJPE< L6PDW@BI8Q>)F*;\EV1#'UL5A1&\%55 FAHSI>H[8HJ9*5N06
M/=,$QEA9%NS!UTQ_4"K%*&>747Z+(M(R)$R47(&P![]0G+\1\A4-%6 RB$)7
M&YMV_A71E(WGX$M"GN"'Q2BWC%%(C*8.W0.,S8:NB4 :XWI>'Q9=D1TCZ!G5
MVU?EYF?UBJY!'THO3",XN^@C$TDH1!66,84$#E$11%/3CTCRT9YWJNM&0TM0
MK "Q;>FY\CZ17+HS<":Z37I'E%HHY9=16GX?R%TYC+W&,!\3/]Y^!AQ$,$-J
MM^4PPR[3$:HWY191*]\3S?I-H49:7\#!RLUJ96.\^91@B-/CF8A_R3Q+J>,$
M0)KYUR_HF<9*81C\*G3.H(ZV,PPV1RS3N)#TG4U=%*XA%92)UE6Y'./YC.]\
MW^YJA;L2JI2:X!8%.PQRCJA9BNO0--T9C:@1U9GV6_3#W]K?IUJM!VWD\1!.
M,\$/_IB3&G%*+"*.<*UKO]<!0RBJF3/ S)'!Y0NNY!N55C3 C6[HYM-:?P%N
MK!-\\DB=##%Y'DU.T0Q+=Z9_<H5'[O>?6E7?-+<[JKY^_B!:-RZ4+NH?:U0X
MN@(U#CJJ@U1A:(HL^;+*_(QVY_-2"6!QZ; R<Q8T>9I']UD#/9D]8S,!'^4S
M9U1F^9HLKE85Z'6:.^.#3A4&*NXLLP54$%/+,RULU8S/4(+R+"FG8!C - I=
ME!,HFAWYHC/-OO4OA#]=KBO2)^LW.*!]"LFJT&K--,Q&@@YL6:]!SDX&3EB@
M'"8>YG267:$S^Q+2G-PH&A+<X+G0TI_^2K6;7#P$5[QK-LNU-N%0W8?'=-F%
M:71XAQND& ,47W@5%&0>%\RBH.LH61JG&D+,,]7.4"@4I^.QTIGFIE)9^:NK
M3P-EPQ9X"'7;KK*K U)GS"P11591-;$?Q"EE"7Q\L(AB'"+Z .;@!4'E_PR,
MQ?5)@X$0Y)= N)I3[)M B%*.(/H _N3.P(2.-D]FV!S)97,>:82'@ E44?64
M#9I*N0X369*E,R23XT-@PH<+<FYY8^7[&TUH'<*%09>@!DSG#N82\??^_F%!
M5_Y3OQ)BD3_A^<*!EM!GX!(*KNVB*-H;SC-!1\"2-NZ:O?'L-@,.(JYD+Q?=
M:'#>KVAZR7Y[%34SO#AYN-C^?VT*8N8RDP.,?$*8J/X#W/Y50,E-0*Y6',MO
M"Z'M)+"O]U1EVJ)R.6X3J8>:)EGF3QK0^'B3(SD^[\&7WIG/3@(T(H*%; 0R
M2/93+.IS VK7R(2$Y3V9R69)CJ(BB?O](B$^<H)(8,A\AMM>TKNO%5355P@Z
MZEX,5B2[<O7GL<MQC:DN)VG6S$#8^6ZZ%Y\L"6?)#,^0V4P*2'CCHF,C69[,
M,7DRF_6Z[1&29'D7R39T,!)DJ?P^ JH!?*P2P1"N'LMTK\%LHMVDK!(;3 )8
M< 8QTH/&G]9'-,)%KP+1C"?*D^48CJ?)3(:-PB\? (VQ\6".RI+97!BQX\.!
M1;]P!.*\-F0]TV8]R(-3HY_I3-7GYTKMK_RDMD-XQ>?M>KMP320>@]B@YMT+
M3);.V2Q)<Q1)Y[QN$Z9NV;'1)5QVALF0V7P,RB&WH!RT$:2Q24,15!-ZY[.N
M\I9]0U?G]"D_/$W9B\ID(,43J?53$?0:%6$!BRU\X$!*$BHJ!+?CO5^'N&0Y
M@"9IFH*R/@6V46@DQ,8/Z.YUEN29, HO@'E?0463P+7\"J2J:@IJ7X8NB\7F
MJPSQ6!FQ9JG B;7^]O:^/]7/ 2$$# DF>!2,$41Q/!SC%M:$,$2U8J:"T[)A
M)5"3#;;,PGS,@FO(I6B-<,7U)KE"\XWC9]&:!GQ'1=#Y@;6)FL)#E; ?S3+0
M(O=B,ROT@*30"IHSL:#9#CGE^&;+R-T)U?$@=6B.CY7S>3*7]XK\V&@V/:Z;
MK,1W2$('J",22E=7=N\:KQ<<R=)ICN5(G@L3Z$@/$N(SW#F6S.2RVZL#QL7
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MYD,;&!^%4I-,3B'I7);DLX=6(SA>:HT]))]ER!RW$:='2^+3#>QC2;B;"-2
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M0T&7E0DR)PBT*F'8'2N"J<%19+4'!0,T5*PI",$@^MHKT*$Q370G^.D[:%S
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MDB6VX_J*\N)MRPKI?BBK-!'YQP1R9P?0^G8DR[VF/Y_*ZBD<% D2R]A%7NP
M0M37',T^ ]&RT+UA7 ' <F6Q>0<-9QW97XK01084_,$#ID!<E>U,;]I4XYY[
MJ4*$I)ZK((+Z,EQEP3" :51D9.9?(_/88IHE]JHLL->&=SM326Q>MZ6F],)E
MX^6S,AR[=&?R][_?-'UP<MXHM%.NT8N0 +$S <U=RYG0NLB7P^X2)%ZDEEUN
MD77J+$]M]P#1>!=@QP+J-]W$/R"ZM%@2]*$.5^3>S(RU1PQ&L71G2C>?*O*@
MJ3^(O=13+,J>:@OOZ_7 (J%ZO]*97C7 ?2\[NBRUXR7//#1OK_DZ.[DH\4!
M:J!8ORD3[<)#.<TT6@(]8%,G[I!C"N_ DJ]0_+[*R E&!Q-]B^ADH2OC2-\0
MF --@H8+-$2Z$VC,6*- 42R\$P*6#7@0W2H%A$@7>6EPN#&TAI"$A78M]*:1
M^RK)/?@V4$4[F&H[87!.G$^,OD*CBG!\Z(")@FZYO&\X_(A^=6;'CSDPRL#V
M/9= @,\(OO,GY,!M'\ER+.TN4)#K.?='!P(*^D S4+3B1!@'CF>/_&=HN6-?
M>QXE@I:Y[G+1';5[Z<1W2#P&"J882)GJ>"NP^\!0=,[2O>/N$U*=T$4 [\)0
MMN+"*" ])R-"&$,:T?%.!!-*F<[TC]IZ8"Y>)@\O6QYI)2Z4&CJB4W/24 35
MA+XO\GM'")_KA53)):2"#M&9MB;&KY>GJ_L\UXU7:G%0J3[0CW\*-^TJIT"E
MVD3'1>U'$CO-#7322V)'NE1N-,O%:MJCO@Y*L5P #CZAT^2R:+%=:+E2R N#
M\D'&/\WE'#HO08D&IXJL0G:QA=U,]T*?&AN[Z!70&R,U_#KWV75@C"!OH "3
M)0B#$3_3F?XNR#=]Z7EZ^\JFG/B]*\/5G5-KJ'TAUB$&$&4;GE;E2G9MN-&@
M'K^K7I7RPMN3^1S[P4?N_D\I.ZF_WC6@G=EJUXN_3R\*K7*)@"J]4:ZUTLX%
M;HTQA$H!*0:H*@EWG51B!+$)]88$B=IRXZ VZ>L"/A5QUU.%.ETC'.T"WH$X
M1GL!YWT&$P(J446; %MSHTC46#$%'"9"0."8M.5X0>X  IS%GAW/A#APSDR:
M%>V6X!\.+UE/8<:TO#R<:W?:$@<:.FBPQH*.HBPBUAUJ$E#<P6BG  =262(D
MLCX2 'V$C%E'0,O#A5#.075'N!#AH9===/GUBU.!U@920)8(6HK+TIC)"A2
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M44Q^]-G5!?JHG.1VO\ZX6O< WS4]NQ=:?N@OZD-A7@@G,K>S&0F"8'C8^WO
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MH#T401'TU/&61Z;P:'PM[FB;C@YOF-?,5F]VASZ5%4GC.+0Q$^0><K!-T#Y
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M)VC@>+L&Z>UT\N+>V!Q'W9F1[EZ<C6:(Q&F2O(A?,O GS\^8S&K=1HQD AG
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M4IOU^R2? APCS/0J*!O NC, M#4Y8;:5,'8"'S\HCH?*5V6)051Q,$"6R!&
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M1R5*7/PG^I+QRJ\XV'\JA*-E0C1SMR\?5^RPUF'5S,EURI&]GQS#1*!1=CK
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M42N.V%C04F6AZ[>?^J S_-Y:(QJS&9-3\DZ7-.$JCUAP:;N:5?M=\6TBB=^
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M4S!LR1HFS/%W#(D O6:K#=8GT"J7YV?//#5&O.=D38W]0LPJ\4-!0[RLJO)
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M8*U29*$ 7PL!1I82918?MS6X/].64SZ6[0GJ<"TH23SA!2R/FN'DN@-2.&^
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M3&"KZ]] 5J:R81.&@O&T[9,X?H=8>P9'-LM],:6AA88Q1C7258VD5_);(V*
M!$9&\D*<+56>8"-$PB!(CT IA-6V%<DJSO/@R,F:)RZTJ3CP^1&9+!('0?_
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M)M+Y.)V(@BPZ>4$S%REZ[\;*J6PBG][%93Y(O>_"C[&1\5T$W]]Q-!7MLDS
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M-P">%AHE4R/ *A9@SK2>;SQRUR<:3#/RGRGB_V+!^/CV9N+#M9(!=73^CPU
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M4,9/8%Z\AH62!SQH?'V5!*@YDQ6H&8Y[V7;M;(,EF;\?\INZC=_ 6+%!'GO
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MH^F\AE2<+X(X7RHF.!L%5W;%#GAM8/32WCEE#;'/*Z9$34ZCAFJ]0WM)DB%
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M%&VUMWA'UVR*4XG6;ZYV# 4X]>9@\X-W&LC0"/YM27R2HF37P*[9C>9JB7/
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M+0@ ERTJ:L%I32E@_(.=H9L64Y>3F]'-^7[9K0A]/\OR/'NFR2*HES-)(_Q
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M'CA7.B"U7+&U,0><3SJORLNFBHZ X]N43SA_R JL._J7PQ-N.5>OV1];H [
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MWZ\!+3ON,%FAK_$EZ25ZT8.>K_T4EXOS=5$29SBW,UM#"W')N-TJV&;DL!+
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M\S$*J/W'8GIBW@>Y&9N0\>=B<LY#-M:U/ J,,\B_KBL"SA+LMUHRK^2T<4M
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M3RWJG3IV^"QXPW1 V:5V?-A5%B@?(9/(^8K2Z\!41>4Q(>_$,2$3/'#Z6\?
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M?YEDM:JQ,PHWU\\J.*C&@Q@@J-S>7YJ)G?B]O\\#FOU]U'H7GA>V1/_4O!O
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M!NFA@;2>+C6009P:@@.M@N)MH!?RKU:/:(HBYJ8P06_)%?W0;_)%D49U77Y
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M A*GD8ZW0NT&P3/K'&89#8&SA/YOB.4:1W[OA2[*9RA[)'DXW7.G51A4PV;
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M)QU6+T>$LF[E"7U=F];.U^S0GTK=-UUVU)*_'0,[P8NL&WD*JRR;F=3&RJM
MF]DV5;UHK'6 :\=>:\5K\T<$Q6'RA5_;,:Y:L\N[PA;N@4$8$0ZL=3=UAU'+
MK.RB5HWHNJNMA"[HI>_ (5ZD"QFHI2)@?@)ET/8@K90%T( \N&]*;'>+@*5[
M5&-;)8LEB^G:9Q2W+H[84]FH\$QV_VV)V)N--_@%^RCT']U$=CK9_J>A(TX:
M.X9KZF3)E+5SUM*?24";8>]Z >AI^>/6KUNM4M5JZLY164N)?T%T5M$':'>+
MTU!=+2+/48/+T\OZ5@YH8;#]/+33[FGHK8H^FU1VSX=B7^9G$YDG*%I<*O2T
MI6]")Z]O5SE;)<HFC6QJ%#[B^+?;"*&[,$%4$Y(CSO[5GX9VK#\-XRFCS0;7
M,U$&:9:B,HV'4W8._0TG\T<4LX$V(=MCY^UE82SU5/O!,&4T"_:.^>?7H=^L
M$\XK[8439=UP$N(DM",.MQ&T-.V*0[*^6!(;WCF\=0YOG</;"4RV>]-!Y_#6
M.;QU#F^=PUOG\-8YO)WZ3C)?GQ<>ALL>CFMAKA-_JKN#,V2E=J*P)8HPH5KM
M1HD%D9T-XE,Z.^^_H<C#,1I%V&OC%,2T ]"6[A147(?"3O$Y:E_Y,ZYWX8A+
MI4B>T,K'NAL]<VI.9:T@7/)7BMB2Y6VR$^_W&J]Y*AO.40KSG!U=U-_%<8K\
M&YX^)Y,^<Y,NGEJO 9"\A%JGK?.]N*L-[#EHU:%C<0T*M&4U[,?[O>9KA=!3
M620H9+\ET13QC'\;Z=M;H59^#/K9<&M7J!)J3D7Y5".O0D0@8VK<$^@7U.TU
MIS5)?0]+"XM/=W_];,%;\+::XDJT&CGIZH<VI.Y[+P>\!DK^XWM6<A6&G>J7
M-P_LDKUMFUWQ*>W[BG>GS4)>.JW=10?&8&MW0%?#W]^5G"&'G=ZKSM'Y+V_<
M!&W\OX]U6:?1$=UQ\-YO\K0YM>0,I1?PUO/L+WLPL+"8,)8HHFY]7?TYO<LU
M,P1/_>V^W3B/4=8TU?XIB1;\"W08)"YFKQ=.R/[*OI?\(PW1ET],&Z7!'G_6
M"?;()8L=O/V^L]QT@$5WY,$<#MGVP7$3A_7"^?+ICP[K2!?IT45Z=)$>7:1'
M%^G117ITD1Y=I$<7Z=%%>IQZI$>7VKA+;=RE-NY2&U=6@3:S;:JZ':F-&QK]
M6;][:3(G+*>%_Q128DI3$,5JY\!=EC!9BO^!'[-C[,-L5PZ$KIUDSL?4P7W)
MZDU !W[,$AUL;RPWIXUB$-N9Q':^=RF=O*J+VCEI-3(ZBG.6#*?3GZOVD<B\
M(X;3PB5!/D\?R7;(.O"^(LY;8] FO7UN2.I]:4M7OX]HD5U#79.0GZRG;L"R
M"WY6Z+4-';33UK:6,Q),!=[EP-BI<H5F.&007;FT.3KCV3(Z5+T\[\AV:V"V
M;YPT/6T6_.A@%CY5'7AGH?"M46B3XC8UIO>EE8WI8QETXUZ=;WB]!62?EYN;
M1CKC$8JX"QJ=M2XX]MIIC?_23EKC9;E#77;CSN>M\WGK?-XZGS=++Y$ZG[?S
M8KGS>>M\WCJ?M\[GS0ICU/F\=3YO5OJ\-36O;;>[V4F'T!ROS9ZH K0]/H9S
MG H#J\QZ[=6R!6F-WIL+09>TO@6MM3JGT0D83 M4O$M:WR6M/WV%[I+6=TGK
M[5'6+FE]E[2^2UI_&F:U2UIOF3:#$'HJBX0N:;VU>MDEK>^2UI^@VG9)Z\_Q
M=+=+6F^*5B,G7>>1"_94#GB[I/7-8-BI?I>TWG)M[I+6:Z+3):T_?0WODM9W
M2>N[I/5=TGI)_2YI?2O'#-9$\_6\!+_@!"-V_C),HZ?P!<44E$?Z7SH-)'D4
M'T>4%1GCMP<2)O.XS[Z^S63?"WWZQZ</TCB_'VO$^;F;#M*2D4/2R$GS/K)8
MO[R3>62?R[O)"_(80?SF+'AO'0[6;L[[/SITU^+P7G>1@+)VNTC +A*PBP3L
M(@$;&H%=)& 7"=A% G:1@%7EH1VINTA &S2[BP3L(@'?922@P,!6;L:E)E9:
M ]K(MJGH15.M =NAQEHT(S;M.+ ^EA'-J.U][^R"]UK&JY%;DX,#F=K72]G=
MT?&T5:\7UAL\:"4V(?-,5;LBL*ME-99^\?P"\%J'#-X?M*YJ-A?&=:C*MM&3
M\PO/ X/R=%5< <;/7$!5Q',3)J3R2^<7LM<:5+#[)M6@VNVRH8]:(\/:I ?G
M%UMW= C/UB)6A,.TO!Z5?O'\PNU:A\QN2VD8;M7VPK)V=\XOH X6S[,UJ-:<
MJ9YGR%SKD#5R^G2@.WIWK+KMQ7D&Q0$!V9)R']W-F%^T98]M%+'+O6L'+L4P
MP2_;=7O1/?C+I[)[\'@RO/[GQ55OW+]QKH</H_Y@W)O<#0<;=UUGTV+GN-LY
M[G:.NSNFK'/<[1QW.\?=SG&W<]RUS#VM<]QM#U- QUT!R/W%,B KA.)>2 =F
M&*=!PB[^^..#DSEB?9&";E ?^I!638(Q&)9X4^<KL)$;):L)-:@Q"TND_;]:
M%7\CGSU,VK##4+4]MY@@8HF3=K%CJMFGJJP=Q)JKLX2Y=N>HZSE&['5A+V7;
M_.%TBCT4_8,:F?CA"GF_24VG9EUH7RNQ3A5-IQ$0+<UEE7V@RWG?G=#!_[PR
M9Z.B,K0SQ@%T"*$X)A\W)'0#?X22!,\B]&K.B: !W26>C<1(,6EGC1%'26%:
MH?\J3RGT1[].V 'H<'H7^O@%^ZD;")80M*R@J!T32FLK!;'@!;=!<-:R=[ #
M+FH\Q\L)Z8<)EJP0JL12-0+,M)@)-6,JT=I9.@Q(N-YOW. (>;2>U!A*RH-Y
M&=1!<]\F*I$ -(%7A-V<3=?]BJ_G+F8/L@FIHI54=<"NUP^G2T.Z5I<4%:I"
M]^J\2SW_!<?F8TA0'>SNN+4A)<7)DH,,%CPYG!:F8_F9A:#XF2\ZY,(7]A^@
M ?X%Z:CF47UTMS\I;NI5SX :-V0'^U)-+@?\FXK8TGD[W7\$65_I+H3_17[>
M+BX/GI>OIOKMG,BKX&C49L;(^S C+Q]]A+-!1O_".>+\T'_\>H]F;I#9?8%5
MI*7V"MDQ&EJSA54B%^(2CL&+8B]%BUBU4:I"; _38^Q_^@_]FPGRYB$)R RC
M^)I$2Q)Q&.0W3NIZ<.9G#[N*2R9=N2U9DW6I>DQ3]?Q@NP-2EZKGG:;JF>!%
MU@W>H3CW")::6WD574L+%R384+8>'>0L,=@C%$T).Y'Q4-99U19+6$&773@/
M^@;858'0ZGD63.ZLSW").4XG>59#HW%]#)<Y>+V&*&(G>$S"_G@XRE3MFH14
MFN>4BC,A[,?BL5JSN;/+DW48'%9IB/3A8K& DA59W0:AW21;4Y,#(6[+]U(C
MXT.]G PGEGC)^K>(]T+&]B5^+DN\DRXB"QC-MZ&J^([&OW9^.8Y:A<L^_:N#
M'?\/$Y":NT<6Y]E&6%'51Z ]Y-K5MF:IL$7)JN='_K14@RL097OGEW+H0$#:
M=J9 ZV^CZ(7.O7'A:HS%<XK=*)05H:,]VEFIZ$/6$F>]!4G#Y)9$W.V&*A+W
MZ: B+G"2(-$J4EGK///4:()EBQ'>"/B5$#^_MI9HF\YTKMO2^65\J0U%J\-7
MNA$MQ "NWT%%_J7(^Z).2V>:$:4^J)8,_5%$/(3\^)8"5MEAR>&]NNKYOJ>M
MC9LE/!^:N^?\7_H]P;-%&$XA<^ UE9@H[_;$?>O%,4IB^I?US_(';G<@#?TK
M%*(I3C9'ML5?BY6]Z>^<[ZO5[3!BB?'M'J4^Z4>I05,A'C[Q'I2ZK[7I]H0.
M88\+H%66J[^[7ZU&@>YKLXR-F3/$A"1N4/P].YP:D.07E#PBC\Q"_+ML6]'B
M)^WW&3O8&Z$MGBS1QT.OW<0I2!\1\_BA/^=.&ZZ7I&XP0='BLV(K<^S.Z.KP
M"1UO0\)Y5MJ]^T#$9DZI.LAK]!J[ZHNZ>GI"!_NM8V:5,AYGTV*0+?OR].X
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M,2YH=&U02P$"% ,4    " #LB M3W1=QEIEB   .70( "P
M@ &C P  97A?,3 M,BYH=&U02P$"% ,4    " #LB M3CKB28!$1  #YFP
M"P              @ %E9@  97A?,3 M,RYH=&U02P$"% ,4    " #LB M3
M:J*</#(\  !]-0$ "P              @ &?=P  97A?,3 M-"YH=&U02P$"
M% ,4    " #LB M3.>C?FOL&  #Z&P  "P              @ 'ZLP  97A?
M,S$M,2YH=&U02P$"% ,4    " #LB M3_-WBR_(&  #Z&P  "P
M    @ $>NP  97A?,S$M,BYH=&U02P$"% ,4    " #LB M3_,CG_F(#  #>
M"@  "P              @ $YP@  97A?,S(M,2YH=&U02P$"% ,4    " #L
MB M32O$.SU\#  #>"@  "P              @ '$Q0  97A?,S(M,BYH=&U0
M2P$"% ,4    " #LB M33LD&@5P0   1EP  $0              @ %,R0
M:W)M9"TR,#(Q,#8S,"YX<V102P$"% ,4    " #LB M3Q-W0^=81  !=P@
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2      X #@!: P  CY0"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
